

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 10-K**

(Mark One)

**ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
For the fiscal year ended **December 31, 2025**

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
OR  
For the transition period from \_\_\_\_\_ to \_\_\_\_\_  
Commission file number **001-33892**

**AMC ENTERTAINMENT HOLDINGS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of incorporation or organization)

**26-0303916**  
(I.R.S. Employer Identification No.)

**One AMC Way**  
**11500 Ash Street, Leawood, KS**  
(Address of principal executive offices)

**66211**  
(Zip Code)

**(913) 213-2000**

Registrant's telephone number, including area code:

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Class A common stock	AMC	New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act: **None.**

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes  No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulations S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and emerging growth company in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer  Non-accelerated filer   
Smaller reporting company  Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262 (b)) by the registered public accounting firm that prepared or issued its audit report.

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing the correction of an error to previously issued financial statements.

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes  No

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant on June 30, 2025, computed by reference to the price at which the registrant's Class A common stock was last sold on the New York Stock Exchange on such date was \$1,342,745,039 (433,143,561 Class A common stock shares at a closing price per share of \$3.10). Shares of Class A common stock outstanding—529,547,465 shares at February 18, 2026

**DOCUMENTS INCORPORATED BY REFERENCE**

Certain portions of the registrant's definitive proxy statement, in connection with its 2025 annual meeting of stockholders, to be filed within 120 days of December 31, 2025, are incorporated by reference into Part III of this Annual Report on Form 10-K.

**AMC ENTERTAINMENT HOLDINGS, INC.**  
**FORM 10-K**  
**FOR THE YEAR ENDED DECEMBER 31, 2025**  
**INDEX**

	<b>Page</b>	
<b><u>PART I</u></b>		
<a href="#">Item 1.</a>	<a href="#">Business</a>	5
<a href="#">Item 1A.</a>	<a href="#">Risk Factors</a>	19
<a href="#">Item 1B.</a>	<a href="#">Unresolved Staff Comments</a>	36
<a href="#">Item 1C.</a>	<a href="#">Cybersecurity</a>	36
<a href="#">Item 2.</a>	<a href="#">Properties</a>	38
<a href="#">Item 3.</a>	<a href="#">Legal Proceedings</a>	38
<a href="#">Item 4.</a>	<a href="#">Mine Safety Disclosures</a>	39
<b><u>PART II</u></b>		
<a href="#">Item 5.</a>	<a href="#">Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a>	40
<a href="#">Item 6.</a>	<a href="#">[Reserved]</a>	43
<a href="#">Item 7.</a>	<a href="#">Management’s Discussion and Analysis of Financial Condition and Results of Operations</a>	43
<a href="#">Item 7A.</a>	<a href="#">Quantitative and Qualitative Disclosures about Market Risk</a>	68
<a href="#">Item 8.</a>	<a href="#">Financial Statements and Supplementary Data</a>	70
<a href="#">Item 9.</a>	<a href="#">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a>	134
<a href="#">Item 9A.</a>	<a href="#">Controls and Procedures</a>	134
<a href="#">Item 9B.</a>	<a href="#">Other Information</a>	134
<a href="#">Item 9C.</a>	<a href="#">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a>	136
<b><u>PART III</u></b>		
<a href="#">Item 10.</a>	<a href="#">Directors, Executive Officers and Corporate Governance</a>	137
<a href="#">Item 11.</a>	<a href="#">Executive Compensation</a>	137
<a href="#">Item 12.</a>	<a href="#">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a>	137
<a href="#">Item 13.</a>	<a href="#">Certain Relationships and Related Transactions, and Director Independence</a>	137
<a href="#">Item 14.</a>	<a href="#">Principal Accountant Fees and Services</a>	137
<b><u>PART IV</u></b>		
<a href="#">Item 15.</a>	<a href="#">Exhibits and Financial Statement Schedules</a>	138
<a href="#">Item 16.</a>	<a href="#">Form 10-K Summary</a>	146

### Forward-Looking Statements

In addition to historical information, this Annual Report on Form 10-K contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “forecast,” “estimate,” “project,” “intend,” “plan,” “expect,” “should,” “believe” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions and speak only as of the date on which it is made. Examples of forward-looking statements include statements we make regarding future attendance levels, revenues and our liquidity. These forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors, including those discussed in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the following:

- the risks and uncertainties relating to the sufficiency of our existing cash and cash equivalents and available borrowing capacity to fund operations and satisfy obligations including cash outflows for planned capital expenditures currently and through the next twelve months. In order to achieve net positive cash flows from operating activities, revenues will need to increase from current levels to levels at least in line with pre-COVID-19 revenues. However, there remain significant risks that may negatively impact revenues and attendance levels, including changes to movie studios release schedules (including as a result of production delays and delays to the release of movies caused by labor stoppages) and direct to streaming or other changing movie studio practices. If we are unable to achieve increased levels of attendance and revenues, we will be required to obtain additional liquidity. If such additional liquidity is not obtained or is insufficient, we likely would seek an in-court or out-of-court restructuring of our liabilities, and in the event of such future liquidation or bankruptcy proceeding, holders of our Class A common stock (“Common Stock”) and other securities would likely suffer a total loss of their investment;
- the risks and uncertainties relating to the 2025 Refinancing Transactions and 2024 Refinancing Transactions (each defined herein), including, but not limited to, (i) the potential for additional future dilution of our Common Stock as a result of issuance of shares underlying our 6.00%/8.00% Cash/PIK Toggle Senior Secured Exchangeable Notes (the “Existing Exchangeable Notes”) or our Senior Secured Exchangeable Notes due 2030 (the “New Exchangeable Notes”), (ii) the possibility that the extension of certain debt maturities will not provide enough time for attendance and revenues to increase to sufficient levels and generate net positive cash flows from operating activities to overcome liquidity concerns or may be insufficient to do so if the Company does not achieve revenue levels at least in line with pre-COVID-19 revenues and (iii) the impact on the market price of our Common Stock and our capital structure of any litigation or claims of default that might arise in connection with the 2025 Refinancing Transactions or 2024 Refinancing Transactions;
- changing practices of distributors, which accelerated during the COVID-19 pandemic, including increased use of alternative film delivery methods including premium video on demand, streaming platforms, shrinking exclusive theatrical release windows or release of movies to theatrical exhibition and streaming platforms on the same date, the theatrical release of fewer movies due to industry consolidation or other reasons, or transitioning to other forms of entertainment;
- the impact of changing movie-going behavior of consumers;
- the risk that the North American and international box office in the near term will not recover sufficiently, resulting in continued cash burn and the need to seek additional financing, which may not be available at favorable terms, or at all;
- risks and uncertainties relating to our significant indebtedness, including our borrowings and our ability to meet our debt covenants;

## [Table of Contents](#)

- the dilution caused by recent and potential future sales of our Common Stock and future potential share issuances to repay, refinance, redeem or repurchase indebtedness (including expenses, accrued interest and premium, if any);
- risks relating to motion picture production, promotion, marketing, and performance, including labor stoppages affecting the production, supply and release schedule of theatrical motion picture content and the financial burden imposed by tariffs on motion picture production;
- the seasonality of our revenue and working capital, which are dependent upon the timing of motion picture releases by distributors, such releases being seasonal and resulting in higher attendance and revenues generally during the summer months and holiday seasons, and higher working capital requirements during the other periods such as the first quarter;
- intense competition in the geographic areas in which we operate among exhibitors, streaming platforms, or from other forms of entertainment;
- certain covenants in the agreements that govern our indebtedness that limit or restrict our ability to take advantage of certain business opportunities, pay dividends, incur additional debt, pre-pay debt, and also to refinance debt and to do so at favorable terms, and such covenants that impose additional administrative and operational burdens on our business;
- risks relating to impairment losses, including with respect to goodwill and other intangibles, and theatre and other closure charges;
- general and international economic, political, regulatory, social and financial market conditions, including potential economic recession, inflation, rising interest rates, the financial stability of the banking industry, and other risks that may negatively impact discretionary income and our revenues and attendance levels;
- our lack of control over distributors of films;
- limitations on the availability of capital or poor financial results may prevent us from deploying strategic initiatives;
- an issuance of preferred stock could dilute the voting power of the common stockholders and adversely affect the market value of our outstanding Common Stock;
- limitations on the authorized number of Common Stock shares could in the future prevent us from raising additional capital through sales of Common Stock;
- our ability to achieve expected synergies, benefits and performance from our strategic initiatives;
- our ability to refinance our indebtedness on terms favorable to us or at all;
- our ability to optimize our theatre circuit through new construction, the transformation of our existing theatres, and strategically closing underperforming theatres may be subject to delay and unanticipated costs;
- failures, unavailability or security breaches of our information systems, including due to cybersecurity incidents;
- our ability to utilize interest expense deductions will be limited annually due to Section 163(j) of the Internal Revenue Code of 1986, as amended (the “Code”), as amended by the One Big Beautiful Bill Act of 2025;
- our ability to recognize interest deduction carryforwards, net operating loss carryforwards, and other tax attributes to reduce our future tax liability;

[Table of Contents](#)

- our ability to recognize certain international deferred tax assets which currently do not have a valuation allowance recorded;
- review by antitrust authorities in connection with acquisition opportunities;
- risks relating to the incurrence of legal liability;
- dependence on key personnel for current and future performance and our ability to attract and retain senior executives and other key personnel, including in connection with any future acquisitions;
- increased costs in order to comply or resulting from a failure to comply with governmental regulation, including the General Data Protection Regulation (“GDPR”) and all other current and pending privacy and data regulations in the jurisdictions where we have operations;
- supply chain disruptions may negatively impact our operating results;
- the availability and/or cost of energy;
- the market price and trading volume of our shares of Common Stock has been and may continue to be volatile, and purchasers of our securities could incur substantial losses;
- future offerings of debt, which would be senior to our Common Stock for purposes of distributions or upon liquidation, could adversely affect the market price of our Common Stock;
- the potential for political, social, or economic unrest, terrorism, hostilities, cyber-attacks or war, including the conflict between Russia and Ukraine and other international conflicts;
- the potential impact of financial and economic sanctions on the regional and global economy, or widespread health emergencies, such as pandemics or epidemics, causing people to avoid our theatres or other public places where large crowds are in attendance;
- anti-takeover protections in our Fourth Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) and our amended and restated bylaws (the “Bylaws”) may discourage or prevent a takeover of our Company, even if an acquisition would be beneficial to our stockholders; and
- other risks and uncertainties referenced from time to time in filings with the Securities and Exchange Commission (“SEC”).

This list of factors that may affect future performance and the accuracy of forward-looking statements is illustrative but not exhaustive. In addition, new risks and uncertainties may arise from time to time. Accordingly, all forward-looking statements should be evaluated with an understanding of their inherent uncertainty and we caution accordingly against relying on forward-looking statements.

Except as required by law, we assume no obligation to publicly update or revise these forward-looking statements for any reason. Actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Readers are urged to consider these factors carefully in evaluating the forward-looking statements. For further information about these and other risks and uncertainties as well as strategic initiatives, see Part I, Item 1. “Business” and Item 1A. “Risk Factors” in this Annual Report on Form 10-K.

All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. The forward-looking statements included herein are made only as of the date of this Annual Report on Form 10-K, and we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

## PART I

### Item 1. Business.

#### General Development of Business

AMC Entertainment Holdings, Inc. (“Holdings”), through its direct and indirect subsidiaries, including American Multi-Cinema, Inc. (“Multi-Cinema”) and its subsidiaries, (collectively with Holdings, unless the context otherwise requires, the “Company” or “AMC”), is principally involved in the theatrical exhibition business and owns, operates or has interests in theatres located in the United States and Europe.

Our business was founded in Kansas City, Missouri in 1920. Holdings was incorporated under the laws of the state of Delaware on June 6, 2007. We maintain our principal executive offices at One AMC Way, 11500 Ash Street, Leawood, Kansas 66211.

#### *Liquidity*

As of December 31, 2025, we had cash and cash equivalents of approximately \$428.5 million.

During the year ended December 31, 2025, we took action to lower the future interest expense of our fixed-rate debt through debt buybacks and exchanges for equity and enhanced liquidity through equity issuances. See Note 7—Corporate Borrowings and Finance Lease Liabilities, Note 8—Stockholders’ Deficit, and Note 14—Subsequent Events in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K, for further information regarding equity issuances and debt repurchases and exchanges.

#### *2025 Refinancing Transactions*

On July 24, 2025, Muvico, LLC, a wholly-owned subsidiary of the Company (“Muvico”), issued \$857.0 million aggregate principal amount of new Senior Secured Notes due 2029 (the “New 2029 Notes”) in exchange for \$590.0 million aggregate principal amount of 7.5% First Lien Senior Secured Notes due 2029 (“Existing 7.5% Notes”) and \$244.4 million of incremental, new money financing. On the same day, Muvico also issued \$194.4 million aggregate principal amount of New Exchangeable Notes in exchange for \$194.4 million aggregate principal amount of Existing Exchangeable Notes. On September 30, 2025, \$39.9 million aggregate principal of New Exchangeable Notes were cancelled pursuant to a downward adjustment feature in the New Exchangeable Notes, which represented the maximum possible downward adjustment. We used the new money financing from the issuance of the New 2029 Notes to fully redeem our outstanding 5.875% Senior Subordinated Notes due 2026 (the “Senior Subordinated Notes due 2026”) and our 10%/12% Cash/PIK Toggle Second Lien Subordinated Secured Notes due 2026 (the “Second Lien Notes”) and also to pay consent fees to the Consenting Term Loan Lenders (as defined herein).

The New Exchangeable Notes were not initially exchangeable into Common Stock. At the 2025 Annual Meeting, our stockholders approved an amendment to the Company’s Certificate of Incorporation for the Authorized Share Increase which allowed for the New Exchangeable Notes to become exchangeable and lowered the interest rate to 1.5% cash interest. The Authorized Share increase also allowed for a \$15.0 million consent fee payable to Consenting Existing Exchangeable Noteholders to be payable in the form of shares of Common Stock, based on a price determined based on the average of the daily volume weighted average price of our Common Stock for the sixty consecutive trading days commencing on December 22, 2025. On December 22, 2025, the Company and the holders of the New Exchangeable Notes agreed to amend the New Exchangeable Notes Indenture, among other things, to amend and restate the Exchange Rate and allow for up to \$150.0 million of net proceeds from sales of at-the-market offerings. The amendments were memorialized in a supplemental indenture dated January 12, 2026 (the “New Exchangeable Notes Supplemental Indenture”). As consideration for the indenture amendments the Company will pay the New Exchangeable Noteholders a consent fee of \$6.25 million payable in shares of Common Stock. The number of shares will be based on the average of the daily volume weighted average price of our Common Stock for the sixty consecutive trading days commencing on December 22, 2025.

See Note 7—Corporate Borrowings and Finance Lease Liabilities and Note—14 Subsequent Events in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for further information regarding these transactions.

[Table of Contents](#)

We expect, from time to time, to continue to seek to retire or purchase our outstanding debt through cash purchases and/or exchanges for equity or debt, in open-market purchases, privately negotiated transactions or otherwise. We continuously monitor the capital markets and our capital structure, and may, from time to time, seek to refinance, amend or otherwise restructure our outstanding debt on an opportunistic basis. Such repurchases, refinancings, amendments, restructurings or exchanges, if any, will be upon such terms and at such prices as we may determine, and will depend on prevailing market conditions, our liquidity requirements, the availability of authorized share capital, contractual restrictions and other factors. The amounts involved may be material, and to the extent equity is used, dilutive. For example, on February 17, 2026, we launched a financing transaction (the “Financing Transaction”) to refinance the New Term Loans and Odeon Notes due 2027 (in each case as defined herein). There can be no assurance that we will successfully enter into an agreement with respect to or complete the Financing Transaction, which is subject to, among other things, market and other conditions, and the negotiation and execution of definitive documents.

**Narrative Description of Business**

We are the world’s largest theatrical exhibition company and an industry leader in innovation and operational excellence. Over the course of our 100+ year history, we have pioneered many of the theatrical exhibition industry’s most important innovations. We introduced multiplex theatres in the 1960s and the North American stadium-seated megaplex theatre format in the 1990s. Most recently, we continued to innovate and evolve the movie-going experience with the deployment of our theatre renovations featuring plush, powered recliner seating and the launch of our U.S. subscription loyalty tier, AMC Stubs® A-List (“A-List”). Our growth has been driven by a combination of organic growth through reinvestment in our existing assets and through the acquisition of some of the most significant companies in the theatrical exhibition industry.

Our business is operated in two theatrical exhibition reportable segments, U.S. markets and International markets. Substantially all of our international operations are attributed to Odeon Cinemas Group Limited (“OCGL”) and its subsidiaries, Odeon and UCI Cinemas Holdings Limited (“Odeon”) and Nordic Cinema Group Holding AB (“Nordic”).

As of December 31, 2025, we owned, leased or operated 855 theatres and 9,640 screens in 11 countries, including 533 theatres with a total of 7,072 screens in the United States and 322 theatres and 2,568 screens in European markets. We have productive assets in each of the capital cities and most densely populated areas of the countries in which we operate.

As of December 31, 2025, we were the market leader in the United States and Europe including in Sweden, Norway, and Finland, and a leading theatre operator in the United Kingdom, Ireland, Italy, Spain, Portugal, and Germany. We have operations in four of the world’s 10 largest economies, including four of the six largest European economies (the United Kingdom, Spain, Italy and Germany) as of December 31, 2025.

As of December 31, 2025, in the U.S. markets, we owned, leased or operated theatres in 41 states and the District of Columbia, with approximately 49% of the U.S. population living within 10 miles of one of our theatres. We have a diversified footprint with complementary global geographic and guest demographic profiles, which we believe gives our circuit a unique profile and offers us strategic and operational advantages while providing our studio partners with a large and diverse distribution channel. We operate some of the most productive theatres in the top markets in the United States and were the market leader in the top two markets for the year ended December 31, 2025: Los Angeles and New York. During 2025, our top five markets, in each of which we held the #1 share position, were New York, Los Angeles, Chicago, Atlanta, and Washington DC according to data provided by Comscore.

[Table of Contents](#)

The following table provides detail with respect to the geographic location of our theatrical exhibition circuit as of December 31, 2025:

U.S. Markets	Theatres(1)	Screens(1)
Alabama	17	222
Arizona	12	187
Arkansas	2	21
California	57	777
Colorado	13	183
Connecticut	9	104
Florida	38	588
Georgia	25	339
Idaho	1	11
Illinois	44	552
Indiana	20	264
Iowa	3	43
Kansas	8	124
Kentucky	2	40
Louisiana	7	99
Maryland	13	158
Massachusetts	11	155
Michigan	10	154
Minnesota	6	95
Missouri	9	107
Montana	5	55
Nebraska	1	14
Nevada	2	28
New Jersey	25	319
New Mexico	1	12
New York	30	322
North Carolina	19	244
North Dakota	1	9
Ohio	11	140
Oklahoma	11	131
Oregon	2	25
Pennsylvania	23	262
South Carolina	2	26
South Dakota	1	10
Tennessee	15	191
Texas	40	589
Utah	3	29
Virginia	13	173
Washington	14	171
West Virginia	1	12
Wisconsin	5	73
District of Columbia	1	14
Total U.S. Markets	533	7,072
<b>International Markets</b>		
Denmark	2	12
Finland	29	170
Germany	21	188
Ireland	11	77
Italy	34	344
Norway	12	91
Portugal	3	42
Spain	35	411
Sweden	72	382
United Kingdom	103	851
Total International Markets	322	2,568
Total	855	9,640

(1) Included in the above table are 64 theatres and 317 screens that we manage or in which we have a partial ownership interest. In the U.S. markets segment, we manage or have a partial interest in four theatres and 55 screens. In the International markets segment, we manage or have a partial interest in 60 theatres and 262 screens.

Our theatrical exhibition revenues are generated primarily from box office admissions and theatre food and beverage sales. We offer consumers a broad range of entertainment alternatives including traditional film programming, private theatre rentals, independent and foreign films, performing arts, music and sports. We also offer food and beverage alternatives beyond traditional concession items, including collectible concession vessels, made-to-order meals, customized coffee, healthy snacks, beer, wine, premium cocktails, and dine-in theatre options. The balance of our revenues is generated from ancillary sources, including on-screen advertising, fees earned from our customer loyalty programs, rental of theatre auditoriums, income from gift card and exchange ticket sales, theatrical distribution, retail popcorn sales, and online ticketing fees.

### ***Our Strategy***

We are committed to maintaining a leadership position in the exhibition industry by focusing on forward-thinking initiatives for the benefit of our guests. We do this through a combination of unique marketing outreach, seamless digital technology and innovative theatre amenities designed for us to 1) be a world-class leader in customer engagement, 2) deliver the best in-person experience while at AMC theatres, 3) selectively enhance our footprint through expansion in attractive markets, investments in Premium Large Format (“PLF”) screens, and strategic closure of underperforming theatres, 4) pursue adjacent opportunities that extend the AMC brand, and 5) explore attractive acquisitions leveraging our existing capabilities and core competencies. Consistent with our history and culture of innovation, we believe our vision and relentless focus on these key elements, which apply strategic and marketing components to traditional theatrical exhibition, will drive our future success.

#### ***1) Be a World-Class Leader in Customer Engagement***

We engage movie-goers through advances in technology and marketing activities to strengthen the bonds with our current guests and create new connections with potential customers that drive both growth and loyalty. We serve our guests, end-to-end, from before they enter our theatres, through their enjoyment of a comprehensive spectrum of film content while at our theatres and then again after the movie when they have left the theatre and are deciding what film to see the next time they visit.

In our U.S. markets, we begin the process of engagement with AMC Stubs® (“Stubs”), our customer loyalty program, which allows members to earn rewards, receive discounts and participate in exclusive members-only offerings and services. There are four different Stubs tiers available: A-List, AMC Stubs Premiere™ (“Premiere”), AMC Stubs® Premiere GO! (“Premiere GO!”), and AMC Stubs Insider™ (“Insider”).

A-List is our monthly subscription-based tier of our Stubs loyalty program. This program offers guests admission to movies at AMC up to four times per week, including multiple movies per day and repeat visits to movies. A-List also includes premium offerings including IMAX® , Dolby Cinema™ at AMC, RealD, Prime and other PLF brands. A-List members can book tickets online in advance with reserved seating at AMC Theatres for no additional cost.

Premiere is a paid tier with a flat annual membership fee that rewards members with reward points, free food and beverage upgrades, discounted tickets on certain days of the week, priority lane access, waived ticket fees, and other various benefits.

Premiere GO! membership is earned by existing Insider members by visiting a certain number of times or earning a certain number of points within a calendar year. Premiere GO! allows members to earn additional points and other exclusive benefits.

Insider is a free tier that rewards loyal guests for their patronage of AMC theatres with reward points, discounted tickets on certain days of the week, and other various benefits.

As of December 31, 2025, we had a combined total of approximately 39 million member households enrolled in Stubs programs. Our Stubs members represented approximately 51% of our U.S. market attendance during the year ended December 31, 2025. Our large database of identified movie-goers also provides us with additional insight into our customers’ movie preferences. This enables us to have an increasingly comprehensive, more personalized and targeted marketing effort.

In our International markets, we currently have loyalty programs in all territories in which we operate. Movie-goers can earn points for spending money at the theatre, and those points can be redeemed for tickets or food and

beverage items, depending on the program, at a later date. We currently have approximately 20 million total members in our various International loyalty and subscription programs.

Our marketing efforts expand beyond our loyalty and subscription programs. We continue to improve our customer connections through our website and mobile apps. Our mobile applications across the U.S. circuit offer the ability to order food and beverage while ordering tickets ahead of scheduled showtimes.

In June 2021, the Company launched AMC Investor Connect (“AIC”), an innovative new communication initiative to engage directly with its sizable retail shareholder base and convert shareholders into AMC customers. AIC allows our shareholders to self-identify through our website and receive special offers and important communications. As part of AIC, domestic members must sign up for a Stubs account, which includes providing additional personalized data that allows us to more precisely engage with our investor customers. As of December 31, 2025, there were approximately 1.8 million global members of AIC, which is comprised of both registered and beneficial shareholders.

In 2025, we brought Netflix content to our theatres by showing the *Stranger Things* series finale and *KPop Demon Hunters*. We are excited about the prospect of bringing more Netflix titles to moviegoers.

## **2) Deliver the Best In-Person Experience while at AMC Theatres**

In conjunction with our advances in technology and marketing initiatives, and consistent with our long-term growth strategy, we plan to continue investing in our theatres to deliver the best in-person experience and take greater advantage of incremental revenue-generating opportunities, primarily through comfort and convenience innovations, imaginative food and beverage initiatives, and exciting PLF offerings.

**Comfort and Convenience.** Recliner seating is a key feature of many of our locations. We believe that maximizing comfort and convenience for our customers will be increasingly necessary to maintain and improve our relevance. These locations include plush, electric recliners that allow customers to deploy a leg rest and fully recline at the push of a button. These locations typically warrant increased ticket prices to reflect the enhanced consumer experience.

As of December 31, 2025, in our U.S. markets, we featured recliner seating in 368 U.S. theatres, including Dine-in-Theatres, totaling approximately 3,658 screens which represents 51.7% of total U.S. screens. In our International markets, as of December 31, 2025, we featured recliner seating in 89 International theatres, totaling 643 screens which represents 25.0% of total International screens.

Open-source internet ticketing makes AMC’s entire universe of seats in the U.S. (approximately 1 million as of December 31, 2025), for all our show times, as available as possible, on as many websites and mobile applications as possible. Our tickets are currently sold either directly at the box office or through mobile apps, at our own website and mobile app and through other third-party ticketing vendors. For the year ended December 31, 2025, approximately 73% of our tickets were purchased online in the U.S., with approximately 87% of total online tickets being purchased through our own website and mobile apps.

**Imaginative Food and Beverage Initiatives.** Our deployment initiatives also apply to food and beverage enhancements. We have expanded our menu of enhanced food and beverage products to include meals, healthy snacks, premium beers, wine and mixed drinks, and other gourmet products. Our long-term growth strategy calls for investment across a spectrum of enhanced food and beverage formats, ranging from simple, less capital-intensive food and beverage design improvements to the development of dine-in theatre options. We have expanded the capabilities of our online and mobile apps to include the ability to pre-order food and beverages when advanced tickets are purchased. Guests then have the items ready upon arrival and available at dedicated pick-up areas or delivered to seats at select theatres.

Our MacGuffins Bar and Lounges (“MacGuffins”) give us an opportunity to offer alcohol to our legal age customers in our U.S. markets. As of December 31, 2025, we offered alcohol in 386 theatres in our U.S. markets and 221 theatres in our International markets.

In 2025, we introduced the AMC Popcorn Pass—a new annual perk for Stubs members. For a yearly fee, members enjoy 50% off a large AMC Perfectly Popcorn every day.

**Expand Movie Themed Merchandise Offerings.** We offer our guests the opportunity to purchase collectible concession vessels associated with films released throughout the year. These unique items drive movie-goers to our

theatres and increase consumer engagement. We continue to look for opportunities to further expand our collectible concession vessel offerings and other movie themed retail merchandise offerings.

**Exciting Premium Large Format and Extra Large Screen Offerings.** PLF auditoriums generate our highest customer satisfaction scores, and we believe the investment in PLFs increases the value of the movie-going experience for our guests, ultimately leading to additional ticket revenue. To that end, we are committed to investing in and expanding our offerings of the best sight and sound experiences through a combination of our partnerships with IMAX® and Dolby Cinema™ and the further development of our own PLF offerings. A description of our various PLF and extra large screen offerings follows:

- **IMAX®.** IMAX® is one of the world's leading entertainment technology companies, specializing in motion picture technologies and presentations. IMAX® auditoriums are customized for optimal viewing experiences, using acousticians, laser-alignment and custom theatre geometry to ensure an immersive design. IMAX® auditoriums also feature an integrated sound system and precise speaker positioning.

As of December 31, 2025, AMC was the largest IMAX® exhibitor in the U.S., with a 56% market share. Each one of our IMAX® local installations is protected by geographic exclusivity, and as of December 31, 2025, our IMAX® screen count was 96% higher than our closest competitor. Additionally, as of December 31, 2025, our per-screen IMAX® grosses were 32% higher than our closest competition. In 2025, we agreed to an expanded partnership with IMAX® for 14 new locations and 68 system updates to be completed by 2033.

- **Dolby Cinema™.** Dolby Cinema™ offers a premium cinema offering for movie-goers that combines state-of-the-art image and sound technologies with inspired theatre design and comfort. Dolby Cinema™ at AMC includes Dolby Vision™ laser projection and object-oriented Dolby Atmos® audio technology, as well as AMC's plush power reclining seats with seat transducers that vibrate with the action on screen.

In 2025, we agreed to an expanded partnership with Dolby to add 40 new Dolby Cinema™ at AMC locations by the end of 2029.

- **SCREENX.** SCREENX is the world's first multi-projection cinema technology with an immersive 270-degree panoramic viewing experience. By extending select scenes onto the left and right walls of the auditorium, SCREENX surrounds the audience with story-enhancing visuals that cannot be replicated at home. The innovative screen format places everyone in the auditorium directly at the center of the motion picture. We have agreed to deploy 10 SCREENX locations in the U.S. with targeted completion in 2026.
- **4DX.** 4DX provides moviegoers with a multi-sensory cinema-going experience, allowing audiences to connect with movies through motion, vibration, water, wind, snow, lightning, scents, and other special effects that enhance the visuals on-screen. Each 4DX auditorium incorporates motion-based seating synchronized with more than 21 different effects and optimized by a team of skilled editors. We have agreed to deploy five 4DX locations in the U.S. with targeted completion in 2026.
- **In-house PLF Brands.** We also offer our private label PLF experience at many of our locations, with superior sight and sound technology and enhanced seating. These PLF auditoriums offer an enhanced theatrical experience for movie-goers beyond our current core theatres, at a lower price premium than IMAX® or Dolby Cinema™. Therefore, they may be especially relevant in smaller or more price-sensitive markets.
- **Extra Large ("XL") Screens.** In addition to PLF offerings, we also offer screens that are at least 40-feet wide and include 4K laser projection.

[Table of Contents](#)

The following table provides detail with respect to PLF screens (IMAX<sup>®</sup>, Dolby Cinema<sup>™</sup>, SCREENX, 4DX, in-house), XL screens, 3D enabled screens, premium seating, and our enhanced food and beverage offerings as deployed throughout our circuit on December 31, 2025 and December 31, 2024:

Format	U.S. Markets		International Markets		Consolidated	
	Year Ended		Year Ended		Year Ended	
	December 31,		December 31,		December 31,	
	2025	2024	2025	2024	2025	2024
Number of theatres:						
IMAX <sup>®</sup>	185	183	38	36	223	219
Dolby Cinema <sup>™</sup> theatres	174	167	7	7	181	174
In-house PLF	76	60	79	79	155	139
Dine-in	48	48	3	3	51	51
Premium seating	368	365	89	86	457	451
XL screens	47	—	74	60	121	60
SCREENX	1	—	6	6	7	6
3D enabled	524	531	249	265	773	796
Number of screens:						
IMAX <sup>®</sup>	186	184	38	36	224	220
Dolby Cinema <sup>™</sup> theatres	174	167	7	7	181	174
In-house PLF	80	60	82	82	162	142
Dine-in	666	666	13	13	679	679
Premium seating	3,658	3,620	643	605	4,301	4,225
XL screens	76	—	91	68	167	68
SCREENX	1	—	6	6	7	6
3D enabled	2,795	2,840	919	1,056	3,714	3,896

**Laser at AMC.** We launched Laser at AMC, a broadscale initiative to upgrade the projectors in at least 3,500 auditoriums throughout the U.S., with cutting-edge laser projectors. The Laser at AMC experience delivered by laser projection from Barco, a global leader in laser-powered cinema solutions, provides guaranteed light levels that are at the top end of the 2D DCI specification. This technology improves image contrast, produces more vivid colors, and maximizes brightness, compared to digital projectors with a xenon light source. We are partnering with Barco through their Cinema-as-a-Service program which requires minimal upfront capital investment by AMC. The initial agreement to install 3,500 projectors is expected to be completed by 2026, with 2,951 installations completed as of December 31, 2025.

We have also started deploying laser projectors across our international markets with 96 projectors installed as of December 31, 2025. We expect to continue to increase our laser projector installations internationally in the coming years.

**3) *Performance-Based Expansion and Strategic Closure of Theatres***

Our long-term growth strategy includes the deployment of our strategic growth initiatives, opening new-build theatres and continued exploration of small acquisitions. By expanding our platform through disciplined new-build theatres and acquisitions, we are able to further deploy our proven strategic initiatives while further diversifying our customer base, leading to greater appeal for more films. The additional scale achieved through new-build theatres and acquisitions also serves to benefit our business through global procurement savings and increased overhead efficiencies. We believe that expansion offers us additional opportunities to introduce our proven guest-focused strategies to movie-goers and will generate meaningful benefits to guests, employees, studio partners and our shareholders.

[Table of Contents](#)

The following table sets forth our historical information concerning new builds (including expansions), acquisitions and dispositions (including permanent closures of underperforming theatres and net construction closures) and end-of-period operated theatres and screens through December 31, 2025:

Fiscal Year	New Builds		Acquisitions		Permanent/Temporary (Closures)/Openings, net		Total Theatres	
	Number of Theatres	Number of Screens	Number of Theatres	Number of Screens	Number of Theatres	Number of Screens	Number of Theatres	Number of Screens
Beginning balance							950	10,543
2021	10	82	11	140	(25)	(203)	946	10,562
2022	7	51	15	157	(28)	(296)	940	10,474
2023	—	—	6	31	(48)	(446)	898	10,059
2024	1	13	2	9	(30)	(283)	871	9,798
2025	—	—	3	36	(19)	(194)	855	9,640
	<u>18</u>	<u>146</u>	<u>37</u>	<u>373</u>	<u>(150)</u>	<u>(1,422)</u>		

**4) Pursue Adjacent Opportunities that Extend the AMC Brand**

We believe there is considerable opportunity to extend and monetize the AMC brand outside of our movie theatre auditoriums. We plan to pursue opportunities that capitalize on our attractive customer base, our leading brand, our 100+ years of food and beverage expertise, and technology capabilities.

As part of that strategy, we have expanded our food and beverage business beyond theatrical exhibition and entered the multi-billion dollar popcorn industry with the launch of AMC Theatres Perfectly Popcorn in the U.S. markets.

- We offer ready-to-eat and microwaveable AMC Theatres Perfectly Popcorn products that are available or will be available for purchase in well-known grocery stores around the country or on-line via Amazon.com.
- Freshly popped AMC Theatres Perfectly Popcorn is available through food delivery-to-home services.
- “To Go” packages at our theatres of freshly popped popcorn are available for takeout and/or pickup.

AMC Theatres Perfectly Popcorn is an opportunity to diversify our business and to create a new food and beverage revenue stream.

During 2024, we rolled out AMC Cinema Sweets™, our line of premium gourmet candy. AMC Cinema Sweets are available to moviegoers at AMC concession stands throughout the United States.

We made our inaugural foray into theatrical distribution in 2023 when we, along with our sub-distribution partners, served as the theatrical distributor for two theatrical releases: *TAYLOR SWIFT | THE ERAS TOUR* and *RENAISSANCE: A FILM BY BEYONCÉ*. During 2024, we distributed *USHER: RENDEZVOUS IN PARIS* and *BILLIE EILISH: HIT ME HARD AND SOFT*, an album listening experience. In 2025, we distributed *TAYLOR SWIFT | THE OFFICIAL RELEASE PARTY OF A SHOWGIRL*, the biggest album-debut event in cinema history, domestically and globally. We have the potential to capitalize on new theatrical distribution opportunities in the future which would lead to additional theatrical distribution revenue and increased admissions revenue.

**5) Explore Attractive Acquisitions Leveraging Our Existing Capabilities and Core Competencies**

As part of our plans to pursue value-enhancing initiatives that lead to diversification of our business, we will consider attractive and opportunistic acquisitions inside and outside the theatrical exhibition industry that leverage our footprint and capabilities, as well as the core competencies and experiences of our management team.

***Our Competitive Strengths***

We believe we have the following competitive strengths:

**Leading guest engagement through digital marketing and technology platforms.** Through our Stubs loyalty programs, we have developed a customer database of approximately 39 million households, representing an estimated 78 million individuals. Our digital marketing and technology platforms allow us to engage with these customers frequently,

efficiently and on a very personalized level. We believe personalized data drives increased engagement, resulting in higher attendance.

**Leading market share in important, affluent and diverse markets.** As of December 31, 2025, across our three biggest metropolitan markets in the United States—New York, Los Angeles and Chicago, representing 17% of the country’s total box office—we held a 45% combined market share. We operated theatres located in the top 25 U.S. markets, holding the #1 or #2 position in 18 of those 25 markets based on box office revenue. As of December 31, 2025, we were the market leader in Sweden, Norway, and Finland; the #2 operator in the United Kingdom, Ireland, Italy, Spain and Portugal, and the #4 operator in Germany. We believe our strong presence in these top markets makes our theatres highly visible and therefore strategically more important to content providers, who rely on the large audiences and marketing momentum provided by major markets to drive opinion-making and deliver a movie’s overall box office results.

We also have a diversified footprint with complementary global geographic and guest demographic profiles. We have theatres in more densely populated major metropolitan markets, where there is also a scarcity of attractive retail real estate opportunities, as well as complementary suburban and rural markets. Guests from different demographic and geographic profiles have different tastes in movies, and we believe by broadening our geographic base, we can help mitigate the impact of film genre volatility on our box office revenues.

**Well located and highly productive theatres.** Our theatres are generally located in the top retail centers across the U.S. We believe this provides for long-term visibility and higher productivity and is a key element in the success of our enhanced food and beverage and more comfort and convenience initiatives. Our location strategy, combined with our strong major market presence, enable us to deliver industry-leading theatre-level productivity. During the year ended December 31, 2025, 8 of the 10 highest grossing theatres in the U.S. were AMC theatres, according to data provided by Comscore. During the same period, AMC’s U.S. markets average total revenues per theatre was approximately \$7.0 million. This per unit productivity is important not only to content providers, but also to developers and landlords, for whom per location and per square foot sales numbers are critical measures.

Our AMC Classic branded theatres are located primarily in smaller, suburban and rural markets, which affects total revenues per theatre. However, in general, theatres located in smaller suburban and rural markets tend to have less competition and a lower cost structure.

In our International markets, many theatres are located in top retail centers in major metropolitan markets with high visibility. We believe that deploying our proven strategic initiatives in these markets will help drive attendance and greatly improve productivity. Other theatres are in larger and mid-sized cities and towns in affluent regions.

**Deployment of unique pricing structures to enhance revenue.** We have developed a dedicated pricing department and, as a result, we have deployed several different strategic pricing structures that have increased revenue and profitability.

A-List is our monthly subscription-based tier of our Stubs loyalty program. This program offers guests admission to movies at AMC up to four times per week, including multiple movies per day and repeat visits to movies. We also offer Stubs members 50% off tickets on Tuesdays and Wednesdays.

### *Sources of Revenue*

**Box Office Admissions and Film Content.** Box office admissions are our largest source of revenue. We predominantly license theatrical films from distributors owned by major film production companies and from independent distributors on a film-by-film and theatre-by-theatre basis. Film exhibition costs are based on a share of admissions revenues and are accrued based on estimates of the final settlement pursuant to our film licenses. These licenses typically state that rental fees are based on the box office performance of each film, though in certain circumstances and less frequently, our rental fees are based on a mutually agreed settlement rate that is fixed. In some European territories, film rental fees are established on a weekly basis and some licenses use a per capita agreement instead of a revenue share, paying a flat amount per ticket.

During the year ended December 31, 2025, films licensed from our seven largest movie studio distributors based on revenues accounted for approximately 83% of our U.S. admissions revenues, which consisted of Disney, Warner Bros., Universal, Sony, Paramount, 20th Century Studios, and Lionsgate Films. In Europe, approximately 76% of our box office revenue came from films attributed to our five largest movie distributor groups, which consisted of

[Table of Contents](#)

Disney, Universal, Warner Bros., Paramount, and Sony. Our revenues attributable to individual distributors may vary significantly from year to year depending upon the commercial success of each distributor's films in any given year.

During 2023 we, along with our sub-distribution partners, served as the theatrical distributor for two theatrical releases: *TAYLOR SWIFT | THE ERAS TOUR* and *RENAISSANCE: A FILM BY BEYONCÉ*. During 2024, we distributed *USHER: RENDEZVOUS IN PARIS* and *BILLIE EILISH: HIT ME HARD AND SOFT*, an album listening experience. In 2025, we distributed *TAYLOR SWIFT | THE OFFICIAL RELEASE PARTY OF A SHOWGIRL*, the biggest album-debut event in cinema history, domestically and globally. The distribution business is a newer source of revenue.

**Food and Beverage.** Food and beverage sales are our second largest source of revenue after box office admissions. We offer enhanced food and beverage products that include meals, healthy snacks, premium liquor, beer and wine options, and other gourmet products. Our long-term growth strategy calls for investment across a spectrum of enhanced food and beverage formats, ranging from simple, less capital-intensive food and beverage menu improvements to the development of dine-in options.

We currently operate 48 Dine-In-Theatres in the U.S. and three Dine-In-Theatres in Europe that deliver chef-inspired menus with seat-side or delivery service to luxury recliners with tables. Our recent Dine-In-Theatre concepts are designed to capitalize on the latest food service trend, the fast and casual eating experience.

MacGuffins give us an opportunity to offer alcohol to our legal age customers in our U.S. markets. As of December 31, 2025, we offered alcohol in approximately 386 theatres in our U.S. markets and 221 theatres in our International markets and continue to explore expansion globally.

We offer ready-to-eat and microwaveable AMC Theatres Perfectly Popcorn products that are available for purchase in well-known grocery stores around the country or on-line via Amazon.com. During 2024, we rolled out AMC Cinema Sweets™, our line of premium gourmet candy. AMC Cinema Sweets are available to moviegoers at AMC concession stands throughout the United States.

**Theatrical Exhibition Industry and Competition**

**U.S. markets.** In the U.S., the movie exhibition business is large and mature. We believe it is the quality of the movie-going experience that will define our future success. Whether through enhanced food and beverage options (Food and Beverage Kiosks, Marketplaces, Coca-Cola Freestyle, MacGuffins or Dine-in-Theatres), more comfort and convenience (recliner seating, open-source internet ticketing, reserved seating), engagement and loyalty (AMC Stubs®, mobile apps, social media, or AIC) or sight and sound (digital and laser projection, 3D, Dolby Cinema™ at AMC, IMAX®, SCREENX, 4DX, or other PLF screens), it is the ease of use and the amenities that these innovations bring to customers that we believe will help drive sustained profitability in the years ahead.

Preliminary estimates indicate that North American box office revenues were approximately \$8.9 billion for 2025, up approximately 1.5% compared with 2024.

The following table represents information about the U.S./Canada exhibition industry obtained from the National Association of Theatre Owners, with the exception of box office revenues for calendar years 2024, 2023, 2022, and 2021 obtained from Comscore. See Management's Discussion and Analysis of Financial Condition and Results of Operations under Part II, Item 7 of this Form 10-K for information regarding our operating data:

Calendar Year	Box Office Revenues (in millions)	Attendance (in millions)	Average Ticket Price
2024	\$ 8,746	760	\$ 11.51
2023	9,034	833	10.84
2022	7,454	708	10.53
2021	4,544	447	10.17
2020	2,205	240	9.18
2019	11,400	1,244	9.16
2018	11,880	1,304	9.11
2017	11,091	1,236	8.97
2016	11,372	1,314	8.65

[Table of Contents](#)

Based on information obtained from Comscore, we believe that the three largest exhibitors, in terms of U.S./Canada box office revenue (AMC, Regal Entertainment Group, and Cinemark Holdings, Inc.) generated approximately 54% of the box office revenues in 2025.

**International markets.** Movie-going is a popular leisure activity with high penetration across key geographies in our International markets. Theatre appeal has proven resilient to competition for consumers' leisure spending and to recessionary periods. The European market lags the U.S. market across a number of factors, including annual spend per customer, number of IMAX® screens, and screens per capita, which causes us to believe that the deployment of our customer initiatives will be successful in these markets. Additionally, our European markets are more densely populated and operate with fewer screens per one million people, making the screens more valuable.

U.S. films generate the majority of the box office in Europe, but movie-goers in specific geographies also welcome locally produced films with local actors and familiar story lines which can mitigate film genre attendance fluctuations.

The following table provides information about the exhibition industry attendance for the International markets where we operate obtained from territory industry trade sources; see Management's Discussion and Analysis of Financial Condition and Results of Operations under Part II, Item 7 of this Form 10-K for information regarding our operating data:

(In millions)	Calendar Year				
	2025	2024	2023	2022	2021
United Kingdom	123.5	126.5	124.4	117.5	74.6
Germany	91.3	89.0	96.3	78.6	42.5
Spain	65.1	71.0	75.9	59.8	41.5
Italy	71.6	74.5	75.0	47.9	26.6
Sweden	9.7	10.4	11.8	10.4	6.1
Ireland	10.6	11.8	11.6	10.7	6.1
Portugal	10.6	11.4	11.2	9.2	5.3
Norway	8.4	8.1	9.3	8.8	5.6
Finland	6.3	6.8	7.2	5.8	3.4
Total	397.1	409.5	422.7	348.7	211.7

**Competition.** Our theatres are subject to varying degrees of competition in the geographic areas in which they operate. Competition is often intense with respect to attracting patrons, licensing motion pictures and finding new theatre sites. Where real estate is readily available, it is easier to open a theatre near one of our theatres, which may adversely affect operations at our theatre. However, in certain of our densely populated major metropolitan markets, we believe a scarcity of attractive retail real estate opportunities enhances the strategic value of our existing theatres. We also believe the complexity inherent in operating in these major metropolitan markets is a deterrent to other less sophisticated competitors, protecting our market share position.

The theatrical exhibition industry faces competition from other forms of out-of-home entertainment, such as concerts, amusement parks and sporting events, and from other distribution channels for filmed entertainment, such as video streaming services, premium video on demand ("PVOD"), cable television, pay-per-view, and home video systems, as well as from all other forms of entertainment.

We believe movie-going is a compelling consumer out-of-home entertainment experience. Movie theatres currently garner a relatively small share of overall consumer entertainment time and spend, and our industry benefits from available capacity to satisfy additional consumer demand.

### ***Seasonality***

Our revenues are dependent upon the timing of motion picture releases by distributors. The most marketable motion pictures are usually released during the summer and the year-end holiday seasons. Therefore, our business is seasonal, with higher attendance and revenues generally occurring during the summer months and holiday seasons.

### ***Regulatory Environment***

Our theatres in the U.S. must comply with Title III of the Americans with Disabilities Act (“ADA”). Compliance with the ADA requires that public accommodations, including websites and mobile apps for such accommodations, be accessible to individuals with disabilities and that new construction or alterations are made to conform to accessibility guidelines. Non-compliance with the ADA could result in the imposition of injunctive relief, fines, and awards of damages to private litigants and additional capital expenditures to remedy such noncompliance. As an employer covered by the ADA, we must make reasonable accommodations to the limitations of employees and qualified applicants with disabilities, provided that such reasonable accommodations do not pose an undue hardship on the operation of our business. In addition, many of our employees are covered by various government employment regulations, including minimum wage, overtime and working conditions regulations. In Europe, all territories have similar national regulations relating to disabilities.

Our operations also are subject to federal, state and local laws regulating such matters as construction, renovation and operation of theatres, as well as wages and working conditions, citizenship, health and sanitation requirements, consumer and employee privacy rights, and licensing, including alcoholic beverage sales. We believe our theatres are in material compliance with such requirements.

We own and operate theatres and other properties in the United States, United Kingdom, Spain, Italy, Germany, Portugal, Ireland, Sweden, Finland, Norway, and Denmark, which are subject to various federal, state and local laws and regulations. Certain of these laws and regulations, including those relating to environmental protection, may impose joint and several liability on certain statutory classes of persons for the costs of investigation or remediation of contamination, regardless of fault or the legality of original disposal. We believe our theatres are in material compliance with such requirements.

Additionally, there are multiple sustainability and Environmental, Social, and Governance (“ESG”) disclosure regulations taking effect in the next several years in the United States and Europe, including the California Climate Accountability Package, the Corporate Sustainability Reporting Directive, and numerous city, county, and state regulations covering commercial building energy usage and emissions.

### ***Human Capital Resources***

**Our People.** AMC promotes a healthy culture where people are encouraged to achieve their personal best and work together with integrity and openness to change. AMC associates are core to our commitment to deliver the best theatrical experience in the world. They uphold AMC’s mission of focusing on the guest experience where excellent customer service is complemented with amazing food and beverage, comfort, and premium sight and sound.

As of December 31, 2025, we employed a total of 33,311 associates consisting of 2,931 full-time and 30,380 part-time associates, down from a total of 33,382 associates consisting of 2,915 full-time and 30,467 part-time associates as of December 31, 2024. Among our 33,311 associates, we employed 23,777 in the United States and 9,534 in our International markets.

**Talent Acquisition, Development and Retention.** Critical to our operation is the hiring, development, and retention of qualified associates who support our guest-focused mission. Acquiring the right talent at speed and scale is a core capability that we regularly monitor and manage, given the need to rapidly staff our frontline operations at certain times of the year. Once hired, we train for success, creating experiences and programs that promote performance, growth, and long-term career opportunities. Programs such as the Leadership Academy, Leadership Institute for Tomorrow, and Hallmark at AMC, along with Incredible Leadership at Odeon, are designed to upskill and enhance managerial capability, facilitate quality execution of our business initiatives, drive guest satisfaction, and increase return on investment.

We continue to advance the accessibility and consistency of our leadership development efforts by embracing training through virtual conferencing tools. Through our internally developed virtual instructors, we provide engaging

## [Table of Contents](#)

and scalable development experiences that reach qualified associates across all locations. Furthermore, our training includes compulsory modules that meet regulatory requirements, policy enforcement and best practices to adhere to employment laws, practical tactics for safety and security, and compliance with anti-corruption regulations. Our measures to maintain a holistic view of the associate experience support the needs of our associates through engagement opportunities, including recognition programs and events.

**Belonging for All.** Belonging for All is a core cultural value and key driver to our success. AMC's commitment to fostering Belonging for All enables us to maintain a global workforce as diverse as the guests we serve and the movies we show on our screens. Through a multi-channel approach, we promote cultural humility and provide continuous learning opportunities that directly contribute to business performance. AMC is guided by six advisory councils, which help shape a workplace where all employees are encouraged to bring their authentic selves to work and contribute to our success. By appointing officers as Executive Sponsors of these councils, we ensure senior leadership and accountability. Odeon maintains nine advisory forums across Europe that reflect the diversity of the communities it serves and support engagement on a broad range of associate needs. This approach has enhanced openness, reinforced the value of diversity, and strengthened our business outcomes. Our culture thrives as we embrace diversity and lead with fairness, creating a more inclusive workplace for all.

Additionally, our work has been recognized externally: AMC earned certification as a **Great Place to Work** from 2024 through 2026, achieved 11 consecutive years as one of the **Best Places to Work** for disability inclusion through the Disability Equality Index, was named one of Forbes **Best Large Employers 2025** and **Best Employers for Women** from 2024 through 2025, recognized by Newsweek in 2025 as one of **America's Best of the Best**, awarded by Time Magazine from 2024 through 2025 as **America's Best Companies** in the Mid-Size category, and commended as a **50/50 Women on Boards**.

**Compensation, Benefits, Safety and Wellness.** We offer market competitive salaries and wages, generally targeting market median, to attract and retain qualified talent. Our compensation programs are designed to drive engagement and support business objectives through pay-for-performance and incentive opportunities that reward the achievement of operational and financial goals. As part of our ongoing efforts to monitor and maintain pay equity, we partner with advisory companies to conduct statistical pay analysis using industry best practices to ensure pay programs are administered equitably. We also use the services of independent compensation consulting firms to advise on matters including market competitiveness and program design.

In addition, we prioritize and invest in our associate's health and welfare. Our "LiveWell" philosophy is based on a whole person approach to physical, fiscal, and emotional wellness tailored to the diverse needs of our global workforce in each country we operate. Examples include global Employee Assistance Programs, Cuckoo application, and Mental Health First Aiders training. Comprehensive health and welfare benefits for eligible associates are supplemented with specific programs to manage or improve common health conditions, a variety of voluntary benefits to satisfy individual needs, and paid time off.

Our commitment to the safety and health of our associates continues to be a top priority as demonstrated by our ongoing professional training and awareness campaigns. All Theatre Support Center and Theatre Leadership associates complete in-person and online courses focused on professionalism, safety, and security that meet or exceed regulatory requirements and best practices as determined by the Equal Employment Opportunities Commission, Payment Card Industry, SEC, and Sarbanes-Oxley Act.

### **Available Information**

We make available free of charge on our website ([www.amctheatres.com](http://www.amctheatres.com)) under "Investor Relations" / "Financial Performance"/ "SEC Filings," annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy materials on Schedule 14A and amendments to those reports as soon as reasonably practicable after we electronically file or furnish such materials with the SEC. The contents of our website are not incorporated into this report. The SEC maintains a website ([www.sec.gov](http://www.sec.gov)) that contains reports, proxy and information statements and other information about the Company.

**Information about our Executive Officers**

The following table sets forth certain information regarding our executive officers and key employees as of February 23, 2026:

<b>Name</b>	<b>Age</b>	<b>Position(s) Held</b>
Adam M. Aron	71	Chairman of the Board, Chief Executive Officer and President
Sean D. Goodman	60	Executive Vice President, International Operations, Chief Financial Officer and Treasurer
Daniel Ellis	57	Executive Vice President, Chief Operations and Development Officer
Nikkole Denson-Randolph	54	Senior Vice President, U.S. Chief Content Officer
Ellen Copaken	49	Senior Vice President, Business Development
Chris A. Cox	59	Senior Vice President, Chief Accounting Officer
Carla C. Chavarria	60	Senior Vice President, Chief Human Resources Officer
Edwin Gladbach	53	Senior Vice President, General Counsel and Secretary
Mark Way	54	President, AMC Europe & Managing Director, Odeon Cinema Group

All our current executive officers hold their offices at the pleasure of our board of directors, subject to rights under their respective employment agreements in some cases. There are no family relationships between or among any executive officers.

*Mr. Adam Aron* has served as Chief Executive Officer, President and a director of the Company since January 2016, and as Chairman of the Board since July 2021. From February 2015 to December 2015, Mr. Aron was Chief Executive Officer of Starwood Hotels and Resorts Worldwide, Inc. and served on its board of directors from 2006 to 2015. Since 2006, Mr. Aron also has served as Chairman and Chief Executive Officer of World Leisure Partners, Inc., which he founded and which serves as a personal consultancy for matters related to travel and tourism, high-end real estate development, and professional sports. Mr. Aron served as Chief Executive Officer and Co-Owner of the Philadelphia 76ers from 2011 to 2013, and remained an investor in the team through early 2023. From 2006 to 2015, Mr. Aron served as Senior Operating Partner of Apollo Management L.P., a leading private equity investor. During the past ten years, Mr. Aron has previously served on the board of directors of Norwegian Cruise Line Holdings, Ltd., Centricus Acquisitions Corp, Prestige Cruise Holdings Inc., and HBSE (which is a private company that owns the NHL's New Jersey Devils and the NBA's Philadelphia 76ers). Mr. Aron received a Master's of Business Administration degree with distinction from The Harvard Business School and a Bachelor of Arts degree cum laude from Harvard College. Mr. Aron brings to the Board significant business and executive leadership experience, including valuable insight into consumer services. In a variety of industries, he has more than 30 years of experience as a Chief Executive Officer, more than 35 years of experience as a corporate director, and more than 45 years of consumer-engagement experience.

*Mr. Sean D. Goodman* is AMC's Executive Vice President, Chief Financial Officer and Treasurer. Mr. Goodman's areas of responsibility at AMC include international operations, information technology, and procurement. Prior to joining AMC in December 2019, Mr. Goodman was the Chief Financial Officer of Fortune 500 retailer Asbury Automotive Group, Inc.. Earlier in his career, Mr. Goodman held Chief Financial Officer roles at Unifi, Inc. and Landis+Gyr, AG. In addition, Mr. Goodman served in strategy and finance leadership roles at Fortune 20 retailer The Home Depot, Inc. Mr. Goodman began his career as an investment banker with Morgan Stanley, Inc. and in various consulting and accounting positions with Deloitte LLP. Mr. Goodman has a Master's of Business Administration degree from The Harvard Business School and a Bachelor of Business Science Degree (with honors) from the University of Cape Town in South Africa. Mr. Goodman is a certified public accountant.

*Mr. Daniel Ellis* has served as the Executive Vice President, Chief Operations and Development Officer since March 2022. From March 2020 to March 2022, he served as Senior Vice President Development & International. From December 21, 2016 to March 2020, he served as Senior Vice President, Domestic Development. From August 2011 until December 2016, Mr. Ellis was Senior Vice President, General Counsel and Secretary of Carmike Cinemas, Inc. From 1999 until 2011, Mr. Ellis served in several roles with Lodgian, Inc., including as President, Chief Executive Officer, and a member of the Board of Directors from 2009 through 2010 and Senior Vice-President, General Counsel and Secretary from 2002 through 2009. Prior to joining Lodgian, Mr. Ellis was engaged in private law practice and also served as an Assistant District Attorney for the State of Georgia. Mr. Ellis holds a Bachelor of Business Administration from Georgia Southern University, a Master's of Business Administration from Mercer University, and a Juris Doctorate degree from the University of Mississippi.

[Table of Contents](#)

*Ms. Nikkole Denson-Randolph* has served as AMC's Senior Vice President, U.S. Chief Content Officer since February 2025, overseeing AMC's U.S. film programming, content acquisition, and movie strategy initiatives, along with AMC's studio and creative community relationships. Prior to her current position, Ms. Denson-Randolph served as AMC's Senior Vice President of Content Strategy & Inclusive Programming from 2020 to 2025, Vice President of Content Strategy & Inclusive Programming from 2018 to 2020, and Vice President, Alternative & Special Content from 2009 until 2018. Before joining AMC, Ms. Denson-Randolph served as the Director of Business Development for Starbucks Coffee Company's entertainment group from 2004 to 2009. Ms. Denson-Randolph also previously served as President of Magic Johnson Entertainment and Vice President of Magic Johnson Enterprises. She earned her Bachelor of Arts from the University of California at Davis. In 1995, she obtained a Doctor of Jurisprudence from The University of San Francisco and has been a member of the California State Bar since 1996.

*Ms. Ellen Copaken* has served as Senior Vice President, Business Development since November 2025 where she focuses on partnerships and new revenue channels. She most recently served as Senior Vice President, Marketing of AMC from August 2023 to November 2025. Between February 2022 and August 2023, Ms. Copaken served as Vice President, Growth Strategy and led all aspects of AMC's Perfectly Popcorn home popcorn product launch. Prior to joining AMC, Ms. Copaken served as Partner at global innovation consulting firm, Sterling Rice Group, where she led client relationships and growth strategy engagements in foodservice, retail, consumer package goods and hospitality industries. Previously, she worked in marketing leadership roles for Frito-Lay, PepsiCo and Hostess Brands in general management, innovation and brand management. During her time in the consumer-packaged goods industry, she launched dozens of new food and beverage products in grocery, retail and restaurant/foodservice. Ms. Copaken has a Bachelor of Arts from University of Pennsylvania and a Master's of Business Administration from The Wharton School.

*Mr. Chris A. Cox* has served as Senior Vice President, Chief Accounting Officer of AMC since June 2010. Prior thereto Mr. Cox served as Vice President and Chief Accounting Officer since May 2002. Prior to May 2002, Mr. Cox had served as Vice President and Controller since November 2000. Previously, Mr. Cox had served as Director of Corporate Accounting for the Dial Corporation from December 1999 until November 2000. Prior to Dial Corporation, Mr. Cox held various positions at PwC LLP. Mr. Cox holds a Bachelor of Business Administration in Accounting and Finance degree from the University of Iowa.

*Ms. Carla C. Chavarria* has served as Senior Vice President, Chief Human Resources Officer of AMC since January 2019 and Senior Vice President, Human Resources of AMC since January 2014. Ms. Chavarria served as Vice President, Human Resources Services from September 2006 to January 2014. Prior thereto, Ms. Chavarria served as Vice President, Recruitment and Development from April 2005 to September 2006. Ms. Chavarria's prior experience includes human resources manager and director of employment practices. Ms. Chavarria holds a B.S. from The Pennsylvania State University.

*Mr. Edwin Gladbach* has served as Senior Vice President, General Counsel & Secretary of AMC since October 2025. He was previously Vice President, Interim General Counsel & Secretary of AMC from March 2025 until October 2025 and Vice President, Legal and Assistant Secretary from February 2009 until March 2025. Prior to joining AMC, Mr. Gladbach was Senior Counsel at Interstate Bakeries Corporation, the maker of Wonder bread and Hostess snack cakes, and an associate at the law firm of Shook, Hardy & Bacon LLP. Mr. Gladbach holds a Bachelor of Science degree in Agricultural Economics and a Juris Doctorate from the University of Missouri—Columbia.

*Mr. Mark Way* has served as Managing Director for Odeon Cinemas Group and President of AMC Europe, based in London, since December 2016, being appointed immediately following the acquisition by AMC. Prior to taking on this role, Mr. Way served as Chief Financial Officer for Odeon & UCI Cinemas from September 2014 when he joined the business. Before Odeon, he spent 17 years in a variety of senior finance and development roles at Hilton Worldwide. This included serving as Senior Vice President Finance Global Operations from 2009 to 2014 and SVP Finance International Operations from 2006 to 2009. Mr. Way is a Chartered Accountant having qualified with Deloitte where he spent the early part of his career and graduated from Oxford University with a BA Hons after studying Politics, Philosophy and Economics.

**Item 1A. Risk Factors.**

The following is a summary list of risk factors:

### **Financial Risks**

- absent significant increases in revenues and attendance, our ability to obtain additional liquidity, which if not realized or is insufficient, likely would result in us seeking an in-court or out-of-court restructuring of our liabilities, and in the event of such future liquidation or bankruptcy proceeding, holders of our Common Stock and other securities would likely suffer a total loss of their investment;
- our substantial level of indebtedness and our current liquidity constraints could adversely affect our financial condition and our ability to service our indebtedness, to pre-pay debt, and to refinance debt and to do so with comparable interest rates or other favorable terms, and our ability to take advantage of certain business opportunities, which could negatively impact the ability of investors to recover their investment in our Common Stock;
- risks relating to impairment losses, including with respect to goodwill and other intangibles, and theatre and other closure charges;
- limitations on the availability of capital or poor financial results may prevent us from deploying strategic initiatives; and
- we are currently not paying dividends and in the future may not generate sufficient cash flows or have sufficient restricted payment capacity under the indentures governing our debt securities to pay dividends on our Common Stock.

### **Operational Risks**

- risks relating to motion picture production and theatrical performance, including increases in alternative film delivery methods, including streaming services or other forms of entertainment;
- intense competition in the geographic areas in which we operate among exhibitors or from other forms of entertainment;
- our lack of control over distributors of films;
- shrinking exclusive theatrical release windows or release of movies to theatrical exhibition and streaming platforms on the same date, and the production and theatrical release of fewer movies as a consequence of labor stoppages, increased cost of production, decreased consumer demand, or changes in strategic focus of studios;
- failures, unavailability or security breaches of our information systems;
- dependence on key personnel for current and future performance and our ability to attract and retain senior executives and other key personnel, including in connection with any future acquisitions;
- supply chain disruptions, labor shortages, and inflation may negatively impact our operating results;
- our ability to achieve expected synergies, benefits and performance from our strategic theatre acquisitions and strategic initiatives;
- the availability and/or cost of energy in Europe may negatively impact our operating results;
- optimizing our theatre circuit through new construction and the transformation of our existing theatres may be subject to delay and unanticipated costs;
- the risk of severe weather events or other events caused by climate change disrupting or limiting operations; and
- incorporating artificial intelligence technologies into some of our operations, which may present operational and reputational risks.

### **Regulatory Risks**

- general and international economic, political, regulatory, social and financial market conditions, including potential economic recession, inflation, and other risks that may negatively impact the discretionary income of moviegoers and our operating revenues and attendance levels;
- increased costs in order to comply or resulting from a failure to comply with governmental regulation, including the GDPR and all other current and pending privacy and data regulations in the jurisdictions where we have operations;
- changes in tax rates, adoption of new tax legislation, and disagreements with tax authorities;

## [Table of Contents](#)

- legal regimes governing our international business operations could require insolvency proceedings;
- review by antitrust authorities in connection with acquisition opportunities; and
- the potential for political, social, or economic unrest, trade disputes, terrorism, hostilities, cyber-attacks or war, including the conflict between Russia and Ukraine and other international conflicts.

### **Risks Related to our Shares**

- there has been significant recent dilution and there may continue to be additional future dilution of our Common Stock, which could adversely affect the market price of shares of our Common Stock;
- the market prices and trading volumes of our shares of Common Stock have experienced, and may continue to experience, extreme volatility, which could cause purchasers of our Common Stock to incur substantial losses;
- the risk of a “short squeeze” due to a sudden increase in demand for shares of our Common Stock that largely exceeds supply and/or focused investor trading in anticipation of a potential short squeeze has led to, may be currently leading to, and could again lead to, extreme price volatility in shares of our Common Stock;
- there is no guarantee that our retail stockholders will continue to support AMC in the future, and negative sentiment among AMC’s retail stockholder base in the future could have a material adverse impact on the market price of the Common Stock and investor’s investment therein;
- information available in public media that is published by third parties, including blogs, articles, online forums, message boards and social and other media may include statements not attributable to the Company and may not be reliable or accurate;
- future offerings of debt, which would be senior to our Common Stock upon liquidation, and/or other preferred equity securities, which may be senior to our Common Stock for purposes of distributions or upon liquidation, could adversely affect the market price of our Common Stock;
- anti-takeover protections in our Certificate of Incorporation and our Bylaws may discourage or prevent a takeover of our Company, even if an acquisition would be beneficial to our stockholders;
- an issuance of preferred stock could dilute the voting power of the common stockholders and adversely affect the market value of our Common Stock; and
- increases in market interest rates may cause potential investors to seek higher returns and therefore reduce demand for our Common Stock, which could result in a decline in the market price of our Common Stock.

### **Financial Risks**

***In the absence of significant increases in revenues and attendance from current levels, or obtaining significant additional sources of liquidity, an investment in our Common Stock is highly speculative; holders of our Common Stock could suffer a total loss of their investment.***

To remain viable beyond the next twelve months, the Company is expected to require additional sources of liquidity and/or significant increases in revenues and attendance levels, see Liquidity and Capital Resources—For the Year Ended December 31, 2025 Compared to the Year Ended December 31, 2024 included in Part II, Item 7 of this Form 10-K for further information regarding revenue and attendance assumptions. The required amounts of additional liquidity may be material. Although the Company believes that cash flows from operating activities together with existing cash on the balance sheet will be sufficient to meet its material cash requirements over the next twelve months, it is actively continuing to explore additional sources of liquidity to offset the cyclical nature of our industry and other potential fluctuations in operating and market conditions. The Company is unable to determine at this time whether any additional sources of liquidity will be available to it or if available, individually or taken together, will be sufficient to address its potential liquidity needs. There is significant uncertainty as to whether these potential sources of liquidity will be realized or that they will be sufficient to generate the material amounts of additional liquidity that may be required until the Company is able to achieve improved levels of attendance and revenues. Any individual source of liquidity that the Company is pursuing may not be sufficient to address all the Company’s future liquidity requirements, and even if all of the potential sources of liquidity that the Company is pursuing are available, they may not be sufficient to address the Company’s liquidity requirements. Further, any relief provided by lenders, governmental agencies, and business partners may not be adequate and may include onerous terms, scheduled film releases may fail to drive increased revenues and attendance, scheduled releases may be postponed

[Table of Contents](#)

or moved to the home video market, or the attendance levels of, and revenues generated by, our theatres may improve at a level that will not support our substantial amount of indebtedness, rent liabilities or other obligations. Due to these factors, if the Company is unable to obtain the necessary additional sources of liquidity, an investment in our Common Stock is highly speculative.

Significant impacts on our business caused by changes in the film exhibition industry during the course of and after the COVID-19 pandemic include, and are likely to continue to include, among others: (1) decreased attendance at our theatres, including due to changes in consumer behavior in favor of viewing feature-length movies at home on directly to video streaming or PVID platforms or spending on alternative forms of entertainment, (2) our inability to generate significant cash flows from operating activities if our theatres continue to operate at significantly lower than historical levels, which could lead to a need to raise additional capital to bolster our liquidity and (3) our inability to service our existing and future indebtedness or other liabilities.

Work stoppages by labor unions such as the Writers Guild of America and Screen Actors Guild–American Federation of Television and Radio Artists have had an impact upon the production pipeline for theatrical releases in the past and, to the extent they occur again, may impact movie production in the future. New collective bargaining agreements with labor unions may lead to increased costs to create content, which could cause studios to demand greater fees for the exhibition of their motion pictures, or further reduce the amount of future theatrical releases.

In the event the Company's revenues do not increase to at least pre-COVID-19 levels, we would seek to negotiate with creditors changes to our balance sheet liabilities and continue to take steps to reach agreements with our landlords to reduce or abate our rent obligations. Ultimately, if revenues do not improve and we are unsuccessful in restructuring our liabilities, we would face the risk of a future liquidation or bankruptcy proceeding, in which case holders of the Company's Common Stock would likely suffer a total loss of their investment.

***Our substantial level of indebtedness and liquidity constraints could adversely affect our financial condition and our ability to service our indebtedness, which could negatively impact an investor's ability to recover their investments in the Common Stock.***

We have a substantial amount of indebtedness, which requires significant interest payments. As of December 31, 2025, the carrying value of our corporate borrowings and finance lease liabilities were \$4,038.5 million (\$4,024.2 million aggregate principal amount) and \$52.5 million, respectively. As of December 31, 2025, we also had approximately \$4.0 billion of discounted rental payments under operating leases (with a weighted average remaining lease term of 7.7 years).

Our substantial level of indebtedness and the current constraints on our liquidity could have important consequences, including the following:

- we must use a substantial portion of our cash flows from operating activities to pay interest and principal on our indebtedness, which reduces or will reduce funds available to us for other purposes such as working capital, capital expenditures, other general corporate purposes and potential acquisitions;
- our ability to refinance such indebtedness or to obtain additional financing for working capital, capital expenditures, acquisitions or general corporate purposes may be impaired;
- we are exposed to fluctuations in interest rates because our term loans have variable rates of interest;
- our leverage may be greater than that of some of our competitors, which may put us at a competitive disadvantage and reduce our flexibility in responding to current and changing industry and financial market conditions;
- there are significant constraints on our ability to incur additional debt; and
- we may be more vulnerable to economic downturn and adverse developments in our business.

We and our subsidiaries may be able to incur additional indebtedness in the future, subject to the restrictions and compliance obligations contained in the agreements governing our indebtedness. To the extent new

indebtedness is added to our debt levels, including as a result of satisfying interest payment obligations on certain of our indebtedness with payments-in-kind, the related risks that we now face could intensify.

Our ability to meet our expenses, to remain in compliance with our covenants under our debt instruments and to make future principal and interest payments in respect of our debt depends on, among other factors, our operating performance, competitive developments and financial market conditions, all of which are significantly affected by financial, business, economic and other factors outside of our control. A failure to comply with our covenants or to make required payments under one debt instrument could trigger cross-default provisions under other debt agreements, potentially accelerating the repayment of a significant portion of our outstanding debt. Given current industry and economic conditions, our cash flow may not be sufficient to allow us to pay principal and interest on our debt and meet our other obligations.

To the extent our relationship with lenders is negatively affected by disputes that may arise from time to time, it may be more difficult to seek covenant relief, if needed, or to raise additional funds in the future.

***We may incur future impairment charges to goodwill, other intangibles, or long-lived assets and future theatre and other closure charges.***

We have a significant amount of goodwill on our balance sheet as a result of acquisitions. As of December 31, 2025, goodwill recorded on our consolidated balance sheet totaled \$2,416.1 million. If the market price of our Common Stock declines, if the fair value of our debt declines, or if other events or circumstances change that would more likely than not reduce the fair value of our reporting units below their respective carrying value, all or a portion of our goodwill may be impaired in future periods.

We review long-lived assets, goodwill, indefinite-lived intangible assets and other intangible assets and theatre assets whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. The review for goodwill compares the fair value for each of our reporting units to their associated carrying value. Factors that could lead to impairment of goodwill and intangible assets include adverse industry or economic trends, reduced estimates of future cash flows, and declines in the market price of our Common Stock or declines in the fair value of our debt. Our valuation methodology for assessing impairment requires management to make judgments and assumptions based on historical experience and projections of future operating performance, including estimating the fair value of our corporate borrowings and finance lease liabilities. We may be required to record future charges to earnings during the period in which an impairment of goodwill or intangible assets is determined to exist. During the years ended December 31, 2025, December 31, 2024, and December 31, 2023, we recorded impairment of long-lived asset charges of \$43.5 million, \$72.3 million, and \$106.9 million, respectively. The assets impaired during year 2025 included 47 theatres in the U.S. markets with 560 screens and 20 theatres in the International markets with 159 screens. We did not record any goodwill non-cash impairment charges during the years ended December 31, 2025, December 31, 2024, and December 31, 2023 as we determined it was not more likely than not that the fair value of our reporting units was below their respective carrying values.

***Limitations on the availability of capital and reductions to capital expenditures may delay or prevent deployment of strategic initiatives.***

Implementation of our key strategic initiatives, including premium sight and sound, other upgrades to auditoriums, and food and beverage enhancements require significant capital expenditures. Our gross capital expenditures were approximately \$246.1 million, \$245.5 million, and \$225.6 million for the years ended December 31, 2025, December 31, 2024 and December 31, 2023, respectively. We estimate that our cash outflows for capital expenditures, net of lease incentives, will be approximately \$175.0 million to \$225.0 million for the year ending December 31, 2026 to maintain and enhance operations. A lack of available capital resources due to business performance or other financial commitments could prevent or delay the deployment of innovations in our theatres. We may reduce capital expenditures significantly or seek additional financing or issue additional securities, which may affect the timing and scope of growth strategy. We cannot be certain that we will be able to obtain new financing on favorable terms, or at all. In addition, covenants under our existing indebtedness limit our ability to incur additional indebtedness, and the performance of any additional or improved theatres may not be sufficient to service the related indebtedness that we are permitted to incur.

***We are currently not paying dividends and in the future may not generate sufficient cash flows or have sufficient restricted payment capacity under our Credit Agreement or the indentures governing our debt securities to pay dividends on our Common Stock.***

We are currently not paying a cash dividend. We are only able to pay dividends from our available cash on hand and funds received from our subsidiaries. Our subsidiaries' ability to make distributions to us will depend on their ability to generate substantial cash flows from operating activities. Our ability to pay dividends to our stockholders in the future is subject to the terms of our Credit Agreement (as defined herein) and the indentures governing our indebtedness. Our cash flows from operating activities and ability to comply with restricted payment covenants in our debt instruments will depend on our future performance, which will be subject to prevailing economic conditions and to financial, business and other factors beyond our control. In addition, dividend payments are not mandatory or guaranteed, and our board of directors may determine not to resume the payment of dividends. We may not pay dividends as a result of the following additional factors, among others:

- we are not legally or contractually required to pay dividends;
- even if we determine to resume paying cash dividends, the actual amount of dividends distributed and the decision to make any distribution is entirely at the discretion of our board of directors and future dividends, if any, will depend on, among other things, our results of operations, cash requirements, financial condition, business opportunities, provisions of applicable law and other factors that our board of directors may deem relevant;
- the inability to deduct all or significant portions of our interest expense for tax purposes, will ultimately increase the need to generate revenues to support our capital structure;
- the amount of dividends distributed is and will be subject to contractual restrictions under the restrictive payment covenants contained in the Credit Agreement, the indentures governing our debt securities and the terms of any other outstanding or future indebtedness incurred by us or any of our subsidiaries; and
- the amount of dividends distributed is subject to state law restrictions.

**Operational Risks**

***Our business depends on motion picture production and performance and is subject to intense competition, including increases in alternative film delivery methods or other forms of entertainment.***

Our ability to operate successfully depends upon the availability, diversity and appeal of motion pictures, our ability to license motion pictures and the performance of such motion pictures in our markets. The most attended films are usually released during the summer and the calendar year-end holidays, making our business seasonal. We primarily license first-run motion pictures, the success of which has increasingly depended on the marketing efforts of the major motion picture studios and the duration of the exclusive theatrical release windows. Poor performance of, or any disruption in the production of these motion pictures (including by reason of a strike or lack of adequate financing), a reduction in, or suspension of, the marketing efforts of the major motion picture studios, the choice by distributors to release fewer feature-length movies theatrically, the choice of distributors to release fewer feature-length films as a result of the additional financial burden imposed by tariffs, or the choice to release feature-length movies directly to video streaming or PVD platforms, either in lieu of or on the same date as a theatrical release, could hurt our business and results of operations. Conversely, the successful performance of these motion pictures, particularly the sustained success of any one motion picture, or an increase in effective marketing efforts of the major motion picture studios and extension of the exclusive theatrical release windows, may generate positive results for our business and operations in a specific fiscal quarter or year that may not necessarily be indicative of, or comparable to, future results of operations. As movie studios rely on a smaller number of higher grossing "tent pole" films there may be increased pressure for higher film licensing fees. Our loyalty program and certain promotional pricing also may affect performance and increase the cost to license motion pictures relative to revenue for admission. In addition, a change in the type and breadth of movies offered by motion picture studios and the theatrical exclusive release window may adversely affect the demographic base of movie-goers.

Motion picture production is highly dependent on labor that is subject to various collective bargaining agreements. Studios are party to collective bargaining agreements with a number of labor unions, and failure to reach timely agreements or renewals of existing agreements, may further affect the production and supply of theatrical motion picture content. Use of artificial intelligence ("AI") technology in the filmmaking process has been a significant issue in

recent negotiations between the film studios that supply the movies we exhibit and the various labor unions involved in the filmmaking process, including the writers and screen actors guilds. If studios and labor unions are unable to agree on the parameters of AI technology utilization in the filmmaking process, it could negatively impact the supply of movies available for exhibition in our theatres. Additionally, audience acceptance of movies made utilizing AI technology is not known.

Our theatres are subject to varying degrees of competition in the geographic areas in which we operate. Competitors may be multi-national circuits, national circuits, regional circuits or smaller independent exhibitors. Competition among theatre exhibition companies is often intense with respect to attracting patrons, terms for licensing of motion pictures, and securing or retaining desirable locations.

We also compete with other film and content delivery methods, including video streaming, network, syndicated cable and satellite television, as well as video-on-demand, pay-per-view services, subscription streaming services, and social media platforms. We also compete for the public's leisure time and disposable income with other forms of entertainment, including sporting events, video gaming, social media, amusement parks, live music concerts, live theatre, and restaurants. In addition, new technology, including generative AI, is evolving rapidly and our ability to compete could be adversely affected if our competitors gain an advantage by using such technologies. An increase in the popularity of these alternative film delivery methods and other forms of entertainment could reduce attendance at our theatres, limit the prices we can charge for admission and materially adversely affect our business and results of operations.

***We rely on distributors of motion pictures, over whom we have no control, for the films that we exhibit, and our business may be adversely affected if our access to motion pictures is limited or delayed.***

Our business depends on maintaining good relations with these distributors, as this affects our ability to negotiate commercially favorable licensing terms for first-run films or to obtain licenses at all. With only seven movie studio distributors representing approximately 83% of our U.S. markets' box office revenues in 2025 and five movie studio distributors representing approximately 76% of our International markets' box office revenues in 2025, there is a high level of concentration and continued consolidation in the industry. Our business may be adversely affected if our access to motion pictures is limited or delayed because of deterioration in our relationships with one or more distributors, consolidation in the industry that reduces the supply of films available for theatrical release, or for some other reason. To the extent that we are unable to license a popular film for exhibition in our theatres or if fewer films are produced due to consolidation in the industry, our operating results may be adversely affected.

***Our results of operations will be impacted by shrinking theatrical exclusive release windows and other practices adopted by movie studios.***

Over the last decade, the average theatrical exclusive release window, which represents the time that elapses from the date of a film's theatrical release to the date a film is available to consumers in-home, has decreased from approximately four months to approximately one-and-one half months or less. Additionally, certain movie studios have adopted strategies that have eliminated the theatrical exclusive release window completely. These practices have significantly impacted our revenues and are expected to continue to have an adverse impact on our business and results of operations going forward.

***We rely on our information systems to conduct our business, and any failure to protect these systems against security breaches or failure of these systems themselves could adversely affect our business, results of operations and liquidity and could result in litigation and penalties. Additionally, if these systems fail or become unavailable for any significant period of time, our business could be harmed.***

Potential cybersecurity incidents could interfere with our business and operations. Computer hacking, installation of malware, installation of ransomware, generative AI impersonation, phishing, and spamming attacks against online networking platforms have become more prevalent and more sophisticated. Though it is difficult to determine what, if any, harm may directly result from any specific attack or interruption, such events could also be expensive to remedy, harm our reputation or brands, lead users to lose trust and confidence in our business, and/or result in costly fines, penalties, and costly remediation requirements. We, and others on our behalf, also store "personally identifiable information" ("PII") with respect to employees, vendors, customers, and others. We and our third-party vendors have been subject to, and will likely continue to be subject to, attempts to gain unauthorized access to our and their information systems. None of these attempts has individually or in the aggregate resulted in a cybersecurity

## [Table of Contents](#)

incident with a material impact on our financial condition or results of operations. While we have implemented safeguards to protect the privacy of PII, there is still a risk of a material cybersecurity incident where hackers or others might obtain information, which could result in potentially costly remedial action, as well as potential fines, penalties, lawsuits, and reputational damage. The rapid evolution and increased adoption of AI technologies may also heighten our cybersecurity risks by making cyber-attacks more difficult to detect, contain, and mitigate. Attackers are also increasingly sophisticated and using techniques and tools, including AI, that can circumvent security controls, evade detection and remove forensic evidence. As a result, we may be unable to detect, investigate, remediate or recover from future attacks or incidents, or to avoid a material adverse impact to our systems, information, or business. Additionally, integrating AI into our operations may increase our cybersecurity and data privacy risks.

Furthermore, we rely on our information systems and those of third parties for storing proprietary company information about our products and intellectual property, as well as for processing patron purchases, loyalty program activity, supporting accounting functions and financial statement preparation, paying our employees, and otherwise running our business. The rapid evolution and increased adoption of AI technologies may intensify our and our service providers' cybersecurity risks. In addition, we may need to enhance our information systems to provide additional capabilities and functionality. The implementation of new information systems and enhancements is frequently disruptive to the underlying business of an enterprise. Any disruptions affecting our ability to accurately report our financial performance on a timely basis could adversely affect our business in a number of respects. If we are unable to successfully implement potential future system enhancements, our financial position, results of operations, and cash flows could be negatively impacted.

### ***We depend on key personnel for our current and future performance.***

Our current and future performance depends to a significant degree upon the retention of our senior management team and other key personnel. The loss or unavailability of any member of our senior management team or a key employee could have a material adverse effect on our business, financial condition, and results of operations. We cannot give assurance that we would be able to locate or employ qualified replacements for senior management or key employees on acceptable terms.

### ***Supply chain disruptions, labor shortages, and inflation may negatively impact our operations and operating results.***

We rely on a limited number of suppliers for certain products, supplies and services, including a single U.S. vendor for the warehousing and distribution of most of the products and supplies for our U.S. food and beverage operations. Shortages, delays, or interruptions in the availability of food and beverage items and other supplies to our theatres may be caused by commodity availability; public health crises or pandemics, including resulting lockdowns in areas where goods are manufactured; social or economic unrest, terrorism, hostilities, cyber-attacks or war, including the conflict between Russia and Ukraine and the potential impact of financial and economic sanctions on the regional and global economy; labor issues or other operational disruptions; the inability of our suppliers to manage adverse business conditions, obtain credit or remain solvent; adverse weather conditions; natural disasters; governmental regulation; recalls; or other conditions beyond our control. Such shortages, delays or interruptions could adversely affect the availability, quality, and cost of the items we buy and the operations of our business. Supply chain risk could increase our costs and limit the availability of products that are critical to our operations. If we raise prices in response to increased costs or shortages, it may negatively impact our sales. If we temporarily remove popular food and beverage options without comparable alternatives, we may experience a reduction in sales during the time affected by the shortage or thereafter if our guests change their purchasing habits.

The success of our business depends on our ability to recruit and retain staff members for our theatres. Without proper staffing, wait times to buy tickets and food and beverage are extended and operating hours may be reduced. These conditions may result in a poor guest experience, perhaps causing them to not return in the future. These labor shortages have also required us to raise wages to be competitive in the available workforce.

In addition, we are dependent upon natural gas and electricity to operate our theatres. The cost of natural gas and electricity may fluctuate widely due to economic and political conditions, government policy and regulations, trade disputes, war, or other unforeseen circumstances. Substantial future increases in prices, including the availability and/or cost of energy in Europe, for, or shortages of, natural gas and electricity could have a negative effect on our profitability. There can be no assurance that we can cover these potential cost increases through future pricing actions.

## [Table of Contents](#)

In an inflationary environment, depending on the market conditions in each region or country, we may be unable to raise the prices of our movie tickets or food and beverage products enough to keep up with the rate of inflation, which would reduce our profitability, and continued inflationary pressures could impact our business, financial condition, and results of operations.

### ***Optimizing our theatre circuit through new construction and the transformation of our existing theatres may be subject to delay and unanticipated costs.***

The availability of attractive site locations for new construction is subject to various factors that are beyond our control. These factors include:

- local conditions, such as scarcity of space or increase in demand for real estate, demographic changes and changes in zoning and tax laws; and
- competition for site locations from both theatre companies and other businesses.

We typically require 18 to 24 months in the United States from the time we reach an agreement with a landlord to when a theatre opens. This timeframe may vary in International markets.

In addition, the improvement of our existing theatres through our enhanced food and beverage offerings, recliner seating, and premium sight and sound initiatives is subject to substantial risks, such as difficulty in obtaining permits, landlord approvals and operating licenses (e.g., liquor licenses). We may also experience cost overruns from delays or other unanticipated costs in both new construction and facility improvements. Furthermore, our new sites and transformed locations may not perform to our expectations.

### ***Climate change, adverse weather conditions and natural disasters could adversely affect our theatre operations, sales or financial results.***

Climate change and natural disasters may adversely affect our ability to keep movie theatres open and operational in affected regions and consumer ability to travel to our theatres if they are open. Relative to normal weather conditions, extended severe weather as a result of climate change can close theatres for days due to pervasive power outages, flooding, or wildfires. These severe weather events can also result in delays in the construction of new theatres, interruptions to the availability or increases in the cost of utilities, and shortages in the supply, or increases in the costs of concessions and other supplies required for operations. Additionally, the seasonal timing of severe weather patterns tends to mimic the fluctuation of our sales. With our busy season being around the winter holidays and in the summer, the risk is even greater for extended severe winter storms and increased hurricanes and tornadoes in the summer months. Further, natural disasters can impact the production of the films we show at our theatres, potentially causing delays in release schedules.

### ***We are incorporating AI technologies into some of our operations, which may present operational and reputational risks.***

We have incorporated and intend to continue to incorporate AI technologies, including generative AI (a subset of AI), into our operations. For example, we currently utilize AI to provide our guests better film recommendations and AI chatbots to improve customer service. We are currently using, and expanding, AI in optimizing and better securing internal software applications and certain marketing automation with plans to continue expansion across film booking and other business applications. As with many innovations, AI presents risks and challenges that could adversely impact our business. AI technologies can create accuracy issues, unintended biases, and discriminatory outcomes, or may create content that appears correct but is inaccurate or flawed. If the recommendations, content, or analyses that AI applications produce are or are alleged to be deficient or inaccurate, we could be subjected to competitive harm, potential legal liability, and brand or reputational harm. The legal and regulatory landscape surrounding AI technologies is rapidly evolving and uncertain, including in the areas of intellectual property, cybersecurity, and privacy and data protection. For example, there is uncertainty around the validity and enforceability of intellectual property rights related to the use, development, and deployment of AI technologies. Compliance with new or changing laws, regulations or industry standards relating to AI may impose significant operational costs and may limit our ability to develop, deploy or use AI technologies. There can be no assurance that the measures we have taken to mitigate the potential risks related to AI, including

but not limited to generative AI, will be sufficient. Failure to appropriately respond to this evolving landscape may result in legal liability, regulatory action, or brand and reputational harm.

***Our implementation of AI technologies in guest experience and operations creates risk exposures that could impact our business performance.***

We utilize AI systems for internal applications, automation routines, business processes, and through third-party provided services and products. These AI implementations expose us to several categories of risk.

AI systems may inadvertently generate content that infringes third-party intellectual property. The entertainment industry's complex IP landscape creates heightened risks that AI-generated content could violate licensing agreements or copyright protections and/or require modifications to AI-usage that could limit revenue generation or AI-related operational efficiencies.

Evolving AI regulations may require significant modifications to our guest data usage, algorithmic decision-making processes, and usage of both internal and external AI capabilities. Long-term, it could impact our ability to fully optimize customer interaction systems, potentially impacting our ability to provide personalized guest experiences that drive attendance and food and beverage revenues.

Service disruptions could impair our guest experience systems during peak attendance periods, negatively impacting revenues and customer satisfaction.

Competitors with superior AI-driven guest experience capabilities, operational optimization, or marketing effectiveness could achieve competitive advantages that materially impact our market position in the highly competitive entertainment industry.

**Regulatory Risks**

***General political, social and economic conditions can reduce our operating revenues and attendance.***

Our success depends on general political, social, and economic conditions and the willingness of consumers to spend money at movie theatres. If going to motion pictures becomes less popular or consumers spend less on food and beverage, our operations could be adversely affected. In addition, our operations could be adversely affected if consumers' discretionary income falls as a result of an economic downturn. Geopolitical events, including the threat of regional war, terrorism or cyber-attacks, or widespread health emergencies, such as pandemics or epidemics, could cause people to avoid our theatres or other public places where large crowds are in attendance. Public health crises have in the past, and could in the future, have significant negative impacts on all aspects of our business. In addition, due to our concentration in certain markets, natural disasters such as hurricanes or earthquakes in those markets could adversely affect our overall results of operations.

***We are subject to substantial government regulation, which could entail significant cost.***

We are subject to various federal, state and local laws, regulations and administrative practices both domestically and internationally affecting our business, and we must comply with provisions regulating antitrust, customary health and sanitation standards, equal employment, environmental, licensing for the sale of food and, in some theatres, alcoholic beverages, and data protection and privacy laws, including GDPR, and all other current and pending privacy and data regulations in the jurisdictions where we have operations. Our new theatre openings could be delayed or prevented or our existing theatres could be impacted by difficulties or failures in our ability to obtain or maintain required approvals or licenses. Changes in existing laws or implementation of new laws, regulations and practices could have a significant impact on our business. A significant portion of our theatre level employees are part-time workers who are paid at or near the applicable minimum wage in the theatre's jurisdiction. Increases in the minimum wage and implementation of reforms requiring the provision of additional benefits will increase our labor costs.

We own and operate facilities throughout the United States and various international markets throughout Europe and are subject to the environmental laws and regulations of those jurisdictions, particularly laws governing the cleanup of hazardous materials and the management of properties. We might in the future be required to participate in the cleanup of a property that we own or lease, or at which we have been alleged to have disposed of hazardous materials from one of our facilities. In certain circumstances, we might be solely responsible for any such liability under

## [Table of Contents](#)

environmental laws, and such claims could be material. Additionally, there are multiple sustainability and ESG disclosure regulations taking effect in the next several years in the United States and Europe including the California Climate Accountability Package, the Corporate Sustainability Reporting Directive, and numerous city, county, and state regulations covering commercial building energy usage and emissions. Costs and operational impacts are unknown at this time, but noncompliance with these regulations could carry financial, operational and reputational risks.

In the United States, our theatres must comply with Title III of the ADA. Compliance with the ADA requires that public accommodations, including websites and mobile apps for such public accommodations, “reasonably accommodate” individuals with disabilities and that new construction or alterations made to “commercial facilities” conform to accessibility guidelines unless “structurally impracticable” for new construction or technically infeasible for alterations. Non-compliance with the ADA could result in the imposition of injunctive relief, fines, and an award of damages to private litigants or additional capital expenditures to remedy such non-compliance, any of which could have a material adverse effect on our operations and financial condition. In Europe, all territories have similar national regulations relating to disabilities that our theatres operate in accordance with. Noncompliance with these regulations could carry financial, operational and reputation risks.

***We are subject to complex taxation, changes in tax rates, adoption of new United States, European Union or international tax legislation and disagreements with tax authorities that could adversely affect our business, financial condition or results of operations.***

We are subject to many different forms of taxation in both the United States and in foreign jurisdictions where we operate. Current economic and political conditions make compliance with domestic and international tax and transfer pricing laws and regulations, including in the United States, United Kingdom, and European Union subject to ongoing change. The cost of compliance is high and likely to increase in the future. Any failure on our part to comply with these laws and regulations can result in negative publicity and diversion of management time and effort and could subject us to significant liabilities and other penalties.

***The legal regimes governing our international business operations could require our international subsidiaries or their directors to pursue insolvency proceedings.***

The legal regimes governing certain of our international subsidiaries (including Germany, Spain, Portugal, Norway and Sweden) impose on directors an obligation to pursue insolvency proceedings in certain circumstances. There are various potential triggers including illiquidity, over-indebtedness and inadequate capitalization. If our international subsidiaries were required to (and did) pursue insolvency proceedings, that could in turn trigger events of default under our international senior secured notes and/or have other material adverse effects on our business and financial position, including additional insolvency proceedings.

***We may be reviewed by antitrust authorities.***

Given our size and market share, pursuit of acquisition opportunities that would increase the number of our theatres in markets where we have a leading market share would likely result in significant review by antitrust regulators in the applicable jurisdictions, and we may be required to dispose of theatres in order to complete such acquisition opportunities. As a result, we may not be able to succeed in acquiring other exhibition companies or we may have to dispose of a significant number of theatres in key markets in order to complete such acquisitions.

We operate in a consolidating industry that is scrutinized from time to time for compliance with antitrust and competition laws, including currently dormant investigations into film clearances and joint ventures among competing exhibitors. If we were found to have violated antitrust laws, it could have a material adverse effect on our operations and financial condition.

***Our business is subject to international economic, political and other risks that could negatively affect our business, results of operations and financial condition.***

As a result of our international operations, 23.6% of our revenues were derived from countries outside the United States for the year ended December 31, 2025. The success of our international operations is subject to risks that are beyond our control. Accordingly, our business is subject to risks associated with doing business internationally, including:

- difficulties and costs of staffing and managing international operations among diverse geographies, languages and cultures;
- the impact of regional or country-specific business cycles and economic instability;
- the potential for political, social, or economic unrest, trade disputes, terrorism, hostilities, cyber-attacks or war, including the conflict between Russia and Ukraine and other international conflicts, and adverse changes in political or economic relations with the United States;
- fluctuations in foreign currency exchange rates which could lead to fluctuations in our reported results of operations or result in significant decreases in the value of our international investments as denominated in U.S. Dollars;
- increased foreign interest rates, foreign exchange fees and other bank charges as a result of financing our foreign operations;
- exposure to anti-corruption laws, including the Foreign Corrupt Practices Act and the U.K. Bribery Act, and export-control regulations and economic sanctions regulations, including those promulgated by the Office of Foreign Assets Control, United States Department of Treasury;
- exposure to local economic conditions, labor and employment conditions, and local laws and regulations, including data privacy laws, tariffs, or other trade barriers;
- difficulty in protecting our brand, reputation and intellectual property; and
- restrictions on the ability to obtain or retain licenses required for operation.

If we are unable to manage the complexity of our global operations successfully, it could have a material adverse effect on our business, financial condition and results of operations.

**Risk Related to our Share Issuances**

***There has been significant recent dilution and there may continue to be additional future dilution of our Common Stock, which could adversely affect the market price of shares of our Common Stock.***

From January 1, 2020 through February 18, 2026, the outstanding shares of our Common Stock have increased by 524,339,457 shares (on a Reverse Stock Split adjusted basis) in a combination of at-the-market sales, forward sales, conversion of Series A Convertible Participating Preferred Stock, shareholder litigation settlement, conversion of Class B common stock, conversion of notes, exchanges of notes, transaction fee payments, and equity grant vesting. On March 14, 2023, we held a special meeting of our stockholders and obtained the requisite stockholder approval for the certain amendments to the Company's Third Amended and Restated Certificate of Incorporation to increase the Company's total number of authorized shares of Common Stock and to effectuate a reverse split at a ratio of one share of Common Stock for every ten shares of Common Stock (the "Charter Amendments") and on August 14, 2023, we filed the amendment to our certificate of incorporation implementing the Charter Amendments, effective as of August 24, 2023. In accordance with the Charter Amendments, we increased the total number of authorized shares of Common Stock from 524,173,073 to 550,000,000 shares of Common Stock and effectuated a reverse stock split at a ratio of one share of Common Stock for every ten shares of Common Stock outstanding (the "Reverse Stock Split"). In accordance with the terms of the Certificate of Designations governing the Series A Convertible Participating Preferred Stock, following the effectiveness of the Charter Amendments all outstanding shares of our Series A Convertible Participating Preferred Stock converted into 99,540,642 shares of Common Stock. In addition, as described below, on December 10, 2025, following approval by our stockholders at the Annual Meeting (as defined herein), we increased the total number of authorized shares of Common Stock from 550,000,000 to 1,100,000,000.

[Table of Contents](#)

On July 22, 2024, the Company and certain of its subsidiaries consummated the 2024 Refinancing Transactions pursuant to which Muvico issued \$414.4 million aggregate principal amount of Existing Exchangeable Notes that were exchangeable into shares of Common Stock. On July 1, 2025, the Company and Muvico commenced the 2025 Refinancing Transactions pursuant to which the Company issued 79,800,000 shares of Common Stock in exchange for \$143.0 million aggregate principal amount of Existing Exchangeable Notes. Subsequently, on July 24, 2025, the Company exchanged approximately \$194.4 million aggregate principal amount of Existing Exchangeable Notes for Muvico's New Exchangeable Notes on a dollar-for-dollar basis. On September 30, 2025, \$39.9 million aggregate principal of New Exchangeable Notes were cancelled pursuant to a downward adjustment feature in the New Exchangeable Notes, which represented the maximum possible downward adjustment under the New Exchangeable Notes.

As of December 31, 2025, approximately \$111.6 million aggregate principal amount of Existing Exchangeable Notes were outstanding, including interest paid-in-kind in the form of additional Existing Exchangeable Notes ("PIK Notes") to the holders thereof on December 15, 2025. If the outstanding Existing Exchangeable Notes were converted fully into shares of Common Stock as of December 31, 2025, they would be converted into an aggregate of approximately 22.3 million shares of Common Stock. If the outstanding Existing Exchangeable Notes were converted fully into shares of our Common Stock at maturity, and we were to elect to issue additional Existing Exchangeable Notes as PIK Notes on such outstanding Existing Exchangeable Notes and PIK Notes to the full extent permitted during the life of the Existing Exchangeable Notes (without regard to any limitations on our authorized share capital or on the conversion therein and giving effect to the changes in the applicable make-whole fee over the period), such Existing Exchangeable Notes (including PIK Notes) would be convertible at maturity into an aggregate of approximately 27.8 million shares of Common Stock.

At the Company's 2025 Annual Meeting of Stockholders held on December 10, 2025 (the "Annual Meeting"), the Company's stockholders approved an amendment to the Company's certificate of incorporation to increase the total number of authorized shares of Common Stock from 550,000,000 shares to 1,100,000,000 shares (the "Authorized Share Increase"), which additional shares may be used for at-the-market sales (subject to certain caps on usage of at-the-market sales for the six months following the Annual Meeting pursuant to the terms of the indenture governing the New Exchangeable Notes), exchanges of notes, private placement transactions, equity grant vesting and other dilutive issuances. Accordingly, we may issue additional shares of Common Stock to raise cash to bolster our liquidity, to repay, refinance, redeem or exchange indebtedness (including expenses, accrued interest and premium, if any), for working capital, to finance strategic initiatives and future acquisitions, to settle conversion of the Existing Exchangeable Notes, including any PIK Notes, to settle conversions of the New Exchangeable Notes, or for other purposes. In addition, in connection with the Authorized Share Increase, the New Exchangeable Notes have become exchangeable, and depending on the stock price fixed for exchange, we expect to reserve between 77.1 million and 141.4 million shares of Common Stock to be exchanged for the New Exchangeable Notes. Furthermore, in connection with the 2025 Refinancing Transactions and the issuance of the New Exchangeable Notes, we agreed to pay a consent fee to Consenting Existing Exchangeable Noteholders, in the form of \$15.0 million payable in shares of Common Stock, based on a price determined based on the average of the daily volume weighted average price of our Common Stock for the sixty consecutive trading days commencing on December 22, 2025. Additionally, as consent fees for amending the respective indentures to provide us with greater flexibility to refinance our capital structure, we agreed to pay fees to (i) consenting holders of the New Exchangeable Notes and (ii) consenting holders of Muvico's Senior Secured Notes due 2029 of \$6.25 million and \$18.9 million, respectively. The consent fees are payable in shares of our Common Stock and the number of shares to be issued will be based on the average of the daily volume-weighted average price of shares of our Common Stock for the sixty consecutive trading days commencing December 22, 2025 for the New Exchangeable Noteholders and the thirty consecutive trading days commencing January 29, 2026 for the consenting Muvico Senior Secured Noteholders.

As of February 18, 2026, there were 529,547,465 shares of Common Stock issued and outstanding. We expect to issue additional shares of Common Stock, including Common Stock having an aggregate offering price up to \$150,000,000 sold pursuant to the prospectus supplement we filed with the SEC on February 9, 2026. In addition, as described above, shares of Common Stock may be used to settle exchanges of the Existing Exchangeable Notes and New Exchangeable Notes, including any additional Existing Exchangeable Notes or New Exchangeable Notes or interest paid in-kind by issuing Existing Exchangeable Notes or New Exchangeable Notes, or for other purposes. We may also issue preferred equity securities or securities convertible into, or exchangeable for, or that represent the right to receive, shares of Common Stock or acquire interests in other companies, or other assets by using a combination of cash and shares of Common Stock, or just shares of Common Stock. Additionally, vesting of outstanding awards pursuant to our current and legacy equity compensation programs results in the issuance of new shares of Common Stock, net of any shares

withheld to cover tax withholding obligations upon vesting. Any of these events may significantly dilute the ownership interests of current stockholders, reduce our earnings per share or have an adverse effect on the price of our shares of Common Stock.

We have approximately 246,368,357 authorized shares of Common Stock that have not been issued or reserved for issuance in connection with our employee plans or conversion under our Existing Exchangeable Notes and New Exchangeable Notes. As a result, we may in the future seek to obtain the requisite stockholder approval for the authorization of an additional number of authorized and unissued and unreserved shares of Common Stock, which may be used for at-the-market sales, exchanges of notes, private placement transactions, equity grant vesting and other dilutive issuances. These future issuances may be dilutive and may result in a decline in the market price of our Common Stock. The remaining authorized shares assume that no additional PIK interest is paid on the Existing Exchangeable Notes, that the shares reserved for the New Exchangeable Notes are issued at the Unadjusted Exchange Price (as defined in the indenture governing the New Exchangeable Notes) of \$1.50, that the shares to be issued with the consent fees payable to the Consenting Existing Exchangeable Noteholders and consenting holders of the New Exchangeable Notes are issued at an assumed price of \$1.24, representing the closing sales price of our Common Stock on February 18, 2026, and that the consent fees payable to consenting Muvico Senior Secured Noteholders are issued at an assumed price of \$1.25, representing the floor price. Actual share issuances will vary based on changes in the market price of our Common Stock.

***The market price and trading volume of our shares of Common Stock have experienced, and may continue to experience, extreme volatility, which could cause purchasers of our Common Stock to incur substantial losses.***

The market prices and trading volume of our shares of Common Stock have experienced, and may continue to experience, extreme volatility, which could cause purchasers of our Common Stock to incur substantial losses. For example, during 2025 through February 19, 2026, the market price of our Common Stock has fluctuated from an intra-day low on the New York Stock Exchange (“NYSE”) of \$1.21 per share on February 19, 2026 to an intra-day high of \$4.13 on January 7, 2025. The last reported sale price of our Common Stock on the NYSE on February 19, 2026 was \$1.22 per share. During 2025 through February 19, 2026, daily trading volume ranged from approximately 4,237,100 to 72,240,900 shares.

We believe that the volatility and our market prices have reflected and may continue to reflect market and trading dynamics unrelated to our underlying business, or macro or industry fundamentals, and we do not know how long these dynamics will last.

Extreme fluctuations in the market price of our Common Stock have been accompanied by reports of strong and atypical retail investor interest, including on social media and online forums. The market volatility and trading patterns we have experienced create several risks for investors, including the following:

- the market price of our Common Stock has experienced and may continue to experience rapid and substantial increases or decreases unrelated to our operating performance or prospects, or macro or industry fundamentals, and substantial increases may be significantly inconsistent with the risks and uncertainties that we continue to face;
- factors in the public trading market for our Common Stock may include the sentiment of retail investors (including as may be expressed on financial trading and other social media sites and online forums), the direct access by retail investors to broadly available trading platforms, the amount and status of short interest in our securities, access to margin debt, trading in options and other derivatives on our Common Stock and any related hedging and other trading factors;
- our market capitalization, as implied by various trading prices, currently reflects valuations that diverge significantly from historical valuations, and to the extent these valuations reflect trading dynamics unrelated to our financial performance or prospects, purchasers of our Common Stock could incur substantial losses if there are declines in market prices;
- to the extent volatility in our Common Stock is caused, or may from time to time be caused, as has widely been reported, by a “short squeeze” in which coordinated trading activity causes a spike in the market price of our Common Stock as traders with a short position make market purchases to avoid or to mitigate potential losses, investors purchase at inflated prices unrelated to our financial performance or prospects, and may thereafter suffer substantial losses as prices decline once the level of short-covering purchases has abated; and

## [Table of Contents](#)

- if the market price of our Common Stock declines, investors may be unable to resell shares of our Common Stock at or above the price at which their investment was made. Our Common Stock may continue to fluctuate or decline significantly in the future, which may result in substantial losses.

Future increases or decreases in the market price of our Common Stock may not coincide in timing with the disclosure of news or developments by or affecting us. Accordingly, the market price of our shares of Common Stock may fluctuate dramatically, and may decline rapidly, regardless of any developments in our business. Overall, there are various factors, many of which are beyond our control, that could negatively affect the market price of our Common Stock or result in fluctuations in the price or trading volume of our Common Stock, including:

- actual or anticipated variations in our annual or quarterly results of operations, including our earnings estimates and whether we meet market expectations with regard to our earnings;
- restrictions on our ability to pay dividends or other distributions;
- publication of research reports by analysts or others about us or the motion picture exhibition industry, which may be unfavorable, inaccurate, inconsistent or not disseminated on a regular basis;
- changes in market interest rates that may cause purchasers of our shares to demand a different yield;
- changes in market valuations of similar companies;
- market reaction to any additional equity, debt or other securities that we may issue in the future, and which may or may not dilute the holdings of our existing stockholders;
- additions or departures of key personnel;
- actions by institutional or significant stockholders;
- short interest in our securities and the market response to such short interest;
- the dramatic increase or decrease in the number of individual holders of our Common Stock and their participation in social media platforms targeted at speculative investing;
- speculation in the press or investment community about our company or industry;
- strategic actions by us or our competitors, such as acquisitions or other investments;
- legislative, administrative, regulatory or other actions affecting our business or our industry, including positions taken by the Internal Revenue Service;
- strategic actions taken by motion picture studios such as the shuffling of film release dates;
- investigations, proceedings, or litigation that involve or affect us;
- ongoing impacts upon the industry resulting from the COVID-19 pandemic;
- the occurrence of any of the other risk factors included or incorporated by reference in this Annual Report on Form 10-K; and
- general market and economic conditions.

***A “short squeeze” due to a sudden increase in demand for shares of our Common Stock that largely exceeds supply and/or focused investor trading in anticipation of a potential short squeeze have led to, and could again lead to, extreme price volatility in shares of our Common Stock.***

Investors may purchase shares of our Common Stock to hedge existing exposure or to speculate on the price of our Common Stock. Speculation on the price of our Common Stock may involve long and short exposures. To the extent aggregate short exposure exceeds the number of shares of our Common Stock available for purchase on the open market, investors with short exposure may have to pay a premium to repurchase shares of our Common Stock for delivery to lenders of our Common Stock. Those repurchases may, in turn, dramatically increase the price of shares of our Common Stock until additional shares of our Common Stock are available for trading or borrowing. This is often referred to as a “short squeeze.” A large proportion of our Common Stock has been traded in the past, and may be traded in the future, by short sellers, which may increase the likelihood that our Common Stock will be the target of a short squeeze, and there is widespread speculation that the trading price of our Common Stock has been from time to time the result of a

[Table of Contents](#)

short squeeze. A short squeeze and/or focused investor trading in anticipation of a short squeeze have led to, and could again lead to, volatile price movements in shares of our Common Stock that may be unrelated or disproportionate to our operating performance or prospects and, once investors purchase the shares of our Common Stock necessary to cover their short positions, or if investors no longer believe a short squeeze is viable, the price of our Common Stock may rapidly decline. Investors that purchase shares of our Common Stock during a short squeeze may lose a significant portion of their investment. Investors that purchase in anticipation of a short squeeze that is never realized may also lose a significant portion of their investment. **Under the circumstances, we caution you against investing in our Common Stock, unless you are prepared to incur the risk of losing all or a substantial portion of your investment.**

***Negative sentiment among AMC's retail stockholder base could have a material adverse impact on the market price of our Common Stock and your investment therein.***

Some of our retail investors have referred to themselves as “Apes” on social media and in other forums. Self-proclaimed “Apes” are widely viewed as playing a significant role in the market dynamics that have resulted in substantial increases and volatility in the market price of our Common Stock and other so-called “meme” stocks. See “Risk Factors—Risk Related to our Share Issuances—The market price and trading volume of our shares of Common Stock have experienced, and may continue to experience, extreme volatility, which could cause purchasers of our Common Stock to incur substantial losses.” While AMC and its management have actively sought to foster positive relationships with its significant retail stockholder base as the owners of AMC, and while AMC’s retail stockholder base has been credited favorably with assisting AMC in raising significant capital in the past, there is no guarantee that AMC will be able to continue to benefit from support from its retail stockholder base in the future. Negative investor sentiment could have a material adverse impact on the market price of our Common Stock.

***Information available in public media that is published by third parties, including blogs, articles, online forums, message boards and social and other media may include statements not attributable to the Company and may not be reliable or accurate.***

We have received, and may continue to receive, a high degree of media coverage that is published or otherwise disseminated by third parties, including blogs, articles, online forums, message boards and social and other media. This includes coverage that is not attributable to statements made by our directors, officers or employees. You should read carefully, evaluate and rely only on the information contained in this Annual Report on Form 10-K, the definitive Proxy Statement on Schedule 14A filed on October 24, 2025, the prospectus supplement filed February 9, 2026, the accompanying prospectus or any applicable free writing prospectus or incorporated documents filed with the SEC in determining whether to purchase our shares of Common Stock. Information provided by third parties may not be reliable or accurate and could materially impact the trading price of our Common Stock which could cause losses to your investments.

***Future offerings of debt, which would be senior to our Common Stock upon liquidation, and/or other preferred equity securities, which may be senior to our Common Stock for purposes of distributions or upon liquidation, could adversely affect the market price of our Common Stock.***

In the future, we may attempt to increase our capital resources by making additional offerings of debt or preferred equity securities, including convertible or non-convertible senior or subordinated notes, convertible or non-convertible preferred stock, medium-term notes and trust preferred securities, to raise cash or bolster our liquidity, to repay, refinance, redeem or repurchase indebtedness (including expenses, accrued interest and premium, if any), for working capital, to finance strategic initiatives and future acquisitions or for other purposes. Upon liquidation, holders of our debt securities and lenders with respect to other borrowings will receive distributions of our available assets prior to the holders of our Common Stock. In addition, any additional preferred stock we may issue could have a preference on liquidating distributions or a preference on distribution payments that could limit our ability to make a distribution to the holders of our Common Stock. Since our decision to issue securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of our future offerings. Thus, our stockholders bear the risk of our future offerings potentially reducing the market price of our Common Stock.

***Anti-takeover protections in our certificate of incorporation and bylaws may discourage or prevent a takeover of our Company, even if an acquisition would be beneficial to our stockholders.***

Provisions contained in our certificate of incorporation and bylaws, as amended, as well as provisions of the Delaware General Corporation Law delay or make it more difficult to remove incumbent directors or for a third-party to acquire us, even if a takeover would benefit our stockholders. These provisions include:

- a classified board of directors;
- the sole power of a majority of the board of directors to fix the number of directors;
- limitations on the removal of directors;
- the sole power of the board of directors to fill any vacancy on the board of directors, whether such vacancy occurs as a result of an increase in the number of directors or otherwise;
- the ability of our board of directors to designate one or more series of preferred stock and issue shares of preferred stock without stockholder approval; and
- the inability of stockholders to call special meetings.

Our issuance of shares of preferred stock could delay or prevent a change of control of our company. Our board of directors has the authority to cause us to issue, without any further vote or action by the stockholders, up to 50,000,000 shares of preferred stock, par value \$0.01 per share, in one or more series, to designate the number of shares constituting any series, and to fix the rights, preferences, privileges and restrictions thereof, including dividend rights, voting rights, rights and terms of redemption, redemption price or prices and liquidation preferences of such series. The issuance of shares of preferred stock may have the effect of delaying, deferring or preventing a change in control of our company without further action by the stockholders, even where stockholders are offered a premium for their shares. As of February 18, 2026, 50,000,000 shares of preferred stock are authorized and available for issuance.

Our incorporation under Delaware law, the ability of our board of directors to create and issue a new series of preferred stock or a stockholder rights plan and certain other provisions of our amended and restated certificate of incorporation and amended and restated bylaws, as amended, could impede a merger, takeover or other business combination involving our company or the replacement of our management or discourage a potential investor from making a tender offer for our Common Stock, which, under certain circumstances, could reduce the market value of our Common Stock.

***An issuance of preferred stock could dilute the voting power of holders of our Common Stock and adversely affect the market value of our Common Stock.***

The issuance of shares of preferred stock with voting rights may adversely affect the voting power of the holders of our other classes of voting stock either by diluting the voting power of our other classes of voting stock if they vote together as a single class or by giving the holders of any such preferred stock the right to block an action on which they have a separate class vote even if the action were approved by the holders of our other classes of voting stock.

In addition, the issuance of shares of preferred stock with dividend or conversion rights, liquidation preferences or other economic terms favorable to the holders of preferred stock could adversely affect the market price for our Common Stock by making an investment in the Common Stock less attractive. For example, investors may not wish to purchase Common Stock at a price above the conversion price of a series of convertible preferred stock because the holders of the preferred stock would effectively be entitled to purchase Common Stock at the lower conversion price causing economic dilution to the holders of Common Stock.

***Increases in market interest rates may cause potential investors to seek higher returns and therefore reduce demand for our Common Stock, which could result in a decline in the market price of our Common Stock.***

One of the factors that may influence the price of our Common Stock is the return on our Common Stock (i.e., the amount of distributions or price appreciation as a percentage of the price of our Common Stock) relative to market interest rates. An increase in market interest rates may lead prospective purchasers of our Common Stock to expect a return, which we may be unable or choose not to provide. Further, higher interest rates would likely increase our borrowing costs and potentially decrease the cash available for distribution. Thus, higher market interest rates could cause the market price of our Common Stock to decline.

**Item 1B. Unresolved Staff Comments.**

None.

**Item 1C. Cybersecurity.**

**Risk Management and Strategy**

The Company recognizes the importance of developing, implementing, and maintaining cybersecurity measures to assess, identify, and manage material risks from cybersecurity (including cybersecurity threats associated with the use of third-party service providers), to safeguard our information systems, and to protect the confidentiality, integrity, and availability of the data on our information systems.

*Managing Material Risks & Integrated Overall Risk Management*

The Company has strategically integrated cybersecurity risk management into our broader risk management framework. Management has formed cross-functional risk and information security committees (the “Security Committees”) to initiate, develop, review and implement cybersecurity policies, procedures and training to mitigate cybersecurity risks. Our information technology (“IT”) cybersecurity leadership team works closely with our Security Committees and internal audit team to evaluate and address cybersecurity risks in alignment with our business objectives and operational needs.

Using a risk-based prioritization approach, the IT cybersecurity leadership team and the Security Committees focus on securing our high value assets, updating our cybersecurity detection and prevention capabilities to identify new threats, and improving compliance processes to protect the Company’s operations and data. During this process, the following factors, among others, are considered: likelihood and severity of risk, impact on the Company and others if a risk materializes, feasibility and cost of controls, and impact of controls on operations.

The Company has also implemented technical safeguards that are designed to protect our information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality, access controls, and vulnerability and patch management. The Company also makes ongoing strategic investments to address cybersecurity risks, including maintaining insurance coverage to mitigate the potential financial consequences of cybersecurity incidents.

*Risk Management Personnel*

The Company’s senior IT leadership, comprised of the Chief Information Officers of both AMC and Odeon, and IT cybersecurity teams have the primary responsibility for assessing, monitoring, and managing, our cybersecurity programs. The Company’s senior IT leadership bring over fifty years of combined IT experience to their roles. Each member of the Company’s IT cybersecurity leadership team, comprised of the AMC Director Cybersecurity, the Odeon Group Head of Cyber, Risk and Operations and the AMC SVP & Chief Information Officer, brings 20+ years of IT experience. The Company regularly invests in training for these teams, and key leadership positions hold Certified Information Systems Security Professional certifications. Our senior IT leadership and IT cybersecurity team, with input as appropriate from the Security Committees, oversee our governance programs, tests our compliance with standards, remediate known risks, and direct employee training.

*Monitoring Cybersecurity Incidents*

The Security Committees are continually informed about the latest developments in cybersecurity, including potential threats and risk management techniques. The Security Committees, and in particular senior IT leadership, IT cybersecurity and internal audit members serving on the Security Committees, implement and oversee processes for the regular monitoring of our information systems. The Company follows the National Institute of Standards and Technology framework to design and implement security processes, tools and procedures, and regular system audits identify and lead to prompt remediation of potential vulnerabilities. In the event of a cybersecurity incident, senior IT leadership and the Security Committees are equipped with a well-defined incident response plan. This plan includes immediate actions to mitigate the impact, internal and external communication plans, and notification requirements.

*Engagement of Consultants for Risk Management Services*

Recognizing the complexity and evolving nature of cybersecurity threats, the Company engages with a range of external experts to perform a variety of functions for the Company. These include, but are not limited to, cybermaturity audits, targeted ransomware assessment and table-top exercises, red and purple team attack simulations, internal penetration tests and other internal and external audits. These partnerships enable us to leverage specialized knowledge and insights into our cybersecurity strategies and processes.

*Overseeing Third-Party Risk*

Because we are aware of the risks associated with third-party service providers, the Company implements processes to oversee and manage these risks. The Company utilizes software products and services to monitor and protect the Company's environment from possible third-party breaches impacting the Company's environment. This approach is designed to mitigate risks related to data breaches or other security incidents originating from third-parties. Third-parties who have access to highly sensitive information due to services performed and data retained are subject to increased scrutiny.

*Risks from Cybersecurity Threats*

We have not experienced any cybersecurity incidents that we believe have materially affected, or are likely to materially affect, the Company.

**Governance**

*Board of Directors and Audit Committee Oversight*

Our board of directors (the "Board") understands the critical nature of managing risks associated with cybersecurity threats. The Board has established robust oversight mechanisms to ensure effective governance in managing risks associated with cybersecurity threats.

The audit committee of the Board (the "Audit Committee") is central to the Board's oversight of cybersecurity risks and bears the primary responsibility for overseeing these risks. Senior IT leadership regularly informs the Audit Committee, the Chief Financial Officer and other members of the Company's senior leadership of cybersecurity risks and incidents. This ensures that the highest levels of management are kept abreast of the cybersecurity posture and potential risks facing the Company.

*Management's Role Managing Risk*

Senior IT leadership play a pivotal role in managing cybersecurity risk and keeping the Audit Committee apprised of cybersecurity developments. Senior IT leadership provide comprehensive briefings to the Audit Committee on a periodic basis. These briefings encompass a broad range of topics, including:

- current cybersecurity landscape and emerging threats;
- status of ongoing cybersecurity initiatives and strategies;
- learnings from any cybersecurity events; and
- compliance with regulatory requirements and industry standards.

In addition to our scheduled meetings, the Audit Committee and senior IT leadership maintain an ongoing dialogue regarding emerging or potential cybersecurity risks. The Company, at the direction of the Audit Committee, conducts periodic reviews of the Company's cybersecurity posture and the effectiveness of its risk management strategies. These reviews help in identifying areas for improvement and ensuring the alignment of cybersecurity efforts with the overall risk management framework.

## Item 2. Properties.

The following table sets forth the general character and ownership classification of our theatre circuit, excluding non-consolidated joint ventures and managed theatres, as of December 31, 2025:

<u>Property Holding Classification</u>	<u>Theatres</u>	<u>Screens</u>
Owned	33	334
Leased	758	8,989
Total	<u>791</u>	<u>9,323</u>

We lease our corporate headquarters in Leawood, Kansas. We believe our facilities are currently adequate for our operations.

Please refer to Narrative Description of Business under Part I, Item 1 of this Annual Report on Form 10-K for the geographic locations of our theatrical exhibition circuit as of December 31, 2025. See Note 3—Leases in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K.

## Item 3. Legal Proceedings.

On May 4, 2023, the Company filed a lawsuit in the Superior Court of the State of Delaware against seventeen insurers participating in its directors & officers insurance program, seeking recovery for losses incurred in connection with its defense and settlement of *In re AMC Entertainment Holdings, Inc. Stockholder Litigation* No. 2023-0215-MTZ (Del. Ch.), including the settlement payment. The insurance recovery action is captioned *AMC Entertainment Holdings, Inc. v. XL Specialty Insurance Co., et al.*, Case No. N23C-05-045 AML CCLD (Del. Super. May 4, 2023) (the “Coverage Action”). In the suit, AMC seeks up to \$80 million in coverage under its Executive and Corporate Securities Liability Insurance Policies sold by the defendants, which provide coverage for the policy period of January 1, 2022 through January 1, 2023 (the “Policies”) in excess of a \$10 million deductible. The primary insurer in the Coverage Action has paid its full \$5.0 million limit. The Company has previously reached confidential settlement agreements with all but one insurer in the Coverage Action.

The remaining insurer contested whether it owed coverage for the settlement payment, claiming it does not constitute a “Loss” under its insurance policy (the “Loss Defense”). On February 28, 2025, the court denied a motion for summary judgment by the remaining insurer in the Coverage Action. Additionally, the court partially granted the Company’s motion for summary judgment, ruling that the settlement payment constituted a covered loss, but that genuine issues of material fact existed for trial regarding whether AMC complied with the consent provisions of the Policies in connection with the settlement payment (the “Consent Defense”). Subsequently, pursuant to a joint stipulated order entered by the court on March 9, 2025, the remaining insurer withdrew its Consent Defense (but preserved its Loss Defense for appeal) and on April 9, 2025, the court entered a final judgment in favor of the Company in the amount of \$5.0 million plus pre-judgment interest of \$0.7 million. On May 8, 2025, the insurer filed a notice of appeal to the Supreme Court of the State of Delaware. On December 9, 2025, the Supreme Court of the State of Delaware affirmed the Superior Court’s decision in favor of the Company. Shortly thereafter, the remaining insurer paid the Company its full limits, plus pre- and post-judgment interest.

AMC also has claims for coverage from additional insurers, however, those insurers’ policies contain mandatory arbitration provisions, so they were not included in the Coverage Action. On January 24, 2025, the Company sent a notice of arbitration to the four remaining insurers with mandatory arbitration provisions on the same grounds as the Coverage Action (the “Coverage Arbitration”).

On October 31, 2025, a purported securities class action captioned *Simons v. AMC Entertainment Holdings, Inc.*, No. 1:25-cv-09042-JLR, was filed by a purported former holder of AMC Preferred Equity Units against the Company in the United States District Court for the Southern District of New York. The complaint asserts a claim under Section 10(b) of the Securities Exchange Act of 1934 based on allegedly false and misleading public statements and omissions by the Company during the period from August 18, 2022 to November 1, 2023 concerning the conversion of the AMC Preferred Equity Units. The complaint alleges damages of at least \$178 million, plus pre-judgment interest. The Company intends to defend the action vigorously.

[Table of Contents](#)

On December 5, 2025, an action captioned *Masoner v. AMC Entertainment Holdings, Inc. et al.*, No. N25C-12-022 was filed by two purported AMC stockholders against the Company, Adam Aron, and unspecified members of the Company's board of directors in the Superior Court of the State of Delaware. The complaint asserts claims for, among other things, fraud, fraud on the court, breach of fiduciary duty, unjust enrichment, and conspiracy based on the 2023 settlement of the action captioned *In re AMC Entertainment Holdings, Inc. Stockholder Litigation* No. 2023-0215-MTZ (Del. Ch.). Plaintiffs seek, among other things, monetary damages of approximately \$4.2 million, disgorgement of approximately \$18 million, declaratory relief, equitable relief, and injunctive relief. Defendants intend to defend the action vigorously.

**Item 4. Mine Safety Disclosures.**

Not applicable

## PART II

### Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

#### Market Information

Our common equity consists of Common Stock. Our Common Stock has traded on the NYSE since December 18, 2013 under the symbol “AMC”.

#### Holder of Shares

As of February 18, 2026, there were 529,547,465 shares of our Common Stock outstanding. Of those outstanding shares, approximately 2.0 million shares (or 0.4%) were held by 14,021 registered holders with our transfer agent and approximately 527.5 (or 99.6%) were held by Cede & Co on behalf of the Depository Trust & Clearing Corporation, commonly referred to as held in “street name” for beneficial holders owning shares through bank or brokerage accounts.

#### Dividend Policy

The payment of future dividends is subject to the Board’s discretion and dependent on many considerations, including limitations imposed by covenants in the agreements governing our indebtedness, operating results, capital requirements, strategic considerations and other factors.

We will only be able to pay dividends from our available cash on hand and funds received from our subsidiaries. Their ability to make any payments to us will depend upon many factors, including our operating results, cash flows, and the indentures governing our debt securities. The declaration and payment of any future dividends will be at the sole discretion of the Board after taking into account various factors, including legal requirements, our subsidiaries’ ability to make payments to us, our financial condition, operating results, cash flow from operating activities, available cash and current and anticipated cash needs. See the Liquidity and Capital Resources section of Part II, Item 7 of this Form 10-K for further information regarding the dividend restrictions.

#### Securities Authorized for Issuance Under Equity Compensation Plans

See Part III, Item 12 of this Annual Report on Form 10-K.

#### Unregistered Sales of Equity Securities and Use of Proceeds

##### *Sale of Unregistered Securities*

Except as reported in Item 3.02 of our Current Reports on Form 8-K filed with the SEC on July 1, 2025, July 25, 2025, and December 22, 2025 all of which are incorporated by reference into this Annual Report on Form 10-K, there were no sales of unregistered securities during the fiscal year ended December 31, 2025.

#### Issuer Purchase of Equity Securities

None.


**Performance Graph**

The following stock price performance graph should not be deemed incorporated by reference by any general statement incorporating by reference this Annual Report on Form 10-K into any filing under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or the Securities Act of 1933, as amended (the “Securities Act”), as amended, except to the extent that we specifically incorporate this information by reference and shall not otherwise be deemed filed under such acts.

The following stock performance graph compares, for the period December 31, 2020 through December 31, 2025, the cumulative total stockholder returns for AMC’s Common Stock, the Standard & Poor’s Corporation Composite 500 Index and a self-determined peer group consisting of Cinemark Holdings, Inc. (CNK) and IMAX Corporation (IMAX). Measurement points are the last trading day for each month ended December 31, 2020 through December 31, 2025. The graph assumes that \$100.00 was invested on December 31, 2020 in our Common Stock and in our peer group and in the Standard & Poor’s Corporation Composite 500 Index and assumes reinvestment of any dividends.

The stock price performance below is not necessarily indicative of future stock price performance.

**COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN\***  
Among AMC Entertainment Holdings, Inc., the S&P 500 Index, and a Peer Group



\*\$100 invested on December 31, 2020 in stock or in index, including reinvestment of dividends. Historical AMC share prices were adjusted by LSEG to reflect the impact of the Special Dividend paid on August 19, 2022 and the reverse stock split on August 24, 2023. Fiscal year ended December 31.

[Table of Contents](#)

	<u>12/20</u>	<u>3/21</u>	<u>6/21</u>	<u>9/21</u>	<u>12/21</u>
AMC Entertainment Holdings, Inc.	100.00	481.60	2,673.58	1,795.28	1,283.02
S&P 500	100.00	106.17	115.25	115.92	128.71
Peer Group	100.00	115.30	123.77	108.63	94.75
		<u>3/22</u>	<u>6/22</u>	<u>9/22</u>	<u>12/22</u>
AMC Entertainment Holdings, Inc.		1,162.26	639.15	535.19	312.51
S&P 500		122.79	103.02	97.99	105.40
Peer Group		101.20	88.78	72.48	60.06
		<u>3/23</u>	<u>6/23</u>	<u>9/23</u>	<u>12/23</u>
AMC Entertainment Holdings, Inc.		384.69	337.85	69.53	53.26
S&P 500		113.30	123.20	119.17	133.10
Peer Group		92.01	94.86	106.25	81.91
		<u>3/24</u>	<u>6/24</u>	<u>9/24</u>	<u>12/24</u>
AMC Entertainment Holdings, Inc.		32.37	43.34	39.60	34.63
S&P 500		147.15	153.46	162.49	166.40
Peer Group		99.20	114.71	145.85	167.06
		<u>3/25</u>	<u>6/25</u>	<u>9/25</u>	<u>12/25</u>
AMC Entertainment Holdings, Inc.		24.98	26.98	25.24	13.58
S&P 500		159.30	176.73	191.08	196.16
Peer Group		144.49	168.36	169.01	158.35

**Item 6. [Reserved].**

Not applicable

**Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.**

The following discussion relates to the consolidated audited financial statements of AMC included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements. Please see “Forward-Looking Statements” and “Risk Factors” in Part I on this Annual Report on Form 10-K for a discussion of the risks, uncertainties and assumptions relating to these statements. See Note 1—The Company and Significant Accounting Policies in Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for information regarding the Company’s significant accounting policies.

**Overview**

AMC is the world’s largest theatrical exhibition company and an industry leader in innovation and operational excellence. As of December 31, 2025 we operated in 11 countries including the United States and throughout Europe.

Our theatrical exhibition revenues are generated primarily from box office admissions and food and beverage sales. The balance of our revenues is generated from ancillary sources, including online ticketing fees, on-screen advertising, income from gift card and exchange ticket sales, rental of theatre auditoriums, retail popcorn and merchandise sales, fees earned from our customer loyalty programs, and theatrical distribution. As of December 31, 2025, we owned, operated or had interests in 855 theatres and 9,640 screens.

**Significant Events—For the Year Ended December 31, 2025**

**2025 Debt Refinancing and Additional Share Authorization.** During the year ended December 31, 2025, we completed a series of refinancing transactions with certain holders of our Existing 7.5% Notes, certain holders of the Existing Exchangeable Notes, and certain lenders of our term loans outstanding under our credit agreement. Additionally, at the 2025 Annual Meeting of Stockholders held on December 10, 2025, the Company’s stockholders approved an amendment to the Company’s certificate of incorporation to increase the total number of authorized shares of the Company’s Common Stock from 550,000,000 to 1,100,000,000 shares of Common Stock. The increase in authorized shares allows for, among other things, the potential conversion of the Company’s New Exchangeable Notes that were issued as part of the refinancing transactions. See Note 7—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for further information regarding these transactions.

**NCM ESA Amendment.** On April 17, 2025, NCM (as defined herein) entered into the Amended ESA (as defined herein) with the Company. The term of the Amended ESA has been extended by five years through February 13, 2042. We treated the Amended ESA as a contract modification pursuant to *ASC 606 – Revenue from Contracts with Customers*. Accordingly, we have allocated the additional consideration received from the contract modification to the exhibitor services agreement contract liability and updated the discount rate used to account for the significant financing component to 16.12%. Prior to the contract modification, the weighted average discount rate used to account for the significant financing component was approximately 7.5%. The contract liability will be reclassified to other theatre revenue over the new term of the Amended ESA as the remaining performance obligations are satisfied. Concurrently with entering into the Amended ESA, NCM and the Company reached an agreement to, among other things, dismiss with prejudice the ongoing litigation between the parties.

[Table of Contents](#)

**Shares Issuances.** During the year ended December 31, 2025, we were paid \$108.7 million as initial gross cash proceeds associated with the establishment of forward positions for 30.0 million shares of Common Stock.

Additionally, during the year ended December 31, 2025, we issued shares of Common Stock through an “at-the-market” offering. The below table summarizes the activity of the “at-the-market offering”:

(In millions)	December 31, 2025	
Shares issued through at-the-market offering		17.1
At-the-market offering gross proceeds	\$	63.0
Sales agent fees paid	\$	0.6
Other third-party issuance costs incurred	\$	0.3
Other third-party issuance costs paid	\$	1.5

See Note 8—Stockholders’ Deficit in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for further information on the share issuances.

**Significant Events—For the Year Ended December 31, 2024**

**Debt Repurchases and Exchanges.** The table below summarizes the various cash debt repurchase transactions, debt for equity exchange transactions, and cash and debt for equity exchange transactions that occurred during the year ended December 31, 2024. The debt for equity transactions were treated as early extinguishments of debt. In accordance with ASC 470-50-40-3, the reacquisition price of the extinguished debt was determined to be the fair value of the Common Stock exchanged. See Note 7—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for further information on these transactions.

(In millions)	Aggregate Principal Repurchased/Exchanged	Shares of Common Stock Exchanged	Reacquisition Cost	(Gain)/Loss on Extinguishment	Accrued Interest Paid/Exchanged
<b>Cash debt repurchase transactions:</b>					
5.75% Senior Subordinated Notes due 2025	\$ 8.9	—	\$ 8.6	\$ (0.3)	\$ 0.1
Second Lien Notes due 2026	50.0	—	50.5	(4.4)	1.4
Total cash debt repurchase transactions	58.9	—	59.1	(4.7)	1.5
<b>Debt for equity exchange transactions:</b>					
5.75% Senior Subordinated Notes due 2025	36.7	9,017,297	39.8	3.2	0.8
Second Lien Notes due 2026	224.1	35,062,835	157.2	(93.1)	8.3
Total debt for equity exchange transactions	260.8	44,080,132	197.0	(89.9)	9.1
<b>Cash and debt for equity exchange transactions:</b>					
5.75% Senior Subordinated Notes due 2025	8.6	447,829	8.4	(0.2)	0.1
5.875% Senior Subordinated Notes due 2026	9.6	432,777	8.1	(1.3)	0.2
Second Lien Notes due 2026	45.0	2,693,717	45.5	(4.0)	1.2
Total cash and debt for equity exchange transactions	63.2	3,574,323	62.0	(5.5)	1.5
Total debt repurchases and exchanges	\$ 382.9	47,654,455	\$ 318.1	\$ (100.1)	\$ 12.1

**Vendor Dispute.** On January 26, 2024, we executed an agreement to collect \$37.5 million as resolution of a dispute with a vendor. The proceeds, net of legal costs, were recorded to other income during the year ended December 31, 2024. The relationship with the vendor has been restored and remains in good standing.

**Share Issuances.** During the year ended December 31, 2024, we raised gross proceeds of \$261.8 million and paid fees to sales agents and incurred other third-party issuance costs of approximately \$6.4 million and \$1.9 million, respectively, through our at-the-market offerings of approximately 75.5 million shares of our Common Stock. We paid \$0.8 million of other third-party issuance costs during the year ended December 31, 2024.

Additionally, we entered into forward transactions to sell 30.0 million shares of our Common Stock. During December 2024, we were paid \$0.01 per share for the par value of the forward shares totaling \$0.3 million. See Note 8—Stockholder’s Deficit in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for further information.

**2024 Refinancing Transactions.** During the year ended December 31, 2024, we completed a series of transactions to refinance \$1,895.0 million aggregate principal amount of our senior secured term loans maturing in 2026 (“Term Loans due 2026”) and \$518.6 million of our Second Lien Notes. As part of the transactions, we issued \$2,024.3 million aggregate principal amount of the New Term Loans (as defined herein) and \$414.4 million aggregate principal of Existing Exchangeable Notes. The repurchases of the Second Lien Notes were accounted for as extinguishments and resulted in a loss on extinguishment of \$61.2 million. See the Liquidity and Capital Resources section below and Note 7—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for further information on these transactions.

**Special Awards.** On February 22, 2024, the compensation committee of AMC’s Board approved modification of the performance goals applicable to all 2023 Tranche Year PSU awards. This was accounted for as a modification to the 2023 Tranche Year PSU awards which lowered the Adjusted EBITDA and free cash flow performance targets such that 200% vesting was achieved for both targets. This modification resulted in the immediate additional vesting of 478,055 2023 Tranche Year PSUs (21,829 cash settled units and 456,226 equity settled units). This was treated as a Type 3 modification (improbable-to-probable) which required the Company to recognize additional stock compensation expense based on the modification date fair values of the incremental PSUs. During the year ended December 31, 2024, the Company recognized \$2.1 million of stock compensation expense related to these awards.

#### **Significant Events—For the Year Ended December 31, 2023**

For a discussion of significant events for the year ended December 31, 2023, see [“Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our annual report on Form 10-K for the year ended December 31, 2023](#), filed with the SEC on February 28, 2024, which is incorporated herein by reference.

#### **Critical Accounting Estimates**

Our consolidated financial statements are prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). In connection with the preparation of our financial statements, we are required to make assumptions and estimates about future events and apply judgments that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosures. We base our assumptions, estimates, and judgments on historical experience, current trends and other factors that management believes to be relevant at the time our consolidated financial statements are prepared. On a regular basis, we review the accounting policies, assumptions, estimates, and judgments to ensure that our financial statements are presented fairly and in accordance with U.S. GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material. We have identified several policies as being critical because they require management to make particularly difficult, subjective and complex judgments about matters that are inherently uncertain, and there is a likelihood that materially different amounts would be reported under different conditions or using different assumptions.

All of our significant accounting policies are discussed in Note 1—The Company and Significant Accounting Policies in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K.

**Long-lived Assets Impairments.** We review long-lived assets whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable.

## [Table of Contents](#)

*Critical estimates.* There are many estimates and significant judgments that are made by management in performing impairment evaluations of long-lived assets, including but not limited to, estimates of future attendance, revenues, operating costs and expenses, capital expenditures, and the cost of capital. These estimates determine whether impairments have been incurred and quantify the amount of any related impairment charge.

*Assumptions and judgment.* Our valuation methodology for assessing impairment requires management to make judgments and assumptions based on historical experience. These assumptions and judgments can significantly affect the cash flow estimates and appropriate discount rates to be used in determining the fair value of long-lived assets.

*Impact if actual results differ from assumptions.* Although we believe that our estimates and judgments are reasonable, actual results may differ from these estimates, many of which fall under Level 3 within the fair value measurement hierarchy. Factors that could lead to impairment of long-lived assets include adverse industry or economic trends that would result in declines in the operating performance of our Domestic and International Theatres. Examples of adverse events or circumstances that could change include (i) limited availability of new theatrical releases; (ii) an adverse change in macroeconomic conditions; (iii) increased cost factors that have a negative effect on our earnings and cash flows and higher interest rates; and (iv) negative or overall declining financial performance compared with our actual and projected results of relevant prior periods.

If we are required to record an impairment charge it may substantially reduce the carrying value of our assets and reduce our income in the year in which it is recorded. Given the nature of our business and our recent history, business conditions that are constantly changing, and the competitive business environment in which we operate future impairments are possible and they may be material.

*Our Current Long-lived Asset Impairment Related Estimates and Changes in those Estimates.* During the year ended December 31, 2025, we recorded non-cash impairment charges related to our long-lived assets of \$28.0 million on 47 theatres in the U.S. markets with 560 screens which were related to property, net and operating lease right-of-use assets, net and \$15.5 million on 20 theatres in the International markets with 159 screens which were related to property, net and operating lease right-of-use assets, net. A hypothetical 10% decline in the fair value of the asset groups would have resulted in approximately \$5.4 million of additional impairment charges.

During the year ended December 31, 2024, we recorded non-cash impairment charges related to our long-lived assets of \$51.9 million on 39 theatres in the U.S. markets with 469 screens which were related to property, net and operating lease right-of-use assets, net and \$20.4 million on 23 theatres in the International markets with 188 screens which were related to property, net and operating lease right-of-use assets, net.

During the year ended December 31, 2023, we recorded non-cash impairment charges related to our long-lived assets of \$49.2 million on 68 theatres in the U.S. markets with 738 screens which were related to property, net and operating lease right-of-use assets, net and \$57.7 million on 57 theatres in the International markets with 488 screens which were related to property, net and operating lease right-of-use assets, net.

At December 31, 2025, estimated cash flows were discounted at 9.5% for the Domestic Theatres and 10.5% for the International Theatres. At December 31, 2024, estimated cash flows were discounted at 9.0% for the Domestic Theatres and 10.5% for the International Theatres. At December 31, 2023, estimated cash flows were discounted at 9.0% for the Domestic Theatres and 11.0% for the International Theatres.

**Goodwill.** We evaluate the goodwill recorded at our two reporting units (Domestic Theatres and International Theatres) for impairment annually as of the beginning of the fourth fiscal quarter or more frequently as specific events or circumstances dictate. Under ASC Topic 350, *Goodwill, Intangibles and Other*, we can elect to perform a qualitative or quantitative impairment assessment of our goodwill. Under the quantitative goodwill impairment analysis, if the estimated fair value of a reporting unit is less than its carrying value, the difference is recorded as a goodwill impairment charge, not to exceed the total amount of goodwill allocated to that reporting unit. Under the qualitative assessment, entities consider a variety of factors to qualitatively assess whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill.

We have elected to perform the optional qualitative assessment during the years ended December 31, 2025, 2024, and 2023. Inherent in the qualitative assessment is an estimated impact on each reporting unit's fair value that events and circumstances might have had and whether or not that impact would have likely reduced the fair value below the reporting units carrying value. Such events and circumstances include, but are not limited to, industry and market conditions, expected cost pressures, expected financial performance, and general macroeconomic conditions.

Additionally, the estimated fair value of our debt and equity at the consolidated level may be a relevant factor in determining whether it is more likely than not that goodwill is impaired.

Estimating the impact of the general macroeconomic conditions, potential cost pressures, and future industry and market conditions requires significant judgment. We must make assumptions around how much weight should be given to each event and circumstance in order to make an overall qualitative assessment on whether it is more likely than not that goodwill is impaired. The estimated fair value of our debt at the consolidated level is based on observable market based inputs and the estimated fair value of our equity is based on quoted prices in active markets.

Based on our qualitative assessments for the years ended December 31, 2025, December 31, 2024, and December 31, 2023, we do not believe it is more likely than not that the goodwill of our reporting units is impaired.

**Derivative Fair Values.** We remeasure the bifurcated embedded derivatives related to our Existing Exchangeable Notes and New Exchangeable Notes at fair value each reporting period with changes in fair value recorded in the consolidated statements of operations. We have obtained independent third-party valuation studies to assist us in determining fair value.

*Critical estimates.* The critical estimates used in determining the fair value of the bifurcated embedded derivatives are discussed by host instrument below:

**Existing Exchangeable Notes.** Our valuation studies use binomial lattice models and are based on significant inputs not observable in the market and thus represent level 3 measurements within the fair value measurement hierarchy. The binomial lattice models consist of simulated Common Stock prices from the valuation date to the maturity of the Existing Exchangeable Notes. The significant inputs used to value the derivative include the share price of our Common Stock, the volatility of the share price, time to maturity, risk-free interest rate, credit spread, and the discount yield. The volatility of our Common Stock, the Common Stock price at the end of each reporting period, and the remaining amount of time until maturity of the Existing Exchangeable Notes are key inputs for the estimation of fair value that are expected to change each reporting period.

**New Exchangeable Notes.** Our valuation studies use a combination of Monte Carlo simulations, binomial lattice models, and discounted cash flow models. The models are based on significant inputs not observable in the market and thus represent level 3 measurements within the fair value measurement hierarchy. The Monte Carlo simulations use repeated random sampling to simulate a wide range of possible outcomes. The binomial lattice approach consists of simulated Common Stock prices from the valuation date to the maturity of the New Exchangeable Notes. The significant inputs used to value the derivative include the share price of our Common Stock, the volatility of the share price, time to maturity, risk-free interest rate, discount yield, and the probability of the required shareholder approval. The volatility of our Common Stock, the Common Stock price at the end of each reporting period, and the remaining amount of time until maturity of the New Exchangeable Notes are key inputs for the estimation of fair value that are expected to change each reporting period.

*Assumptions and judgment.* Selecting the appropriate method and model to use in the valuation of the bifurcated embedded derivatives associated with the Existing Exchangeable Notes and New Exchangeable Notes requires judgment and careful consideration of the common valuation practice for similar instruments. Selection of significant assumptions such as volatility and the discount yield also requires judgment and both inputs exhibit a greater degree of subjectivity than more observable inputs such as the risk-free rate.

*Impact if actual results differ from assumptions.* If actual results differ from assumptions, the value of the bifurcated embedded derivatives could be overstated or understated which could increase or decrease net earnings by a material amount.

*Our Current Estimates and Changes in those Estimates.* During the years ended December 31, 2025 and December 31, 2024, we recorded other (income) related to changes in the estimated fair value of the bifurcated embedded derivatives of our Existing Exchangeable Notes of \$(56.7) million and \$(75.8) million, respectively. During the year ended December 31, 2025, we recorded other expense related to changes in the estimated fair value of the bifurcated embedded derivatives of our New Exchangeable Notes of \$19.3 million. A hypothetical 10% increase in the fair value of the derivatives would have resulted in an increase of other expense of approximately \$14.5 million for the year ended December 31, 2025. Similarly, a hypothetical 10% decrease in the fair value of the derivatives would have resulted in a decrease to other expense of approximately \$14.5 million for the year ended December 31, 2025. We expect there will be future changes in the fair value of our derivatives and that the related amounts recorded as income or

[Table of Contents](#)

expense may be material. See Note 7—Corporate Borrowings and Finance Lease Liabilities and Note 10—Fair Value Measurements in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for further information.

## Operating Results

The following table sets forth our consolidated revenues, operating costs and expenses attributable to our theatrical exhibition operations and segment operating results. Reference is made to Note 11—Segment Reporting in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for additional information therein:

(In millions)	U.S. Markets			International Markets			Consolidated		
	Year Ended December 31,			Year Ended December 31,			Year Ended December 31,		
	2025	2024	% Change	2025	2024	% Change	2025	2024	% Change
<b>Revenues</b>									
Admissions	\$ 1,992.0	\$ 1,916.7	3.9 %	\$ 660.8	\$ 643.8	2.6 %	\$ 2,652.8	\$ 2,560.5	3.6 %
Food and beverage	1,335.5	1,301.6	2.6 %	335.8	323.3	3.9 %	1,671.3	1,624.9	2.9 %
Other theatre	378.6	325.9	16.2 %	146.2	125.9	16.1 %	524.8	451.8	16.2 %
Total revenues	3,706.1	3,544.2	4.6 %	1,142.8	1,093.0	4.6 %	4,848.9	4,637.2	4.6 %
<b>Operating Costs and Expenses</b>									
Film exhibition costs	1,020.5	988.8	3.2 %	254.7	250.4	1.7 %	1,275.2	1,239.2	2.9 %
Food and beverage costs	241.2	225.7	6.9 %	85.8	79.9	7.4 %	327.0	305.6	7.0 %
Operating expense, excluding depreciation and amortization below	1,327.1	1,252.1	6.0 %	458.9	427.3	7.4 %	1,786.0	1,679.4	6.3 %
Rent	650.1	649.9	0.0 %	237.2	223.7	6.0 %	887.3	873.6	1.6 %
General and administrative expense:									
Merger, acquisition and other costs	3.6	0.1	* %	—	—	NA %	3.6	0.1	* %
Other, excluding depreciation and amortization below	144.1	150.6	(4.3)%	86.2	76.2	13.1 %	230.3	226.8	1.5 %
Depreciation and amortization	239.1	247.5	(3.4)%	74.3	72.0	3.2 %	313.4	319.5	(1.9)%
Impairment of long-lived assets	28.0	51.9	(46.1)%	15.5	20.4	(24.0)%	43.5	72.3	(39.8)%
Operating costs and expenses	3,653.7	3,566.6	2.4 %	1,212.6	1,149.9	5.5 %	4,866.3	4,716.5	3.2 %
Operating income (loss)	52.4	(22.4)	* %	(69.8)	(56.9)	22.7 %	(17.4)	(79.3)	(78.1)%
Other expense, net:									
Other expense (income)	153.5	(124.4)	* %	(41.1)	(31.8)	29.2 %	112.4	(156.2)	* %
Interest expense:									
Corporate borrowings	398.6	341.9	16.6 %	60.9	59.9	1.7 %	459.5	401.8	14.4 %
Finance lease obligations	—	0.1	(100.0)%	6.0	5.3	13.2 %	6.0	5.4	11.1 %
Non-cash NCM exhibitor service agreement	64.7	36.5	77.3 %	—	—	NA %	64.7	36.5	77.3 %
Investment income	(31.0)	(14.0)	* %	(1.1)	(2.3)	(52.2)%	(32.1)	(16.3)	96.9 %
Total other expense, net	585.8	240.1	* %	24.7	31.1	(20.6)%	610.5	271.2	* %
Loss before income taxes	(533.4)	(262.5)	* %	(94.5)	(88.0)	7.4 %	(627.9)	(350.5)	79.1 %
Income tax provision	2.7	—	NA %	1.8	2.1	(14.3)%	4.5	2.1	* %
Net loss	\$ (536.1)	\$ (262.5)	* %	\$ (96.3)	\$ (90.1)	6.9 %	\$ (632.4)	\$ (352.6)	79.4 %

\* Percentage change in excess of 100%.

Operating Data:	U.S. Markets		International Markets		Consolidated	
	Year Ended December 31,		Year Ended December 31,		Year Ended December 31,	
	2025	2024	2025	2024	2025	2024
Screen additions	—	—	—	13	—	13
Screen acquisitions	16	—	20	9	36	9
Screen dispositions	128	185	71	78	199	263
Screen construction openings (closures), net	(1)	1	6	(21)	5	(20)
Average screens (1)	7,057	7,206	2,318	2,376	9,375	9,582
Number of screens operated	7,072	7,185	2,568	2,613	9,640	9,798
Number of theatres operated	533	544	322	327	855	871
Screens per theatre	13.3	13.2	8.0	8.0	11.3	11.2
Attendance (in thousands) (1)	155,810	156,866	63,602	67,289	219,412	224,155

(1) Includes consolidated theatres only and excludes screens offline due to construction.

## Adjusted EBITDA

We present Adjusted EBITDA as a supplemental measure of our performance. We define Adjusted EBITDA as net earnings (loss) plus (i) income tax provision (benefit), (ii) interest expense and (iii) depreciation and amortization, as further adjusted to eliminate the impact of certain items that we do not consider indicative of our ongoing operating performance and to include attributable EBITDA from equity investments in theatre operations in International markets. These further adjustments are itemized below. You are encouraged to evaluate these adjustments and the reasons we consider them appropriate for supplemental analysis. In evaluating Adjusted EBITDA, you should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. Our definition of Adjusted EBITDA and adjustments made to net earnings (loss) to calculate it are broadly consistent with how Adjusted EBITDA is defined and calculated in the Company's debt indentures.

The following tables set forth our Adjusted EBITDA by reportable segment and our reconciliation of Adjusted EBITDA:

Adjusted EBITDA (In millions)	Year Ended	
	December 31, 2025	December 31, 2024
U.S. markets	\$ 346.0	\$ 301.5
International markets	41.5	42.4
Total Adjusted EBITDA	\$ 387.5	\$ 343.9

(In millions)	Year Ended	
	December 31, 2025	December 31, 2024
Net loss	\$ (632.4)	\$ (352.6)
Plus:		
Income tax provision (1)	4.5	2.1
Interest expense	530.2	443.7
Depreciation and amortization	313.4	319.5
Impairment of long-lived assets (2)	43.5	72.3
Certain operating expense (3)	14.6	5.4
Equity in earnings of non-consolidated entities (4)	(6.8)	(12.4)
Attributable EBITDA (5)	2.3	1.9
Investment income (6)	(32.1)	(16.3)
Other expense (income) (7)	129.8	(141.8)
Merger, acquisition and other costs (8)	3.6	0.1
Stock-based compensation expense (9)	16.9	22.0
Adjusted EBITDA	\$ 387.5	\$ 343.9

- (1) For information regarding the income tax provision, see Note 9—Income Taxes in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K.
- (2) During the year ended December 31, 2025, we recorded non-cash impairment charges related to our long-lived assets of \$28.0 million on 47 theatres in the U.S. markets with 560 screens which were related to property, net and operating lease right-of-use assets, net and \$15.5 million on 20 theatres in the International markets with 159 screens which were related to property, net and operating lease right-of-use assets, net.  
During the year ended December 31, 2024, we recorded non-cash impairment charges related to our long-lived assets of \$51.9 million on 39 theatres in the U.S. markets with 469 screens which were related to property, net and operating lease right-of-use assets, net and \$20.4 million on 23 theatres in the International markets with 188 screens which were related to property, net and operating lease right-of-use assets, net.
- (3) Amounts represent preopening expense related to temporarily closed screens under renovation, theatre and other closure expense for the permanent closure of screens, disposition of assets and other non-operating gains or losses included in operating expenses. We have excluded these items as they are non-cash in nature or are non-operating in nature.

[Table of Contents](#)

- (4) Equity in earnings of non-consolidated entities during the year ended December 31, 2025, primarily consisted of equity in earnings from AC JV, LLC (“AC JV”) of \$(4.8) million. Equity in earnings of non-consolidated entities during the year ended December 31, 2024, primarily consisted of equity in earnings from AC JV of \$(10.0) million.
- (5) Attributable EBITDA includes the EBITDA from equity investments in theatre operators in certain International markets. See below for a reconciliation of our equity in (earnings) of non-consolidated entities to attributable EBITDA. Because these equity investments are in theatre operators in regions where we hold a significant market share, we believe attributable EBITDA is more indicative of the performance of these equity investments and management uses this measure to monitor and evaluate these equity investments.

(In millions)	Year Ended	
	December 31, 2025	December 31, 2024
Equity in (earnings) of non-consolidated entities	\$ (6.8)	\$ (12.4)
Less:		
Equity in (earnings) of non-consolidated entities excluding International theatre joint ventures	(5.7)	(11.5)
Equity in earnings of International theatre joint ventures	1.1	0.9
Income tax provision	0.1	—
Investment income	(0.5)	(0.4)
Interest expense	0.2	0.1
Depreciation and amortization	1.4	1.3
Attributable EBITDA	\$ 2.3	\$ 1.9

- (6) Investment income during the year ended December 31, 2025, includes interest income of \$(8.0) million and realized and unrealized gains on our investments in Hycroft Mining Holding Corporation (“Hycroft”) of \$(34.4) million, partially offset by an impairment of an equity security without a readily determinable fair value of \$10.3 million.

Investment income during the year ended December 31, 2024, includes interest income of \$(19.2) million, partially offset by unrealized losses on our investments in Hycroft of \$2.9 million.

- (7) Other expense during the year ended December 31, 2025, includes net losses on debt extinguishments of \$196.0 million, an increase in the fair value of the bifurcated embedded derivative in the New Exchangeable Notes of \$19.3 million, and term loan modification third party fees of \$3.1 million, partially offset by a decrease in the fair value of the bifurcated embedded derivative in the Existing Exchangeable Notes of \$(56.7) million, foreign currency transaction gains of \$(28.1) million, and shareholder litigation recoveries of \$(3.8) million.

Other income for the year ended December 31, 2024, includes a decrease in the fair value of the bifurcated embedded derivative in the Existing Exchangeable Notes of \$(75.8) million, shareholder litigation recoveries of \$(40.2) million, net gains on debt extinguishments of \$(38.9) million, and a vendor dispute settlement of \$(36.2) million, partially offset by term loan modification third party fees of \$42.3 million and foreign currency transaction losses of \$7.0 million.

- (8) Merger, acquisition and other costs are excluded as they are non-operating in nature.
- (9) Non-cash expense included in general and administrative: other.

Adjusted EBITDA is a non-GAAP financial measure commonly used in our industry and should not be construed as an alternative to net earnings (loss) as an indicator of operating performance (as determined in accordance with U.S. GAAP). Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. We have included Adjusted EBITDA because we believe it provides management and investors with additional information to measure our performance and estimate our value.

Adjusted EBITDA has important limitations as an analytical tool, and you should not consider it in isolation, or as a substitute for analysis of our results as reported under U.S. GAAP. For example, Adjusted EBITDA:

- does not reflect our capital expenditures, future requirements for capital expenditures or contractual commitments;
- does not reflect changes in, or cash requirements for, our working capital needs;

## [Table of Contents](#)

- does not reflect the significant interest expenses, or the cash requirements necessary to service interest or principal payments, on our debt;
- excludes income tax payments that represent a reduction in cash available to us; and
- does not reflect any cash requirements for the assets being depreciated and amortized that may have to be replaced in the future.

During the year ended December 31, 2025, Adjusted EBITDA in the U.S. markets was \$346.0 million compared to \$301.5 million during the year ended December 31, 2024. The year-over-year improvement was primarily driven by increases in average ticket price, food and beverage per patron, other revenues including advertising income due to the Amended ESA, income from ticket fees due to the increase in the percentage of guests paying ticket fees, retail food and beverage income, retail merchandise income, co-brand credit card revenue, distribution revenue, and the decrease in film exhibition cost percentage. These improvements were partially offset by increases in operating expenses including salaries and wages expense, utilities expense, computer maintenance costs, retail merchandise costs, premium format expense, decreases in attendance, and the increase in food and beverage cost percentage.

During the year ended December 31, 2025, Adjusted EBITDA in the International markets was \$41.5 million compared to \$42.4 million during the year ended December 31, 2024. The year-over-year decline was primarily driven by increases in operating expenses including salaries and wages expense and utilities expense, increases in rent expense, increases in general and administrative: other expenses, decreases in attendance, and increases in food and beverage cost percentage. These declines were partially offset by increases in average ticket prices, food and beverage per patron, other revenues including income from expirations of package tickets and gift cards, retail merchandise income, the decrease in film exhibition cost percentage and the increase in foreign currency translation rates.

During the year ended December 31, 2025, Adjusted EBITDA in the U.S. markets and International markets was \$387.5 million compared to \$343.9 million during the year ended December 31, 2024, driven by the aforementioned factors impacting Adjusted EBITDA.

### **Segment Information**

Our historical results of operations for the years ended December 31, 2025 and December 31, 2024 reflect the results of operations for our two theatrical exhibition reportable segments, U.S. markets and International markets.

### **Results of Operations—For the Year Ended December 31, 2025, Compared to the Year Ended December 31, 2024**

#### **Consolidated Results of Operations**

**Revenues.** Total revenues increased \$211.7 million, or 4.6%, during the year ended December 31, 2025, compared to the year ended December 31, 2024. Admissions revenues increased \$92.3 million, or 3.6%, during the year ended December 31, 2025, compared to the year ended December 31, 2024, primarily due to a 5.9% increase in average ticket price and increase in our market share in our U.S. markets, partially offset by a decrease in attendance of 2.1% from 224.2 million patrons to 219.4 million patrons. The increase in average ticket price was primarily due to increased ticket prices for all formats, increases in attendance for 3D, IMAX and other PLF screens and increases in foreign currency translation rates. Attendance decreased in U.S. and International markets due to the popularity of film product compared to the prior year. In our U.S. markets the market share increase was driven by our loyalty program initiatives, discount days, and the interplay between the film slate and our geographic theatre mix. The availability and popularity of film product released during the year ended December 31, 2024, was negatively impacted by the Writers Guild of America and the Screen Actors Guild – American Federation of Television and Radio Artists strikes during 2023.

Food and beverage revenues increased \$46.4 million, or 2.9%, during the year ended December 31, 2025, compared to the year ended December 31, 2024, primarily due to the increase in food and beverage per patron, partially offset by a decrease in attendance. Food and beverage per patron increased 5.1% from \$7.25 to \$7.62 primarily due to an increase in average prices and the percentage of guests making transactions and increases in foreign currency translation rates, partially offset by lower units per transaction by guests and more frequent attendance from our AMC Stubs members.

[Table of Contents](#)

Total other theatre revenues increased \$73.0 million, or 16.2%, during the year ended December 31, 2025, compared to the year ended December 31, 2024, primarily due to increases in advertising income, income from ticket fees due to the increase in the percentage of guests paying ticket fees, increases in income from expirations of package tickets in our International markets, retail food and beverage income, retail merchandise income, co-brand credit card revenue, distribution revenue, and increases in foreign currency translation rates. As a result of our Amended ESA, advertising income increased from the prior year by \$15.6 million due to an increase in discount rates related to the significant financing component of the Amended ESA, partially offset by lower amortization of deferred revenues due to an increase in the term of the Amended ESA. See Note 2—Revenue Recognition in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for additional information about the Amended ESA.

**Operating costs and expenses.** Operating costs and expenses increased \$149.8 million, or 3.2%, during the year ended December 31, 2025, compared to the year ended December 31, 2024. Film exhibition costs increased \$36.0 million, or 2.9%, during the year ended December 31, 2025, compared to the year ended December 31, 2024, primarily due to the increase in admissions revenue due to the factors discussed above, partially offset by lower film rental terms. As a percentage of admissions revenues, film exhibition costs were 48.1% for the year ended December 31, 2025, compared to 48.4% for the year ended December 31, 2024. The decrease in film exhibition cost percentage is primarily due to the concentration of box office revenues in U.S. and International markets in lower grossing films in the current year, which typically results in lower film exhibition costs.

Food and beverage costs increased \$21.4 million, or 7.0%, during the year ended December 31, 2025, compared to the year ended December 31, 2024. The increase in food and beverage costs was primarily due to the increase in food and beverage revenues due to the factors discussed above. As a percentage of food and beverage revenues, food and beverage costs were 19.6% for the year ended December 31, 2025, compared to 18.8% for the year ended December 31, 2024.

Operating expense increased by \$106.6 million, or 6.3%, during the year ended December 31, 2025, compared to the year ended December 31, 2024. The increase in operating expense was primarily due to increases in salaries and wages expense, utilities expense, computer maintenance costs, retail merchandise costs, premium format expense, losses on disposition of assets and the increase in foreign currency translation rates. As a percentage of revenues, operating expense was 36.8% for the year ended December 31, 2025, compared to 36.2% for the year ended December 31, 2024. The increase in operating expense as a percentage of revenues is primarily due to the operating leverage lost as attendance decreases. Rent expense increased \$13.7 million, or 1.6%, during the year ended December 31, 2025, compared to the year ended December 31, 2024, primarily due to increases in foreign currency translation rates, partially offset by a decrease in average screens of 2.2%.

**Merger, acquisition, and other costs.** Merger, acquisition, and other costs were \$3.6 million during the year ended December 31, 2025, compared to \$0.1 million during the year ended December 31, 2024. The current year expense relates to severance costs in U.S. markets.

**Other.** Other general and administrative expense increased \$3.5 million, or 1.5%, during the year ended December 31, 2025, compared to the year ended December 31, 2024 primarily due to increases in bonus expense as a result of higher than expected annual performance compared to annual industry box office indexed targets in the current year compared to the prior year and increases in foreign currency translation rates, partially offset by declines in stock-based compensation expense due to lower than expected annual performance compared to annual unindexed targets in the current year compared to the prior year, lower insurance costs and lower legal costs.

**Depreciation and amortization.** Depreciation and amortization decreased \$6.1 million, or 1.9%, during the year ended December 31, 2025, compared to the year ended December 31, 2024, primarily due to theatre closures and lower depreciation expense on theatres impaired during the year ended December 31, 2024, partially offset by increases in foreign currency translation rates.

**Impairment of long-lived assets.** During the year ended December 31, 2025, we recognized non-cash impairment losses of \$28.0 million on 47 theatres in the U.S. markets with 560 screens (in Alabama, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Louisiana, Massachusetts, Michigan, Minnesota, New Jersey, New York, North Carolina, Pennsylvania, Tennessee, Texas, Utah, Virginia, Washington, Wisconsin) and \$15.5 million on 20 theatres in the International markets with 159 screens (in Germany, Italy, Spain, Sweden, and the United Kingdom), which were related to property, net and operating lease right-of-use assets, net.

[Table of Contents](#)

During the year ended December 31, 2024, we recognized non-cash impairment losses of \$51.9 million on 39 theatres in the U.S. markets with 469 screens (in Alabama, California, Florida, Illinois, Indiana, Massachusetts, Michigan, Minnesota, New Jersey, New York, Pennsylvania, Texas, Virginia, and Washington) and \$20.4 million on 23 theatres in the International markets with 188 screens (in Germany, Italy, Spain, and the United Kingdom), which were related to property, net and operating lease right-of-use assets, net.

**Other expense (income).** Other expense of \$112.4 million during the year ended December 31, 2025 was primarily due to a \$103.3 million loss on extinguishment of \$337.4 million aggregate principal amount of our Existing Exchangeable Notes, a \$99.0 million loss on extinguishment of \$590.0 million aggregate principal amount of our Existing 7.5% Notes, \$19.3 million of expense related to the increase in fair value of the derivative liability for the embedded derivative features in the New Exchangeable Notes, and \$3.1 million in term loan modification third party fees, partially offset by \$(56.7) million of income related to the decrease in fair value of the derivative liability for the embedded conversion feature in the Existing Exchangeable Notes, \$(28.1) million in foreign currency transaction gains, \$(10.8) million of governmental assistance, \$(6.8) million of equity in earnings of non-consolidated entities and \$(6.6) million of gain on the extinguishment of our Second Lien Notes. Other income of \$(156.2) million during the year ended December 31, 2024, was primarily due to \$(75.8) million of income related to the decrease in fair value of the bifurcated embedded derivative in the Existing Exchangeable Notes, a gain on extinguishment of debt of \$(40.3) million related to the redemption of \$837.7 million aggregate principal amount of the Second Lien Notes, \$(40.2) million of recoveries related to shareholder litigation, the favorable settlement of a vendor dispute of \$(36.2) million, \$(12.4) million of equity in earnings of non-consolidated entities, and \$(3.6) million of other settlement proceeds, partially offset by \$42.3 million of third party costs related to the modification of the Term Loans due 2026 and \$7.0 million of foreign currency transaction losses. See Note 1—The Company and Significant Accounting Policies in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for additional information about the components of other expense (income).

**Interest expense.** Interest expense increased \$86.5 million to \$530.2 million for the year ended December 31, 2025 compared to \$443.7 million during the year ended December 31, 2024 primarily due to increased interest expense of \$51.4 million on the New 2029 Notes issued on July 24, 2025, \$36.8 million on the New Term Loans compared to the Term Loans due 2026, \$28.2 million related to higher discount rates on the significant financing component of the Amended ESA, \$9.3 million on the Existing Exchangeable Notes issued on July 22, 2024, \$8.8 million on the New Exchangeable Notes issued on July 1, 2025, partially offset by declines in interest expense of \$23.1 million on the Second Lien Notes due to redemptions of the remaining principal balances, \$19.7 million on the Existing 7.5% Notes due to redemptions of \$590.0 million aggregate principal amount on July 24, 2025, \$4.0 million on the Senior Subordinated Notes due 2025 due to redemptions of the remaining principal balances, and \$1.5 million on the Senior Subordinated Notes due 2026 due to redemptions of the remaining principal balances. See Note 2—Revenue Recognition in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for additional information about the Amended ESA, and Note 7—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for additional information about our indebtedness.

**Investment income.** Investment income was \$(32.1) million for the year ended December 31, 2025, compared to investment income of \$(16.3) million for the year ended December 31, 2024. Investment income in the current year includes \$(34.4) million of realized and unrealized gains on our investments in common shares and warrants to purchase common shares in Hycroft, and interest income of \$(8.0) million, partially offset by an impairment charge of \$10.3 million related to our investment in an equity security without a readily determinable fair value measured at cost less any impairments. Investment income in the prior year includes interest income of \$(19.2) million, partially offset by unrealized losses of \$2.9 million on our investment in common shares and warrants to purchase common shares in Hycroft. See Note 1—The Company and Significant Accounting Policies in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for additional information about our investments in Hycroft.

**Income tax provision.** The income tax provision was \$4.5 million and \$2.1 million for the years ended December 31, 2025 and December 31, 2024, respectively. See Note 9—Income Taxes in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for further information.

**Net loss.** Net loss was \$632.4 million and \$352.6 million during the years ended December 31, 2025, and December 31, 2024, respectively. Net loss during the year ended December 31, 2025 compared to net loss for the year ended December 31, 2024 was negatively impacted by decreases in other income due to losses on extinguishment of corporate borrowings and declines in income related to our bifurcated embedded derivatives during the current period

and gains on extinguishment of corporate borrowings and vendor and legal settlements and recoveries during the prior period, increases in food and beverage cost percentage, increases in operating expense, increases in rent, increases in general and administrative expenses, increases in interest expense, increases in income tax provision and increases in foreign currency translation rates, partially offset by the increase in average ticket prices and food and beverage per patron, the decrease in film exhibition cost percentage compared to the prior year, increases in other revenues increases in investment income and decreases in depreciation and amortization and impairment of long-lived assets.

#### **Theatrical Exhibition—U.S. Markets**

**Revenues.** Total revenues increased \$161.9 million, or 4.6%, during the year ended December 31, 2025, compared to the year ended December 31, 2024. Admissions revenues increased \$75.3 million, or 3.9%, during the year ended December 31, 2025, compared to the year ended December 31, 2024, primarily due to an increase in average ticket price of 4.6% and increase in our market share, partially offset by a decrease in attendance of 0.7% from 156.9 million patrons to 155.8 million patrons. The increase in average ticket price was primarily due to increased ticket prices for all formats and increases in attendance for 3D, IMAX and other PLF screens. Attendance decreased due to the popularity of film product compared to the prior year. The market share increase was driven by our loyalty program initiatives, discount days, and the interplay between the film slate and our geographic theatre mix. The availability and popularity of film product released during the year ended December 31, 2024, was negatively impacted by the Writers Guild of America and the Screen Actors Guild – American Federation of Television and Radio Artists strikes during 2023.

Food and beverage revenues increased \$33.9 million, or 2.6%, during the year ended December 31, 2025, compared to the year ended December 31, 2024, primarily due to the increase in food and beverage per patron, partially offset by the decrease in attendance. Food and beverage per patron increased 3.3% from \$8.30 to \$8.57 primarily due to an increase in average prices and the percentage of guests making transactions, partially offset by lower units per transaction by guests and more frequent attendance from our AMC Stubs members.

Total other theatre revenues increased \$52.7 million, or 16.2%, during the year ended December 31, 2025, compared to the year ended December 31, 2024 primarily due to increases in advertising income, income from ticket fees due to the increase in the percentage of guests paying ticket fees, retail food and beverage income, retail merchandise income, co-brand credit card revenue, and distribution revenue. As a result of our Amended ESA, advertising income increased from the prior year by \$15.6 million due to an increase in discount rates related to the significant financing component of the Amended ESA, partially offset by lower amortization of deferred revenues due to an increase in the term of the Amended ESA. See Note 2—Revenue Recognition in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for additional information about the Amended ESA.

**Operating costs and expenses.** Operating costs and expenses increased \$87.1 million, or 2.4%, during the year ended December 31, 2025, compared to the year ended December 31, 2024. Film exhibition costs increased \$31.7 million, or 3.2%, during the year ended December 31, 2025, compared to the year ended December 31, 2024, primarily due to the increase in admissions revenues due to the factors discussed above, partially offset by lower film rental terms. As a percentage of admissions revenues, film exhibition costs were 51.2% for the year ended December 31, 2025, compared to 51.6% for the year ended December 31, 2024. The decrease in film exhibition cost percentage is primarily due to the concentration of box office revenues in lower grossing films in the current year, which typically results in lower film exhibition costs.

Food and beverage costs increased \$15.5 million, or 6.9%, during the year ended December 31, 2025, compared to the year ended December 31, 2024. The increase in food and beverage costs was primarily due to the increase in food and beverage revenues due to the factors discussed above. As a percentage of food and beverage revenues, food and beverage costs were 18.1% for the year ended December 31, 2025, compared to 17.3% for the year ended December 31, 2024.

Operating expense increased by \$75.0 million, or 6.0%, during the year ended December 31, 2025, compared to the year ended December 31, 2024. The increase in operating expense was primarily due to increases in salaries and wages expense, utilities expense, computer maintenance costs, retail merchandise costs, premium format expense and losses on disposition of assets. As a percentage of revenues, operating expense was 35.8% for the year ended December 31, 2025, compared to 35.3% for the year ended December 31, 2024. The increase in operating expense as a percentage of revenues is primarily due to the operating leverage lost as attendance decreases. Rent expense increased \$0.2 million during the year ended December 31, 2025 compared to the year ended December 31, 2024.

[Table of Contents](#)

**Merger, acquisition, and other costs.** Merger, acquisition, and other costs were \$3.6 million during the year ended December 31, 2025, compared to \$0.1 million during the year ended December 31, 2024. The current year expense relates to severance costs in U.S. markets.

**Other.** Other general and administrative expense decreased \$6.5 million, or 4.3%, during the year ended December 31, 2025, compared to the year ended December 31, 2024, primarily due to declines in stock-based compensation expense due to lower than expected annual performance compared to unindexed annual targets in the current year compared to the prior year, lower insurance costs, and lower legal costs, partially offset by increases in bonus expense as a result of higher than expected annual performance compared to industry box office indexed annual targets in the current year compared to the prior year.

**Depreciation and amortization.** Depreciation and amortization decreased \$8.4 million, or 3.4%, during the year ended December 31, 2025, compared to the year ended December 31, 2024, primarily due to theatre closures and lower depreciation expense on theatres impaired during the year ended December 31, 2024.

**Impairment of long-lived assets.** During the year ended December 31, 2025, we recognized non-cash impairment losses of \$28.0 million on 47 theatres in the U.S. markets with 560 screens (in Alabama, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Louisiana, Massachusetts, Michigan, Minnesota, New Jersey, New York, North Carolina, Pennsylvania, Tennessee, Texas, Utah, Virginia, Washington, Wisconsin).

During the year ended December 31, 2024, we recognized non-cash impairment losses of \$51.9 million on 39 theatres in the U.S. markets with 469 screens (in Alabama, California, Florida, Illinois, Indiana, Massachusetts, Michigan, Minnesota, New Jersey, New York, Pennsylvania, Texas, Virginia, and Washington).

**Other expense (income).** Other expense of \$153.5 million during the year ended December 31, 2025 was primarily due to a \$103.3 million loss on extinguishment of \$337.4 million aggregate principal amount of our Existing Exchangeable Notes, a \$99.0 million loss on extinguishment of \$590.0 million aggregate principal amount of our Existing 7.5% Notes, \$19.3 million of expense related to the increase in fair value of the derivative liability for the embedded derivative features in the New Exchangeable Notes, and \$3.1 million in term loan modification third party fees, partially offset by \$(56.7) million of income related to the decrease in fair value of the derivative liability for the embedded conversion feature in the Existing Exchangeable Notes, \$(5.7) million of equity in earnings of non-consolidated entities and \$(6.6) million of gain on the extinguishment of our Second Lien Notes. Other income of \$(124.4) million during the year ended December 31, 2024 was primarily due to \$(75.8) million of income related to the decrease in fair value of the bifurcated embedded derivative in the Existing Exchangeable Notes, a gain on extinguishment of debt of \$(40.3) million related to the redemption of \$837.7 million aggregate principal amount of the Second Lien Notes, \$(40.2) million of recoveries related to shareholder litigation, \$(10.7) million of equity in earnings of non-consolidated entities, and \$(3.6) million of other settlement proceeds, partially offset by \$42.3 million of third party costs related to the modification of the Term Loans due 2026. See Note 1—The Company and Significant Accounting Policies in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for additional information about the components of other expense (income).

**Interest expense.** Interest expense increased \$84.8 million to \$463.3 million for the year ended December 31, 2025, compared to \$378.5 million during the year ended December 31, 2024, primarily due to increased interest expense of \$51.4 million on the New 2029 Notes issued on July 24, 2025, \$36.8 million on the New Term Loans compared to the Term Loans due 2026, \$28.2 million related to higher discount rates on the significant financing component of the Amended ESA, \$9.3 million on the Existing Exchangeable Notes issued on July 22, 2024, and \$8.8 million on the New Exchangeable Notes issued on July 1, 2025, partially offset by declines in interest expense of \$23.1 million on the Second Lien Notes due to redemptions of the remaining principal balances, \$19.7 million on the Existing 7.5% Notes due 2029 due to redemptions of \$590.0 million aggregate principal amount on July 24, 2025, \$4.0 million on the Senior Subordinated Notes due 2025 due to redemptions of the remaining principal balances and \$1.5 million on the Senior Subordinated Notes due 2026 due to redemptions of the remaining principal balances. See Note 2—Revenue Recognition in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for additional information about the Amended ESA, and see Note 7—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for additional information about our indebtedness.

**Investment income.** Investment income was \$(31.0) million for the year ended December 31, 2025, compared to investment income of \$(14.0) million for the year ended December 31, 2024. Investment income in the current year

includes \$(34.4) million of realized and unrealized gains on our investments in common shares and warrants to purchase common shares in Hycroft and interest income of \$(6.9) million, partially offset by an impairment charge of \$10.3 million related to our investment in an equity security without a readily determinable fair value measured at cost less any impairments. Investment income in the prior year includes interest income of \$(16.9) million, partially offset by unrealized losses of \$2.9 million on our investments in common shares and warrants to purchase common shares in Hycroft. See Note 1—The Company and Significant Accounting Policies in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for additional information about our investments in Hycroft.

**Income tax provision.** The income tax provision was \$2.7 million and \$0.0 million for the years ended December 31, 2025, and December 31, 2024, respectively. See Note 9—Income Taxes in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for further information.

**Net loss.** Net loss was \$536.1 million and \$262.5 million during the years ended December 31, 2025, and December 31, 2024, respectively. Net loss during the year ended December 31, 2025 compared to net loss for the year ended December 31, 2024 was negatively impacted by decreases in other income due to losses on extinguishment of corporate borrowings, declines in income related to our bifurcated embedded derivatives during the current period, declines in gains on extinguishment of corporate borrowings, and declines in legal settlements and recoveries during the prior period, increases in food and beverage cost percentage, increases in operating expense, increases in rent, increases in interest expense, and increases in income tax provision, partially offset by the increase in average ticket prices and food and beverage per patron, the decrease in film exhibition cost percentage, increases in other revenues, increases in investment income, decreases in general and administrative expenses, decreases in depreciation and amortization and decreases in impairment of long-lived assets.

### **Theatrical Exhibition—International Markets**

**Revenues.** Total revenues increased \$49.8 million, or 4.6%, during the year ended December 31, 2025, compared to the year ended December 31, 2024. Admissions revenues increased \$17.0 million, or 2.6%, during the year ended December 31, 2025, compared to the year ended December 31, 2024, primarily due to an increase in average ticket price of 8.6%, partially offset by a decrease in attendance of 5.5% from 67.3 million patrons to 63.6 million patrons. The increase in average ticket price was primarily due to increased ticket prices and increases in foreign currency translation rates. Attendance decreased due to the popularity of film product compared to the prior year.

Food and beverage revenues increased \$12.5 million, or 3.9%, during the year ended December 31, 2025, compared to the year ended December 31, 2024, due to the increase in food and beverage per patron, partially offset by the decrease in attendance. Food and beverage per patron increased 10.0% from \$4.80 to \$5.28 primarily due to an increase in average prices, increases in the percentage of guests making transactions, and increases in foreign currency translation rates, partially offset by lower units per transaction by guests.

Total other theatre revenues increased \$20.3 million, or 16.1%, during the year ended December 31, 2025, compared to the year ended December 31, 2024, primarily due to increases in income from expirations of package tickets and gift cards in our International markets, retail merchandise income, and increases in foreign currency translation rates.

**Operating costs and expenses.** Operating costs and expenses increased \$62.7 million, or 5.5%, during the year ended December 31, 2025, compared to the year ended December 31, 2024. Film exhibition costs increased \$4.3 million, or 1.7%, during the year ended December 31, 2025, compared to the year ended December 31, 2024, primarily due to the increase in admissions revenues due to the factors discussed above, partially offset by lower film rental terms. As a percentage of admissions revenues, film exhibition costs were 38.5% for the year ended December 31, 2025, compared to 38.9% for the year ended December 31, 2024. The decrease in film exhibition cost percentage is primarily due to the concentration of box office revenues in lower grossing films in the current year, which typically results in lower film exhibition costs.

Food and beverage costs increased \$5.9 million, or 7.4%, during the year ended December 31, 2025, compared to the year ended December 31, 2024. The increase in food and beverage costs was primarily due to the increase in food and beverage revenues due to the factors discussed above. As a percentage of food and beverage revenues, food and beverage costs were 25.6% for the year ended December 31, 2025, compared to 24.7% for the year ended December 31, 2024.

Operating expense increased by \$31.6 million, or 7.4%, during the year ended December 31, 2025, compared to the year ended December 31, 2024. The increase in operating expense was primarily due to increases in salaries and wages expense, utilities expense, and increases in foreign currency translation rates. As a percentage of revenues, operating expense was 40.2% for the year ended December 31, 2025, compared to 39.1% for the year ended December 31, 2024. The increase in operating expense as a percentage of revenues is primarily due to the operating leverage lost as attendance decreases. Rent expense increased \$13.5 million, or 6.0%, during the year ended December 31, 2025, compared to the year ended December 31, 2024, primarily due to increases in foreign currency translation rates.

**Other.** Other general and administrative expense increased \$10.0 million, or 13.1%, during the year ended December 31, 2025, compared to the year ended December 31, 2024, primarily due to increases in bonus expense as a result of higher than expected annual performance compared to annual industry box office indexed targets in the current year compared to the prior year and increases in foreign currency translation rates, partially offset by declines in stock-based compensation expense due to lower than expected annual performance compared to annual unindexed targets in the current year compared to the prior year and lower professional and consulting costs.

**Depreciation and amortization.** Depreciation and amortization increased \$2.3 million, or 3.2%, during the year ended December 31, 2025, compared to the year ended December 31, 2024, primarily due to increases in foreign currency translation rates, partially offset by theatre closures and lower depreciation expense on theatres impaired during the year ended December 31, 2024.

**Impairment of long-lived assets.** During the year ended December 31, 2025, we recognized non-cash impairment losses of \$15.5 million on 20 theatres in the International markets with 159 screens (in Germany, Italy, Spain, Sweden, and the United Kingdom), which were related to property, net and operating lease right-of-use assets, net.

During the year ended December 31, 2024, we recognized non-cash impairment losses of \$20.4 million on 23 theatres in the International markets with 188 screens (in Germany, Italy, Spain, and the United Kingdom), which were related to property, net and operating lease right-of-use assets, net.

**Other income.** Other income of \$(41.1) million during the year ended December 31, 2025 includes \$(28.1) million in foreign currency transaction gains, \$(10.8) million of governmental assistance, and \$(1.2) million of equity in earnings of non-consolidated entities. Other income of \$(31.8) million during the year ended December 31, 2024 was primarily due to the favorable settlement of a vendor dispute of \$(36.2) million, \$(1.7) million of equity in earnings of non-consolidated entities, partially offset by \$7.0 million of foreign currency transaction losses. See Note 1—The Company and Significant Accounting Policies in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for additional information about the components of other (income) expense.

**Interest expense.** Interest expense increased \$1.7 million to \$66.9 million for the year ended December 31, 2025, compared to \$65.2 million during the year ended December 31, 2024, primarily due to increased interest expense on corporate borrowings and finance lease obligations. See Note 3—Leases and Note 7—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for additional information about our indebtedness and finance leases.

**Investment income.** Investment income was \$1.1 million for the year ended December 31, 2025, compared to investment income of \$2.3 million for the year ended December 31, 2024. Investment income is comprised of interest income in the current and prior periods.

**Income tax provision.** The income tax provision was \$1.8 million and \$2.1 million for the years ended December 31, 2025, and December 31, 2024, respectively. See Note 9—Income Taxes in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for further information.

**Net loss.** Net loss was \$96.3 million and \$90.1 million during the years ended December 31, 2025, and December 31, 2024, respectively. Net loss during the year ended December 31, 2025 compared to net loss for the year ended December 31, 2024 was negatively impacted by increases in food and beverage cost percentage, increases in operating expense, increases in rent, increases in general and administrative expenses, increases in depreciation and amortization, increases in interest expense, decreases in investment income, and increases in foreign currency translation rates, partially offset by the increase in average ticket prices, the increase in food and beverage per patron, the decrease in film exhibition cost percentage compared to the prior year, increases in other revenues, decreases in impairment of long-lived assets, increases in other income, and decreases in income tax provision.

### **Results of Operations—For the Year Ended December 31, 2024, Compared to the Year Ended December 31, 2023**

For a comparison of our results of operations for the year ended December 31, 2024, compared to the year ended December 31, 2023, see “[Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations](#)” of our annual report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 26, 2025, which is incorporated herein by reference.

### **Liquidity and Capital Resources—For the Year Ended December 31, 2025, Compared to the Year Ended December 31, 2024**

Our consolidated revenues are primarily collected in cash, principally through admissions and food and beverage sales. We have an operating “float” which partially finances our operations and which generally permits us to maintain a smaller amount of working capital capacity. This float exists because admissions revenues are received in cash, while exhibition costs (primarily film rentals) are ordinarily paid to distributors from 20 to 45 days following receipt of admissions revenues. Film distributors generally release the films which they anticipate will be the most successful during the summer and year-end holiday seasons. Consequently, we typically generate higher revenues during such periods and experience higher working capital requirements following such periods.

We had working capital deficits (excluding restricted cash) as of December 31, 2025 and December 31, 2024 of \$(1,090.6) million and \$(846.1) million, respectively. As of December 31, 2025 and December 31, 2024, working capital included operating lease liabilities of \$560.0 million and \$524.9 million, respectively, and deferred revenues of \$465.5 million and \$432.4 million, respectively.

As of December 31, 2025, we had cash and cash equivalents of approximately \$428.5 million compared to \$632.3 million as of December 31, 2024.

During the year ended December 31, 2025, we took action to lower our future interest expense of our fixed-rate debt through debt buybacks and exchanges for equity and enhanced liquidity through equity issuances. See Note 7—Corporate Borrowings and Finance Lease Liabilities, Note 8—Stockholders’ Deficit, and Note 14—Subsequent Events in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for further information regarding equity issuances and debt repurchases and exchanges.

#### ***2025 Refinancing Transactions***

On July 24, 2025, Muvico issued \$857.0 million aggregate principal amount of New 2029 Notes in exchange for \$590.0 million aggregate principal amount of Existing 7.5% Notes and \$244.4 million of incremental, new money financing. On the same day, Muvico also issued \$194.4 million aggregate principal amount of New Exchangeable Notes in exchange for \$194.4 million aggregate principal amount of Existing Exchangeable Notes. On September 30, 2025, \$39.9 million aggregate principal of New Exchangeable Notes were cancelled pursuant to a downward adjustment feature in the New Exchangeable Notes, which represented the maximum possible downward adjustment. We used the new money financing from the issuance of the New 2029 Notes to fully redeem our Senior Subordinated Notes due 2026 and our Second Lien Notes, and also to pay consent fees to the Consenting Term Loan Lenders.

The New Exchangeable Notes were not initially exchangeable into Common Stock. At the 2025 Annual Meeting, our stockholders approved an amendment to the Company’s Certificate of Incorporation for the Authorized Share Increase which allowed for the New Exchangeable Notes to become exchangeable and lowered the interest rate to 1.5% cash interest. The Authorized Share Increase also allowed for a \$15.0 million consent fee payable to Consenting Existing Exchangeable Noteholders to be payable in the form of shares of Common Stock, based on a price determined based on the average of the daily volume weighted average price of our Common Stock for the sixty consecutive trading days commencing on December 22, 2025. On December 22, 2025, the Company and the holders of the New Exchangeable Notes agreed to amend the New Exchangeable Notes Indenture to amend and restate the Exchange Rate and allow for up to \$150.0 million of net proceeds from sales of at-the-market offerings. The amendments were memorialized in a supplemental indenture dated January 12, 2026 (the “New Exchangeable Notes Supplemental Indenture”). As consideration for the indenture amendments the Company will pay the New Exchangeable Noteholders a consent fee of \$6.25 million payable in shares of Common Stock. The number of shares will be based on the average of the daily volume weighted average price of our Common Stock for the sixty consecutive trading days commencing on December 22, 2025.

[Table of Contents](#)

See Note 7—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for further information regarding these transactions.

**2024 Refinancing Transactions**

In 2024, we completed the 2024 Refinancing Transactions with two creditor groups to refinance and extend to 2029 and 2030 the maturities of our debt previously maturing in 2026.

In connection with the refinancing:

- We entered into the New Term Loans.
- The New Term Loans were (i) used as consideration for open market purchases of \$1,895.0 million of our Term Loans due 2026 and (ii) exchanged for \$104.2 million of our Second Lien Notes.
- Muvico also completed a private offering for cash of \$414.4 million aggregate principal of Existing Exchangeable Notes and used the proceeds from the offering to repurchase \$414.4 million aggregate principal amount of Second Lien Notes.

See Note 7—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for further information.

We expect, from time to time, to continue to seek to retire or purchase our outstanding debt through cash purchases and/or exchanges for equity or debt, in open-market purchases, privately negotiated transactions or otherwise. Such repurchases or exchanges, if any, will be upon such terms and at such prices as we may determine, and will depend on prevailing market conditions, our liquidity requirements, the availability of authorized share capital, contractual restrictions, and other factors. The amounts involved may be material and, to the extent equity is used, dilutive. For example, on February 17, 2026, we launched the Financing Transaction to refinance the New Term Loans and Odeon Notes due 2027. There can be no assurance that we will successfully enter into an agreement with respect to or complete the Financing Transaction, which is subject to, among other things, market and other conditions, and the negotiation and execution of definitive documents.

**Liquidity Requirements**

We believe our existing cash and cash equivalents, together with cash generated from operations, will be sufficient to fund our operations and satisfy our obligations currently and through the next twelve months. Our current cash burn rates are not sustainable long-term. In order to achieve net positive cash flows from operating activities we believe that revenues will need to increase to levels at least in line with pre-COVID-19 revenues. North America box office grosses were down approximately 22% for the year ended December 31, 2025, compared to the year ended December 31, 2019. Until such time as we are able to achieve net positive cash flows from operating activities, it is difficult to estimate our future cash burn rates and liquidity requirements. Depending on our assumptions regarding the timing and ability to achieve levels of revenue, the estimates of amounts of required liquidity vary significantly.

There can be no assurance that the revenues, attendance levels and other assumptions used to estimate our liquidity requirements and future cash burn rates will be correct, and our ability to be predictive is uncertain due to limited ability to predict studio film release dates, the overall production and theatrical release levels and success of individual titles. Further, there can be no assurances that we will be successful in generating the additional liquidity necessary to meet our obligations beyond twelve months from the issuance of this Annual Report on terms acceptable to us or at all.

The following is a summary of our net cash flows for the years ended December 31, 2025 and December 31, 2024:

<b>(in millions)</b>	<b>December 31, 2025</b>		<b>December 31, 2024</b>	
Operating activities	\$	(119.8)	\$	(50.8)
Investing activities		(221.6)		(242.9)
Financing activities		125.2		68.4

### ***Cash Flows from Operating Activities***

Net cash used in operating activities increased by \$69.0 million primarily due to a decrease in cash received from working capital, increases in operating expenses including salaries and wages expense, utilities expense, computer maintenance costs, retail merchandise costs, premium format expense, decrease in attendance, increases in general and administrative: other expenses, the increase in food and beverage cost percentage, an increase in cash paid for interest, a decrease in cash received from vendor dispute settlements, a decrease in shareholder litigation recoveries, and a decrease in other settlement proceeds. The preceding items were partially offset by an increase in average ticket price, an increase in food and beverage per patron, an increase in income from ticket fees due to the increase in percentage of guests paying ticket fees, an increase in retail food and beverage income, an increase in retail merchandise income, an increase in co-brand credit card revenue, an increase in distribution revenue, a decrease in film exhibition cost percentage, a decrease in third-party fees paid in connection with the modifications of term loans and an increase in government assistance received.

### ***Cash Flows from Investing Activities***

Net cash used in investing activities decreased by \$21.3 million primarily due to proceeds from the sale of part of our investment in Hycroft and increases in proceeds from sales of long-term assets, partially offset by an investment in a non-consolidated entity, and an increase in capital expenditures.

We fund the costs of constructing, maintaining and remodeling our theatres through existing cash balances, cash generated from operations, lease incentives, or capital raised, as necessary. We generally lease our theatres pursuant to long-term, non-cancelable operating leases, which may require the developer who owns the property, to reimburse us for the construction costs. We estimate that our capital expenditures, net of lease incentives, will be approximately \$175.0 million to \$225.0 million for the year ending December 31, 2026 to maintain and enhance operations.

### ***Cash Flows from Financing Activities***

Net cash provided by financing activities increased \$56.8 million, primarily due to increased proceeds from debt refinancing activities, partially offset by a decrease in proceeds from equity issuances and a decrease in taxes paid for restricted unit withholdings.

### **Dividends**

The payment of future dividends is subject to the Board's discretion, and dependent on many considerations, including limitations imposed by covenants in the agreements governing our indebtedness, operating results, capital requirements, strategic considerations and other factors.

### **Future Contractual Obligations**

Our estimated future obligations as of December 31, 2025 include both current and long-term obligations. Our expected material contractual cash requirements over the next twelve months primarily consist of capital related betterments of \$22.8 million, minimum operating lease payments of \$945.6 million, finance lease payments of \$9.0 million, and corporate borrowings principal and interest payments of \$19.9 million and \$381.3 million, respectively.

**Pension funding.** Our U.S., United Kingdom, and Sweden defined benefit plans are frozen. We fund our U.S. pension plans such that the plans are in compliance with Employee Retirement Income Security Act ("ERISA") and the plans are not considered "at risk" as defined by ERISA guidelines. We expect to make \$3.0 million of contributions to the defined pension plans during the year ended December 31, 2026.

**Minimum operating lease and finance lease payments.** We have current and long-term minimum cash requirements for operating lease payments of \$945.6 million and \$4,970.8 million, respectively. We have current and long-term minimum cash requirements for finance lease payments of \$9.0 million and \$68.7 million, respectively. The total amounts do not equal the carrying amount due to imputed interest. See Note 3—Leases in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K, for a summary of the estimated future repayment terms for the minimum operating lease and finance lease amounts.

**Corporate borrowings principal and interest payments.** We have current and long-term cash requirements for the payment of principal related to corporate borrowings of \$19.9 million and \$4,004.3 million, respectively. The

## [Table of Contents](#)

total amount does not equal the carrying amount due to unamortized discounts, premiums and deferred charges. Based upon the December 31, 2025 outstanding principal balances and interest rates, we have current and long-term cash interest payment requirements related to our corporate borrowings of \$381.3 million and \$769.0 million, respectively. The cash interest payment requirements for our New Term Loans and New 2029 Notes were estimated using interest rates of 10.731% and 9.0%, respectively, based on the interest rates in effect as of December 31, 2025. In 2026, we assume that we will pay interest on the Existing Exchangeable Notes in-kind in the form of additional Existing Exchangeable Notes.

See Note 7—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for further information, including a schedule of outstanding principal balances, applicable interest rates, and maturity dates for each individual borrowing and a schedule of required principal payments and maturities of corporate borrowings as of December 31, 2025.

### **Covenant Compliance**

As of December 31, 2025, we believe that we were in full compliance with all agreements, including related covenants, governing our outstanding debt.

### **Liquidity and Capital Resources—For the Year Ended December 31, 2024, Compared to the Year Ended December 31, 2023**

For a comparison of our liquidity and capital resources for the year ended December 31, 2024, compared to the year ended December 31, 2023, see [“Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our annual report on Form 10-K for the year ended December 31, 2024](#), filed with the SEC on February 26, 2025, which is incorporated herein by reference.

### **New Accounting Pronouncements**

See Note 1—The Company and Significant Accounting Policies in the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Form 10-K for information regarding recently issued accounting standards.

### **Formation of Unrestricted Subsidiaries**

On July 22, 2024, American-Multi Cinema Inc. (“Multi-Cinema”), a Missouri corporation and a direct subsidiary of Holdings, assigned or transferred the net assets (“Theatre Net Assets”) of 175 theatres and transferred a 100% interest in certain intellectual property assets to its direct subsidiary Centertainment Development, LLC (“Centertainment”), and the Theatre Net Assets were in turn transferred to Centertainment’s direct wholly-owned subsidiary Muvico. Theatre Net Assets include lease contracts and theatre property, including furniture, fixtures, plant and equipment, and other working capital items associated directly with the theatre locations. At the same time, Muvico licensed the intellectual property back to Multi-Cinema for its continued use in the operation of its retained theatres and entered into a management agreement for Multi-Cinema to operate the theatres transferred to Muvico. Muvico and Centertainment (collectively, the “Muvico Group”) are unrestricted subsidiaries under the indenture governing Holdings’ Existing 7.5% Notes.

### **Unrestricted Subsidiaries’ Financial Information and Operating Metrics**

Pursuant to the indenture governing Holdings’ Existing 7.5% Notes, the indenture governing Muvico’s New Exchangeable Notes, and the Credit Agreement governing Holdings’ and Muvico’s New Term Loans, we are presenting the following financial information and operating metrics for the Muvico Group separately from Holdings and its restricted subsidiaries (the “Restricted Subsidiaries”) and collectively with Holdings, the “AMC Group”). AMC Theatres of UK Limited, which is an unrestricted subsidiary under the indenture governing Holdings’ Existing 7.5% Notes has been included with the Restricted Subsidiaries for the purposes of the following presentation of financial information and operating metrics (this subsidiary is individually immaterial). The financial information presented for AMC Group and Muvico Group is presented on a standalone basis with discrete identification of the assets, liabilities, revenues and expenses associated with the Theatre Net Assets that were transferred to Muvico. Intercompany transactions between entities within the AMC Group or within the Muvico Group have been eliminated. Certain entities within the AMC Group and within the Muvico Group are parties to intercompany management, licensing, and debt agreements with each other. These transactions are reflected discretely within the columnar presentation below and are properly eliminated

[Table of Contents](#)

upon consolidation. The financial information is also prepared using the historical cost carrying values of Holdings, the top parent entity.

Holdings and Muvico are co-borrowers and joint and severally liable for the New Term Loans. Pursuant to ASC 405-40 we have allocated fifty percent (50%) of the liabilities, interest expense and cash flows each to Muvico and Holdings, respectively. The basis of this allocation is the amount we expect each party to pay.

(In millions)	Year Ended December 31, 2025			
	AMCEH & Restricted Subsidiaries/AMC Group (1) (unaudited)	Muvico Group Unrestricted Subsidiaries (unaudited)	Eliminations (unaudited)	Consolidated
<b>Revenues</b>				
Admissions	\$ 1,867.1	\$ 785.7	\$ —	\$ 2,652.8
Food and beverage	1,262.6	408.7	—	1,671.3
Other theatre (3)	459.0	94.9	(29.1)	524.8
<b>Total revenues</b>	<b>3,588.7</b>	<b>1,289.3</b>	<b>(29.1)</b>	<b>4,848.9</b>
<b>Operating costs and expenses</b>				
Film exhibition costs	877.3	397.9	—	1,275.2
Food and beverage costs	254.6	72.4	—	327.0
Operating expense, excluding depreciation and amortization below	1,359.3	426.7	—	1,786.0
Rent	663.9	223.4	—	887.3
<b>General and administrative:</b>				
Merger, acquisition and other costs	3.6	—	—	3.6
Other, excluding depreciation and amortization below (3)	242.4	17.0	(29.1)	230.3
Depreciation and amortization	236.7	76.7	—	313.4
Impairment of long-lived assets	40.4	3.1	—	43.5
Operating costs and expenses	3,678.2	1,217.2	(29.1)	4,866.3
<b>Operating income (loss)</b>	<b>(89.5)</b>	<b>72.1</b>	<b>—</b>	<b>(17.4)</b>
<b>Other expense, net:</b>				
Other expense	45.8	66.6	—	112.4
<b>Interest expense:</b>				
Corporate borrowings	250.4	209.1	—	459.5
Finance lease obligations	6.0	—	—	6.0
Intercompany interest expense	2.6	5.4	(8.0)	—
Non-cash NCM exhibitor services agreement	64.7	—	—	64.7
Intercompany interest income	(5.4)	(2.6)	8.0	—
Investment income	(26.7)	(5.4)	—	(32.1)
<b>Total other expense, net</b>	<b>337.4</b>	<b>273.1</b>	<b>—</b>	<b>610.5</b>
Loss before income taxes	(426.9)	(201.0)	—	(627.9)
Income tax provision (2)	4.5	—	—	4.5
<b>Net loss</b>	<b>\$ (431.4)</b>	<b>\$ (201.0)</b>	<b>\$ —</b>	<b>\$ (632.4)</b>

(In millions)	Year Ended December 31, 2025		
	AMCEH & Restricted Subsidiaries/AMC Group (1) (unaudited)	Muvico Group Unrestricted Subsidiaries (unaudited)	Consolidated
Net loss	\$ (431.4)	\$ (201.0)	\$ (632.4)
Other comprehensive income:			
Unrealized foreign currency translation adjustments	95.0	—	95.0
Pension adjustments:			
Net loss arising during the period	(5.2)	—	(5.2)
Other comprehensive income:	89.8	—	89.8
Total comprehensive loss	\$ (341.6)	\$ (201.0)	\$ (542.6)

- (1) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indentures governing the New Exchangeable Notes and Existing 7.5% Notes and (ii) AMC Group under the Credit Agreement. Transactions between Holdings and its restricted subsidiaries have been eliminated.
- (2) Muvico is a disregarded entity for federal and state income tax purposes with all tax expense and deferred taxes recorded at the AMC Group level.
- (3) Includes intercompany management fee revenues of \$17.0 million recorded by AMCEH & Restricted Subsidiaries/AMC Group and intercompany license fee revenues of \$12.1 million recorded by Muvico Group Unrestricted Subsidiaries. Corresponding amounts of expense are included in general and administrative: other for Muvico Group Unrestricted Subsidiaries and AMCEH & Restricted Subsidiaries/AMC Group.

Key operating metrics:	Year Ended December 31, 2025		
	AMCEH & Restricted Subsidiaries/AMC Group (3) (unaudited)	Muvico Group Unrestricted Subsidiaries (unaudited)	Consolidated (unaudited)
Average ticket price	\$ 11.63	\$ 13.36	\$ 12.09
Attendance (in thousands) (1)	160,606	58,806	219,412
Number of screens operated (2)	7,416	2,224	9,640
Number of theatres operated (2)	683	172	855
Adjusted EBITDA (4)	\$ 235.8	\$ 151.7	\$ 387.5

- (1) Includes consolidated theatres only and excludes screens offline due to construction.
- (2) The screens and theatres of the Muvico Group are operated by Multi-Cinema pursuant to the management agreement.
- (3) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indentures governing the New Exchangeable Notes and Existing 7.5% Notes and (ii) AMC Group under the Credit Agreement.
- (4) Below is a reconciliation of net loss to Adjusted EBITDA for AMCEH & Restricted Subsidiaries/AMC Group and Muvico Group. The reconciling items below have the same definitions and are of the same nature as the reconciling items presented previously in Management's Discussion and Analysis section of this Form 10-K.

[Table of Contents](#)

(In millions)	Year Ended December 31, 2025			
	AMCEH & Restricted Subsidiaries/AMC Group (1) (unaudited)	Muvico Group Unrestricted Subsidiaries (unaudited)	Eliminations (unaudited)	Consolidated
Net loss	\$ (431.4)	\$ (201.0)	\$ —	\$ (632.4)
Plus:				
Income tax provision	4.5	—	—	4.5
Interest expense	323.7	214.5	(8.0)	530.2
Depreciation and amortization	236.7	76.7	—	313.4
Impairment of long-lived assets	40.4	3.1	—	43.5
Certain operating expense (income)	14.8	(0.2)	—	14.6
Equity in earnings of non-consolidated entities	(6.8)	—	—	(6.8)
Attributable EBITDA	2.3	—	—	2.3
Investment income	(32.1)	(8.0)	8.0	(32.1)
Other expense, net	63.2	66.6	—	129.8
Merger, acquisition and other costs	3.6	—	—	3.6
Stock-based compensation expense	16.9	—	—	16.9
Adjusted EBITDA	<u>\$ 235.8</u>	<u>\$ 151.7</u>	<u>\$ —</u>	<u>\$ 387.5</u>

- (1) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indentures governing the New Exchangeable Notes and Existing 7.5% Notes and (ii) AMC Group under the Credit Agreement.

	As of December 31, 2025			
(In millions, except share data)	AMCEH & Restricted Subsidiaries/AMC Group (3) (unaudited)	Muvico Group Unrestricted Subsidiaries (unaudited)	Eliminations (unaudited)	Consolidated
<b>ASSETS</b>				
Current assets:				
Cash and cash equivalents (1)	\$ 249.8	\$ 178.7	\$ —	\$ 428.5
Restricted cash	48.8	—	—	48.8
Receivables, net	150.2	5.8	—	156.0
Other current assets	61.0	36.2	—	97.2
Total current assets	509.8	220.7	—	730.5
Property, net	1,032.4	341.8	—	1,374.2
Operating lease right-of-use assets, net	2,383.3	754.0	—	3,137.3
Intangible assets, net	43.0	104.4	—	147.4
Goodwill	2,416.1	—	—	2,416.1
Other long-term assets	211.6	0.7	—	212.3
Intercompany receivables (2)	—	2,139.9	(2,139.9)	—
Investment in subsidiary	418.7	—	(418.7)	—
Total assets	<u>\$ 7,014.9</u>	<u>\$ 3,561.5</u>	<u>\$ (2,558.6)</u>	<u>\$ 8,017.8</u>
<b>LIABILITIES AND STOCKHOLDERS' DEFICIT</b>				
Current liabilities:				
Accounts payable	\$ 339.4	\$ 43.5	\$ —	\$ 382.9
Accrued expenses and other liabilities	301.6	36.6	—	338.2
Deferred revenues and income	462.0	3.5	—	465.5
Current maturities of corporate borrowings	10.0	9.9	—	19.9
Current maturities of finance lease liabilities	5.8	—	—	5.8
Current maturities of operating lease liabilities	411.2	148.8	—	560.0
Total current liabilities	1,530.0	242.3	—	1,772.3
Corporate borrowings	1,821.0	2,197.6	—	4,018.6
Finance lease liabilities	46.7	—	—	46.7
Operating lease liabilities	2,784.3	700.7	—	3,485.0
Exhibitor services agreement	459.1	—	—	459.1
Deferred tax liability, net (4)	35.7	—	—	35.7
Intercompany payables (2)	2,139.9	—	(2,139.9)	—
Other long-term liabilities	93.0	2.2	—	95.2
Total liabilities	8,909.7	3,142.8	(2,139.9)	9,912.6
Commitments and contingencies				
Stockholders' or member's equity (deficit):				
Preferred stock	—	—	—	—
Class A common stock	5.1	—	—	5.1
Additional paid-in capital	7,121.5	558.3	(558.3)	7,121.5
Accumulated other comprehensive loss	(42.2)	—	—	(42.2)
Accumulated deficit	(8,979.2)	(139.6)	139.6	(8,979.2)
Total stockholders' or member's equity (deficit)	(1,894.8)	418.7	(418.7)	(1,894.8)
Total liabilities and stockholders' or member's equity (deficit)	<u>\$ 7,014.9</u>	<u>\$ 3,561.5</u>	<u>\$ (2,558.6)</u>	<u>\$ 8,017.8</u>

- (1) The cash held in bank accounts differs from the book balance due to deposits in transit, payments in transit, and certain cash equivalents.
- (2) Intercompany receivables (payables) includes intercompany loans, fees receivable/payable pursuant to the management agreement and intellectual property license agreement, the intercompany receivable/payable created by allocating the New Term Loans borrowings between Holdings and Muvico, and other intercompany balances created as a result of the 2025 Refinancing Transactions and 2024 Refinancing Transactions.
- (3) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indentures governing the New Exchangeable Notes and Existing 7.5% Notes and (ii) AMC Group under the Credit Agreement.

[Table of Contents](#)

- (4) Muvico is a disregarded entity for federal and state income tax purposes with all tax expense and deferred taxes recorded at the AMC Group level.

(In millions)	Year Ended December 31, 2025		
	AMCEH & Restricted Subsidiaries/AMC Group (1) (unaudited)	Muvico Group Unrestricted Subsidiaries (unaudited)	Consolidated
Net loss	\$ (431.4)	\$ (201.0)	\$ (632.4)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:			
Depreciation and amortization	236.7	76.7	313.4
Loss on extinguishment of debt	92.7	103.3	196.0
Gain on derivatives	—	(37.4)	(37.4)
Deferred income taxes	2.0	—	2.0
Impairment of long-lived assets	40.4	3.1	43.5
Gain on investments in Hycroft	(34.4)	—	(34.4)
Impairment of equity security	10.3	—	10.3
Amortization of net discount on corporate borrowings to interest expense	7.5	7.1	14.6
Amortization of deferred financing costs to interest expense	6.8	4.5	11.3
PIK interest expense	—	44.4	44.4
Non-cash portion of stock-based compensation	16.9	—	16.9
Equity in earnings from non-consolidated entities, net of distributions	(0.2)	—	(0.2)
Lease incentives	45.6	—	45.6
Non-cash rent benefit	(95.3)	(14.0)	(109.3)
Net periodic benefit cost	1.2	—	1.2
Change in assets and liabilities:			
Receivables	13.5	(0.3)	13.2
Other assets	0.3	4.0	4.3
Accounts payable	(9.9)	2.4	(7.5)
Accrued expenses and other liabilities	3.6	7.3	10.9
Intercompany receivables and payables	(140.8)	140.8	—
Other, net	(26.2)	—	(26.2)
Net cash provided by (used in) operating activities	(260.7)	140.9	(119.8)
<b>Cash flows from investing activities:</b>			
Capital expenditures	(199.0)	(47.1)	(246.1)
Proceeds from disposition of long-term assets	2.9	—	2.9
Proceeds from sale of securities	24.1	—	24.1
Investments in non-consolidated entities	(4.0)	—	(4.0)
Other, net	1.5	—	1.5
Net cash used in investing activities	(174.5)	(47.1)	(221.6)
<b>Cash flows from financing activities:</b>			
Net proceeds from equity issuances	169.6	—	169.6
Proceeds from issuance of Senior Secured Notes due 2029	—	244.4	244.4
Principal payments under Second Lien Notes due 2026	(131.2)	—	(131.2)
Principal payments under Senior Subordinated Notes due 2025	(42.8)	—	(42.8)
Principal payments under Senior Subordinated Notes due 2026	(41.9)	—	(41.9)
Scheduled principal payments under Term Loan borrowings	(10.1)	(10.0)	(20.1)
Principal payments under finance lease obligations	(4.2)	—	(4.2)
Repurchase of Senior Subordinated Notes due 2025	(1.3)	—	(1.3)
Cash used to pay deferred financing costs	(11.2)	(29.3)	(40.5)
Debt extinguishment costs	(2.4)	—	(2.4)
Taxes paid for restricted unit withholdings	(4.4)	—	(4.4)
Proceeds (payments) of intercompany loans	412.8	(412.8)	—
Net cash provided by (used in) financing activities	332.9	(207.7)	125.2
Effect of exchange rate changes on cash and cash equivalents and restricted cash	12.7	—	12.7
<b>Net decrease in cash and cash equivalents and restricted cash</b>	<b>(89.6)</b>	<b>(113.9)</b>	<b>(203.5)</b>
<b>Cash and cash equivalents and restricted cash at beginning of period</b>	<b>388.2</b>	<b>292.6</b>	<b>680.8</b>
<b>Cash and cash equivalents and restricted cash at end of period</b>	<b>\$ 298.6</b>	<b>\$ 178.7</b>	<b>\$ 477.3</b>

- (1) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indentures governing the New Exchangeable Notes and Existing 7.5% Notes and (ii) AMC Group under the Credit Agreement.

**Item 7A. Quantitative and Qualitative Disclosures about Market Risk.**

In the ordinary course of business, our financial results are exposed to fluctuations in interest rates and foreign currency exchange rates. We manage the risk of fluctuations in interest rates by maintaining an appropriate balance between our fixed and floating-rate debt. In accordance with applicable guidance, we presented a sensitivity analysis showing the potential impact to net income of changes in interest rates and foreign currency exchange rates. For the years ended December 31, 2025 and December 31, 2024, our analysis utilized a hypothetical 100 basis-point increase or decrease to the average interest rate on our variable rate debt instruments to illustrate the potential impact to interest expense of changes in interest rates. Our analysis also utilized a hypothetical 100 basis-point increase or decrease to market interest rates on our performance-based variable-rate financial instruments and fixed rate financial instruments to illustrate the potential impact to fair value of changes in interest rates.

Similarly, for the same period, our analysis used a uniform and hypothetical 10% increase in foreign currency translation rates to depict the potential impact to net income of changes in foreign currency exchange rates. These market risk instruments and the potential impacts to the consolidated statements of operations as presented below.

**Market risk on performance-based & market-based variable-rate hybrid financial instruments.** As of December 31, 2025, we had an aggregate of \$1,994.2 million outstanding principal amount of our New Term Loans which bear interest, at our option, at rates equal to either (i) a base rate plus a margin of between 500 and 600 basis points depending on the total leverage ratio of the Company and its subsidiaries on a consolidated basis (the “Total Leverage Ratio”) or (ii) Term SOFR plus a margin of between 600 and 700 basis points depending on the Total Leverage Ratio.

Prior to the 2024 Refinancing Transactions we had outstanding Term Loans due 2026 under the Credit Agreement dated April 30, 2013, as amended, restated, amended and restated, supplemented or otherwise modified (the “2013 Credit Agreement”) which bore interest at a rate per annum equal to, at our option, either (1) a base rate determined by reference to the highest of (a) 0.50% per annum plus the Federal Funds Effective Rate, (b) the prime rate announced by the administrative agent and (c) 1.00% per annum plus Adjusted Term SOFR (as defined herein) for a 1-month tenor or (2) Term SOFR plus a credit spread adjustment of 0.11448% per annum, 0.26161% per annum, and 0.42826% per annum for interest periods of one-month, three-months, or six-months or longer, respectively (“Adjusted Term SOFR”) plus (x) in the case of the Term Loans due 2026, 2.0% for base rate loans or 3.0% for SOFR loans.

The rate in effect for the outstanding New Term Loans was 10.731% per annum at December 31, 2025, and 11.356% per annum for the Term Loans due 2026 at December 31, 2024.

Increases in market interest rates would cause interest expense to increase and earnings before income taxes to decrease. The change in interest expense and earnings before income taxes would be dependent upon the weighted average outstanding borrowings during the reporting period following an increase in market interest rates. A 100-basis point change in market interest rates would have increased or decreased interest expense on the New Term Loans by approximately \$20.1 million during the year ended December 31, 2025.

At December 31, 2024, we had an aggregate principal balance of \$2,014.2 million outstanding under the New Term Loans. A 100-basis point change in market interest rates would have increased or decreased interest expense on our New Term Loans by \$20.1 million during the year ended December 31, 2024.

**Market risk on performance-based variable-rate financial instruments.** As of December 31, 2025, we had an aggregate of \$877.1 million outstanding principal amount of our New 2029 Notes which bear interest ranging from 11.5% to 15.0% per annum depending on the Total Leverage Ratio. The New 2029 Notes were issued as part of the 2025 Refinancing Transactions. The rate in effect for the outstanding New 2029 Notes was 15% per annum at December 31, 2025.

A 100-basis point change in market interest rates would have caused an increase (decrease) in the fair value of our performance-based variable-rate financial instruments of approximately \$24.1 million and \$(23.3) million, respectively, as of December 31, 2025.

**Market risk on fixed-rate financial instruments.** Included in corporate borrowings as of December 31, 2025 were principal amounts of \$155.8 million of our New Exchangeable Notes, \$111.6 million of our Existing Exchangeable Notes, \$360.0 million of our Existing 7.5% Notes, \$400.0 million of our 12.75% Odeon Senior Secured Notes due 2027 (“Odeon Notes due 2027”), and \$125.5 million of our 6.125% Senior Subordinated Notes due 2027 (“Senior Subordinated Notes due 2027”). A 100-basis point change in market interest rates would have caused an increase or (decrease) in the fair value of our fixed rate financial instruments of approximately \$25.5 million and \$(24.7) million, respectively, during the year ended December 31, 2025.

Included in corporate borrowings as of December 31, 2024 were principal amounts of \$427.6 million of our Existing Exchangeable Notes, \$950.0 million of our Existing 7.5% Notes, \$131.2 million of our Second Lien Notes, \$400.0 million of our Odeon Notes due 2027, \$44.1 million of our Senior Subordinated Notes due 2025, \$41.9 million Senior Subordinated Notes due 2026, and \$125.5 million of our Senior Subordinated Notes due 2027. A 100-basis point change in market interest rates would have caused an increase or (decrease) in the fair value of our fixed rate financial instruments of approximately \$65.6 million and \$(62.9) million, respectively, during the year ended December 31, 2024.

**Foreign currency exchange rate risk.** We are also exposed to market risk arising from changes in foreign currency exchange rates affecting our International markets operations. International markets revenues and operating expenses are transacted in British Pounds, Euros, Swedish Krona and Norwegian Krone. U.S. GAAP requires that our subsidiaries use the currency of the primary economic environment in which they operate as their functional currency. If any international subsidiary operates in a highly inflationary economy, U.S. GAAP requires that the U.S. dollar be used as the functional currency. Currency fluctuations in the countries in which we operate result in us reporting exchange gains (losses) or foreign currency translation adjustments. Based upon the functional currencies in the International markets as of December 31, 2025, holding everything else constant, a hypothetical 10% increase in foreign currency translation rates to depict the potential impact to net loss from changes in foreign exchange rates would increase the aggregate net loss of our International theatres for the year ended December 31, 2025 by approximately \$9.6 million. Based upon the functional currencies in the International markets as of December 31, 2024, holding everything else constant, a hypothetical 10% increase in foreign currency translation rates to depict the potential impact to net loss of changes in foreign exchange rates would increase the aggregate net loss of our International theatres for the year ended December 31, 2024 by approximately \$9.0 million.

Our foreign currency translation rates increased by approximately 4.5% for the year ended December 31, 2025 compared to the year ended December 31, 2024.

**Item 8. Financial Statements and Supplementary Data.**

**MANAGEMENT'S ANNUAL REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING**

**AMC Entertainment Holdings, Inc.**

**TO THE STOCKHOLDERS OF AMC ENTERTAINMENT HOLDINGS, INC.**

Management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company as defined in Rule 13a-15(f) of the Exchange Act. With management's participation, an evaluation of the effectiveness of internal control over financial reporting was conducted as of December 31, 2025, based on the framework and criteria established in *Internal Control—Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management has concluded that the Company's internal control over financial reporting was effective as of December 31, 2025. The effectiveness of our internal control over financial reporting has been audited by Ernst & Young LLP, an independent registered public accounting firm, as stated in their attestation report that follows this report.

/s/ ADAM M. ARON

*Chairman of the Board, Chief Executive Officer and President*

/s/ SEAN D. GOODMAN

*Executive Vice President, International Operations, Chief Financial Officer and Treasurer*

## Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of AMC Entertainment Holdings, Inc.

### Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of AMC Entertainment Holdings, Inc. (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations, comprehensive loss, stockholders' deficit, and cash flows for each of the three years in the period ended December 31, 2025, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 23, 2026 expressed an unqualified opinion thereon.

### Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

### Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

#### Impairment of long-lived assets

*Description of the Matter*

For the year ended December 31, 2025, the Company recorded impairment charges related to long-lived assets of \$28.0 million and \$15.5 million on theatres in the US and International markets, respectively. As discussed in Note 1 to the consolidated financial statements, the Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset group may not be fully recoverable. Asset groups are evaluated for impairment on an individual theatre basis, which management believes is the lowest level for which there are identifiable cash flows. The Company estimates the future undiscounted

cash flows to be generated by the asset groups and compares those estimates to the carrying value of the related asset groups. If the carrying value exceeds the future undiscounted cash flows, the asset group may be impaired. If the asset is determined to be impaired, the carrying value of the asset group is reduced to fair value as estimated by a discounted cash flow model, with the difference recorded as an impairment charge.

Auditing management's long-lived asset impairment analysis was judgmental due to the estimation required in determining the undiscounted cash flows and related fair values of an impaired asset group. In particular, the cash flows were sensitive to significant assumptions such as the industry outlook, admissions revenue expectations, and long-term revenue growth rates.

*How We Addressed  
the Matter in Our  
Audit*

We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company's assessment of the projected undiscounted cash flows to be generated by the asset groups, and cash flows used to determine fair value of the related asset groups. This included internal controls over management's review of the significant assumptions underlying the undiscounted cash flow and fair value determination. We also tested management's controls to validate that the data used in the analysis was complete and accurate.

To test the significant assumptions described above, we performed audit procedures that included testing those significant assumptions discussed above and the underlying data used by the Company in the analysis. We met with individuals outside of the accounting department to obtain information supporting the Company's forecasts for the industry and its admissions revenues. We also compared the significant assumptions used by the Company to current industry and economic trends, reviewing analyst and industry publications for new or contrary evidence around the industry outlook and admissions revenue projections. We performed a sensitivity analysis of the impact of certain assumptions on the estimates and recalculated management's estimates.

#### **Initial Recognition of Exchangeable Notes and Related Features**

*Description of the  
Matter*

In July 2025, the Company issued Senior Secured Exchangeable Notes due 2030 ("New Exchangeable Notes"). The issuance of the New Exchangeable Notes involved bifurcating, and accounting for separately, certain derivatives embedded within the New Exchangeable Notes. These embedded derivatives included: 1) Interest Reset Feature 2) Principal Adjustment Feature; 3) Contingent Conversion Option; and 4) Consent Fee Feature. The fair value of the derivative liability associated with the embedded features was \$41.7 million on the date of their issuance.

As discussed in Note 10 to the consolidated financial statements, the Company estimates the fair value of the derivative liability using a combination of Monte Carlo simulations, binomial lattice models, and discounted cash flow models. The significant inputs used to value the derivative liability include the Company's common stock price, the volatility of the stock price, time to maturity, risk-free interest rate, credit spread, and discount yield.

Auditing the Company's accounting for the initial identification and valuation of the embedded derivatives was challenging given the complexity of the underlying accounting framework for analyzing the embedded derivatives and the complexity of the underlying methods and models used to measure the fair value of the embedded derivatives, which included certain assumptions that exhibit a higher degree of subjectivity.

*How We Addressed  
the Matter in Our  
Audit*

We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company's assessment of the embedded features of the New Exchangeable Notes as well as the Company's controls over the initial valuation of the derivative liability. This included internal controls over management's review of the significant assumptions of the fair value determination. We also tested management's controls to validate that the data used in the fair value calculation was complete and accurate.

To test management's analysis of the embedded features and initial valuation of the bifurcated embedded derivatives described above, we performed audit procedures that included reviewing, with the assistance of professionals in our firm with expertise in this area, the contractual

[Table of Contents](#)

agreements to understand the nature of the embedded features and the Company's application of the various provisions of ASC 815 that govern the evaluation of whether embedded features require bifurcation. We also leveraged our valuation professionals to assist us in evaluating the appropriateness of the methods and models used by management to estimate the initial fair value of the derivative liability as well as the key assumptions used in the valuation. We also tested the completeness and accuracy of the underlying data and the clerical accuracy of the model used to estimate the fair value of the derivative liability.

/s/ Ernst & Young LLP  
We have served as the Company's auditor since 2020  
Kansas City, Missouri  
February 23, 2026

## Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of AMC Entertainment Holdings, Inc.

### Opinion on Internal Control Over Financial Reporting

We have audited AMC Entertainment Holdings, Inc.'s internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, AMC Entertainment Holdings, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2025 and 2024, the related consolidated statements of operations, comprehensive loss, stockholders' deficit, and cash flows for each of the three years in the period ended December 31, 2025, and the related notes and our report dated February 23, 2026 expressed an unqualified opinion thereon.

### Basis for Opinion

The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.

Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

### Definition and Limitations of Internal Control Over Financial Reporting

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Ernst & Young LLP  
Kansas City, Missouri  
February 23, 2026

**AMC ENTERTAINMENT HOLDINGS, INC.**  
**CONSOLIDATED STATEMENTS OF OPERATIONS**

(In millions, except share and per share amounts)	Year Ended		
	December 31, 2025	December 31, 2024	December 31, 2023
<b>Revenues</b>			
Admissions	\$ 2,652.8	\$ 2,560.5	\$ 2,690.5
Food and beverage	1,671.3	1,624.9	1,669.8
Other theatre	524.8	451.8	452.3
Total revenues	4,848.9	4,637.2	4,812.6
<b>Operating costs and expenses</b>			
Film exhibition costs	1,275.2	1,239.2	1,291.1
Food and beverage costs	327.0	305.6	315.3
Operating expense, excluding depreciation and amortization below	1,786.0	1,679.4	1,691.5
Rent	887.3	873.6	873.5
<b>General and administrative:</b>			
Merger, acquisition and other costs	3.6	0.1	1.7
Other, excluding depreciation and amortization below	230.3	226.8	241.9
Depreciation and amortization	313.4	319.5	365.0
Impairment of long-lived assets	43.5	72.3	106.9
Operating costs and expenses	4,866.3	4,716.5	4,886.9
Operating loss	(17.4)	(79.3)	(74.3)
<b>Other expense, net:</b>			
Other expense (income)	112.4	(156.2)	(76.8)
<b>Interest expense:</b>			
Corporate borrowings	459.5	401.8	369.6
Finance lease obligations	6.0	5.4	3.7
Non-cash NCM exhibitor services agreement	64.7	36.5	37.9
Investment income	(32.1)	(16.3)	(15.5)
Total other expense, net	610.5	271.2	318.9
Loss before income taxes	(627.9)	(350.5)	(393.2)
Income tax provision	4.5	2.1	3.4
Net loss	\$ (632.4)	\$ (352.6)	\$ (396.6)
<b>Net loss per share:</b>			
Basic and diluted	\$ (1.34)	\$ (1.06)	\$ (2.37)
<b>Weighted average shares outstanding:</b>			
Basic and diluted (in thousands)	472,899	332,920	167,644

See Notes to Consolidated Financial Statements.

## AMC ENTERTAINMENT HOLDINGS, INC.

## CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In millions)	Year Ended		
	December 31, 2025	December 31, 2024	December 31, 2023
Net loss	\$ (632.4)	\$ (352.6)	\$ (396.6)
Other comprehensive income (loss):			
Unrealized foreign currency translation adjustments	95.0	(55.6)	1.1
Pension adjustments:			
Net gain (loss) arising during the period	(5.2)	1.8	(2.0)
Other comprehensive income (loss)	89.8	(53.8)	(0.9)
Total comprehensive loss	<u>\$ (542.6)</u>	<u>\$ (406.4)</u>	<u>\$ (397.5)</u>

See Notes to Consolidated Financial Statements.

AMC ENTERTAINMENT HOLDINGS, INC.

CONSOLIDATED BALANCE SHEETS

(In millions, except share data)	December 31, 2025	December 31, 2024
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 428.5	\$ 632.3
Restricted cash	48.8	48.5
Receivables, net	156.0	168.1
Other current assets	97.2	98.3
Total current assets	730.5	947.2
Property, net	1,374.2	1,442.3
Operating lease right-of-use assets, net	3,137.3	3,220.1
Intangible assets, net	147.4	144.3
Goodwill	2,416.1	2,301.1
Other long-term assets	212.3	192.5
Total assets	<u>\$ 8,017.8</u>	<u>\$ 8,247.5</u>
<b>LIABILITIES AND STOCKHOLDERS' DEFICIT</b>		
Current liabilities:		
Accounts payable	\$ 382.9	\$ 378.3
Accrued expenses and other liabilities	338.2	340.6
Deferred revenues and income	465.5	432.4
Current maturities of corporate borrowings	19.9	64.2
Current maturities of finance lease liabilities	5.8	4.4
Current maturities of operating lease liabilities	560.0	524.9
Total current liabilities	1,772.3	1,744.8
Corporate borrowings	4,018.6	4,010.9
Finance lease liabilities	46.7	44.9
Operating lease liabilities	3,485.0	3,627.6
Exhibitor services agreement	459.1	464.0
Deferred tax liability, net	35.7	33.9
Other long-term liabilities	95.2	81.9
Total liabilities	<u>9,912.6</u>	<u>10,008.0</u>
Commitments and contingencies		
Stockholders' deficit:		
AMC Entertainment Holdings, Inc.'s stockholders' deficit:		
Preferred stock, \$.01 par value per share, 50,000,000 shares authorized; no shares issued and outstanding as of December 31, 2025, and December 31, 2024	—	—
Class A common stock (\$.01 par value, 1,100,000,000 shares authorized; 512,943,561 shares issued and outstanding as of December 31, 2025; 550,000,000 authorized; 414,417,797 shares issued and outstanding as of December 31, 2024)	5.1	4.1
Additional paid-in capital	7,121.5	6,714.2
Accumulated other comprehensive loss	(42.2)	(132.0)
Accumulated deficit	(8,979.2)	(8,346.8)
Total stockholders' deficit	<u>(1,894.8)</u>	<u>(1,760.5)</u>
Total liabilities and stockholders' deficit	<u>\$ 8,017.8</u>	<u>\$ 8,247.5</u>

See Notes to Consolidated Financial Statements.

**AMC ENTERTAINMENT HOLDINGS, INC.**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**

(In millions)	Year Ended		
	December 31, 2025	December 31, 2024	December 31, 2023
<b>Cash flows from operating activities:</b>			
Net loss	\$ (632.4)	\$ (352.6)	\$ (396.6)
Adjustments to reconcile net loss to net cash used in operating activities:			
Depreciation and amortization	313.4	319.5	365.0
Loss (gain) on extinguishment of debt	196.0	(38.9)	(142.8)
Gain on derivatives	(37.4)	(75.8)	—
Deferred income taxes	1.8	1.5	0.7
Impairment of long-lived assets	43.5	72.3	106.9
Loss (gain) on investments in Hycroft	(34.4)	2.9	12.6
Impairment of equity security without readily determinable fair value	10.3	—	1.0
Amortization of net discount (premium) on corporate borrowings to interest expense	14.6	(17.5)	(55.6)
Amortization of deferred financing costs to interest expense	11.3	8.3	9.6
PIK interest expense	44.4	14.7	—
Non-cash portion of stock-based compensation	16.9	22.0	42.5
Gain on disposition of Saudi Cinema Company	—	—	(15.5)
Equity in earnings from non-consolidated entities, net of distributions	(0.2)	(1.6)	(0.2)
Lease incentives	45.6	31.8	23.9
Non-cash rent benefit	(109.3)	(106.1)	(159.1)
Net periodic benefit cost	1.2	1.8	1.4
Non-cash shareholder litigation expense	—	—	99.3
Change in assets and liabilities:			
Receivables	13.2	37.4	(45.6)
Other assets	4.6	(10.7)	(6.7)
Accounts payable	(7.5)	60.1	(0.7)
Accrued expenses and other liabilities	10.9	(13.8)	(26.7)
Other, net	(26.3)	(6.1)	(28.6)
Net cash used in operating activities	(119.8)	(50.8)	(215.2)
<b>Cash flows from investing activities:</b>			
Capital expenditures	(246.1)	(245.5)	(225.6)
Acquisition of theatre assets	—	—	(4.0)
Proceeds from disposition of Saudi Cinema Company	—	—	30.0
Proceeds from disposition of long-term assets	2.9	0.5	16.5
Proceeds from sale of securities	24.1	—	—
Investment in non-consolidated entities	(4.0)	—	—
Other, net	1.5	2.1	3.0
Net cash used in investing activities	(221.6)	(242.9)	(180.1)
<b>Cash flows from financing activities:</b>			
Net proceeds from equity issuances	169.6	254.9	832.7
Proceeds from issuance of Senior Secured Notes due 2029	244.4	—	—
Proceeds from issuance of Term Loan due 2029	—	27.0	—
Principal payments under the Second Lien Notes due 2026	(131.2)	—	—
Principal payments under Senior Subordinated Notes due 2024	—	(5.0)	—
Principal payments under Senior Subordinated Notes due 2025	(42.8)	—	—
Principal payments under Senior Subordinated Notes due 2026	(41.9)	—	—
Principal payments under Term Loan due 2026	—	(27.0)	—
Principal payments under finance lease obligations	(4.2)	(4.6)	(5.6)
Scheduled principal payments under Term Loan borrowings	(20.1)	(20.1)	(20.0)
Repurchase of Senior Subordinated Notes due 2025	(1.3)	(14.8)	—
Repurchase of Senior Subordinated Notes due 2026	—	(6.0)	(1.7)
Repurchase of Second Lien Notes due 2026	—	(83.2)	(139.9)
Cash used to pay deferred financing costs	(40.5)	(46.7)	(2.0)

[Table of Contents](#)

Debt extinguishment costs	(2.4)	(3.9)	—
Taxes paid for restricted unit withholdings	(4.4)	(2.2)	(14.2)
Net cash provided by financing activities	125.2	68.4	649.3
Effect of exchange rate changes on cash and cash equivalents and restricted cash	12.7	(5.3)	3.0
<b>Net increase (decrease) in cash and cash equivalents and restricted cash</b>	<b>(203.5)</b>	<b>(230.6)</b>	<b>257.0</b>
<b>Cash and cash equivalents and restricted cash at beginning of period</b>	<b>680.8</b>	<b>911.4</b>	<b>654.4</b>
<b>Cash and cash equivalents and restricted cash at end of period</b>	<b>\$ 477.3</b>	<b>\$ 680.8</b>	<b>\$ 911.4</b>
<b>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</b>			
<b>Cash paid during the period for:</b>			
Interest	\$ 406.9	\$ 401.6	\$ 421.2
Income taxes paid, net (1)	\$ 2.8	\$ 0.7	\$ 4.3
<b>Schedule of non-cash activities:</b>			
Construction payables at period end	\$ 43.1	\$ 35.1	\$ 42.3
Other third-party equity issuance costs payable	\$ —	\$ 1.2	\$ 0.1
Deferred financing costs payable	\$ 4.7	\$ 0.2	\$ —
Extinguishment of 6.00%/8.00% Cash/PIK Toggle Senior Secured Exchangeable Notes due 2030 in exchange for share issuance (2) Principal only	\$ 143.0	\$ —	\$ —
Extinguishment of 7.5% First Lien Notes due 2029 in exchange for Senior Secured Notes due 2029 (2)	\$ 599.6	\$ —	\$ —
Extinguishment of 6.00%/8.00% Cash/PIK Toggle Senior Secured Exchangeable Notes due 2030 in exchange for Senior Secured Exchangeable Notes due 2030 (2) Principal only	\$ 194.4	\$ —	\$ —
Cancellation of Senior Secured Exchangeable Notes due 2030 pursuant to principal adjustment feature (2) Principal only	\$ 39.9	\$ —	\$ —
Extinguishment of Second Lien Notes due 2026 in exchange for share issuance (2)	\$ —	\$ 263.6	\$ 238.6
Extinguishment of Senior Subordinated Notes due 2025 in exchange for share issuance (2)	\$ —	\$ 38.8	\$ —
Extinguishment of Senior Subordinated Notes due 2026 in exchange for share issuance (2)	\$ —	\$ 2.4	\$ —
Extinguishment of Second Lien Notes due 2026 in exchange for Term Loans due 2029 (2)	\$ —	\$ 2.3	\$ —
Extinguishment of principal amount of the Second Lien Notes due 2026 in exchange for Term Loan due 2029 (2)	\$ —	\$ 104.2	\$ —
Extinguishment of principal amount of the Second Lien Notes due 2026 in exchange for Exchangeable Notes due 2030 (2)	\$ —	\$ 414.4	\$ —

(1) Income taxes paid, net are individually immaterial in each taxing jurisdiction and in the aggregate.

(2) See Note 7—Corporate Borrowings and Finance Lease Liabilities for further information on debt extinguishments and refinancing transactions.

See Notes to Consolidated Financial Statements.

**AMC ENTERTAINMENT HOLDINGS, INC.  
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT**

(In millions, except share and per share data)	Class A Common Stock		Preferred Stock			Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total Stockholders' Deficit
	Shares (1)	Amount	Series A Convertible Participating Preferred Stock Shares (1)	Depository Shares of AMC Preferred Equity Units (1)	Amount				
Balance December 31, 2022	51,683,892	\$ 0.5	7,245,872	72,458,705	\$ 0.1	\$ 5,049.8	\$ (77.3)	\$ (7,597.6)	\$ (2,624.5)
Net loss	—	—	—	—	—	—	—	(396.6)	(396.6)
Other comprehensive loss	—	—	—	—	—	—	(0.9)	—	(0.9)
Share issuances	88,030,843	0.9	705,036	7,050,362	—	759.4	—	—	760.3
Antara Forward Purchase Agreement (2)	—	—	1,976,213	19,762,130	—	193.7	—	—	193.7
AMC Preferred Equity Units issuance	99,540,642	1.0	(9,954,065)	(99,540,642)	(0.1)	(0.9)	—	—	—
Settlement payment	6,897,018	0.1	—	—	—	99.2	—	—	99.3
Debt for equity exchange	14,186,651	0.1	—	—	—	92.8	—	—	92.9
Taxes paid for restricted unit withholdings	—	—	—	—	—	(14.2)	—	—	(14.2)
Stock-based compensation	235,346	—	26,944	269,445	—	42.1	—	—	42.1
Balance December 31, 2023	260,574,392	\$ 2.6	—	—	\$ —	\$ 6,221.9	\$ (78.2)	\$ (7,994.2)	\$ (1,847.9)
Net loss	—	—	—	—	—	—	—	(352.6)	(352.6)
Other comprehensive loss	—	—	—	—	—	—	(53.8)	—	(53.8)
Share issuances	75,497,216	0.7	—	—	—	252.8	—	—	253.5
Forward purchase agreements	30,000,000	0.3	—	—	—	—	—	—	0.3
Debt for equity exchange	47,654,455	0.5	—	—	—	219.8	—	—	220.3
Taxes paid for restricted unit withholdings	—	—	—	—	—	(2.2)	—	—	(2.2)
Stock-based compensation	691,734	—	—	—	—	21.9	—	—	21.9
Balance December 31, 2024	414,417,797	\$ 4.1	—	—	\$ —	\$ 6,714.2	\$ (132.0)	\$ (8,346.8)	\$ (1,760.5)
Net loss	—	—	—	—	—	—	—	(632.4)	(632.4)
Other comprehensive income	—	—	—	—	—	—	89.8	—	89.8
Share issuances	17,052,756	0.2	—	—	—	170.6	—	—	170.8
Debt for equity exchange	79,800,000	0.8	—	—	—	224.2	—	—	225.0
Taxes paid for restricted unit withholdings	—	—	—	—	—	(4.4)	—	—	(4.4)
Stock-based compensation (3)	1,673,008	—	—	—	—	16.9	—	—	16.9
Balance December 31, 2025	512,943,561	\$ 5.1	—	—	\$ —	\$ 7,121.5	\$ (42.2)	\$ (8,979.2)	\$ (1,894.8)

- (1) Share counts have been retroactively adjusted to reflect the effect of the reverse stock split.  
(2) Includes \$75.1 million of cash proceeds and \$118.6 million carrying value of the debt exchanged for AMC Preferred Equity Units.  
(3) Includes 370,586 Common Stock shares awarded to the Board and 1,302,422 vested Common Stock restricted stock units and performance stock units.

See Notes to Consolidated Financial Statements

**AMC ENTERTAINMENT HOLDINGS, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**Years Ended December 31, 2025, 2024, 2023**

**NOTE 1—THE COMPANY AND SIGNIFICANT ACCOUNTING POLICIES**

AMC Entertainment Holdings, Inc. (“Holdings”), through its direct and indirect subsidiaries, including American Multi-Cinema, Inc. (“Multi-Cinema”) and its subsidiaries, (collectively with Holdings, unless the context otherwise requires, the “Company” or “AMC”), is principally involved in the theatrical exhibition business and owns, operates or has interests in theatres located in the United States and Europe.

**Reverse Stock Split.** On August 24, 2023, the Company effectuated a reverse stock split at a ratio of one share of Common Stock for every ten shares of Common Stock. As a result of the reverse stock split, each share of Series A Convertible Participating Preferred Stock became convertible into ten shares of Common Stock, and by extension each AMC Preferred Equity Unit became equivalent to one-tenth (1/10th) of a share of Common Stock. The reverse stock split did not impact the number of AMC Preferred Equity Units outstanding. The Company concluded that this change in conversion ratio is analogous to a reverse stock split of the AMC Preferred Equity Units even though the reverse stock split did not have an effect on the number of AMC Preferred Equity Units outstanding.

Accordingly, all references made to share, per share, unit, per unit, or common share amounts in the accompanying consolidated financial statements and applicable disclosures have been retroactively adjusted to reflect the effects of the subsequent reverse stock split. References made to AMC Preferred Equity Units have been retroactively adjusted to reflect the effect of the reverse stock split on their equivalent Common Stock shares.

**Liquidity.** The Company believes its existing cash and cash equivalents, together with cash generated from operations, will be sufficient to fund its operations and satisfy its obligations currently and through the next twelve months. The Company’s cash burn rates are not sustainable long-term. In order to achieve sustainable net positive cash flows from operating activities and long-term profitability, the Company believes that revenues will need to increase to levels at least in line with pre-COVID-19 revenues. North America box office grosses were down approximately 22% for the year ended December 31, 2025, compared to the year ended December 31, 2019. Until such time as the Company is able to achieve sustainable net positive cash flows from operating activities, it is difficult to estimate the Company’s future cash burn rates and liquidity requirements. Depending on the Company’s assumptions regarding the timing and ability to achieve increased levels of revenue, the estimates of amounts of required liquidity vary significantly.

There can be no assurance that the revenues, attendance levels, and other assumptions used to estimate the Company’s liquidity requirements and future cash burn rates will be correct, and the ability to be predictive is uncertain due to limited ability to predict studio film release dates, the overall production and theatrical release levels, and success of individual titles. Further, there can be no assurances that the Company will be successful in generating the additional liquidity necessary to meet the Company’s obligations beyond twelve months from the issuance of these financial statements on terms acceptable to the Company or at all.

The Company expects, from time to time, to continue to seek to retire or purchase its outstanding debt through cash purchases and/or exchanges for equity or debt, in open-market purchases, privately negotiated transactions or otherwise. Such repurchases or exchanges, if any, will be upon such terms and at such prices as it may determine, and will depend on prevailing market conditions, its liquidity requirements, the availability of authorized share capital, contractual restrictions and other factors. The amounts involved may be material and to the extent equity is used, dilutive. See Note 7—Corporate Borrowings and Finance Lease Liabilities for a summary of debt transactions that occurred during the years ended December 31, 2025, December 31, 2024, and December 31, 2023. Additionally, the Company has bolstered its liquidity through sales of its Common Stock, see Note 8—Stockholders’ Deficit and Note 14—Subsequent Events for further information on these sales.

**Use of Estimates.** The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

**Principles of Consolidation.** The consolidated financial statements include the accounts of Holdings and all subsidiaries, as discussed above. All significant intercompany balances and transactions have been eliminated in consolidation. The Company manages its business under two reportable segments for its theatrical exhibition operations: U.S. markets and International markets.

**Revenues.** The Company recognizes revenue, net of sales tax, when it satisfies a performance obligation by transferring control over a product or service to a customer. Admissions and food and beverage revenues are recorded at a point in time when a film is exhibited to a customer and when a customer takes possession of food and beverage offerings.

The Company defers 100% of the revenue associated with the sales of gift cards and exchange tickets until such time as the items are redeemed or estimated income from non-redemption is recorded. The Company recognizes revenue from non-redeemed or partially redeemed gift cards in proportion to the pattern of rights exercised by the customer (the “Proportional Method”). The Company estimates the non-redemption rate for its gift card sales and then applies the rates to the current month sales. The non-redemption rates range from 13% to 30%. The Company recognizes the total amount of expected revenue for non-redemption for that current month’s sales as income over the next one to 36 months in proportion to the pattern of actual redemptions. The non-redemption revenue is recorded in other theatre revenues. The Company has used significant amounts of historical data to estimate its non-redemption rates and redemption patterns. The Company also recognizes revenue from non-redeemed or partially redeemed exchange tickets using the Proportional Method. In the International markets, certain exchange tickets are subject to expiration dates, which triggers recognition of non-redemption in other revenues.

The Company recognizes ticket fee revenues based on a gross transaction price. The Company is a principal (as opposed to agent) in the arrangement with third-party internet ticketing companies in regard to the sale of online tickets because the Company controls the online tickets before they are transferred to the customer. The online ticket fee revenues and the third-party commission or service fees are recorded in the line items other theatre revenues and operating expense, respectively, in the consolidated statements of operations.

**Film Exhibition Costs.** Film exhibition costs are accrued based on the applicable box office receipts and estimates of the final settlement to the film licensors. Film exhibition costs include certain advertising costs. As of December 31, 2025 and December 31, 2024, the Company recorded film payables of \$144.4 million and \$143.9 million, respectively, which are included in accounts payable in the accompanying consolidated balance sheets. During the year ended December 31, 2025, films licensed from the Company’s seven largest movie studio distributors based on revenues accounted for approximately 83% of our U.S. admissions revenues, which consisted of Disney, Warner Bros., Universal, Sony, Paramount, 20th Century Studios, and Lionsgate Films. In Europe, approximately 76% of the Company’s box office revenue came from films attributed to our five largest movie distributor groups, which consisted of Disney, Universal, Warner Bros., Paramount, and Sony. The Company’s revenues attributable to individual distributors may vary significantly from year to year depending upon the commercial success of each distributor’s films in any given year.

**Food and Beverage Costs.** The Company records rebate payments from vendors as a reduction of food and beverage costs when earned.

**Exhibitor Services Agreement.** The Company recognizes advertising revenues, which are included in other theatre revenues in the consolidated statements of operations, when it satisfies a performance obligation by transferring a promised good or service to the customers. The advertising contracts with customers generally consist of a series of distinct periods of service, satisfied over time, to provide rights to advertising services. The Company’s exhibitor services agreement with National CineMedia, LLC (“NCM”) includes a significant financing component due to the significant length of time between receiving the non-cash consideration and fulfilling the performance obligation. On April 17, 2025, NCM and the Company entered into the Second Amended and Restated Exhibitor Services Agreement (the “Amended ESA”). The term of the Amended ESA has been extended by five years through February 13, 2042. The Company treated the Amended ESA as a contract modification pursuant to *ASC 606 – Revenue from Contracts with Customers*. Accordingly, the Company has allocated the additional consideration received from the contract modification to the exhibitor services agreement contract liability and updated the discount rate used for the significant financing component to 16.12%. Prior to the contract modification, the weighted average discount rate used to account for the significant financing component was approximately 7.5%. The contract liability will be reclassified to other theatre revenue over the new term of the Amended ESA as the remaining performance obligations are satisfied. See Note 2—Revenue Recognition for further information regarding the Amended ESA.

[Table of Contents](#)

**Customer Loyalty Programs.** The Company offers a range of customer loyalty programs worldwide. Depending on the specific program, members can earn rewards, receive discounts, and access exclusive offers and services available only to members. Certain loyalty programs we offer, such as A-List, operate on a subscription model and enable members to watch multiple movies for a recurring fee. Rewards earned by members are redeemable on future purchases at our locations.

The portion of the admissions and food and beverage revenues attributed to the rewards is deferred. Upon redemption or expiration, deferred revenues associated with the rewards are recognized as revenues. The Company estimates reward non-redemption rates using historical information when assigning value to the rewards at the time of sale. Membership fees, net of estimated refunds, for our paid loyalty programs are initially deferred and allocated to the material rights for discounted or free products and services. Revenue is recognized as the rights are redeemed based on estimated utilization, over the membership period in admissions, food and beverage, and other revenues.

Membership fees for our subscription programs are recognized ratably over the subscription period in admissions revenue.

**Advertising Costs.** The Company expenses advertising costs as incurred and does not have any direct-response advertising recorded as assets. Advertising costs were \$21.5 million, \$22.2 million, and \$43.6 million for the years ended December 31, 2025, December 31, 2024, and December 31, 2023, respectively. Advertising costs are recorded in operating expense in the accompanying consolidated statements of operations.

**Cash and Cash Equivalents.** All investments purchased with an original maturity of three months or less are classified as cash equivalents. As of December 31, 2025, cash and cash equivalents for the U.S. markets and International markets were \$302.6 million and \$125.9 million, respectively. As of December 31, 2024, cash and cash equivalents were \$513.0 million and \$119.3 million, respectively.

**Restricted Cash.** Restricted cash includes cash held in the Company's bank accounts as a guarantee for certain landlords, legal settlements, and cash collateralized letters of credit relating to the Company's insurance and utilities programs. The following table provides a reconciliation of cash and cash equivalents and restricted cash reported in the consolidated balance sheet to the total of the amounts in the consolidated statements of cash flows.

(In millions)	Year Ended		
	December 31, 2025	December 31, 2024	December 31, 2023
Cash and cash equivalents	\$ 428.5	\$ 632.3	\$ 884.3
Restricted cash	48.8	48.5	27.1
Total cash and cash equivalents and restricted cash in the statement of cash flows	\$ 477.3	\$ 680.8	\$ 911.4

As of December 31, 2025, restricted cash for the U.S. markets and International markets was \$20.5 million and \$28.3 million, respectively. As of December 31, 2024, restricted cash for the U.S. markets and International markets was \$20.7 million and \$27.8 million, respectively.

**Intangible Assets.** Amortizable intangible assets are being amortized on a straight-line basis over the estimated remaining useful lives of the assets. The Company evaluates definite-lived intangible assets whenever events or changes in circumstances indicate that the carrying amount of the intangible asset may not be fully recoverable. Indefinite-lived intangible assets are not amortized but rather evaluated for impairment annually as of the beginning of the fourth quarter or more frequently if events or circumstances indicate that it is more likely than not that the asset is impaired.

The Company first assesses the qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not the fair value of an indefinite-lived intangible asset is less than its carrying amount as a basis for determining whether it is necessary to perform the quantitative impairment test. There were no intangible asset impairment charges incurred during the years ended December 31, 2025, December 31, 2024, and December 31, 2023.

**Investments.** The Company accounts for its investments in non-consolidated entities using the equity method when Company's ownership interest provides the Company with significant influence. The Company follows the guidance in ASC 323-30-35-3, investment in a limited liability company, which prescribes the use of the equity method for investments where the Company has significant influence. Under the equity method, the Company shall recognize its

## [Table of Contents](#)

share of the earnings or losses of an investee. In 2024, the Company reclassified equity earnings and losses to other expense (income), all comparative periods have also been reclassified. Equity investments without readily determinable fair values are recorded at cost less impairment. The Company classifies gains and losses on sales of investments or impairments of investments without a readily determinable fair value in investment expense (income). Investments in non-consolidated entities are presented within other long-term assets in the consolidated balance sheets.

The Company holds common shares and warrants to purchase common shares of Hycroft. The common shares and warrants are recorded at fair value at each reporting period and unrealized gains and losses are reported in investment expense (income). In December 2025, the Company sold 2.3 million shares of Hycroft common stock and warrants for 1.3 million shares for \$24.1 million. The Company retained warrants to purchase approximately 1 million Hycroft common shares and approximately 64,000 Hycroft common shares.

During the years ended December 31, 2025, December 31, 2024, and December 31, 2023, the Company recorded realized and unrealized losses (gains) related to the investments in Hycroft of \$(34.4) million, \$2.9 million, and \$12.6 million, respectively in investment income.

On December 30, 2022, the Company entered into an agreement to sell its 10.0% investment in Saudi Cinema Company LLC for SAR 112.5 million (\$30.0 million), and on January 24, 2023, the Saudi Ministry of Commerce recorded the sale of equity and the Company received the proceeds on January 25, 2023. The Company recorded a gain on the sale of \$(15.5) million in investment income during the year ended December 31, 2023.

**Related Party Transactions.** The Company conducts business with certain of its equity method investees in the ordinary course of business. Transactions primarily relate to advertising revenue and film exhibition costs for film rent. The Company recorded related party advertising revenue of \$26.9 million, \$26.7 million, and \$28.6 million during the years ended December 31, 2025, December 31, 2024, and December 31, 2023, respectively. The Company recorded related party film exhibition costs of \$17.5 million, \$29.6 million, and \$17.5 million during the years ended December 31, 2025, December 31, 2024, and December 31, 2023, respectively.

**Derivatives.** The Company remeasures the derivative liabilities related to the conversion features in its Existing Exchangeable Notes and New Exchangeable Notes at fair value each reporting period, with changes in fair value recorded in the consolidated statement of operations in other expense (income). The Company has obtained independent third-party valuation studies to assist in determining fair value. The valuation studies use binomial lattice models and are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value measurement hierarchy. The binomial lattice models consist of simulated Common Stock prices from the valuation date to the maturity of the Existing Exchangeable Notes and New Exchangeable Notes. The inputs used to value the derivative include the share price of the Common Stock, the volatility of the share price, time to maturity, risk-free interest rate, credit spread, and the discount yield. The volatility of the Company's Common Stock, the Common Stock price at the end of each reporting period, and the remaining amount of time until maturity of the Existing Exchangeable Notes and New Exchangeable Notes are key inputs for the estimation of fair value that are expected to change each reporting period.

The Company recorded other income related to the change in fair value of the derivatives of \$(37.4) million and \$(75.8) million as of December 31, 2025 and December 31, 2024, respectively. See Note 7—Corporate Borrowings and Finance Lease Obligations and Note 10—Fair Value Measurements for further discussions regarding the Company's derivatives.

**Goodwill.** The Company's recorded goodwill was \$2,416.1 million and \$2,301.1 million as of December 31, 2025 and December 31, 2024, respectively. Goodwill represents the excess of purchase price over fair value of net tangible and identifiable intangible assets resulting from the acquisition of Holdings on August 30, 2012 and subsequent business combinations. The Company has assigned goodwill to two reporting units (Domestic Theatres and International Theatres). The Company performs a qualitative assessment of goodwill at least annually as of the beginning of the fourth quarter or more frequently if events or circumstances indicate that it is more likely than not that the fair value for a reporting unit is less than its carrying amount, including goodwill.

The Company will perform a quantitative impairment test of goodwill if the qualitative assessment concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The quantitative impairment test of goodwill involves estimating the fair value of the reporting unit and comparing that value to its

[Table of Contents](#)

carrying value. If the estimated fair value of the reporting unit is less than its carrying value, the difference is recorded as goodwill impairment charge, not to exceed the total amount of goodwill allocated to that reporting unit.

The Company performed qualitative assessments as of October 1, 2025 and October 1, 2024 and concluded that it was not more likely than not that the fair value of either of the Company's two reporting units was less than their respective carrying amounts. The Company also concluded that there were no triggering events requiring additional assessments that had occurred between October 1, 2025 and December 31, 2025 and October 1, 2024 and December 31, 2024, respectively.

**Leases.** The Company leases theatres and equipment under operating and finance leases. Many of the leases contain options to extend the leases for additional periods. The Company typically does not believe that the exercise of the renewal options is reasonably assured at the inception of the lease agreements and, therefore, considers the initial base term as the lease term. Lease terms vary but generally, the leases provide for fixed and escalating rentals, contingent escalating rentals based on the Consumer Price Index or other indexes not to exceed certain specified amounts, and variable rentals based on a percentage of revenues. The Company often receives incentives from lessors to assist with renovations at existing locations. The Company records the incentives received from the lessors as an adjustment to the right-of-use asset which results in a reduction to lease costs over the lease term. Operating lease cost for theatre properties are recorded as rent expense in the consolidated statements of operations, except when the lease costs pertain to periods before a theatre opens or after it closes; in those cases, the costs are recorded to operating expense. Operating lease cost for equipment leases is recorded in operating expense in the consolidated statements of operations. The operating lease cost relating to the fixed lease payments is recorded on a straight-line basis over the lease term. Finance lease cost for both theatre properties and equipment are recorded as finance lease interest and depreciation and amortization in the consolidated statements of operations.

Lease right-of-use assets and lease liabilities are recorded at the lease commencement date based on the present value of minimum lease payments over the remaining lease term. The minimum lease payments include base rent and other fixed payments, including fixed maintenance costs. The present value of the lease payments is calculated using the incremental borrowing rate, which was determined using a portfolio approach based on the rate of interest that the Company would have to pay to borrow an amount equal to the lease payments on a collateralized basis over a similar term.

The Company elected the practical expedient to not separate lease and non-lease components and also elected the short-term practical expedient for all leases that qualify. As a result, the Company will not recognize right-of-use assets or liabilities for short-term leases that qualify for the short-term practical expedient, but instead will recognize the lease payments as lease cost on a straight-line basis over the lease term. The Company's lease agreements do not contain residual value guarantees. Short-term leases and sublease arrangements are immaterial. Equipment leases primarily consist of food and beverage and digital equipment.

**Impairment of Long-lived Assets.** The Company reviews long-lived assets, including definite-lived intangibles, theatre assets (including operating lease right-of-use assets), and internal-use software whenever events or changes in circumstances indicate that the carrying amount of the asset or asset group may not be fully recoverable. The Company evaluates events or circumstances, including competition in the markets where it operates, that would indicate the carrying value of the asset groups may not be fully recoverable. If an event or circumstance is identified that indicates the carrying value may not be recoverable, the sum of future undiscounted cash flows is compared to the carrying value. If the carrying value exceeds the future undiscounted cash flows, the asset group may be impaired. If the asset group is determined to be impaired, the carrying value of the asset group is reduced to fair value as estimated primarily by using a discounted cash flow model, with the difference recorded as an impairment charge. Management believes that individual theatres are the lowest level for which there are identifiable cash flows and therefore each individual theatre represents an asset group. The Company evaluates theatre asset groups for recoverability using projected data of theatre level cash flow as its primary indicator of potential impairment, giving consideration to the seasonality of its business when making these evaluations. The fair value of assets is determined as either the expected selling price less selling costs (where appropriate) or the present value of the estimated future cash flows, adjusted as necessary for market participant factors.

There is considerable management judgment necessary to determine the estimated future cash flows and fair values of the Company's theatres and other long-lived assets. Actual future cash flows could vary significantly from such

[Table of Contents](#)

estimates. The estimated future cash flows are considered Level 3 inputs within the fair value measurement hierarchy, see Note 10—Fair Value Measurements for further information.

The following table summarizes the Company's impairments, including impairments of equity investments, for the years ended December 31, 2025, December 31, 2024, and December 31, 2023:

(In millions)	Year Ended		
	December 31, 2025	December 31, 2024	December 31, 2023
Impairment of long-lived assets	\$ 43.5	\$ 72.3	\$ 106.9
Impairment of equity investments recorded in investment income	10.3	—	1.0
Total impairment loss	\$ 53.8	\$ 72.3	\$ 107.9

During the year ended December 31, 2025, the Company recorded non-cash impairment of long-lived assets of \$28.0 million on 47 theatres in the U.S. markets with 560 screens (in Alabama, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Louisiana, Massachusetts, Michigan, Minnesota, New Jersey, New York, North Carolina, Pennsylvania, Tennessee, Texas, Utah, Virginia, Washington, and Wisconsin) and \$15.5 million on 20 theatres in the International markets with 159 screens (in Germany, Italy, Spain, Sweden, and the United Kingdom), which were related to property, net and operating lease right-of-use assets, net. In addition, during the year ended December 31, 2025, the Company recorded impairment losses of \$10.3 million within investment income related to an equity investment without a readily determinable fair value in the U.S. markets.

During the year ended December 31, 2024, the Company recorded non-cash impairment of long-lived assets of \$51.9 million on 39 theatres in the U.S. markets with 469 screens and \$20.4 million on 23 theatres in the International markets with 188 screens, which were related to property, net and operating lease right-of-use assets, net.

During the year ended December 31, 2023, the Company recorded non-cash impairment of long-lived assets of \$49.2 million on 68 theatres in the U.S. markets with 738 screens and \$57.7 million on 57 theatres in the International markets with 488 screens, which were related to property, net and operating lease right-of-use assets, net. In addition, during the year ended December 31, 2023, the Company recorded impairment losses of \$1.0 million within investment income, related to an equity investment without a readily determinable fair value in the U.S. markets.

**Foreign Currency Translation.** Operations outside the United States are generally measured using the local currency as the functional currency. Assets and liabilities are translated to U.S. dollars using exchange rates as of the balance sheet date. Income and expense items are translated using average exchange rates. The foreign currency translation adjustments are a separate component of accumulated other comprehensive income (loss). Gains and losses from foreign currency transactions are included in net earnings (loss), except intercompany transactions of a long-term investment nature, which are included in comprehensive income (loss). Upon substantial liquidation of an investment in a foreign entity, the related foreign currency translation adjustment in accumulated other comprehensive income (loss) is reclassified into earnings as part of the gain or loss on disposition.

**Contingencies.** The Company, in the normal course of business, is a party to various ordinary course claims from vendors (including food and beverage suppliers and film distributors), landlords, competitors, and other legal proceedings. If management believes that a loss arising from these actions is probable and can reasonably be estimated, the Company records the amount of the loss, or the minimum estimated liability when the loss is estimated using a range and no point is more probable than another. As additional information becomes available, any potential liability related to these actions is assessed and the estimates are revised, if necessary. Management believes that the ultimate outcome of such matters discussed below, individually and in the aggregate, will not have a material adverse effect on the Company's financial position or overall trends in results of operations. However, litigation and claims are subject to inherent uncertainties and unfavorable outcomes can occur. An unfavorable outcome might include monetary damages. If an unfavorable outcome were to occur, there exists the possibility of a material adverse impact on the results of operations in the period in which the outcome occurs or in future periods. An unfavorable outcome could also have a material adverse effect on the Company's financial position or the market prices of the Company's securities, including the Company's Common Stock.

**Employee Benefit Plans.** The Company sponsors frozen non-contributory qualified and non-qualified defined benefit pension plans in the U.S. and frozen defined benefit pension plans in the United Kingdom and Sweden. The Company also sponsors various defined contribution plans.

[Table of Contents](#)

The following table sets forth the plans' benefit obligations and plan assets included in the consolidated balance sheets:

(In millions)	U.S. Pension Benefits		International Pension Benefits	
	December 31, 2025	December 31, 2024	December 31, 2025	December 31, 2024
Aggregated projected benefit obligation at end of period	\$ (73.9)	\$ (73.8)	\$ (71.4)	\$ (63.7)
Aggregated fair value of plan assets at end of period	61.5	59.5	67.2	66.6
Net asset (liability) for benefit cost - funded status	\$ (12.4)	\$ (14.3)	\$ (4.2)	\$ 2.9

All pension plans are frozen; therefore, aggregated accumulated benefit obligations are equal to aggregated projected benefit obligations as of December 31, 2025 and December 31, 2024, respectively.

The Company expects to contribute \$3.0 million to the U.S. pension plans during the year ended December 31, 2026. The Company intends to make future cash contributions to the plans in an amount necessary to meet minimum funding requirements according to applicable benefit plan regulations.

The weighted-average assumptions used to determine benefit obligations are as follows:

	U.S. Pension Benefits		International Pension Benefits	
	December 31, 2025	December 31, 2024	December 31, 2025	December 31, 2024
Discount rate	5.28%	5.43%	4.78%	5.18%
Rate of compensation increase	N/A	N/A	2.13%	2.22%

The weighted-average assumptions used to determine net periodic benefit cost are as follows:

	U.S. Pension Benefits			International Pension Benefits		
	Year Ended			Year Ended		
	December 31, 2025	December 31, 2024	December 31, 2023	December 31, 2025	December 31, 2024	December 31, 2023
Discount rate	5.43%	4.76%	4.97%	5.18%	4.53%	4.82%
Weighted average expected long-term return on plan assets	6.56%	6.56%	6.56%	5.41%	4.34%	4.32%
Rate of compensation increase	N/A	N/A	N/A	2.22%	2.07%	2.19%

Pension actuarial gains and losses are recorded in stockholders' deficit as a component of accumulated other comprehensive loss. For further information, see Note 12—Accumulated Other Comprehensive Loss for pension amounts and activity recorded in accumulated other comprehensive loss.

For the years ended December 31, 2025, December 31, 2024, and December 31, 2023, net periodic benefit costs were \$1.2 million, \$1.8 million, and \$1.4 million, respectively. The non-operating component of net periodic benefit costs is recorded in other expense (income) in the consolidated statements of operations.

The following table provides the benefits expected to be paid in each of the next five years, and in the aggregate for the five years thereafter:

(In millions)	U.S. Pension Benefits	International Pension Benefits
2026	\$ 6.3	\$ 4.2
2027	5.9	4.3
2028	6.4	4.5
2029	6.7	4.3
2030	6.2	4.8
Years 2031 - 2035	27.1	25.9

The Company's investment objectives for its U.S. defined benefit pension plan investments are: (1) to preserve the value of its principal; (2) to maximize a real long-term return with respect to the plan assets consistent with

minimizing risk; (3) to achieve and maintain adequate asset coverage for accrued benefits under the plan; and (4) to maintain sufficient liquidity for payment of the plan obligations and expenses. The Company uses a diversified allocation of equity, debt, commodity and real estate exposures that are customized to the plan's cash flow benefit needs. A weighted average targeted allocation percentage is assigned to each asset class as follows: equity securities of 30%, debt securities of 67%, and private real estate of 3%. The International pension benefit plans do not have an established asset target allocation.

Investments in the pension plan assets are measured at fair value on a recurring basis. As of December 31, 2025, for the U.S. investment portfolio, 95% were valued using the net asset value per share (or its equivalent) as a practical expedient and 5% of the investment included pooled separate accounts valued using market prices for the underlying instruments that were observable in the market or could be derived by observable market data from independent external valuation information (Level 2 of the fair value hierarchy). As of December 31, 2025, for the International investment portfolio, 8% consisting of cash and equivalents was valued using quoted market prices from actively traded markets (Level 1 of the fair value hierarchy), 38% was an insurance contract whose value has been set equal to the present value of the related benefit obligation (Level 3 of the fair value hierarchy), and 54% were valued using the net asset value per share (or its equivalent) as a practical expedient.

In June 2023, the High Court in the UK issued a ruling in respect of *Virgin Media Limited v NTL Pension Trustees II Limited*, that decided certain amendments were invalid when amending contracted-out salary-related defined benefit pension plans in the period from April 6, 1997 until April 6, 2016, if these amendments were not accompanied by actuarial confirmations (section 37 certificates). An appeal on this decision was heard in June 2024 and The Court of Appeal ruled in July 2024 that the appeal was unsuccessful, i.e., it upheld the original High Court judgment, removing uncertainty around its application. In light of the ruling, the Company initiated an investigation with its pension trustees, of all known amendments to its two UK defined benefit pension plans during the affected period, with a view to determining whether section 37 certificates have been obtained where deemed required. The initial review concluded that across the two plans there are three documents where a section 37 certificate may have been required but the amendment document is silent. In June 2025, the UK government announced it will introduce legislation to give pension plans the ability to retrospectively obtain written actuarial confirmations that historic benefit changes met the necessary standards. This therefore provides clarity around plan liabilities and member benefit levels. On September 1, 2025, the UK government published the bill with these amendments. This legislation will not be in place until it has received royal assent, which is expected to occur in 2026. The Company will continue to monitor this change in legislation and assess any further reviews and potential retrospective confirmation with the trustees in due course.

The Company sponsors various defined contribution plans worldwide which include company match features. The expense related to defined contribution plans for the years ended December 31, 2025, December 31, 2024, and December 31, 2023, was \$11.7 million, \$10.5 million, and \$9.8 million, respectively.

**Income and Operating Taxes.** The Company accounts for income taxes in accordance with ASC 740-10. Under ASC 740-10, deferred income tax effects of transactions reported in different periods for financial reporting and income tax return purposes are recorded by the asset and liability method. This method gives consideration to the future tax consequences of deferred income or expense items and recognizes changes in income tax laws in the period of enactment.

Holdings and its U.S. subsidiaries file a consolidated U.S. federal income tax return and combined income tax returns in certain state jurisdictions. Foreign subsidiaries file income tax returns in foreign jurisdictions. Income taxes are determined based on separate company computations of income or loss. Tax sharing arrangements are in place and utilized when tax benefits from affiliates in the consolidated group are used to offset what would otherwise be taxable income generated by Holdings or another affiliate.

**Casualty Insurance.** The Company is self-insured for general liability up to \$1.0 million per occurrence and carries a \$0.5 million deductible limit per occurrence for workers' compensation claims. The Company utilizes actuarial projections of its ultimate losses to calculate its reserves and expense. The actuarial method includes an allowance for adverse developments on known claims and an allowance for claims which have been incurred but which have not yet been reported. As of December 31, 2025 and December 31, 2024, the Company recorded casualty insurance reserves of \$33.7 million and \$25.7 million, respectively. The Company recorded expenses related to general liability and workers' compensation claims of \$64.2 million, \$65.5 million, and \$53.1 million for the years ended December 31, 2025, December 31, 2024, and December 31, 2023, respectively. Casualty insurance expense is recorded in operating expense.

[Table of Contents](#)

**Government Assistance.** The Company recognizes government assistance when the conditions of the grant have been met and there is reasonable assurance that the assistance will be received. Grants relating to specific costs are treated as a reduction of that cost in the consolidated statement of operations. General grants are recorded within other expense (income). Grants related to the construction of long-lived assets are treated as reductions to the cost of the associated assets.

During the year ended December 31, 2025, the Company recognized government assistance in other expense (income) of \$10.8 million related to cash grants received in the International markets to support businesses impacted by the COVID-19 pandemic. The Company concluded all grant criteria had been met and that the likelihood of recapture was remote, therefore the entire award has been recognized. During the year ended December 31, 2024, the Company recognized government assistance in other income of \$0.1 million related to government assistance for theatres impacted by flooding in Spain. During the year ended December 31, 2023, the Company recognized government assistance in other income of \$4.8 million, primarily related to grants in the International markets. The general requirements of the grants were that the grantees must have lost income due to the COVID-19 pandemic. The Company concluded all grant criteria had been met and therefore have recognized the entire award.

Additionally, the Company recognized \$1.1 million, \$4.5 million and \$3.2 million of government assistance as reduction to property, net during the years ended December 31, 2025, December 31, 2024, and December 31, 2023, respectively. The assistance relates to the construction of capital assets related to the innovation, modernization, and digitalization of the theatrical exhibition industry in certain countries in the International markets.

During the years ended December 31, 2025, December 31, 2024, and December 31, 2023, the Company was awarded \$0.0 million, \$9.7 million and \$10.0 million, respectively, of tax credits in our International markets that have been or will be utilized to offset employer payroll tax or value-added tax liabilities. The tax credits are granted by the government to support entities in the film exhibition industry. The Company recorded these credits as reductions to operating expense in 2024 and as reductions to rent and operating expense during 2023 as those expenses were the basis for the tax credits awarded.

**Other Expense (Income):** The following table sets forth the components of other expense (income):

(In millions)	Year Ended		
	December 31, 2025	December 31, 2024	December 31, 2023
Governmental assistance - International markets	\$ (10.8)	\$ (0.1)	\$ (3.8)
Governmental assistance - U.S. markets	—	—	(1.0)
Foreign currency transaction (gains) losses	(28.1)	7.0	(17.8)
Non-operating components of net periodic benefit cost	1.2	1.8	1.4
Gain on extinguishment - Second Lien Notes due 2026	(6.6)	(40.3)	(140.5)
Loss on extinguishment - Senior Subordinated Notes due 2025	—	2.7	—
Loss (gain) on extinguishment - Senior Subordinated Notes due 2026	0.3	(1.3)	(2.3)
Loss on extinguishment - 6.00%/8.00% Cash/PIK Toggle Senior Secured Exchangeable Notes due 2030	103.3	—	—
Loss on extinguishment - 7.5% First Lien Notes due 2029	99.0	—	—
Term Loan modifications - third party fees	3.1	42.3	—
Increase in fair value of bifurcated embedded derivative liability - Senior Secured Exchangeable Notes due 2030	19.3	—	—
Decrease in fair value of bifurcated embedded derivative liability - 6.00%/8.00% Cash/PIK Toggle Senior Secured Exchangeable Notes due 2030	(56.7)	(75.8)	—
Equity in earnings of non-consolidated entities	(6.8)	(12.4)	(7.7)
Derivative stockholder settlement (1)	—	—	(14.0)
Shareholder litigation expense and (recoveries) (2)	(3.8)	(40.2)	110.2
Vendor dispute settlement (3)	—	(36.2)	—
Other settlement proceeds	—	(3.6)	—
Business interruption insurance recoveries	(1.0)	(0.1)	(1.3)
<b>Total other expense (income)</b>	<b>\$ 112.4</b>	<b>\$ (156.2)</b>	<b>\$ (76.8)</b>

## [Table of Contents](#)

- (1) The Company received \$14.0 million as a result of a derivative stockholder settlement which was recorded as other income during the year ended December 31, 2023.
- (2) The Company recorded a \$110.2 million charge for the settlement of shareholder litigation during the year ended December 31, 2023. The Company recorded other income related to recoveries of insurance claims associated with the shareholder litigation of \$3.8 million and \$40.2 million during the years ended December 31, 2025 and December 31, 2024, respectively.
- (3) The Company executed an agreement to collect \$37.5 million as a resolution of a dispute with a vendor. The proceeds, net of legal costs, were recorded to other income during the year ended December 31, 2024.

### **Accounting Pronouncements Recently Adopted**

**Income Tax Disclosures.** In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, Income Taxes (Topic 740) Improvements to Income Tax Disclosures (“ASU 2023-09”). The amendments in ASU 2023-09 require entities to disclose on an annual basis (1) specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. The amendments also require that entities disclose various information about income taxes paid and (1) income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and (2) foreign and income tax expense (or benefit) from continuing operations disaggregated by federal (national), state, and foreign. The Company adopted the new standard during the fourth quarter of 2025 on a full retrospective basis and recast certain prior period amounts and disclosures to conform to current year presentation. See Note 9—Income Taxes for the required disclosure information resulting from ASU 2023-09.

### **Accounting Pronouncements Issued Not Yet Adopted**

**Disaggregation of Income Statement Expenses.** In November 2024, the FASB issued ASU 2024-03, Income Statement (Subtopic 220-40)—Reporting Comprehensive Income—Expense Disaggregation Disclosures (“ASU 2024-03”). The amendments in ASU 2024-03 require that public business entities disclose additional information about specific expense categories in the notes to financial statements for interim and annual reporting periods. ASU 2024-03 is effective for the Company for the year ended December 31, 2027. The Company is currently evaluating the effect that ASU 2024-03 will have on its consolidated financial statements.

**Induced Conversions of Convertible Debt Instruments.** In November 2024, the FASB issued ASU 2024-04, Debt—Debt with Conversion and Other Options (Subtopic 470-20) Induced Conversions of Convertible Debt Instruments (“ASU 2024-04”). The amendments in ASU 2024-04 clarify the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. The amendments are effective for annual reporting periods beginning after December 15, 2025. The Company is currently evaluating the effect that ASU 2024-04 will have on its consolidated financial statements.

**Internal-Use Software.** In September 2025, the FASB issued ASU 2025-06, Intangibles—Goodwill and Other (Subtopic 350-40) Targeted Improvements to the Accounting for Internal-Use Software (“ASU 2025-06”), which is intended to modernize the accounting for software costs that are accounted for under Subtopic 350-40. ASU 2025-06 removes references to prescriptive and sequential software development stages and replaces them with a probable-to-complete recognition threshold. ASU 2025-06 also clarifies which disclosures apply to capitalized internal-use software costs. ASU 2025-06 is effective for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those reporting periods. Early adoption at the beginning of a fiscal year is permitted. The Company is currently evaluating the effect that ASU 2025-06 will have on its consolidated financial statements.

**Derivatives Scope Refinements and Share-Based Noncash Consideration.** In September 2025, the FASB issued ASU 2025-07, Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606) (“ASU 2025-07”), which (1) refines the scope of the guidance on derivatives in Topic 815 and (2) clarifies the guidance on share-based payments from a customer in ASC 606. ASU 2025-07 is intended to address concerns about the application of derivative accounting to contracts that have features based on the operations or activities of one of the parties to the contract and to reduce diversity in the accounting for share-based payments in revenue contracts. ASU 2025-07 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those reporting periods. Early adoption is permitted. The Company is currently evaluating the effect that ASU 2025-07 will have on its consolidated financial statements.

**Accounting for Government Grants.** In December 2025, the FASB issued ASU 2025-10, Accounting for Government Grants Received by Business Entities (Topic 832) (“ASU 2025-10”), which establishes the accounting for a government grant received by a business entity, including guidance for a grant related to an asset and a grant related to income. ASU 2025-10 adds guidance on Topic 832 on the recognition, measurement, and presentation of government grants. ASU 2025-10 is effective for annual reporting periods beginning after December 15, 2028, and interim reporting periods within those annual reporting periods. Early adoption is permitted in both interim and annual reporting periods in which financial statements have not yet been issued or made available for issuance. The Company is currently evaluating the impact of ASU 2025-10 on its consolidated financial statements.

**Interim Reporting Narrow-Scope Improvements.** In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270) Narrow-Scope Improvements (“ASU 2025-11”). The amendments in ASU 2025-11 clarify interim disclosure requirements and the applicability of Topic 270. The amendments in ASU 2025-11 also include a disclosure principle that requires entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. ASU 2025-11 is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2025-11 on its consolidated financial statements.

**NOTE 2—REVENUE RECOGNITION**

**Disaggregation of Revenue.** Revenue is disaggregated in the following tables by major revenue types and by timing of revenue recognition:

(In millions)	Year Ended		
	December 31, 2025	December 31, 2024	December 31, 2023
<b>Major revenue types</b>			
Admissions	\$ 2,652.8	\$ 2,560.5	\$ 2,690.5
Food and beverage	1,671.3	1,624.9	1,669.8
Other theatre:			
Advertising	152.1	132.9	129.5
Other theatre	372.7	318.9	322.8
Other theatre	524.8	451.8	452.3
Total revenues	\$ 4,848.9	\$ 4,637.2	\$ 4,812.6

(In millions)	Year Ended		
	December 31, 2025	December 31, 2024	December 31, 2023
<b>Timing of revenue recognition</b>			
Products and services transferred at a point in time	\$ 4,362.5	\$ 4,224.7	\$ 4,424.1
Products and services transferred over time (1)	486.4	412.5	388.5
Total revenues	\$ 4,848.9	\$ 4,637.2	\$ 4,812.6

(1) Amounts primarily include subscription and advertising revenues.

The following tables provide the balances of receivables, net and deferred revenues and income:

(In millions)	December 31, 2025	December 31, 2024
<b>Current assets</b>		
Receivables related to contracts with customers	\$ 95.1	\$ 86.0
Miscellaneous receivables	60.9	82.1
Receivables, net	\$ 156.0	\$ 168.1

[Table of Contents](#)

(In millions)	December 31, 2025	December 31, 2024
<b>Current liabilities</b>		
Deferred revenues related to contracts with customers	\$ 462.4	\$ 425.6
Miscellaneous deferred income	3.1	6.8
Deferred revenues and income	<u>\$ 465.5</u>	<u>\$ 432.4</u>

The significant changes in contract liabilities with customers included in deferred revenues and income are as follows:

(In millions)	Deferred Revenues Related to Contracts with Customers	
Balance December 31, 2023	\$	415.3
Cash received in advance (1)		354.1
Customer loyalty rewards accumulated, net of expirations:		
Admission revenues (2)		22.6
Food and beverage revenues (2)		39.5
Other theatre revenues (2)		(2.6)
Reclassification to revenue as the result of performance obligations satisfied:		
Admission revenues (3)		(254.1)
Food and beverage revenues (3)		(75.8)
Other theatre revenues (4)		(73.2)
Foreign currency translation adjustment		(0.2)
Balance December 31, 2024	\$	425.6
Cash received in advance (1)		393.8
Customer loyalty rewards accumulated, net of expirations:		
Admission revenues (2)		19.7
Food and beverage revenues (2)		55.1
Reclassification to revenue as the result of performance obligations satisfied:		
Admission revenues (3)		(256.9)
Food and beverage revenues (3)		(91.0)
Other theatre revenues (4)		(88.6)
Foreign currency translation adjustment		4.7
Balance December 31, 2025	<u>\$</u>	<u>462.4</u>

(1) Includes movie tickets, food and beverage, gift cards, exchange tickets, subscription membership fees, and other loyalty membership fees.

(2) Amount of rewards accumulated, net of expirations, that are attributed to loyalty programs.

(3) Amount of revenue recognized from redemption of gift cards, exchange tickets, movie tickets, and rewards related to loyalty programs.

(4) Amounts relate to income from non-redeemed or partially redeemed gift cards, non-redeemed exchange tickets, subscription membership fees, and loyalty programs membership fees.

The significant changes to contract liabilities included in the exhibitor services agreement in the consolidated balance sheets are as follows:

(In millions)	Exhibitor Services Agreement (1)	
Balance December 31, 2023	\$	486.6
Other theatre revenue recognized, net of adjustments, as performance obligations are satisfied		(22.6)
Balance December 31, 2024	\$	464.0
Contract modification consideration (1)		5.3
Other theatre revenue recognized as performance obligations are satisfied		(10.2)
Balance December 31, 2025	<u>\$</u>	<u>459.1</u>

- (1) The exhibitor services agreement contract liability relates to NCM common units that were previously received under the exhibitor services agreement dated February 13, 2007 and amended and restated as of December 13, 2013. On April 17, 2025, NCM entered into the Amended ESA with the Company. The term of the Amended ESA has been extended by five years through February 13, 2042. The Company treated the Amended ESA as a contract modification pursuant to *ASC 606 – Revenue from Contracts with Customers*. Accordingly, the Company has allocated the additional consideration received from the contract modification to the exhibitor services agreement contract liability and updated the discount rate used to account for the significant financing component to 16.12%. Prior to the contract modification, the weighted average discount rate used to account for the significant financing component was approximately 7.5%. The contract liability will be reclassified to other theatre revenue over the new term of the Amended ESA as the remaining performance obligations are satisfied.

**NCM Bankruptcy.** On April 11, 2023, NCM filed a petition under Chapter 11 of the U.S. Bankruptcy Code in the Southern District of Texas. The Chapter 11 plan of reorganization became effective on August 7, 2023 (the “Plan”). The Company appealed certain terms of the Plan and rulings of the bankruptcy court with the United States District Court for the Southern District of Texas, which affirmed the rulings of the bankruptcy court, and subsequently with the United States Court of Appeals for the Fifth Circuit. On April 17, 2025, concurrently with entering into the Amended ESA, NCM and the Company reached an agreement to, among other things, dismiss with prejudice the ongoing litigation between the parties.

**Transaction Price Allocated to the Remaining Performance Obligations.** The following table includes the amount of the exhibitor services agreement contract liability that is expected to be recognized as revenues in the future related to performance obligations that are unsatisfied as of December 31, 2025:

<b>(In millions)</b>	<b>Exhibitor Services Agreement</b>
Year ended 2026	\$ 6.5
Year ended 2027	7.6
Year ended 2028	8.9
Year ended 2029	10.5
Year ended 2030	12.3
Years ended 2031 through February 2042	413.3
<b>Total</b>	<b>\$ 459.1</b>

**Gift Cards and Exchange Tickets.** The total amount of non-redeemed gift cards and exchange tickets included in deferred revenues and income as of December 31, 2025 was \$341.8 million. This will be recognized as revenues as the gift cards and exchange tickets are redeemed, as the estimated non-redeemed gift card and exchange ticket revenues are recognized in proportion to the pattern of actual redemptions which is estimated to occur over the next one to 36 months, or as the gift cards or exchange tickets expire.

**Loyalty Programs.** As of December 31, 2025, the amount of deferred revenues related to loyalty programs included in deferred revenues and income was \$94.4 million. The earned points will be recognized as revenue as the points are redeemed or expire. Subscription membership fees and loyalty membership fees are recognized ratably over their respective membership periods.

The Company applies the practical expedient in ASC 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less.

**NOTE 3—LEASES**

The following table reflects the lease costs for the years indicated below:

(In millions)	Consolidated Statements of Operations	Year Ended		
		December 31, 2025	December 31, 2024	December 31, 2023
<b>Operating lease cost</b>				
Theatre properties	Rent	\$ 771.1	\$ 775.3	\$ 788.1
Theatre properties	Operating expense	7.2	5.6	2.0
Equipment	Operating expense	43.7	31.1	17.5
Office and other	General and administrative: other	5.2	5.4	5.4
<b>Finance lease cost</b>				
Amortization of finance lease assets				
	Depreciation and amortization	2.9	2.7	2.0
	Interest expense on lease liabilities	3.3	3.4	3.7
<b>Variable operating and finance lease cost</b>				
Theatre properties	Rent	116.2	98.3	85.4
Theatre properties	Interest expense	2.7	2.0	—
Equipment	Operating expense	75.6	65.4	63.3
<b>Total lease cost</b>		<b>\$ 1,027.9</b>	<b>\$ 989.2</b>	<b>\$ 967.4</b>

The following table represents the weighted-average remaining lease term and discount rate as of December 31, 2025:

Lease Term and Discount Rate	Weighted Average Remaining Lease Term (years)	Weighted Average Discount Rate
Operating leases	7.7	11.0%
Finance leases	12.4	6.5%

Cash flow and supplemental information is presented below:

(In millions)	Year Ended		
	December 31, 2025	December 31, 2024	December 31, 2023
<b>Cash paid for amounts included in the measurement of lease liabilities:</b>			
Operating cash flows used in finance leases	\$ (2.8)	\$ (3.4)	\$ (3.7)
Operating cash flows used in operating leases	(925.0)	(925.1)	(986.4)
Financing cash flows used in finance leases	(4.2)	(4.6)	(5.6)
<b>Lease incentives:</b>			
Operating cash flows provided by operating leases	45.6	31.8	23.9
<b>Supplemental disclosure of noncash leasing activities:</b>			
Right-of-use assets obtained in exchange for new operating lease liabilities (1)	302.9	196.3	214.1
Right-of-use assets obtained in exchange for new finance lease liabilities	2.9	2.6	—

(1) Includes lease extensions and option exercises.

[Table of Contents](#)

Minimum annual payments required under existing operating and finance leases and the net present value thereof as of December 31, 2025 are as follows:

(In millions)	Operating Lease Payments	Finance Lease Payments
2026	\$ 945.6	\$ 9.0
2027	889.9	9.0
2028	801.1	9.0
2029	694.1	8.8
2030	591.1	7.9
Thereafter	1,994.6	34.0
Total lease payments	5,916.4	77.7
Less imputed interest	(1,871.4)	(25.2)
Total operating and finance lease liabilities, respectively	\$ 4,045.0	\$ 52.5

As of December 31, 2025, the Company had signed an operating lease agreement for one theatre that has not yet commenced. The lease has a 10 year term and total lease payments of approximately \$7.1 million. The timing of lease commencement is dependent on the landlord providing the Company with control and access to the related facility.

During the year ended December 31, 2023, the Company received a \$13.0 million buyout incentive from a landlord which provided the landlord the right to terminate the lease of one theatre. The incentive was treated as a reduction to rent expense in the Company's consolidated statement of operations.

**NOTE 4—PROPERTY**

A summary of property, net is as follows:

(In millions)	December 31, 2025	December 31, 2024
Property owned:		
Land	\$ 56.8	\$ 62.3
Buildings and improvements	191.0	205.5
Leasehold improvements	2,149.5	2,018.6
Furniture, fixtures and equipment	2,443.7	2,386.6
	4,841.0	4,673.0
Less: accumulated depreciation	3,502.7	3,265.1
	1,338.3	1,407.9
Finance lease right-of-use assets:		
Buildings, improvements, and equipment	65.8	57.4
Less: accumulated depreciation and amortization	29.9	23.0
	35.9	34.4
Property, net	\$ 1,374.2	\$ 1,442.3

Property is recorded at cost or fair value, in the case of property resulting from acquisitions. The Company uses the straight-line method in computing depreciation and amortization for financial reporting purposes. The estimated useful lives for leasehold improvements and buildings subject to a ground lease reflect the shorter of the expected useful lives of the assets or the remaining lease terms of the corresponding lease agreements. The estimated useful lives of each major class of depreciable assets are as follows:

Buildings and improvements	1 to 40 years
Leasehold improvements	1 to 20 years
Furniture, fixtures and equipment	1 to 15 years

Expenditures for additions (including interest during construction) and betterments are capitalized, and expenditures for maintenance and repairs are charged to expense as incurred. The cost of assets retired or otherwise

[Table of Contents](#)

disposed of and the related accumulated depreciation and amortization are eliminated from the accounts in the year of disposal. Gains or losses resulting from property disposals are included in operating expense in the accompanying consolidated statements of operations.

Depreciation expense was \$286.8 million, \$295.4 million, and \$337.5 million for the years ended December 31, 2025, December 31, 2024 and December 31, 2023, respectively.

**NOTE 5—GOODWILL AND INTANGIBLE ASSETS**

The following table summarizes the changes in goodwill by reporting unit:

(In millions)	U.S. Markets			International Markets			Consolidated Goodwill		
	Gross Carrying Amount	Accumulated Impairment Losses	Net Carrying Amount	Gross Carrying Amount	Accumulated Impairment Losses	Net Carrying Amount	Gross Carrying Amount	Accumulated Impairment Losses	Net Carrying Amount
Balance December 31, 2023	\$ 3,072.6	\$ (1,276.1)	\$ 1,796.5	\$ 1,589.5	\$ (1,027.3)	\$ 562.2	\$ 4,662.1	\$ (2,303.4)	\$ 2,358.7
Currency translation adjustment	—	—	—	(72.5)	14.9	(57.6)	(72.5)	14.9	(57.6)
Balance December 31, 2024	\$ 3,072.6	\$ (1,276.1)	\$ 1,796.5	\$ 1,517.0	\$ (1,012.4)	\$ 504.6	\$ 4,589.6	\$ (2,288.5)	\$ 2,301.1
Currency translation adjustment	—	—	—	188.2	(73.2)	115.0	188.2	(73.2)	115.0
Balance December 31, 2025	\$ 3,072.6	\$ (1,276.1)	\$ 1,796.5	\$ 1,705.2	\$ (1,085.6)	\$ 619.6	\$ 4,777.8	\$ (2,361.7)	\$ 2,416.1

Detail of non-amortizing intangible assets is presented below:

(In millions)	December 31, 2025	December 31, 2024
Non-amortizing intangible assets:		
AMC trademark	\$ 104.4	\$ 104.4
Odeon trade names	39.5	36.0
Nordic trade names	2.9	2.5
Total non-amortizing intangible assets	\$ 146.8	\$ 142.9

Amortizing intangible assets had carrying values of \$0.6 million and \$1.4 million as of December 31, 2025 and December 31, 2024, respectively.

**NOTE 6—SUPPLEMENTAL BALANCE SHEET INFORMATION**

Other assets and liabilities consist of the following:

(In millions)	December 31, 2025	December 31, 2024
<b>Other current assets:</b>		
Income taxes receivable	\$ 1.3	\$ 1.4
Prepays	43.1	36.0
Merchandise inventory	42.6	51.2
Other	10.2	9.7
	<u>\$ 97.2</u>	<u>\$ 98.3</u>
<b>Other long-term assets:</b>		
Investments in real estate	\$ 6.9	\$ 3.5
Investments in equity method investees	61.1	53.6
Computer software	97.2	86.4
Investments in equity securities without readily determinable fair values	4.1	10.4
Pension asset	8.3	14.2
Other	34.7	24.4
	<u>\$ 212.3</u>	<u>\$ 192.5</u>
<b>Accrued expenses and other liabilities:</b>		
Taxes other than income	\$ 75.1	\$ 79.8
Interest	31.0	43.1
Payroll and vacation	38.9	57.9
Current portion of casualty claims and premiums	12.4	9.8
Accrued bonus	64.5	47.7
Accrued licensing and variable rent	33.4	27.5
Current portion of pension	0.2	0.2
Group insurance reserve	2.3	1.5
Accrued tax payable	1.1	1.5
Other	79.3	71.6
	<u>\$ 338.2</u>	<u>\$ 340.6</u>
<b>Other long-term liabilities:</b>		
Pension	\$ 24.7	\$ 25.4
Lease incentive obligations	26.9	19.7
Casualty claims and premiums	21.9	16.2
Contingencies	13.2	9.4
Other	8.5	11.2
	<u>\$ 95.2</u>	<u>\$ 81.9</u>

**NOTE 7—CORPORATE BORROWINGS AND FINANCE LEASE LIABILITIES**

A summary of the carrying value of corporate borrowings and finance lease liabilities is as follows:

(In millions)	December 31, 2025	December 31, 2024
<b>Secured Debt:</b>		
Credit Agreement-Term Loans due 2029 (10.731% as of December 31, 2025 and 11.356% as of December 31, 2024)	\$ 1,994.2	\$ 2,014.2
12.75% Odeon Senior Secured Notes due 2027	400.0	400.0
Senior Secured Exchangeable Notes due 2030 (1.5% cash interest)	155.8	—
Senior Secured Notes due 2029 (9.0% cash interest & 6.0% PIK interest as of December 31, 2025)	877.1	—
6.00%/8.00% Cash/PIK Toggle Senior Secured Exchangeable Notes due 2030	111.6	427.6
7.5% First Lien Notes due 2029	360.0	950.0
<b>Unsecured/Retired Debt:</b>		
10%/12% Cash/PIK Toggle Second Lien Subordinated Notes due 2026	—	131.2
5.75% Senior Subordinated Notes due 2025	—	44.1
5.875% Senior Subordinated Notes due 2026	—	41.9
6.125% Senior Subordinated Notes due 2027	125.5	125.5
Total principal amount of corporate borrowings	\$ 4,024.2	\$ 4,134.5
Finance lease liabilities	52.5	49.3
Accrued paid-in-kind interest	2.7	1.5
Deferred financing costs	(64.4)	(47.2)
Net discount (1)	(68.5)	(171.3)
Bifurcated embedded derivative – Senior Secured Exchangeable Notes due 2030	131.9	—
Bifurcated embedded derivative – 6.00%/8.00% Cash/PIK Toggle Senior Secured Exchangeable Notes due 2030	12.6	157.6
Total carrying value of corporate borrowings and finance lease liabilities	\$ 4,091.0	\$ 4,124.4
Less:		
Current maturities of corporate borrowings	(19.9)	(64.2)
Current maturities of finance lease liabilities	(5.8)	(4.4)
Total noncurrent carrying value of corporate borrowings and finance lease liabilities	\$ 4,065.3	\$ 4,055.8

(1) The following table provides the net discount amounts of corporate borrowings:

(In millions)	December 31, 2025	December 31, 2024
10%/12% Cash/PIK Toggle Second Lien Subordinated Notes due 2026	\$ —	\$ 10.9
12.75% Odeon Senior Secured Notes due 2027	(14.6)	(20.9)
Senior Secured Notes due 2029	62.5	—
Senior Secured Exchangeable Notes due 2030	(57.4)	—
Credit Agreement-Term Loans due 2029	(32.6)	(43.4)
6.00%/8.00% Cash/PIK/Toggle Senior Secured Exchangeable Notes due 2030	(26.4)	(117.9)
Net discount	\$ (68.5)	\$ (171.3)

[Table of Contents](#)

The following table provides the principal payments required and maturities of corporate borrowings as of December 31, 2025:

(In millions)	Principal Amount of Corporate Borrowings
2026	\$ 19.9
2027	545.2
2028	19.5
2029	3,172.2
2030	267.4
Total	<u>\$ 4,024.2</u>

**Debt Repurchases and Exchanges**

The table below summarizes the various cash debt repurchase transactions during the year ended December 31, 2025. It does not include the 2025 Refinancing Transactions described in further detail below.

(In millions)	Aggregate Principal Repurchased	Reacquisition Cost	(Gain)/Loss on Extinguishment	Accrued Interest Paid
5.75% Senior Subordinated Notes due 2025	\$ 1.3	\$ 1.3	\$ —	\$ —

The total carrying value of the debt extinguished in the above transactions during the year ended December 31, 2025 was \$1.3 million.

The table below summarizes the various cash debt repurchase transactions, debt for equity exchange transactions, and cash and debt for equity exchange transactions that occurred during the year ended December 31, 2024. The debt for equity exchange transactions were treated as early extinguishments of debt. In accordance with ASC 470-50-40-3, the reacquisition price of the extinguished debt was determined to be the fair value of the Common Stock exchanged. It does not include the 2024 Refinancing Transactions described further below.

(In millions, except for share data)	Aggregate Principal Repurchased/Exchanged	Shares of Common Stock Exchanged	Reacquisition Cost	(Gain)/Loss on Extinguishment	Accrued Interest Paid/Exchanged
<b>Cash debt repurchase transactions:</b>					
5.75% Senior Subordinated Notes due 2025	\$ 8.9	—	\$ 8.6	\$ (0.3)	\$ 0.1
Second Lien Notes due 2026	50.0	—	50.5	(4.4)	1.4
Total cash debt repurchase transactions	58.9	—	59.1	(4.7)	1.5
<b>Debt for equity exchange transactions:</b>					
5.75% Senior Subordinated Notes due 2025	36.7	9,017,297	39.8	3.2	0.8
Second Lien Notes due 2026	224.1	35,062,835	157.2	(93.1)	8.3
Total debt for equity exchange transactions	260.8	44,080,132	197.0	(89.9)	9.1
<b>Cash and debt for equity exchange transactions:</b>					
5.75% Senior Subordinated Notes due 2025	8.6	447,829	8.4	(0.2)	0.1
5.875% Senior Subordinated Notes due 2026	9.6	432,777	8.1	(1.3)	0.2
Second Lien Notes due 2026	45.0	2,693,717	45.5	(4.0)	1.2
Total cash and debt for equity exchange transactions	63.2	3,574,323	62.0	(5.5)	1.5
Total debt repurchases and exchanges	<u>\$ 382.9</u>	<u>47,654,455</u>	<u>\$ 318.1</u>	<u>\$ (100.1)</u>	<u>\$ 12.1</u>

The total carrying value of the debt extinguished in the above transactions during the year ended December 31, 2024 was \$418.2 million.

[Table of Contents](#)

The table below summarizes the various cash debt repurchase and debt for equity exchange transactions during the year ended December 31, 2023, including related party transactions. These transactions were executed at terms equivalent to an arms-length transaction.

(In millions, except for share data)	Aggregate Principal Repurchased/Exchanged	Shares of Common Stock Exchanged	Reacquisition Cost	(Gain) on Extinguishment	Accrued Interest Paid/Exchanged
<b>Cash debt repurchase transactions:</b>					
Related party transactions:					
Second Lien Notes due 2026	\$ 75.9	—	\$ 48.5	\$ (40.9)	\$ 1.1
5.875% Senior Subordinated Notes due 2026	4.1	—	1.7	(2.3)	0.1
Total related party transactions	80.0	—	50.2	(43.2)	1.2
Non-related party transactions:					
Second Lien Notes due 2026	139.7	—	91.4	(71.3)	4.5
Total non-related party transactions	139.7	—	91.4	(71.3)	4.5
Total cash debt repurchase transactions	<u>\$ 219.7</u>	<u>—</u>	<u>\$ 141.6</u>	<u>\$ (114.5)</u>	<u>\$ 5.7</u>
<b>Debt for equity exchange transactions:</b>					
Second Lien Notes due 2026	105.3	14,186,651	91.7	(28.3)	1.2
Total debt repurchases and exchanges	<u>\$ 325.0</u>	<u>14,186,651</u>	<u>\$ 233.3</u>	<u>\$ (142.8)</u>	<u>\$ 6.9</u>

The total carrying value of the debt extinguished in the above transactions during the year ended December 31, 2023 was \$376.1 million.

**6.00%/8.00% Cash/PIK Toggle Senior Secured Exchangeable Notes due 2030**

(In millions)	Carrying Value as of December 31, 2024	(Increase) Decrease to Net Earnings (Loss)	Debt Extinguishment (1)	Carrying Value as of December 31, 2025
Principal balance	\$ 427.6	\$ 21.4	\$ (337.4)	\$ 111.6
Discount	(117.9)	5.0	86.5	(26.4)
Debt issuance costs	(23.3)	1.0	17.1	(5.2)
Accrued paid-in-kind interest	1.5	0.1	(1.2)	0.4
Bifurcated embedded derivative	157.6	(56.7)	(88.3)	12.6
Carrying value	<u>\$ 445.5</u>	<u>\$ (29.2)</u>	<u>\$ (323.3)</u>	<u>\$ 93.0</u>

(1) For more information on the loss on extinguishment see the 2025 Refinancing Transactions section below.

The Existing Exchangeable Notes have an effective interest rate of 15.12%.

**Senior Secured Exchangeable Notes due 2030**

(In millions)	Carrying Value as of July 1, 2025	(Increase) Decrease to Net Earnings (Loss)	Principal Cancellation & Interest Adjustment Features	Additional Deferred Charges	Carrying Value as of December 31, 2025
Principal balance	\$ 194.4	\$ 1.3	\$ (39.9)	\$ —	\$ 155.8
Discount	(35.4)	2.7	(24.7)	—	(57.4)
Debt issuance costs	(6.4)	0.5	—	(8.9)	(14.8)
Bifurcated embedded derivative	41.7	19.3	64.6	6.3	131.9
Carrying value	<u>\$ 194.3</u>	<u>\$ 23.8</u>	<u>\$ —</u>	<u>\$ (2.6)</u>	<u>\$ 215.5</u>

The New Exchangeable Notes have an effective interest rate of 17.0%.

## 2025 Refinancing Transactions

On July 1, 2025, the Company and Muvico entered into a Transaction Support Agreement (the “Transaction Support Agreement”) providing for a series of refinancing transactions (the “2025 Refinancing Transactions”). The creditors party to the Transaction Support Agreement included certain holders of the Company’s Existing 7.5% Notes (the “Consenting 7.5% Noteholders”), certain holders of the Existing Exchangeable Notes, (the “Consenting Exchangeable Noteholders”) and certain lenders of the Company’s term loans outstanding under its credit agreement (the “Credit Agreement”, and any such consenting lenders, the “Consenting Term Loan Lenders” together with the Consenting 7.5% Noteholders and Consenting Exchangeable Noteholders, the “Consenting Parties”).

On July 1, 2025, the Consenting Exchangeable Noteholders exchanged \$143.0 million aggregate principal amount of Existing Exchangeable Notes held by the Consenting Exchangeable Noteholders for 79,800,000 shares of Common Stock, which were reserved or authorized to be exchanged for the Existing Exchangeable Notes held by such holders.

On July 24, 2025 (the “2025 Transactions Closing Date”), the Company and Muvico completed the 2025 Refinancing Transactions as contemplated by the Transaction Support Agreement. In connection with the 2025 Refinancing Transactions, on the 2025 Transactions Closing Date:

- The Consenting 7.5% Noteholders (i) provided approximately \$244.4 million of gross proceeds of incremental, new money financing and (ii) exchanged \$590.0 million aggregate principal amount of Existing 7.5% Notes held by the Consenting 7.5% Noteholders on a dollar-for-dollar basis for a total of \$857.0 million aggregate principal amount of new Senior Secured Notes due 2029 (the “New 2029 Notes”).
- The Consenting Exchangeable Noteholders exchanged approximately \$194.4 million aggregate principal amount of the remaining Existing Exchangeable Notes held by the Consenting Exchangeable Noteholders, on a dollar-for-dollar basis, for New Exchangeable Notes. The principal amount of New Exchangeable Notes was subject to potential downward adjustment, depending on the trading price of the Company’s Common Stock for a period following the initial exchange (the “Principal Adjustment Feature”). The Company also agreed to pay certain transaction fees, subject to certain conditions described in the Transaction Support Agreement, either in the form of Common Stock or as additional New Exchangeable Notes.
- The Consenting Term Loan Lenders and certain other lenders party to the Credit Agreement (which constituted the “Required Lenders” as defined in the Credit Agreement), the Company, Muvico and Wilmington Savings Fund Society, FSB, as administrative agent and as collateral agent under the Credit Agreement, entered into an amendment to the Credit Agreement permitting the 2025 Refinancing Transactions. The Consenting Term Loan Lenders were paid consent fees of approximately \$22.3 million.
- The Company and the Consenting Parties entered into a settlement and mutual release agreement with respect to the 2025 Refinancing Transactions, pursuant to which the parties have agreed that they will not directly or indirectly take any action in furtherance of the Intercreditor Litigation and to dismiss with prejudice any claims with respect to the Intercreditor Litigation.

On September 30, 2025, \$39.9 million aggregate principal of New Exchangeable Notes was cancelled pursuant to the Principal Adjustment Feature, representing the maximum possible downward adjustment.

## [Table of Contents](#)

At the 2025 Annual Meeting, our stockholders approved an amendment to the Company's Certificate of Incorporation for the Authorized Share Increase (the "Required Shareholder Approval") which allowed for the New Exchangeable Notes to become exchangeable and lowered the interest rate to 1.5% cash interest per annum. The Authorized Share increase also allowed for a \$15.0 million consent fee payable to Consenting Existing Exchangeable Noteholders to be payable in the form of shares of Common Stock, based on a price determined based on the average of the daily volume weighted average price of our Common Stock for the sixty consecutive trading days commencing on December 22, 2025.

On December 22, 2025, the Company and the holders of the New Exchangeable Notes agreed to amend the New Exchangeable Notes Indenture to amend and restate the Exchange Rate and allow for up to \$150.0 million of net proceeds from sales of at-the-market offerings. The amendments were memorialized in a supplemental indenture dated January 12, 2026 (the "New Exchangeable Notes Supplemental Indenture"). As consideration for the indenture amendments the Company will pay the New Exchangeable Noteholders a consent fee of \$6.25 million payable in shares of Common Stock. The number of shares will be based on the average of the daily volume weighted average price of our Common Stock for the sixty consecutive trading days commencing on December 22, 2025.

The following sections provide summaries of the key terms and provisions of the New 2029 Notes Indenture (as defined herein), the New Exchangeable Notes Indenture, and the Credit Agreement Amendment (as defined herein).

### ***New 2029 Notes Indenture***

#### *Interest, Guarantees and Security*

The New 2029 Notes were issued pursuant to an indenture (the "New 2029 Notes Indenture"), dated as of the 2025 Transactions Closing Date, by and among Muvico, as issuer, the Company, as a guarantor, the other guarantors party thereto and CSC Delaware Trust Company, as trustee and as collateral agent (in such capacity, the "New 2029 Notes Collateral Agent").

The New 2029 Notes bear interest at a rate per annum equal to the Applicable Rate (as defined in the New 2029 Notes Indenture), payable semi-annually in arrears in cash and, to the extent required, in payment-in-kind ("PIK") interest on June 15 and December 15 of each year, beginning on December 15, 2025. The Applicable Rate ranges from 11.5% cash interest to 15.0% total interest (comprised of 9.0% cash and 6.0% PIK) depending on the Company's Total Leverage Ratio. The New 2029 Notes will mature on February 19, 2029, unless redeemed in full prior to such maturity date, pursuant to the terms contained in the New 2029 Notes Indenture.

Muvico's obligations under the New 2029 Notes are fully and unconditionally guaranteed on a joint and several basis by the Company and each of the Company's subsidiaries that guarantee the Company's and Muvico's obligations under the Credit Agreement, and all of the Company's future subsidiaries that guarantee the Company's or any of the Company's subsidiaries other material indebtedness, including under the Credit Agreement. The New 2029 Notes are secured (a) on a first lien priority basis on the assets of the Company and the guarantors under the indenture governing the Company's Existing 7.5% Notes (the "Existing 7.5% Notes Indenture") (such guarantors, collectively, the "AMC Group Guarantors"), *pari passu* with the liens securing the term loans under the Credit Agreement, and, other than with respect to any turnover in favor of the Credit Agreement by the Existing Exchangeable Notes, the Existing Exchangeable Notes, and (b) on a 1.5 lien priority basis on the assets of Muvico, Centertainment, and their guarantor subsidiaries under the Existing Exchangeable Notes Indenture (as defined herein) and AMC Theatres of UK Limited (together with Centertainment and such guarantor subsidiaries, collectively, the "Muvico Group Guarantors"; the Muvico Group Guarantors, together with the AMC Group Guarantors, collectively, the "Existing Guarantors"), which lien will only be junior to the liens securing the term loans under the Credit Agreement and the New Exchangeable Notes and senior to the liens securing any other funded debt of Muvico, including, but not limited to, the Existing Exchangeable Notes.

#### *Covenants and Events of Default*

The New 2029 Notes Indenture contains covenants that limit the ability of Muvico, the Company and its subsidiaries to, among other things: (i) incur additional indebtedness or guarantee indebtedness; (ii) create liens; (iii) declare or pay dividends, redeem stock or make other distributions to stockholders; (iv) make investments; (v) enter into transactions with its affiliates; (vi) consolidate, merge, sell or otherwise dispose of all or substantially all of their respective assets; and (vii) impair the security interest in the collateral. These covenants are subject to a number of important limitations and exceptions. The New 2029 Notes Indenture also provides for events of default, which, if any of

them occurs, would permit or require the principal, premium, if any, interest and any other monetary obligations on all the then outstanding New 2029 Notes to be due and payable immediately.

### ***New Exchangeable Notes Indenture***

#### *Interest, Guarantees and Security*

The New Exchangeable Notes were issued pursuant to an indenture (the “New Exchangeable Notes Indenture”), dated as of the 2025 Transactions Closing Date, by and among Muvico, as issuer, the Company, as a guarantor, the other guarantors party thereto and GLAS Trust Company LLC, as trustee and as collateral agent (in such capacity, the “New Exchangeable Notes Collateral Agent”).

The New Exchangeable Notes initially bore interest at a rate per annum of 6.00% cash interest and 2.00% PIK interest. Once the Required Shareholder Approval was obtained on December 10, 2025 (the “Interest Adjustment Date”), the interest rate was decreased, from and after the Interest Adjustment Date, to 1.50% cash interest (and no PIK interest) per annum payable semi-annually in arrears on June 15 and December 15 of each year, beginning on December 15, 2025. The New Exchangeable Notes will mature on April 30, 2030, unless redeemed or exchanged in full prior to such maturity date, pursuant to the terms contained in the New Exchangeable Notes Indenture.

Muvico’s obligations under the New Exchangeable Notes are fully and unconditionally guaranteed on a joint and several basis by the Company and the Company’s subsidiaries that guarantee the Company and Muvico’s obligations under the Credit Agreement, and all of the Company’s future subsidiaries that guarantee the Company’s other material indebtedness, including under the Credit Agreement. The New Exchangeable Notes are secured (a) on a first lien priority basis on the assets of the Company and the guarantors under the Existing 7.5% Notes Indenture, *pari passu* with the liens securing the term loans under the Credit Agreement, the Existing Exchangeable Notes, the New 2029 Notes and the remaining Existing 7.5% Notes, subject to the Existing 1L Intercreditor Agreement, and will be subject to the same turnover provisions as the Existing Exchangeable Notes for the benefit of the term loans under the Credit Agreement and (b) on a 1.25 lien priority basis on the assets of Muvico, Centertainment and their guarantor subsidiaries under the Existing Exchangeable Notes Indenture and AMC Theatres of UK Limited, which lien will only be junior to the liens securing the term loans under the Credit Agreement and senior to the liens securing the New 2029 Notes and the liens securing any other funded debt of Muvico, including, but not limited to, the Existing Exchangeable Notes.

#### *Exchange Mechanics; Soft Call; Fundamental Change; Redemption*

The New Exchangeable Notes are exchangeable, at the option of the holders thereof, into Common Stock at a stock price (the “Exchange Price”) calculated based on a formula described in the New Exchangeable Notes Indenture.

Under the terms of the New Exchangeable Notes Indenture, the Company has also agreed that for a period of six months following the Required Shareholder Approval, the Company will not engage in at-the-market offerings that exceed the lesser of 25,000,000 aggregate shares of Common Stock or \$50,000,000 in aggregate net proceeds raised through such at-the-market offerings; provided, however, that if either (i) the share price of the Common Stock exceeds 200% of the Soft Call Trigger Price (as defined in the New Exchangeable Notes Indenture) at any time, determined based on the average of the Daily VWAPs (as defined in the New Exchangeable Notes Indenture) for any period of two consecutive Trading Days (as defined in the New Exchangeable Notes Indenture) or (ii) at least 100,000,000 shares of Common Stock have traded above 200% of the Soft Call Trigger Price, then, in either case, all such restrictions with respect to the Company’s ability to engage in at-the-market offerings will no longer apply, so long as any Common Stock sold in any such offering is sold at a price no less than 200% of the Soft Call Trigger Price.

At any time from and after the date that is one business day following the date on which the Exchange Price has been initially determined until the close of business on the second Trading Day immediately preceding the maturity date of the New Exchangeable Notes, each holder of the New Exchangeable Notes will have the right, at its option, to surrender for exchange all or a portion of its New Exchangeable Notes at the Exchange Rate for Common Stock based on the applicable Exchange Rate (as defined in the New Exchangeable Notes Indenture) then in effect. During such period, Muvico will have the right, at its election, to redeem all (but not less than all) of the outstanding New Exchangeable Notes at a price equal to the aggregate principal amount of the New Exchangeable Notes, plus accrued and unpaid interest thereon to, but excluding, the date of such redemption if the Daily VWAP per share of Common Stock exceeds 110% of the Exchange Price for fifteen consecutive Trading Days ending on (and including) the Trading Day

## [Table of Contents](#)

immediately before the date on which Muvico sends a notice to holders calling such New Exchangeable Notes for redemption (a “New Exchangeable Notes Soft Call Notice”). Any such New Exchangeable Notes Soft Call Notice will provide that the applicable redemption of the New Exchangeable Notes will occur on a business day of Muvico’s choosing, not more than ten and not less than five business days after the date of the New Exchangeable Notes Soft Call Notice. Notwithstanding the foregoing, holders of New Exchangeable Notes will be entitled within two business days of such New Exchangeable Notes Soft Call Notice to submit their New Exchangeable Notes for exchange under the terms of the New Exchangeable Notes Indenture. On December 22, 2025, the Company and the holders of the New Exchangeable Notes agreed to amend the Exchange Rate which was memorialized in the New Exchangeable Notes Supplemental Indenture. The New Exchangeable Notes Supplemental Indenture also increases the limit on at-the-market offerings to \$150.0 million of aggregate net proceeds. As consideration for the indenture amendments the Company will pay the New Exchangeable Noteholders a consent fee of \$6.25 million payable in shares of Common Stock. The number of shares will be based on the average of the daily volume weighted average price of our Common Stock for the sixty consecutive trading days commencing on December 22, 2025.

In the event that holders of New Exchangeable Notes voluntarily elect to exchange their New Exchangeable Notes, such holders will also be entitled to a make-whole premium (the “New Exchangeable Notes Exchange Adjustment Consideration”) equal to (i) prior to July 22, 2027, 21.0% of the aggregate principal amount of the New Exchangeable Notes being exchanged; (ii) on or after July 22, 2027 and prior to July 22, 2028, 14.0% of the aggregate principal amount of the New Exchangeable Notes being exchanged; (iii) on or after July 22, 2028 and prior to July 22, 2029, 7.0% of the aggregate principal amount of the New Exchangeable Notes being exchanged; and (iv) on or after July 22, 2029, zero. Muvico, at its option, will be entitled to pay the New Exchangeable Notes Exchange Adjustment Consideration in the form of shares of Common Stock (using a modified exchange price equal to 110% of the Exchange Price), subject to restrictions under the Credit Agreement, or cash in twelve equal installments over the twelve-month period following the applicable exchange or a combination thereof.

If certain corporate events that constitute a Fundamental Change (as defined in the New Exchangeable Notes Indenture) occur, then holders will have the right to require Muvico to repurchase their New Exchangeable Notes at a cash repurchase price equal to 100% of the aggregate principal amount of the New Exchangeable Notes to be repurchased, plus accrued and unpaid interest, if any, thereon to, but excluding, the Fundamental Change Repurchase Date (as defined in the New Exchangeable Notes Indenture). The definition of Fundamental Change includes certain business combination transactions involving the Company, stockholder approval of any plan or proposal for the liquidation or dissolution of the Company and certain de-listing events with respect to Common Stock.

Muvico will also be required to mandatorily redeem all of the issued and outstanding New Exchangeable Notes at a purchase price equal to 100% of the aggregate principal amount thereof, plus accrued and unpaid interest to, but excluding, the date of purchase in the event that, as of November 17, 2028, the aggregate principal amount outstanding of the Existing 7.5% Notes and New 2029 Notes exceeds an aggregate principal amount of \$190.0 million.

### *Covenants and Events of Default*

The New Exchangeable Notes Indenture contains covenants that limit the ability of Centertainment and Muvico and their future respective subsidiaries to, among other things: (i) incur additional indebtedness or guarantee indebtedness; (ii) create liens; (iii) declare or pay dividends, redeem stock or make other distributions to stockholders; (iv) make investments; (v) enter into transactions with its affiliates; (vi) consolidate, merge, sell or otherwise dispose of all or substantially all of their respective assets; and (vii) impair the security interest in the collateral. These covenants are subject to a number of important limitations and exceptions. The New Exchangeable Notes Indenture also incorporates the other restrictive covenants contained in the New 2029 Notes Indenture. The New Exchangeable Notes Indenture also provides for events of default, which, if any of them occurs, would permit or require the principal, premium, if any, interest and any other monetary obligations on all the then outstanding New Exchangeable Notes to be due and payable immediately.

### *Embedded Derivatives*

The New Exchangeable Notes contained a feature that would increase or decrease the interest rate on December 10, 2025, depending on the outcome of the Required Shareholder Approval (the “Interest Reset Feature”). The Company bifurcated the Interest Reset Feature as: (i) the economic characteristics and risks of the interest rate change are not clearly and closely related to the economic characteristics and risks of the host instrument because the change is dependent on authorization of additional Common Stock; (ii) the host debt instrument is not remeasured at fair value but

## [Table of Contents](#)

rather, is measured at amortized cost; and (iii) the Interest Reset Feature does not qualify for derivative scope exception under ASC 815-10-15-74(a).

The Company will pay a consent fee to an ad hoc group of creditors, in the form of \$21.3 million payable in shares of Common Stock, based on a price determined during the sixty consecutive trading days commencing December 22, 2025 (the “Consent Fee Feature”). The Consent Fee Feature was also bifurcated for the same reasons as the Interest Reset Feature.

The Company also bifurcated the Principal Adjustment Feature as: (i) the economic characteristics and risks were not clearly and closely related to the economic characteristics and risks of the host instrument given that the Principal Adjustment Feature was tied to the price of the Company’s Common Stock; (ii) the host debt instrument is not remeasured at fair value but rather, is measured at amortized cost; and (iii) the Principal Adjustment Feature does not qualify for derivative scope exception under ASC 815-10-15-74(a).

The Company analyzed the contingent conversion option and New Exchangeable Notes Exchange Adjustment Consideration as one single contingent conversion option (the “Contingent Conversion Option”). The Company bifurcated the Contingent Conversion Option from the host contract as: (i) the economic characteristics of a conversion option embedded in a debt instrument are not clearly and closely related to the economic characteristics and risks of a debt host contract, as stated in ASC 815-15-25-51; (ii) the host debt instrument is not remeasured at fair value but rather, is measured at amortized cost; and (iii) the Contingent Conversion Option does not qualify for derivative scope exception under ASC 815-10-15-74(a). The New Exchangeable Notes Exchange Adjustment Consideration (i.e., make-whole payment) does not meet the criteria for indexation under ASC 815-40-15-7C because the design of the feature does not meet the time-value scope exception and as a result is accounted for as a derivative.

The Company combined the embedded derivatives for the Interest Reset Feature, Principal Adjustment Feature, Consent Fee Feature, and the Contingent Conversion Option into a single compound derivative liability. The derivative liability is remeasured at fair value each reporting period with changes in fair value recorded in the consolidated statement of operations as other expense or income.

The Principal Adjustment Feature was recorded at fair value and transferred to the carrying value of the New Exchangeable Notes upon cancellation of \$39.9 million aggregate principal amount of New Exchangeable Notes on September 30, 2025. The Interest Reset Feature was recorded at fair value and transferred to the carrying value of the New Exchangeable Notes after the receipt of the Required Shareholder Approval on December 10, 2025. See Note 10–Fair Value Measurements for a discussion of the valuation methodologies.

### ***Credit Agreement Amendment***

On the 2025 Transactions Closing Date, the Company entered into that certain First Amendment to Credit Agreement (the “Credit Agreement Amendment”), by and among the Company and Muvico, as borrowers, the Existing Guarantors, the lenders party thereto (which constituted the “Required Lenders” as defined in the Credit Agreement) and Wilmington Savings Fund Society, FSB, as administrative agent and as collateral agent, which amends the Credit Agreement. Pursuant to the Credit Agreement Amendment, certain covenants were amended to permit the consummation of the 2025 Refinancing Transactions and directed Wilmington Savings Fund Society, FSB, as collateral agent in respect of the existing term loans (in such capacity, the “Credit Agreement Collateral Agent”), to enter into the A&R First Lien/Second Lien Entertainment Group Intercreditor Agreement (as defined below) and the First Lien/Intermediate Lien Intercreditor Agreement (as defined below).

### ***Intercreditor Agreements***

#### ***A&R First Lien/Second Lien Entertainment Group Intercreditor Agreement***

On the 2025 Transactions Closing Date, the Company, Entertainment, Muvico and the other Existing Guarantors, the Credit Agreement Collateral Agent, the collateral agent for the noteholders of the Existing Exchangeable Notes (the “Existing Exchangeable Notes Collateral Agent”), the New Exchangeable Notes Collateral Agent and the New 2029 Notes Collateral Agent entered into that certain Amended and Restated First Lien/Second Lien Intercreditor Agreement (the “A&R First Lien/Second Lien Entertainment Group Intercreditor Agreement”) to govern the relative priorities of the security interests of the Credit Agreement Collateral Agent, the Existing Exchangeable Notes Collateral

## [Table of Contents](#)

Agent, the New Exchangeable Notes Collateral Agent and the New 2029 Notes Collateral Agent in the collateral granted by the Muvico Group Guarantors and certain other matters related to the administration of security interests.

### *Existing First Lien Restricted Group Intercreditor Joinder Agreement*

On the 2025 Transactions Closing Date, the Company, the AMC Group Guarantors, the Credit Agreement Collateral Agent, in its capacity as controlling collateral agent, the New Exchangeable Notes Collateral Agent and the New 2029 Notes Collateral Agent entered into that certain Joinder No. 5 to the First Lien Intercreditor Agreement (the “Existing First Lien Restricted Group Intercreditor Joinder Agreement”), pursuant to which the New Exchangeable Notes Collateral Agent and the New 2029 Notes Collateral Agent joined that certain First Lien Intercreditor Agreement, dated as of April 24, 2020 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Existing Restricted Group First Lien Intercreditor Agreement”), among the Company, the AMC Group Guarantors, the Credit Agreement Collateral Agent and the other agents party thereto, and became bound by the Existing Restricted Group First Lien Intercreditor Agreement, which governs the relative priorities of the collateral agents party thereto and their respective security interests in the collateral granted by the Company and the AMC Group Guarantors and certain other matters related to the administration of security interests.

### *First Lien/Intermediate Lien Entertainment Group Intercreditor Agreement*

On the 2025 Transactions Closing Date, the Company, Centertainment, Muvico and the other Existing Guarantors, the Credit Agreement Collateral Agent, the New Exchangeable Notes Collateral Agent and the New 2029 Notes Collateral Agent entered into that certain First Lien/Intermediate Lien Intercreditor Agreement (the “First Lien/Intermediate Lien Entertainment Group Intercreditor Agreement”) to govern the relative priorities of the security interests of the Credit Agreement Collateral Agent, the New Exchangeable Notes Collateral Agent and the New 2029 Notes Collateral Agent in the collateral granted by the Muvico Group Guarantors and certain other matters related to the administration of security interests.

### *1.25 Lien/1.5 Lien Entertainment Group Intercreditor Agreement*

On the 2025 Transactions Closing Date, the Company, Muvico, Centertainment and the other Muvico Group Guarantors, the New Exchangeable Notes Collateral Agent and the New 2029 Notes Collateral Agent entered into that certain 1.25 Lien/1.5 Lien Intercreditor Agreement (the “1.25 Lien/1.5 Lien Entertainment Group Intercreditor Agreement”) to govern the relative priorities of the security interests of the New Exchangeable Notes Collateral Agent and the New 2029 Notes Collateral Agent in the collateral granted by the Muvico Group Guarantors and certain other matters related to the administration of security interests.

### ***Supplemental Indentures***

In connection with entering into the Transaction Support Agreement, with the consent of the holders of a majority of the Existing Exchangeable Notes, Muvico entered into a supplemental indenture (the “Supplemental Indenture”) to the indenture governing the Company’s Existing Exchangeable Notes, with the guarantors party thereto and the trustee and notes collateral agent thereunder. Among other things, the Supplemental Indenture makes amendments to the indenture to permit the 2025 Refinancing Transactions.

Prior to the 2025 Refinancing Transactions, with the consent of the holders of a majority in aggregate principal amount of the outstanding Existing 7.5% Notes, the Company, the guarantors party thereto and CSC Delaware Trust Company, as trustee and collateral agent, entered into a supplemental indenture (the “Existing 7.5% Notes Supplemental Indenture”) to the Existing 7.5% Notes Indenture. Among other things, the Existing 7.5% Notes Supplemental Indenture made amendments to the Existing 7.5% Notes Indenture to permit the 2025 Refinancing Transactions.

[Table of Contents](#)

**Extinguishments & Subordinated Note Redemption**

The Company determined that July 1, 2025 was the appropriate date to apply extinguishment accounting to the Existing Exchangeable Notes as it was the date that the Common Stock was issued and also the date the Company had a firm commitment to issue the New Exchangeable Notes. The exchanges of the Existing Exchangeable Notes for shares of Common Stock and New Exchangeable Notes resulted in a loss on extinguishment as follows:

<b>(In millions)</b>	<b>Amount</b>
Fair value of New Exchangeable Notes	\$ 159.0
Fair value of bifurcated embedded derivatives New Exchangeable Notes	41.7
Fair value of Common Stock issued	225.0
Total consideration	425.7
Principal Existing Exchangeable Notes	337.4
Discount Existing Exchangeable Notes	(86.5)
Debt issuance costs Existing Exchangeable Notes	(17.1)
Gain on cash paid for PIK interest	0.3
Bifurcated embedded derivatives Existing Exchangeable Notes	88.3
Carrying value Existing Exchangeable Notes	322.4
Loss on extinguishment of Existing Exchangeable Notes	<u>\$ 103.3</u>

The exchanges of the Existing 7.5% Notes for New 2029 Notes were accounted for as extinguishments and resulted in a loss on extinguishment as follows:

<b>(In millions)</b>	<b>Amount</b>
Fair value of New 2029 Notes (1)	\$ 925.4
Gross proceeds	(244.4)
Cash fee paid to Existing 7.5% Notes lenders	2.4
Total consideration	683.4
Principal Existing 7.5% Notes	590.0
Debt issuance costs Existing 7.5% Notes	(5.6)
Carrying value Existing 7.5% Notes	584.4
Loss on extinguishment of Existing 7.5% Notes	<u>\$ 99.0</u>

- (1) Fair value of the New 2029 Notes was estimated on July 24, 2025 using observed prices for transactions of the New 2029 Notes shortly after issuance. The market for the New 2029 Notes is considered an inactive market and the observed prices are considered a Level 2 input in the fair value hierarchy.

On July 7, 2025, the Company delivered notices of conditional full redemption (the “Notices”) to holders of the Company’s outstanding 5.875% Senior Subordinated Notes due 2026 (the “Senior Subordinated Notes due 2026”) and 10%/12% Cash/PIK Toggle Second Lien Subordinated Secured Notes due 2026 (the “Second Lien Notes”) (collectively, the “Subordinated Notes”) to redeem the Subordinated Notes in full, in each case, at a redemption price of 100% of the principal amount of the Subordinated Notes outstanding, plus accrued and unpaid interest to the applicable redemption date (the “Redemptions”). On July 28, 2025, the Company used the proceeds from the issuance of the New 2029 Notes to fully redeem the Second Lien Notes. On August 6, 2025, the Company fully redeemed the Senior Subordinated Notes due 2026. The Company recorded a gain on extinguishment of \$6.6 million and a loss on extinguishment of \$0.3 million related to the Second Lien Notes redemption and Senior Subordinated Notes due 2026 redemption, respectively.

The Credit Agreement Amendment was accounted for as a modification and resulted in expense of approximately \$3.1 million for costs paid to third parties.

## 2024 Refinancing Transactions

On July 22, 2024, the Company completed a series of refinancing transactions (the “2024 Refinancing Transactions”) with two creditor groups to refinance and extend to 2029 and 2030 the maturities of the Company’s debt previously maturing in 2026.

In connection with the refinancing:

- The Company and Muvico, entered into the Credit Agreement, by and among the Company and Muvico, each, as a borrower, pursuant to which the Company and Muvico jointly and severally borrowed \$2,024.3 million of new term loans maturing in 2029 (the “New Term Loans”).
- The New Term Loans were (i) used as consideration for the open market purchase of \$1,895.0 million of Company’s Term Loans due 2026 and (ii) exchanged for \$104.2 million of the Company’s Second Lien Notes.
- Muvico also completed a private offering for cash of \$414.4 million aggregate principal amount of Existing Exchangeable Notes and used the proceeds from the offering to repurchase \$414.4 million aggregate principal amount of the Company’s Second Lien Notes.

The debt repurchases and exchanges for the Second Lien Notes were accounted for as extinguishments and resulted in a loss on extinguishment as follows:

(In millions)	Amount
Fair value of Exchangeable Notes due 2030	\$ 293.6
Fair value of Conversion Option	233.4
Fair value of New Term Loans due 2029	104.2
PIK fee paid to Second Lien Lenders	2.3
Cash fee paid to Second Lien Lenders	2.3
Second Lien Notes consideration	635.8
Principal Second Lien Notes	518.6
Premium Second Lien Notes	56.0
Carrying value Second Lien Notes	574.6
Loss on extinguishment of Second Lien Notes	\$ 61.2

The debt exchanges for the Term Loans due 2026 were accounted for as modifications and resulted in expense of approximately \$42.3 million for costs paid to third parties.

### *Existing Exchangeable Notes*

On July 22, 2024, Muvico issued \$414.4 million aggregate principal amount of its Existing Exchangeable Notes. The Existing Exchangeable Notes will bear interest at a rate of 6.00% per annum, if paid in cash, and 8.00% per annum, if paid in-kind by issuing PIK Notes having the same terms and conditions as the Existing Exchangeable Notes (“PIK Interest”) in each case, payable semi-annually in arrears on June 15 and December 15, beginning on December 15, 2024. The Existing Exchangeable Notes will mature on April 30, 2030, unless redeemed or exchanged in full prior to such maturity date, pursuant to the terms contained in the Existing Exchangeable Notes Indenture as further discussed below.

At the time prior to the close of business on the second Trading Day (as defined in the Existing Exchangeable Notes Indenture) immediately preceding the final maturity date of the Existing Exchangeable Notes, each holder of the Existing Exchangeable Notes shall have the right, at its option, to surrender for exchange all or a portion of its Existing Exchangeable Notes at the Exchange Rate (as defined in the Existing Exchangeable Notes Indenture) for Common Stock. The Exchange Rate is initially set at 176.6379 shares of the Common Stock per \$1,000 principal amount of Existing Exchangeable Notes exchanged, which reflects a price of \$5.66 per share Common Stock (“Existing Exchangeable Notes Exchange Price”), which price is equal to 113% of the closing price per share of the Common Stock

[Table of Contents](#)

on July 19, 2024. The Exchange Rate is subject to customary adjustments and anti-dilution protections (as provided in the Existing Exchangeable Notes Indenture).

At any time prior to the close of business on the second Trading Day immediately preceding the final maturity date of the Existing Exchangeable Notes, Muvico will also have the right, at its election, to redeem all (but not less than all) of the outstanding Existing Exchangeable Notes at a price equal to the aggregate principal amount of the Existing Exchangeable Notes, plus accrued and unpaid interest thereon to, but excluding, the date of such redemption if the Daily VWAP (as defined in the Existing Exchangeable Notes Indenture) per share of Common Stock exceeds 140% of the Existing Exchangeable Notes Exchange Price for fifteen (15) consecutive Trading Days ending on (and including) the Trading Day immediately before the date on which Muvico sends a notice to holders calling such Existing Exchangeable Notes for redemption (a “Existing Exchangeable Notes Soft Call Notice”). Any such Existing Exchangeable Notes Soft Call Notice will provide that the applicable redemption of the Existing Exchangeable Notes will occur on a business day of Muvico’s choosing, not more than ten (10) and not less than five (5) business days after the date of the Existing Exchangeable Notes Soft Call Notice. Notwithstanding the foregoing, holders of Existing Exchangeable Notes will be entitled within two (2) business days of such Existing Exchangeable Notes Soft Call Notice to submit their Existing Exchangeable Notes for exchange under the terms of the Existing Exchangeable Notes Indenture.

In the event that holders of Existing Exchangeable Notes voluntarily elect to exchange their Existing Exchangeable Notes, such holders will also be entitled to a make-whole premium (the “Existing Exchangeable Notes Exchange Adjustment Consideration”) equal to (i) prior to the third anniversary of the Issue Date, 18.0% of the aggregate principal amount of the Existing Exchangeable Notes being exchanged; (ii) on or after the third anniversary and prior to the fourth anniversary of the Issue Date, 12.0% of the aggregate principal amount of the Existing Exchangeable Notes being exchanged; and (iii) on or after the fourth anniversary of the Issue Date and prior to the fifth anniversary, 6.0% of the aggregate principal amount of the Existing Exchangeable Notes being exchanged. Muvico, at its option, will be entitled to pay the Existing Exchangeable Notes Exchange Adjustment Consideration in the form of shares of Common Stock (using a modified exchange price equal to 140% of the Existing Exchangeable Notes Exchange Price), subject to restrictions under the Credit Agreement, cash in twelve (12) equal installments over the twelve-month period following the applicable exchange or a combination thereof.

If certain corporate events that constitute a Fundamental Change (as defined in the Existing Exchangeable Notes Indenture) occur, then holders will have the right to require Muvico to repurchase their Existing Exchangeable Notes at a cash repurchase price equal to 100% of the aggregate principal amount of the Existing Exchangeable Notes to be repurchased, plus accrued and unpaid interest, if any, thereon to, but excluding, the Fundamental Change Repurchase Date (as defined in the Existing Exchangeable Notes Indenture). The definition of Fundamental Change includes certain business combination transactions involving the Company, stockholder approval of any plan or proposal for the liquidation or dissolution of the Company and certain de-listing events with respect to the Common Stock.

Muvico will also be required to mandatorily redeem all of the issued and outstanding Existing Exchangeable Notes at a purchase price equal to 100% of the aggregate principal amount, plus accrued and unpaid interest to, but excluding, the date of purchase in the event that, as of ninety (90) days prior to the maturity date of the Existing 7.5% Notes, the aggregate principal amount outstanding of the Existing 7.5% Notes with a maturity date prior to April 30, 2030 exceeds \$190,000,000.

The Existing Exchangeable Notes Indenture also provides for events of default, which, if any of them occur, would permit or require the principal, premium, if any, interest and any other monetary obligations on all the then outstanding Existing Exchangeable Notes to be due and payable immediately.

The Company analyzed the conversion option and Existing Exchangeable Notes Exchange Adjustment Consideration as one single conversion option (the “Conversion Option”). The Company bifurcated the Conversion Option from the principal balance of the Existing Exchangeable Notes as a derivative liability. The Company bifurcated the Conversion Option as: (i) the economic characteristics of a conversion option embedded in a debt instrument are not clearly and closely related to the economic characteristics and risks of a debt host contract, as stated in ASC 815-15-25-51; (ii) the host debt instrument is not remeasured at fair value but rather, the Existing Exchangeable Notes are measured at amortized cost; and (iii) the Conversion Option does not qualify for derivative scope exception under ASC 815-10-15-74(a). The Conversion Option also includes a make-whole adjustment, the Existing Exchangeable Notes Exchange Adjustment Consideration. The Existing Exchangeable Notes Exchange Adjustment Consideration (i.e., make-whole payment) does not meet the criteria for indexation under ASC 815-40-15-7C because the design of the feature does not

meet the time-value scope exception and as a result is accounted for as a derivative. The derivative liability is remeasured at fair value each reporting period with changes in fair value recorded in the consolidated statement of operations as other expense or income. See Note 10–Fair Value Measurements for a discussion of the valuation methodologies.

#### ***New Term Loans due 2029***

The New Term Loans mature on January 4, 2029 (or, if at least \$190,000,000 remains outstanding of the (i) Existing 7.5% Notes or (ii) any indebtedness in respect of any modification, refunding, replacement, substitution, restructuring or other refinancing of the Existing 7.5% Notes on or prior to October 5, 2028, then October 5, 2028). The New Term Loans are subject to amortization of principal, payable in quarterly installments on the last business day of each fiscal quarter, commencing on September 30, 2024, equal to 1.00% per annum. The remaining aggregate principal amount outstanding (together with accrued and unpaid interest on the principal amount) of the New Term Loans is payable at maturity.

The New Term Loans bear interest, at the option of the New Term Loan Borrowers, at rates equal to either (i) a base rate plus a margin of between 500 and 600 basis points depending on the Total Leverage Ratio or (ii) Term SOFR plus a margin of between 600 and 700 basis points depending on the Total Leverage Ratio.

The New Term Loans are guaranteed, subject to limited exceptions, by Centertainment and the future subsidiaries of Centertainment and Muvico (collectively with Muvico, the “Centertainment Group Parties”) and the Existing Guarantors, and are secured by liens on substantially all of the tangible and intangible assets owned by the Company, in each case, subject to limited exceptions set forth in the Credit Agreement.

The Credit Agreement contains covenants that limit the Company’s ability to, among other things: (i) incur additional indebtedness or guarantee indebtedness; (ii) create liens; (iii) declare or pay dividends, redeem stock or make other distributions to stockholders; (iv) make investments; (v) enter into transactions with its affiliates; (vi) consolidate, merge, sell or otherwise dispose of all or substantially all of their respective assets; and (vii) maintain cash in the accounts of the Company (other than the Centertainment Group Parties). These covenants are subject to a number of limitations and exceptions. The Credit Agreement also provides for events of default, which, if any of them occur, would permit or require the principal, premium, if any, interest and any other monetary obligations on all the then outstanding New Term Loans to become immediately due and payable.

Unamortized discounts and deferred charges related to the Term Loans due 2026 of \$6.5 million and fees paid to Term Loans due 2026 lenders of \$45.7 million were recorded as deferred charges related to the New Term Loans and the Company will amortize those costs to interest expense following the effective interest method over the term of the New Term Loans.

#### ***Senior Secured Credit Facilities***

Holdings entered into the 2013 Credit Agreement. The 2013 Credit Agreement (as amended, restated, amended and restated, supplemented or otherwise modified) provided senior secured financing of \$2,225.0 million in aggregate, consisting of (i) \$2,000.0 million Term Loans due 2026 and (ii) a \$225.0 million senior secured revolving credit facility (which was also available for letters of credit and for swingline borrowings on same-day notice) maturing April 22, 2024 (the “Senior Secured Revolving Credit Facility” and together with the Term Loans due 2026, the “Senior Secured Credit Facilities”).

The Term Loans due 2026 bore interest at a rate per annum equal to, at Holdings’ option, either (1) a base rate determined by reference to the highest of (a) 0.50% per annum plus the Federal Funds Effective Rate, (b) the prime rate announced by the Administrative Agent from time to time and (c) 1.00% per annum plus Adjusted Term SOFR for a 1-month tenor, or (2) Adjusted Term SOFR plus (x) in the case of the Term Loans due 2026, 2.0% for base rate loans or 3.0% for SOFR loans or (y) in the case of the Senior Secured Revolving Credit Facility, an applicable margin based on the Secured Leverage Ratio (as defined in the 2013 Credit Agreement).

The Company’s obligations under the Senior Secured Credit Facilities were completely repaid following the completion of the 2024 Refinancing Transactions.

***Existing 7.5% Notes***

On February 14, 2022, Holdings issued \$950.0 million aggregate principal amount of its 7.5% First Lien Senior Secured Notes due 2029 (“Existing 7.5% Notes”), pursuant to an indenture, dated as of February 14, 2022, among Holdings, the guarantors named therein and U.S. Bank Trust Company, National Association, as trustee and collateral agent.

The Existing 7.5% Notes bear cash interest at a rate of 7.5% per annum payable semi-annually in arrears on February 15 and August 15. The Existing 7.5% Notes have not been registered under the Securities Act and will mature on February 15, 2029. Holdings may redeem some or all of the Existing 7.5% Notes at any time on or after February 15, 2025, at the redemption prices equal to (i) 103.750% for the twelve-month period beginning on February 15, 2025; (ii) 101.875% for the twelve-month period beginning on February 15, 2026; and (iii) 100.0% at any time thereafter, plus accrued and unpaid interest. Upon a Change of Control (as defined in the indenture governing the Existing 7.5% Notes), Holdings must offer to purchase the Existing 7.5% Notes at a purchase price equal to 101% of the principal amounts, plus accrued and unpaid interest.

The Existing 7.5% Notes are guaranteed by the Existing Guarantors and are secured by liens on substantially all of the tangible and intangible assets owned by Holdings and the Existing Guarantors, subject to certain thresholds, exceptions and permitted liens.

On July 24, 2025, the Company entered into a supplemental indenture to the indenture governing the Existing 7.5% Notes that, among other things, (i) permit the 2025 Refinancing Transactions, and (ii) eliminated many of the restrictive covenants contained in the indenture governing the Existing 7.5% Notes. The indenture governing the Existing 7.5% Notes, as amended, contains covenants that restrict the ability of the Company to, among other things: (i) create liens ranking pari passu in right of payment with or subordinated in right of payment to Existing 7.5% Notes; and (ii) merge or consolidate with other companies or transfer all or substantially all of their respective assets. These covenants are subject to a number of important limitations and exceptions. The indenture governing the Existing 7.5% Notes also provides for events of default, which, if any occur, would permit or require the principal, interest and any other monetary obligations on all the then outstanding Existing 7.5% Notes to be due and payable immediately.

***Odeon Senior Secured Notes due 2027***

On October 20, 2022, Odeon Finco PLC, a direct subsidiary of OCGL and an indirect subsidiary of Holdings, issued \$400.0 million aggregate principal amount of its Odeon Notes due 2027, at an issue price of 92.00%. The Odeon Notes due 2027 bear a cash interest rate of 12.75% per annum and will be payable semi-annually in arrears on May 1 and November 1, beginning on May 1, 2023. The Odeon Notes due 2027 are guaranteed on a senior secured basis by OCGL and certain of its subsidiaries and by Holdings on a standalone and unsecured basis. The indenture governing the Odeon Notes due 2027 contains covenants that limit OCGL and certain of its subsidiaries’ ability to, among other things: (i) incur additional indebtedness or guarantee indebtedness; (ii) create liens; (iii) declare or pay dividends, redeem stock or make other distributions to stockholders; (iv) make investments; (v) enter into transactions with affiliates; (vi) consolidate, merge, sell or otherwise dispose of all or substantially all of their respective assets; and (vii) impair the security interest in the collateral. These covenants are subject to several important limitations and exceptions. The indenture governing the Odeon Notes due 2027 also provides for events of default, which, if any occur, would permit or require principal, interest and any other monetary obligations on all the then outstanding Odeon Notes due 2027 to be due and payable immediately.

## [Table of Contents](#)

On or after November 1, 2024, the Odeon Notes due 2027 will be redeemable, in whole or in part, at redemption prices equal to (i) 106.375% for the twelve-month period beginning on November 1, 2024; (ii) 103.188% for the twelve-month period beginning on November 1, 2025; and (iii) 100.000% at any time thereafter, plus accrued and unpaid interest, if any. If the Company or its restricted subsidiaries sell assets under certain circumstances, the Company will be required to use the net proceeds to repay the Odeon Notes due 2027 or any additional First Lien Obligations at a price no less than 100% of the issue price of the Odeon Notes due 2027, plus accrued and unpaid interest, if any. Upon a Change of Control (as defined in the indenture governing the Odeon Notes due 2027), the Company must offer to purchase the Odeon Notes due 2027 at a purchase price equal to 101% of the principal amount, plus accrued and unpaid interest, if any. On December 14, 2022, the Odeon Notes due 2027 were admitted to the official list of The International Stock Exchange (“TISE”). The Odeon Notes due 2027 will automatically delist from TISE on the business day following the maturity date of November 1, 2027, unless adequate notice is given together with supporting documents setting out any changes to the date of maturity or confirmation that the Odeon Notes due 2027 have not been fully repaid.

### ***Second Lien Notes due 2026***

On July 31, 2020, Holdings issued \$1,462.3 million aggregate principal amount of its Second Lien Notes in exchange for the 6.375% Senior Subordinated Notes due 2024 (the “Sterling Notes due 2024”), 5.75% Senior Subordinated Notes due 2025, Senior Subordinated Notes due 2026, and Senior Subordinated Notes due 2027. The Second Lien Notes were issued pursuant to an indenture, dated as of July 31, 2020, among Holdings, the guarantors named therein and GLAS Trust Company LLC, as trustee and collateral agent (the “Second Lien Notes Indenture”). The Company recorded a premium of \$535.1 million on the Second Lien Notes as the difference between the principal balance of the Second Lien Notes and the \$1,997.4 million carrying value of the notes exchanged.

The Second Lien Notes bore cash interest at a rate of 10% or 12% PIK per annum payable semi-annually in arrears on June 15 and December 15. For the first two interest periods Holdings elected to pay in PIK interest. For all interest periods after the first three interest periods, interest was payable solely in cash at a rate of 10% per annum.

On July 28, 2025, the Company redeemed the remaining outstanding \$131.2 million principal in full.

### ***Senior Subordinated Notes due 2027***

On March 17, 2017, Holdings issued \$475.0 million aggregate principal amount of its Senior Subordinated Notes due 2027. The Company recorded deferred financing costs of approximately \$19.8 million related to the issuance of the Senior Subordinated Notes due 2027. The Senior Subordinated Notes due 2027 mature on May 15, 2027. Holdings pays interest on the Senior Subordinated Notes due 2027 at 6.125% per annum, semi-annually in arrears on May 15 and November 15. Holdings may redeem some or all of the Senior Subordinated Notes due 2027 at any time on or after May 15, 2025 at 100.0% plus accrued and unpaid interest, if any.

On March 17, 2017, in connection with the issuance of the Senior Subordinated Notes due 2027, Holdings entered into a registration rights agreement. Subject to the terms of the registration rights agreement, Holdings filed a registration statement with the SEC on April 19, 2017 pursuant to the Securities Act relating to an offer to exchange the original Senior Subordinated Notes due 2027 for exchange Senior Subordinated Notes due 2027; the registration statement was declared effective on June 7, 2017, and Holdings commenced the exchange offer. The exchange notes have terms substantially identical to the original notes except that the exchange notes do not contain terms with respect to transfer restrictions and registration rights and additional interest payable for the failure to consummate the exchange offer. All of the original notes were exchanged as of July 12, 2017.

On July 31, 2020, as part of the exchange for the Second Lien Notes, the Company reduced the aggregate principal amount of the Senior Subordinated Notes due 2027 by approximately \$344.3 million, or 72.48% of the then outstanding Senior Subordinated Notes due 2027.

***Senior Subordinated Notes due 2026***

On November 8, 2016, Holdings issued \$595.0 million aggregate principal amount of its Senior Subordinated Notes due 2026 in a private offering. Holdings paid interest on the Senior Subordinated Notes due 2026 at 5.875% per annum, semi-annually in arrears on May 15 and November 15.

On July 31, 2020, as part of the exchange for the Second Lien Notes, the Company reduced the aggregate principal amount of the Senior Subordinated Notes due 2026 by approximately \$539.4 million, or 90.65% of the then outstanding Senior Subordinated Notes due 2026.

On August 6, 2025, the Company redeemed the remaining outstanding \$41.9 million principal in full.

***Senior Subordinated Notes due 2025***

On June 5, 2015, Holdings issued \$600.0 million aggregate principal amount of its 5.75% Senior Subordinated Notes due 2025 (the “Senior Subordinated Notes due 2025”) in a private offering. Holdings paid interest on the Senior Subordinated Notes due 2025 at 5.75% per annum, semi-annually in arrears on June 15 and December 15.

On July 31, 2020, as part of the exchange for the Second Lien Notes, the Company reduced the aggregate principal amount of the Senior Subordinated Notes due 2025 by approximately \$501.7 million, or 83.61% of the then outstanding Senior Subordinated Notes due 2025.

On June 15, 2025, the maturity date, the Company redeemed the remaining outstanding \$42.8 million principal in full.

***Sterling Notes due 2024***

On November 8, 2016, Holdings issued £250.0 million aggregate principal amount of its Sterling Notes due 2024 in a private offering. Holdings paid interest on the Sterling Notes due 2024 at 6.375% per annum, semi-annually in arrears on May 15 and November 15.

On March 17, 2017, Holdings issued £250.0 million additional aggregate principal amount of its Sterling Notes due 2024 at 106% plus accrued interest from November 8, 2016 in a private offering. These additional Sterling Notes due 2024 were offered as additional notes under an indenture pursuant to which Holdings had previously issued its Sterling Notes due 2024.

On July 31, 2020, as part of the exchange for the Second Lien Notes, the Company reduced the aggregate principal amount of Sterling Notes due 2024 by approximately \$632.1 million (£496.0 million par value), or 99.2% of the then outstanding Sterling Notes due 2024.

On November 15, 2024, the maturity date, Holdings repaid the remaining £4.0 million (\$5.0 million) principal in full.

**Covenant Compliance**

As of December 31, 2025, the Company believes that it was in full compliance with all agreements, including related covenants, governing its outstanding debt.

## **NOTE 8—STOCKHOLDERS' DEFICIT**

### **Share Rights and Privileges**

#### *Common Stock*

Holders of the Company's Common Stock are entitled to one vote per each share. Holders of Common Stock share ratably (based on the number of shares of Common Stock held) in any dividend declared by its board of directors, subject to any preferential rights of any outstanding preferred stock. The Common Stock is not convertible into any other shares of the Company's capital stock.

At the 2025 Annual Meeting of Stockholders held on December 10, 2025, the Company's stockholders approved an amendment to the Company's certificate of incorporation to increase the total number of authorized shares of the Company's Common Stock from 550,000,000 to 1,100,000,000 shares of Common Stock.

#### *AMC Preferred Equity Units*

Each AMC Preferred Equity Unit was a depositary share and represented an interest in a share of Series A Convertible Participating Preferred Stock evidenced by a depositary receipt pursuant to a deposit agreement. Each AMC Preferred Equity Unit was designed to have the same economic and voting rights as a share of Common Stock.

#### *Preferred Stock*

The Company has 50,000,000 authorized shares of preferred stock, none of which are issued or outstanding as of December 31, 2025 and December 31, 2024, respectively.

### **Shareholder Litigation**

Two putative stockholder class actions were filed in the Delaware Chancery Court that assert a breach of fiduciary duty against certain of the Company's directors and a claim for breach of 8 *Del. C. § 242* against those directors and the Company, arising out of the Company's creation of AMC Preferred Equity Units, the transactions between the Company and Antara Capital LP ("Antara") that the Company announced on December 22, 2022 (the "Antara Transactions"), and the Charter Amendments.

This litigation prevented the Company from immediately implementing the Charter Amendments. On April 2, 2023, the parties entered into a binding settlement term sheet to settle the litigation and allow implementation of the Charter Amendments. Pursuant to the settlement term sheet, record holders of Common Stock at the close of business on August 24, 2023, after giving effect to the Reverse Stock Split, but prior to the conversion of AMC Preferred Equity Units into Common Stock ("Settlement Payment Recipients"), received a payment of one share of Common Stock for every 7.5 shares of Common Stock owned by such Settlement Payment Recipients. On August 28, 2023, the Company made the settlement payment and issued 6,897,018 shares of Common Stock.

### **Charter Amendments and AMC Preferred Equity Unit Conversion**

On August 14, 2023, the Company filed the third amendment to its certificate of incorporation to effectuate the Charter Amendments as of August 24, 2023. The Charter Amendments permitted the conversion of all of the Company's outstanding AMC Preferred Equity Units into shares of Common Stock (the "Conversion"). On August 25, 2023, 99,540,642 shares of Common Stock were issued as part of the Conversion, the AMC Preferred Equity Units ceased trading and were subsequently delisted from the NYSE, and the Company filed a Certificate of Elimination of Series A Convertible Participating Preferred Stock with the Secretary of State of Delaware that eliminated the Series A Convertible Participating Preferred Stock from the Company's certificate of incorporation.

### **Reverse Stock Split**

On August 24, 2023, the Company effectuated a reverse stock split at a ratio of one share of Common Stock for every ten shares of Common Stock. As a result of the reverse stock split, each share of Series A Convertible Participating Preferred Stock became convertible into ten shares of Common Stock, and by extension each AMC Preferred Equity Unit became equivalent to one-tenth (1/10th) of a share of Common Stock. The reverse stock split did not impact the

[Table of Contents](#)

number of AMC Preferred Equity Units outstanding. The Company concluded that this change in conversion ratio is analogous to a reverse stock split of the AMC Preferred Equity Units even though the reverse stock split did not have an effect on the number of AMC Preferred Equity Units outstanding.

Accordingly, all references made to share, per share, unit, per unit, or common share amounts in the accompanying consolidated financial statements and applicable disclosures have been retroactively adjusted to reflect the effect of the subsequent reverse stock split. References made to AMC Preferred Equity Units have been retroactively adjusted to reflect the effect of the reverse stock split on their equivalent Common Stock shares.

**Share Issuances**

On December 6, 2024, the Company entered into a sales and registration agreement (the “2024 Sales and Registration Agreement”) with Goldman Sachs & Co. LLC (the “Sales Agent”) relating to an aggregate of up to 50,000,000 shares of Common Stock of the Company.

In accordance with the terms of the 2024 Sales and Registration Agreement, the Company issued and sold shares of Common Stock covered by the prospectus supplement from time to time through the Sales Agent. The Sales Agent either acted as agent on the Company’s behalf or purchased shares of Common Stock from the Company as principal for its own account.

In December 2024, the Company entered into forward sales to sell 30,000,000 shares of Common Stock in the aggregate. The Company evaluated the forwards under ASC 815—Derivatives and Hedging and concluded that the transactions consist of a subscription receivable accounted for under ASC 505-10-45-2 reflecting the Company’s right to receive prepayments and to deliver shares to the forward counterparty. Accordingly, pursuant to Regulation S-X 5-02.29, the Company recorded the prepayment as an increase to additional paid-in capital with an equal and offsetting subscription receivable as a decrease to additional paid-in capital. The subscription receivable was considered a debt-like host and the Company’s right to receive additional cash consideration up to a cap price based on the movement of the share price during a valuation period is an embedded feature that meets the definition of a derivative that meets the equity classification scope exception in ASC 815-40 and is not accounted for outside of equity.

In January 2025, the Company was paid \$108.7 million for prepayments in respect of the forwards. The Company reduced the subscription receivable which resulted in an increase in total additional paid-in capital. The valuation period ended on March 17, 2025 with no additional consideration owed to the Company.

During the years ended December 31, 2025, December 31, 2024, and December 31, 2023, the Company entered into various equity distribution agreements with sales agents to sell shares of the Company’s Common Stock and AMC Preferred Equity Units, from time to time, through “at-the-market” offering programs. Subject to the terms and conditions of the equity distribution agreements, the sales agents used reasonable efforts consistent with their normal trading and sales practices, applicable law and regulations, and the rules of the NYSE to sell the Common Stock and AMC Preferred Equity Units from time to time based upon the Company’s instructions for the sales, including any price, time or size limits specified by the Company.

The below table summarizes the activity of the various “at-the-market” offerings for the years ending December 31, 2025, December 31, 2024, and December 31, 2023.

(In millions)	Common Stock			AMC Preferred Equity Units		
	December 31,			December 31,		
	2025	2024	2023	2025	2024	2023
Shares or units issued	17.1	75.5	88.0	-	-	7.1
Gross proceeds	\$ 63.0	261.8	675.5	\$ -	-	114.5
Sales agent fees paid	\$ 0.6	6.4	16.9	\$ -	-	2.9
Other third-party issuance costs incurred	\$ 0.3	1.9	1.1	\$ -	-	8.8
Other third-party issuance costs paid	\$ 1.5	0.8	0.9	\$ -	-	11.7

The Company has used and intends to use the net proceeds from the sale of Common Stock and AMC Preferred Equity Units pursuant to the equity distribution agreements to repay, refinance, redeem or repurchase the Company’s existing indebtedness (including expenses, accrued interest and premium, if any), capital expenditures and otherwise for general corporate purposes.

## Antara Transactions

On February 7, 2023, the Company issued 19,762,130 AMC Preferred Equity Units to Antara in exchange for \$75.1 million in cash and \$100.0 million aggregate principal amount of the Company's Second Lien Notes. The Company recorded \$193.7 million to stockholders' deficit as a result of the transaction. The Company paid \$1.4 million of accrued interest in cash upon exchange of the notes.

## Stock-Based Compensation

### Equity Incentive Plans

On June 5, 2024, the Company's shareholders approved a new equity incentive plan ("2024 EIP"). Awards that may be granted under the 2024 EIP include options, stock appreciation rights, restricted stock awards, restricted stock units ("RSUs"), performance stock units ("PSUs"), cash awards, and other equity-based awards. The 2024 EIP will be unlimited in duration and, in the event of termination, will remain in effect as long as any shares of awards under it are outstanding and not fully vested.

The 2013 equity incentive plan, as amended ("2013 EIP"), provided for grants of non-qualified stock options, incentive stock options, stock appreciation rights, restricted stock awards, RSUs, PSUs, stock awards, and cash performance awards. The 2013 EIP expired on December 17, 2023 and was replaced by the 2024 EIP. Awards granted under the 2013 EIP will continue to vest over their remaining requisite service periods, the latest of which ends in January 2026.

In 2023, AMC's Board approved equitable adjustments to all outstanding awards under the 2013 EIP subsequent to the effectiveness of the Charter Amendments. The outstanding awards were proportionally adjusted consistent with the ratio used for the Reverse Stock Split and all awards previously convertible into AMC Preferred Equity Units are now convertible into Common Stock.

The following table presents the stock-based compensation expense recorded within general and administrative: other:

(In millions)	Year Ended		
	December 31, 2025	December 31, 2024	December 31, 2023
Special awards expense	\$ 1.0	\$ 2.1	\$ 20.2
Board of director stock award expense	1.3	1.0	0.9
Restricted stock unit expense	13.4	12.3	14.3
Performance stock unit expense	1.2	6.5	6.7
Total equity classified awards:	16.9	21.9	42.1
Liability classified awards:			
Restricted and performance stock unit expense	—	0.1	0.4
Total liability classified awards:	—	0.1	0.4
Total stock-based compensation expense	\$ 16.9	\$ 22.0	\$ 42.5

As of December 31, 2025, the estimated remaining unrecognized compensation cost related to stock-based compensation arrangements was approximately \$8.1 million. The weighted average period over which this remaining compensation expense will be recognized is approximately 1.3 years. The Company accounts for forfeitures when they occur.

### Awards Granted

The Compensation Committee granted awards of stock, RSUs, and PSUs to certain of the Company's employees and directors under the Company's equity incentive plans. Each RSU or PSU is convertible into one share of Common Stock upon vesting.

Each RSU and PSU held by a participant as of a dividend record date is entitled to a dividend equivalent equal to the amount paid in respect to one share of Common Stock underlying the unit. Any such accrued dividend equivalents

are paid to the holder only upon vesting of the units. The grant date fair value of the awards are based on the closing share price of the Company's Common Stock on such grant date.

The awards granted under the Company's equity incentive plans generally had the following features:

- **Board of Directors Stock Awards:** The Company granted fully vested shares of Common Stock and AMC Preferred Equity Units to the independent members of its Board of Directors during the years ended December 31, 2025, December 31, 2024, and December 31, 2023 as follows:

	Year Ended		
	December 31, 2025	December 31, 2024	December 31, 2023
Common Stock	370,586	202,392	8,560
AMC Preferred Equity Units	—	—	15,376

- **Restricted Stock Unit Awards:** Each vested RSU will be settled by delivery of a single share of the Company's Common Stock and therefore accounted for as equity instruments. Awards are generally settled as each individual tranche vests under the relevant agreements. The Company records stock-based compensation expense on a straight-line recognition method over the requisite vesting period. The RSUs granted during 2025, 2024, and 2023 vest over three years with 1/3 vesting in each year. These RSUs will be settled within 30 days of vesting.
- **Performance Stock Unit Awards:** PSUs awards are granted to certain members of management and executive officers. The total PSUs divided into three separate year tranches, with each tranche allocated to a fiscal year within the performance period ("Tranche Year"). The PSUs within each Tranche Year are further divided between three performance targets; the Adjusted EBITDA performance target, the free cash flow performance target and various strategic initiatives. The PSU awards will vest if 80% to 120% of the performance targets are attained, with the corresponding vested unit amount ranging from 50% to 200% of the PSUs awarded. The strategic initiative based 2025 PSU awards will vest if three to seven one-year strategic initiatives are achieved by the end of the 2025 Tranche Year and/or if four to ten two-year strategic initiatives are achieved by the end of the 2026 Tranche Year, with the corresponding vested unit amount ranging from 50% to 200% of the PSUs awarded.

The Compensation Committee establishes the annual performance targets at the beginning of each year. Therefore, in accordance with ASC 718, Compensation - Stock Compensation, the grant date (and fair value measurement date) for each Tranche Year is the date at the beginning of each year when a mutual understanding of the key terms and conditions are reached.

#### *Special Awards*

On February 19, 2025, the compensation committee of AMC's Board of Directors ("Compensation Committee") approved modification of the performance goals applicable to all 2024 Tranche Year PSU awards. This was accounted for as a modification to the 2024 Tranche Year PSU awards which lowered the Adjusted EBITDA performance target such that 146% vesting was achieved. This modification resulted in the immediate additional vesting of 270,093 of the 2024 Tranche Year PSUs (4,181 cash settled units and 265,912 equity settled units). This was treated as a Type 3 modification (improbable-to-probable) which required the Company to recognize additional stock compensation expense based on the modification date fair values of the incremental PSUs. During the year ended December 31, 2025, the Company recognized \$1.0 million of stock compensation expense related to these awards.

On February 22, 2024, the Compensation Committee approved modification of the performance goals applicable to all 2023 Tranche Year PSU awards. This was accounted for as a modification to the 2023 Tranche Year PSU awards which lowered the Adjusted EBITDA and free cash flow performance targets such that 200% vesting was achieved for both targets. This modification resulted in the immediate additional vesting of 478,055 of the 2023 Tranche Year PSUs (21,829 cash settled units and 456,226 equity settled units). This was treated as a Type 3 modification (improbable-to-probable) which required the Company to recognize additional stock compensation expense based on the modification date fair values of the incremental PSUs. During the year ended December 31, 2024, the Company recognized \$2.1 million of stock compensation expense related to these awards.

[Table of Contents](#)

On February 23, 2023, the Compensation Committee approved special awards in lieu of vesting of the 2022 Tranche Year PSU awards. The special awards were accounted for as modification to the 2022 Tranche Year PSU awards which lowered the Adjusted EBITDA and free cash flow performance targets such that 200% vesting was achieved for both tranches. This modification resulted in the immediate additional vesting of 238,959 Common Stock 2022 PSUs and 238,959 AMC Preferred Equity Unit PSUs. This was treated as a Type 3 modification (improbable-to-probable) which requires the Company to recognize additional stock compensation expense based on the modification date fair values of the Common Stock PSUs and AMC Preferred Equity Units PSUs of \$14.9 million and \$5.3 million, respectively. During the year ended December 31, 2023, the Company recognized \$20.2 million of stock compensation expense related to these awards.

The activity related to the Company's RSU and PSU awards for the year ended December 31, 2025 consisted of the following:

	RSUs		PSUs	
	Number of RSUs	Weighted Average Grant Date Fair Value	Number of PSUs	Weighted Average Grant Date Fair Value
Nonvested at December 31, 2024	2,594,497	\$ 9.35	1,281,617	\$ 5.03
Granted (1)	3,122,126	3.57	324,969	3.57
Granted - Special Award	—	—	265,912	3.57
Vested	(479,247)	13.03	(682,193)	5.03
Vested - Special Award	—	—	(140,982)	3.57
Forfeited (1)	(211,485)	7.02	—	—
Cancelled (2)	(452,813)	13.36	(599,424)	5.03
Cancelled - Special Award (2)	—	—	(124,930)	3.57
Nonvested at December 31, 2025	4,573,078	4.73	324,969	3.57
Tranche Years 2026 and 2027 awarded under the 2025 PSU award and Tranche Year 2026 awarded under the 2024 PSU award with grant date fair values to be determined in year 2026 and 2027, respectively	—	—	3,000,921	—
Total nonvested at December 31, 2025	4,573,078	—	3,325,890	—

- (1) The number of PSUs granted and forfeited under the Tranche Year 2025 is based on attainment of performance targets at 0% for the Adjusted EBITDA target, 0% for the free cash flow target and 200% for the strategic initiatives. The number of PSUs granted under the Tranche Year 2026 assumes the Company will attain a performance target at 100% for strategic initiatives.
- (2) Represents vested RSUs and PSUs surrendered in lieu of taxes and cancelled awards returned. As a result, the Company paid taxes for restricted unit withholdings of approximately \$4.4 million during the year ended December 31, 2025.

The weighted-average grant date fair values of the RSU awards granted during the years ended December 31, 2025, December 31, 2024, and December 31, 2023 was \$3.57, \$5.15 and \$35.04, respectively. The weighted-average grant date fair values for the PSU awards granted during the years ended December 31, 2025, December 31, 2024, and December 31, 2023 was \$3.57, \$5.03 and \$40.40, respectively.

**NOTE 9—INCOME TAXES**

Current income tax expense represents the amounts expected to be reported on the Company's income tax returns, and deferred tax expense or benefit represents the change in net deferred tax assets and liabilities. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and

[Table of Contents](#)

liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. Valuation allowances are recorded as appropriate to reduce deferred tax assets to the amount considered likely to be realized.

The Company evaluates its deferred tax assets each period to determine if a valuation allowance is required based on whether it is “more likely than not” that some portion of the deferred tax assets would not be realized. The ultimate realization of these deferred tax assets is dependent upon the generation of sufficient taxable income during future periods on a federal, state and foreign jurisdiction basis. The Company conducts its evaluation by considering all available positive and negative evidence, including historical operating results, forecasts of future profitability, the duration of statutory carryforward periods, and the outlooks for the motion picture industry and broader economy, among others. A significant piece of objective negative evidence evaluated was the cumulative losses incurred over the three-year period ended December 31, 2025 for each taxing jurisdiction. Such objective evidence limits the ability to consider other subjective evidence, such as the Company’s projections of future taxable income.

The Company maintains a valuation allowance against U.S. deferred tax assets as well as international jurisdictions in which it operates, with the exception of Finland.

The income tax provision reflected in the consolidated statements of operations consists of the following components:

(In millions)	Year Ended		
	December 31, 2025	December 31, 2024	December 31, 2023
<b>Current:</b>			
Federal	\$ —	\$ —	\$ —
Foreign	1.4	2.4	1.9
State	1.3	(1.8)	0.8
<b>Total current</b>	<b>2.7</b>	<b>0.6</b>	<b>2.7</b>
<b>Deferred:</b>			
Federal	0.4	0.5	0.4
Foreign	0.4	(0.3)	(0.2)
State	1.0	1.3	0.5
<b>Total deferred</b>	<b>1.8</b>	<b>1.5</b>	<b>0.7</b>
<b>Total provision</b>	<b>\$ 4.5</b>	<b>\$ 2.1</b>	<b>\$ 3.4</b>

Pre-tax losses consisted of the following:

(In millions)	Year Ended		
	December 31, 2025	December 31, 2024	December 31, 2023
Domestic	\$ (445.9)	\$ (192.4)	\$ (216.7)
Foreign	(182.0)	(158.1)	(176.5)
<b>Total</b>	<b>\$ (627.9)</b>	<b>\$ (350.5)</b>	<b>\$ (393.2)</b>

[Table of Contents](#)

The difference between the effective tax rate on net loss from continuing operations before income taxes and the U.S. federal income tax statutory rate is as follows:

(In millions)	Year Ended					
	December 31, 2025		December 31, 2024		December 31, 2023	
<b>Income tax expense (benefit) at the federal statutory rate</b>	\$ (131.9)	21.0 %	\$ (73.6)	21.0 %	\$ (82.5)	21.0 %
<b>State and Local Income Taxes (1)</b>	(21.1)	3.4 %	(5.8)	1.7 %	(16.8)	4.3 %
State Valuation allowance adjustments	23.4	(3.7) %	5.0	(1.4) %	18.1	(4.6) %
<b>Foreign Tax Effects</b>						
United Kingdom						
Statutory Tax Rate Difference between the UK and the United States	(5.4)	0.9 %	(5.0)	1.4 %	(3.7)	0.9 %
Valuation allowance adjustments	33.5	(5.3) %	29.6	(8.4) %	35.2	(9.0) %
Other	5.4	(0.9) %	2.1	(0.6) %	—	— %
Italy						
Valuation allowance adjustments	1.4	(0.2) %	6.0	(1.7) %	12.1	(3.1) %
Return-to-provision	(0.2)	0.0 %	(3.9)	1.1 %	(7.0)	1.8 %
Other	(0.3)	0.0 %	(2.4)	0.7 %	(3.1)	0.8 %
Germany						
Nondeductible items	3.3	(0.5) %	0.9	(0.3) %	0.9	(0.2) %
Valuation allowance adjustments	(5.5)	0.9 %	0.2	(0.1) %	(1.4)	0.4 %
Other	1.4	(0.2) %	1.5	(0.4) %	(2.5)	0.6 %
Other Foreign Jurisdictions	6.4	(1.0) %	6.4	(1.8) %	8.2	(2.1) %
<b>Enactment of New Tax Laws</b>						
Change in Tax Rate	—	— %	—	— %	—	— %
<b>Enactment of Cross-Border Tax Laws</b>						
Global Intangible low-taxed income (GILTI)	—	— %	—	— %	—	— %
<b>Tax Credits</b>	(1.4)	0.2 %	(1.5)	0.4 %	(1.3)	0.3 %
<b>Change in Valuation Allowances</b>	78.9	(12.6) %	37.1	(10.6) %	51.7	(13.2) %
<b>Nontaxable or nondeductible items</b>						
Nondeductible compensation	4.3	(0.7) %	9.5	(2.7) %	3.9	(1.0) %
Litigation	—	— %	(8.4)	2.4 %	20.8	(5.3) %
Disqualified debt interest	7.5	(1.2) %	3.8	(1.1) %	(38.4)	9.8 %
Other	0.5	(0.1) %	0.6	(0.2) %	(2.7)	0.7 %
<b>Changes in unrecognized tax benefits</b>	—	— %	—	— %	(0.2)	0.1 %
<b>Other Adjustments</b>	4.3	(0.7) %	—	— %	12.1	(3.1) %
<b>Income tax expense/Effective income tax rate</b>	<u>\$ 4.5</u>	<u>(0.7) %</u>	<u>\$ 2.1</u>	<u>(0.6) %</u>	<u>\$ 3.4</u>	<u>(0.9) %</u>

(1) State taxes in California, Illinois, New Jersey and New York made up the majority (greater than 50%) of the tax effect in this category for 2025. California, Illinois and New York made up the majority in 2024 and 2023.

[Table of Contents](#)

The significant components of deferred income tax assets and liabilities as of December 31, 2025 and December 31, 2024 are as follows:

(In millions)	December 31, 2025		December 31, 2024	
	Deferred Income Tax		Deferred Income Tax	
	Assets	Liabilities	Assets	Liabilities
Tangible assets	\$ —	\$ (55.9)	\$ —	\$ (60.8)
Right-of-use assets	—	(802.2)	—	(831.5)
Accrued liabilities	13.7	—	11.2	—
Intangible assets	—	(135.5)	—	(128.0)
Receivables	—	(2.2)	12.1	—
Investments	2.5	—	44.4	—
Capital loss carryforwards	2.1	—	4.6	—
Pension and deferred compensation	16.1	—	15.5	—
Corporate borrowings	—	(1.1)	—	(52.8)
Disallowed interest	785.1	—	663.2	—
Deferred revenue	164.9	—	163.2	—
Lease liabilities	1,041.5	—	1,077.5	—
Other credit carryovers	32.6	—	31.1	—
Net operating loss carryforwards	769.3	—	727.9	—
Total	\$ 2,827.8	\$ (996.9)	\$ 2,750.7	\$ (1,073.1)
Less: Valuation allowance	(1,866.6)	—	(1,711.5)	—
Net deferred income taxes	\$ 961.2	\$ (996.9)	\$ 1,039.2	\$ (1,073.1)

A rollforward of the Company's valuation allowance for deferred tax assets is as follows:

(In millions)	Balance at Beginning of Period	Additions Charged to Expenses(1)	Charged (Credited) to Other Accounts(2)	Balance at End of Period
Calendar Year 2025				
Valuation allowance-deferred income tax assets	\$ 1,711.5	126.1	29.0	\$ 1,866.6
Calendar Year 2024				
Valuation allowance-deferred income tax assets	\$ 1,641.3	84.5	(14.3)	\$ 1,711.5
Calendar Year 2023				
Valuation allowance-deferred income tax assets	\$ 1,513.0	122.1	6.2	\$ 1,641.3

(1) Primarily relates to the Company's increase in the current year's federal, state, and international net operating losses.

(2) Primarily relates to amounts resulting from the Company's changes in deferred tax assets and associated valuation allowance that are not related to income statement activity, as well as amounts charged to other comprehensive income.

The Company has federal income tax net operating loss carryforwards of \$1,780.1 million. Approximately \$313.7 million will expire between 2026 and 2037 and will be limited annually due to certain change in ownership provisions of the Code. Approximately \$1,466.4 million can be used indefinitely. The Company's foreign net operating losses of \$1,068.4 million can be used indefinitely. The Company also has state income tax loss carryforwards of \$3,042.6 million. Approximately \$2,254.9 million may be used over various periods ranging from 1 to 20 years. Approximately \$787.7 million can be used indefinitely.

[Table of Contents](#)

A reconciliation of the change in the amount of unrecognized tax benefits was as follows:

(In millions)	Year Ended		
	December 31, 2025	December 31, 2024	December 31, 2023
Balance at beginning of period	\$ 5.5	\$ 5.5	\$ 7.4
Gross decreases—expiration of statute of limitations	—	—	(1.9)
Balance at end of period	\$ 5.5	\$ 5.5	\$ 5.5

The Company, or one of its subsidiaries, files income tax returns in the U.S. federal jurisdiction, and various state and foreign jurisdictions. Generally, tax years beginning after December 31, 2006 are still open to examination by various taxing authorities. Additionally, as discussed above, the Company has net operating loss (“NOL”) carryforwards for tax years ended December 31, 2007 through December 31, 2025, in the U.S. and various state jurisdictions which have carryforwards of varying lengths of time. These NOLs are subject to adjustment based on the statute of limitations applicable to the return in which they are utilized, not the year in which they are generated. Various state, local and foreign income tax returns are also under examination by taxing authorities. The Company does not believe that the outcome of any examination will have a material impact on its consolidated financial statements.

**NOTE 10—FAIR VALUE MEASUREMENTS**

Fair value refers to the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the entity transacts business. The inputs used to develop these fair value measurements are established in a hierarchy, which ranks the quality and reliability of the information used to determine the fair values. The fair value classification is based on levels of inputs. Assets and liabilities that are carried at fair value are classified and disclosed in one of the following categories:

- Level 1: Quoted market prices in active markets for identical assets or liabilities.
- Level 2: Observable inputs that are corroborated by market data.
- Level 3: Unobservable inputs that are not corroborated by market data.

**Recurring Fair Value Measurements.** The following tables summarize the fair value hierarchy of the Company’s financial instruments carried at fair value on a recurring basis:

(In millions)	Total Carrying Value at December 31, 2025	Fair Value Measurements at December 31, 2025 Using		
		Quoted prices in active market (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
<i>Corporate Borrowings:</i>				
Bifurcated embedded derivative - 6.00%/8.00% Cash/PIK Toggle Senior Secured Exchangeable Notes due 2030	\$ 12.6	\$ —	\$ —	\$ 12.6
Bifurcated embedded derivative - Senior Secured Exchangeable Notes due 2030	131.9	—	—	131.9
Total liabilities at fair value	\$ 144.5	\$ —	\$ —	\$ 144.5

(In millions)	Total Carrying Value at December 31, 2024	Fair Value Measurements at December 31, 2024 Using		
		Quoted prices in active market (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
<i>Corporate Borrowings:</i>				
Bifurcated embedded derivative - 6.00%/8.00% Cash/PIK Toggle Senior Secured Exchangeable Notes due 2030	\$ 157.6	\$ —	\$ —	\$ 157.6
Total liabilities at fair value	\$ 157.6	\$ —	\$ —	\$ 157.6

[Table of Contents](#)

*Senior Secured Notes due 2030 embedded derivative valuation.* The Company's Senior Secured Exchangeable Notes due 2030 have conversion features that required bifurcation from the host instrument pursuant to ASC 815—Derivatives and Hedging. These conversion features were combined into a single derivative that comprises all features requiring bifurcation. The derivative features have been valued using a combination of Monte Carlo simulations, binomial lattice models, and discounted cash flow models. Monte Carlo simulations use repeated random sampling to simulate a wide range of possible outcomes. The binomial lattice models consist of simulated Common Stock prices from the valuation date to the maturity of the notes. The significant inputs used to value the derivative include the share price of the Common Stock, the volatility of the share price, time to maturity, risk-free interest rate, credit spread, and discount yield. The Company measures the derivative at fair value at the end of each reporting period with any changes in fair value recorded to other expense (income) in the consolidated statements of operations.

*6.00%/8.00% Cash/PIK Toggle Senior Secured Exchangeable Notes due 2030.* The Company's Existing Exchangeable Notes have conversion features that required bifurcation from the host instrument pursuant to ASC 815—Derivatives and Hedging. These conversion features were combined into a single derivative that comprises all features requiring bifurcation, see Note 7—Corporate Borrowings and Finance Lease Liabilities for further information. The derivative features have been valued using binomial lattice models. The binomial lattice models consist of simulated Common Stock prices from the valuation date to the maturity of the notes. The significant inputs used to value the derivative include the share price of the Common Stock, the volatility of the share price, time to maturity, risk-free interest rate, credit spread, and the discount yield. The Company measures the derivative at fair value at the end of each reporting period with any changes in fair value recorded to other expense (income) in the consolidated statements of operations.

**Nonrecurring Fair Value Measurements.** The following tables summarize the Company's assets that were written down to their fair value on a nonrecurring basis as part of the Company's impairment evaluation:

(In millions)	Total Carrying Value at December 31, 2025	Fair Value Measurements at December 31, 2025 Using			Total Impairment Losses
		Quoted prices in active market (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)	
<b>Property, net:</b>					
Property, net	\$ 22.5	\$ —	\$ —	\$ 22.5	\$ 19.2
<b>Operating lease right-of-use assets:</b>					
Operating lease right-of-use assets	42.0	—	—	42.0	24.3
<b>Total</b>	<b>\$ 64.5</b>	<b>\$ —</b>	<b>\$ —</b>	<b>\$ 64.5</b>	<b>\$ 43.5</b>

(In millions)	Total Carrying Value at December 31, 2024	Fair Value Measurements at December 31, 2024 Using			Total Impairment Losses
		Quoted prices in active market (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)	
<b>Property, net:</b>					
Property, net	\$ 16.5	\$ —	\$ —	\$ 16.5	\$ 18.1
<b>Operating lease right-of-use assets:</b>					
Operating lease right-of-use assets	45.6	—	—	45.6	54.2
<b>Total</b>	<b>\$ 62.1</b>	<b>\$ —</b>	<b>\$ —</b>	<b>\$ 62.1</b>	<b>\$ 72.3</b>

[Table of Contents](#)

*Valuation Techniques.* The Company primarily uses a discounted cash flow method in estimating the fair value of its long-lived assets. There is considerable management judgment with respect to cash flow estimates and appropriate discount rates to be used in determining fair value, and accordingly, actual results could vary significantly from such estimates. Such judgments and estimates include estimates of future attendance, revenues, cost expectations, capital expenditures, and the cost of capital, among others. At December 31, 2025, estimated cash flows were discounted at 9.5% for theatres in U.S. markets and 10.5% for theatres in the International markets. At December 31, 2024, estimated cash flows were discounted at 9.0% for theatres in U.S. markets and 10.5% for theatres in International markets.

[Table of Contents](#)

The following table summarizes the fair value hierarchy of the debt component of the Company's Senior Secured Exchangeable Notes due 2030 as of July 1, 2025:

(In millions)	Total Carrying Value at July 1, 2025	Fair Value Measurements at July 1, 2025 Using		
		Quoted prices in active market (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
<b>Corporate Borrowings:</b>				
Senior Secured Exchangeable Notes due 2030	\$ 159.0	\$ —	\$ 159.0	\$ —

*Valuation Technique.* The Company estimated the fair value utilizing a discounted cash flow analysis with a discount yield interpolated by reference to the Company's other outstanding debt instruments with consideration given to the nature of collateral available to the security relative to the Company's other debt instruments. See Note 7—Corporate Borrowings and Finance Lease Liabilities for further information.

**Other Fair Value Measurement Disclosures.** The Company is required to disclose the fair value of financial instruments that are not recognized at fair value in the statement of financial position for which it is practicable to estimate that value:

(In millions)	Total Carrying Value at December 31, 2025	Fair Value Measurements at December 31, 2025 Using		
		Quoted prices in active market (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Current maturities of corporate borrowings	\$ 19.9	\$ —	\$ 19.9	\$ —
Corporate borrowings (excluding derivatives)	3,874.1	—	3,864.0	—

(In millions)	Total Carrying Value at December 31, 2024	Fair Value Measurements at December 31, 2024 Using		
		Quoted prices in active market (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Current maturities of corporate borrowings	\$ 64.2	\$ —	\$ 65.0	\$ —
Corporate borrowings (excluding derivatives)	3,853.3	—	3,866.3	—

*Valuation Technique.* Quoted market prices and observable market-based inputs were used to estimate fair value for Level 2 inputs. The Company valued these notes at principal value less an estimated discount reflecting a market yield to maturity. See Note 7—Corporate Borrowings and Finance Lease Liabilities for further information.

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value because of the short maturity of these instruments.

**NOTE 11—SEGMENT REPORTING**

The Company reports information about operating segments in accordance with ASC 280-10, Segment Reporting, which requires financial information to be reported based on the way management organizes segments within a company for making operating decisions and evaluating performance. Management has organized the Company around differences in geographic areas. The Company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. The International markets reportable segment has operations in or partial interest in theatres in the United Kingdom, Germany, Spain, Italy, Ireland, Portugal, Sweden, Finland, Norway, and Denmark.

Each segment's revenue is derived from admissions, food and beverage sales and other ancillary revenues, primarily screen advertising, loyalty membership fees, ticket sales, gift card income and exchange ticket income. The

[Table of Contents](#)

measure of segment profit and loss the Company’s chief operating decision maker (“CODM”) uses to evaluate performance and allocate its resources is Adjusted EBITDA, as defined in the reconciliation table below. During the year ended December 31, 2024, the Company changed the definition of Adjusted EBITDA to no longer further adjust for “cash distributions from non-consolidated entities” and “other non-cash rent benefit.” All comparative period information for Adjusted EBITDA has been re-cast to conform with the current definition.

The Company’s CODM is the chief executive officer. The Company does not report asset information by segment because that information is not used to evaluate the performance of or allocate resources between segments. The CODM assess segment performance quarterly by comparing segment annual Adjusted EBITDA against budgeted and/or forecasted Adjusted EBITDA.

The CODM uses Adjusted EBITDA for each segment to determine how to allocate resources for future capital expenditures and for general corporate purposes. The Company defines Adjusted EBITDA as net earnings (loss) plus (i) income tax provision (benefit), (ii) interest expense and (iii) depreciation and amortization, as further adjusted to eliminate the impact of certain items that the Company does not consider indicative of the Company’s ongoing operating performance and to include attributable EBITDA from equity investments in theatre operations in International markets.

The following tables below provide reconciliation of segment revenues to Adjusted EBITDA:

(In millions)	Year Ended December 31, 2025		
	U.S. Markets	International Markets	Consolidated
Revenues (1)	\$ 3,706.1	\$ 1,142.8	\$ 4,848.9
Less:			
Film exhibition costs	1,020.5	254.7	1,275.2
Food and beverage costs	241.2	85.8	327.0
Operating expense, excluding depreciation and amortization (2)	1,318.9	452.5	1,771.4
Rent	650.1	237.2	887.3
General and administrative expense - other, excluding depreciation and amortization (3)	128.3	85.1	213.4
Other segment items (4)	1.1	(14.0)	(12.9)
Adjusted EBITDA	\$ 346.0	\$ 41.5	\$ 387.5

(In millions)	Year Ended December 31, 2024		
	U.S. Markets	International Markets	Consolidated
Revenues (1)	\$ 3,544.2	\$ 1,093.0	\$ 4,637.2
Less:			
Film exhibition costs	988.8	250.4	1,239.2
Food and beverage costs	225.7	79.9	305.6
Operating expense, excluding depreciation and amortization (2)	1,249.0	425.0	1,674.0
Rent	649.9	223.7	873.6
General and administrative expense - other, excluding depreciation and amortization (3)	130.6	74.2	204.8
Other segment items (4)	(1.3)	(2.6)	(3.9)
Adjusted EBITDA	\$ 301.5	\$ 42.4	\$ 343.9

[Table of Contents](#)

(In millions)	Year Ended December 31, 2023		
	U.S. Markets	International Markets	Consolidated
Revenues	\$ 3,688.7	\$ 1,123.9	\$ 4,812.6
Less:			
Film exhibition costs	1,023.3	267.8	1,291.1
Food and beverage costs	233.9	81.4	315.3
Operating expense, excluding depreciation and amortization (2)	1,261.8	427.2	1,689.0
Rent	651.5	222.0	873.5
General and administrative expense - other, excluding depreciation and amortization (3)	130.9	68.5	199.4
Other segment items (4)	(3.8)	(6.2)	(10.0)
Adjusted EBITDA	\$ 391.1	\$ 63.2	\$ 454.3

- (1) All segment revenues are comprised of revenues from external customers.
- (2) Operating expense, excluding depreciation and amortization excludes certain operating expenses as further defined in the reconciliation of net loss to Adjusted EBITDA below.
- (3) General and administrative expense – other, excluding depreciation and amortization excludes stock compensation expense.
- (4) Other segment items include government assistance, business interruption insurance recoveries, net periodic pension cost (benefit), and attributable EBITDA from international theatre joint ventures.

Other segment disclosures:

(In millions)	Year Ended December 31, 2025		
	U.S. Markets	International Markets	Consolidated
Depreciation and amortization	\$ 239.1	\$ 74.3	\$ 313.4
Income tax provision	2.7	1.8	4.5
Other expense (income)	159.2	(40.0)	119.2
Other significant noncash items:			
Stock-based compensation expense	15.8	1.1	16.9
Impairment of long-lived assets	28.0	15.5	43.5
Equity in earnings of non-consolidated entities	(5.7)	(1.1)	(6.8)
Capital expenditures	174.2	71.9	246.1

(In millions)	Year Ended December 31, 2024		
	U.S. Markets	International Markets	Consolidated
Depreciation and amortization	\$ 247.5	\$ 72.0	\$ 319.5
Income tax provision	—	2.1	2.1
Other income	(113.7)	(30.1)	(143.8)
Other significant noncash items:			
Stock-based compensation expense	20.0	2.0	22.0
Impairment of long-lived assets	51.9	20.4	72.3
Equity in earnings of non-consolidated entities	(10.7)	(1.7)	(12.4)
Capital expenditures	171.4	74.1	245.5

[Table of Contents](#)

(In millions)	Year Ended December 31, 2023		
	U.S. Markets	International Markets	Consolidated
Depreciation and amortization	\$ 286.5	\$ 78.5	\$ 365.0
Income tax provision	1.8	1.6	3.4
Other income	(47.3)	(21.8)	(69.1)
Other significant noncash items:			
Stock-based compensation expense	38.3	4.2	42.5
Impairment of long-lived assets	49.2	57.7	106.9
Equity in earnings of non-consolidated entities	(5.5)	(2.2)	(7.7)
Capital expenditures	167.0	58.6	225.6

The following table sets forth a reconciliation of net loss to Adjusted EBITDA:

(In millions)	Year Ended		
	December 31, 2025	December 31, 2024	December 31, 2023
Net loss	\$ (632.4)	\$ (352.6)	\$ (396.6)
Plus:			
Income tax provision (1)	4.5	2.1	3.4
Interest expense	530.2	443.7	411.2
Depreciation and amortization	313.4	319.5	365.0
Impairment of long-lived assets (2)	43.5	72.3	106.9
Certain operating expense (3)	14.6	5.4	2.5
Equity in earnings of non-consolidated entities (4)	(6.8)	(12.4)	(7.7)
Attributable EBITDA (5)	2.3	1.9	2.2
Investment income (6)	(32.1)	(16.3)	(15.5)
Other expense (income) (7)	129.8	(141.8)	(61.3)
Merger, acquisition and other costs (8)	3.6	0.1	1.7
Stock-based compensation expense (9)	16.9	22.0	42.5
Adjusted EBITDA	\$ 387.5	\$ 343.9	\$ 454.3

(1) For information regarding the income tax provision (benefit), see Note 9—Income Taxes.

(2) During the year ended December 31, 2025, the Company recorded non-cash impairment charges related to its long-lived assets of \$28.0 million on 47 theatres in the U.S. markets with 560 screens which were related to property, net and operating lease right-of-use assets, net and \$15.5 million on 20 theatres in the International markets with 159 screens which were related to property, net and operating lease right-of-use assets, net.

During the year ended December 31, 2024, the Company recorded non-cash impairment charges related to its long-lived assets of \$51.9 million on 39 theatres in the U.S. markets with 469 screens which were related to property, net and operating lease right-of-use assets, net and \$20.4 million on 23 theatres in the International markets with 188 screens which were related to property, net and operating lease right-of-use assets, net.

During the year ended December 31, 2023, the Company recorded non-cash impairment charges related to its long-lived assets of \$49.2 million on 68 theatres in the U.S. markets with 738 screens which were related to property, net and operating lease right-of-use assets, net and \$57.7 million on 57 theatres in the International markets with 488 screens which were related to property, net and operating lease right-of-use assets, net.

(3) Amounts represent preopening expense related to temporarily closed screens under renovation, theatre and other closure expense for the permanent closure of screens, disposition of assets, and other non-operating gains or losses included in operating expenses. The Company has excluded these items as they are non-cash in nature or are non-operating in nature.

[Table of Contents](#)

- (4) Equity in earnings of non-consolidated entities during the year ended December 31, 2025, primarily consisted of equity in earnings from AC JV of \$(4.8) million. Equity in earnings of non-consolidated entities during the year ended December 31, 2024, primarily consisted of equity in earnings from AC JV of \$(10.0) million. Equity in earnings of non-consolidated entities during the year ended December 31, 2023, primarily consisted of equity in earnings from AC JV of \$(4.9) million.
- (5) Attributable EBITDA includes the EBITDA from equity investments in theatre operators in certain International markets. See below for a reconciliation of the Company's equity in (earnings) of non-consolidated entities to attributable EBITDA. Because these equity investments are in theatre operators in regions where the Company holds a significant market share, the Company believes attributable EBITDA is more indicative of the performance of these equity investments and management uses this measure to monitor and evaluate these equity investments.

(In millions)	Year Ended		
	December 31, 2025	December 31, 2024	December 31, 2023
Equity in (earnings) of non-consolidated entities	\$ (6.8)	\$ (12.4)	\$ (7.7)
Less:			
Equity in (earnings) of non-consolidated entities excluding International theatre joint ventures	(5.7)	(11.5)	(6.6)
Equity in earnings of International theatre joint ventures	1.1	0.9	1.1
Income tax provision	0.1	—	0.1
Investment income	(0.5)	(0.4)	(0.6)
Interest expense	0.2	0.1	0.2
Depreciation and amortization	1.4	1.3	1.4
Attributable EBITDA	\$ 2.3	\$ 1.9	\$ 2.2

- (6) Investment income during the year ended December 31, 2025 includes interest income of \$(8.0) million and realized and unrealized gains on the Company's investments in Hycroft of \$(34.4) million, partially offset by an impairment of an equity security without a readily determinable fair value of \$10.3 million.

Investment income during the year ended December 31, 2024 includes interest income of \$(19.2) million, partially offset by unrealized losses on the Company's investments in Hycroft of \$2.9 million.

Investment income during the year ended December 31, 2023 included a \$(15.5) million gain on sale of the Company's investment in Saudi Cinema Company LLC and interest income of \$(15.4) million, partially offset by unrealized losses on the Company's investments in Hycroft of \$12.6 million, \$1.8 million of expense for NCM common units, and a \$1.0 million impairment of an equity security without a readily determinable fair value.

- (7) Other expense during the year ended December 31, 2025 includes net losses on debt extinguishment of \$196.0 million, an increase in the fair value of the bifurcated embedded derivative in the New Exchangeable Notes of \$19.3 million, and term loan modification third party fees of \$3.1 million, partially offset by a decrease in the fair value of the bifurcated embedded derivative in the Existing Exchangeable Notes of \$(56.7) million, foreign currency transaction gains of \$(28.1) million, and shareholder litigation recoveries of \$(3.8) million.

Other income for the year ended December 31, 2024 includes a decrease in the fair value of the bifurcated embedded derivative in the Existing Exchangeable Notes of \$(75.8) million, shareholder litigation recoveries of \$(40.2) million, net gains on debt extinguishment of \$(38.9) million, and a vendor dispute of \$(36.2) million, partially offset by term loan modification third party fees of \$42.3 million and foreign currency transaction losses of \$7.0 million.

Other income for the year ended December 31, 2023 includes gains on debt extinguishment of \$(142.8) million and foreign currency transaction gains of \$(17.8) million, partially offset by a non-cash litigation charge of \$99.3 million.

- (8) Merger, acquisition and other costs are excluded as they are non-operating in nature.

[Table of Contents](#)

(9) Non-cash expense included in general and administrative: other.

Financial information about geographic area is as follows:

Revenues (In millions)	Year Ended		
	December 31, 2025	December 31, 2024	December 31, 2023
United States	\$ 3,706.1	\$ 3,544.2	\$ 3,688.7
United Kingdom	428.5	408.8	400.9
Spain	153.4	143.3	148.2
Sweden	122.5	116.4	124.9
Italy	147.3	147.6	151.9
Germany	124.3	111.6	125.8
Finland	84.7	90.1	97.9
Ireland	33.1	32.5	32.2
Other foreign countries	49.0	42.7	42.1
Total revenues	\$ 4,848.9	\$ 4,637.2	\$ 4,812.6

Long-term assets, net (In millions)	As of	
	December 31, 2025	December 31, 2024
United States	\$ 5,267.4	\$ 5,474.2
International	2,019.9	1,826.1
Total long-term assets (1)	\$ 7,287.3	\$ 7,300.3

(1) Long-term assets are comprised of property, operating lease right-of-use assets, intangible assets, goodwill, deferred tax assets, net and other long-term assets.

**NOTE 12—ACCUMULATED OTHER COMPREHENSIVE LOSS**

The following table presents the change in accumulated other comprehensive loss by component:

(In millions)	Foreign Currency	Pension Benefits	Total
Balance December 31, 2023	\$ (77.7)	\$ (0.5)	\$ (78.2)
Other comprehensive income (loss)	(55.6)	1.8	(53.8)
Balance December 31, 2024	\$ (133.3)	\$ 1.3	\$ (132.0)
Other comprehensive income (loss)	95.0	(5.2)	89.8
Balance December 31, 2025	\$ (38.3)	\$ (3.9)	\$ (42.2)

The tax effects allocated to each component of other comprehensive income (loss) is as follows:

(In millions)	Year Ended								
	December 31, 2025			December 31, 2024			December 31, 2023		
	Pre-Tax Amount	Tax (Expense) Benefit	Net-of-Tax Amount	Pre-Tax Amount	Tax (Expense) Benefit	Net-of-Tax Amount	Pre-Tax Amount	Tax (Expense) Benefit	Net-of-Tax Amount
Unrealized foreign currency translation adjustment	\$ 94.8	\$ 0.2	\$ 95.0	\$ (55.5)	\$ (0.1)	\$ (55.6)	\$ 0.5	\$ 0.6	\$ 1.1
Pension and other benefit adjustments:									
Net gain (loss) arising during the period, net of tax	(5.2)	—	(5.2)	1.8	—	1.8	(2.0)	—	(2.0)
Other comprehensive income (loss)	\$ 89.6	\$ 0.2	\$ 89.8	\$ (53.7)	\$ (0.1)	\$ (53.8)	\$ (1.5)	\$ 0.6	\$ (0.9)

**NOTE 13—LOSS PER SHARE**

Basic loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding. Diluted loss per share includes the effects of unvested RSUs with a service condition only, unvested contingently issuable PSUs that have service and performance conditions, and shares issuable upon conversion of the Existing Exchangeable Notes and New Exchangeable Notes, if dilutive. Diluted earnings per share is computed using the treasury stock method for the RSUs and PSUs and the if-converted method for the Existing Exchangeable Notes and New Exchangeable Notes.

The following table sets forth the computation of basic and diluted loss per common share:

<u>(In millions)</u>	<u>Year Ended December 31, 2025</u>	<u>Year Ended December 31, 2024</u>	<u>Year Ended December 31, 2023</u>
<b>Numerator:</b>			
Net loss for basic and diluted loss per share	\$ (632.4)	\$ (352.6)	\$ (396.6)
<b>Denominator (shares in thousands):</b>			
Weighted average shares for basic and diluted loss per common share	472,899	332,920	167,644
Basic and diluted loss per common share	<u>\$ (1.34)</u>	<u>\$ (1.06)</u>	<u>\$ (2.37)</u>

Vested RSUs and PSUs have dividend rights identical to the Company's Common Stock and are treated as outstanding shares for purposes of computing basic and diluted loss per share.

Included in the computation of basic loss per share are 1,869,173 contingently issuable RSUs whose issuance conditions were satisfied when the grantee attained retirement eligibility or when the normal service conditions had been met. These contingently issuable RSUs will not be issued until their vesting dates. For the year ended December 31, 2025, December 31, 2024, and December 31, 2023, unvested RSUs of 2,703,905; 1,662,429; and 272,469, respectively, were not included in the computation of diluted loss per share because they would be anti-dilutive.

All Tranche Year PSUs which had been attained at December 31, 2025, December 31, 2024, and December 31, 2023 were included in basic loss per share for each respective period because the issuance of the related shares were contingent only upon the passage of time. Therefore, no granted Tranche Year PSUs at December 31, 2025, December 31, 2024, and December 31, 2023 could further dilute basic loss per share.

The Company has excluded approximately 22.3 million shares issuable upon conversion of the Existing Exchangeable Notes from the computation of diluted loss per share for the year ended December 31, 2025, because they would be anti-dilutive. The Company had excluded approximately 85.2 million shares issuable upon conversion of the Existing Exchangeable Notes from the computation of diluted loss per share for the year ended December 31, 2024, because they would have been anti-dilutive.

The New Exchangeable Notes are convertible into between 77.1 million and 141.4 million shares of Common Stock which could potentially dilute future basic earnings per share. Additionally, the Company has agreed to pay \$21.3 million of fees payable in shares of Common Stock to holders of the New Exchangeable Notes. These additional shares could also potentially dilute future basic earnings per share. See Note 7—Corporate Borrowings and Finance Lease Liabilities for more information.

**NOTE 14—SUBSEQUENT EVENTS**

**Share Issuances.** In February 2026, the Company entered into a sales and registration agreement (the "2026 Sales and Registration Agreement") with (1) Goldman Sachs & Co. LLC, B. Riley Securities, Inc. and Yorkville Securities, LLC, from time to time acting as sales agents (in such capacity, the "Sales Agents") and (2) Goldman Sachs & Co. LLC, as the Forward Seller of any and all Hedging Shares offered by the Forward Counterparty (in each case, as

[Table of Contents](#)

defined below), and Goldman Sachs International, acting in its capacity as Forward Counterparty, relating to shares of Common Stock of the Company having an aggregate offering price of up to \$150,000,000.

In accordance with the terms of the 2026 Sales and Registration Agreement, the Company may issue and sell shares of Common Stock covered by the prospectus supplement at any time and from time to time through the Sales Agents. The Sales Agents may act as agent on the Company's behalf or purchase shares of Common Stock from the Company as principal for its own account.

The Company also entered into a master confirmation (the "Master Confirmation") with Goldman Sachs International (in its capacity as buyer under any Forward (as defined herein), the "Forward Counterparty") pursuant to which the Company expects to enter into one or more collared forward transactions (each a "Forward"), under which the Company agreed to sell up to the number of shares of Common Stock specified in such Forward (subject to adjustment as set forth therein) to the Forward Counterparty. If the Company enters into a Forward with the Forward Counterparty, to establish a hedge position under such Forward, the Forward Counterparty will have a pledge of up to the maximum number of shares of Common Stock deliverable under such Forward (the "Hedging Shares") from the Company, with a right to rehypothecate the pledged shares, and will rehypothecate and sell up to such maximum number of shares through Goldman Sachs & Co. LLC acting as the statutory underwriter (in such capacity, the "Forward Seller") in an offering under a prospectus supplement and accompanying prospectus over a period of time to be agreed between the Company and the Forward Counterparty for such Forward (an "Initial Hedging Period"), all subject to the terms of the 2026 Sales and Registration Agreement. The Initial Hedging Period for any Forward that the Company may enter into during a reporting quarter is expected to terminate during such reporting quarter or shortly thereafter. The establishment of such hedge positions could have the effect of decreasing, or limiting an increase in, the market price of Common Stock.

The Company has been advised by the Forward Counterparty that it expects that, on the same days during the Initial Hedging Period when it is selling a number of Hedging Shares underlying the Forward, the Forward Counterparty or its affiliate(s) will be contemporaneously purchasing a substantial portion of such number of shares in the open market for its own account, as the Forward Counterparty expects its initial hedge position in respect of any Forward to be substantially less than the number of shares underlying such Forward. Such purchases in the open market may have the effect of increasing, or limiting a decrease in the market price of Common Stock. The number of shares underlying any Forward will be reduced in the event that the Forward Counterparty is unable to introduce the maximum number of shares deliverable under the Forward into the public market during the Initial Hedging Period (including as a result of the prospectus being unavailable at any time during such Initial Hedging Period).

In addition, the Company has been advised by the Forward Counterparty that the Forward Counterparty expects to dynamically modify its hedge positions for its own account by it or its affiliate(s) buying or selling shares of Common Stock or engaging in derivatives or other transactions with respect to Common Stock from time to time during the term of a particular Forward, including during the valuation period for such Forward. The purchases and sales of shares of Common Stock or other hedging transactions by the Forward Counterparty to modify the Forward Counterparty's hedge positions from time to time during the term of the Forward may variously have a positive, negative or neutral impact on the market price of Common Stock, depending on market conditions at such times.

The settlement price per share under a Forward at maturity (whether on the scheduled maturity date or an accelerated maturity date, as applicable, for the Forward or a portion thereof) will be based on the arithmetic average of volume weighted prices of Common Stock during the valuation period for such Forward that will run between the completion of the Initial Hedging Period for such Forward or shortly thereafter and applicable maturity (the "Reference Price"), subject to the agreed forward floor and cap prices. The Forward will specify the floor percentage (which will be less than 100%) and the cap percentage (which will be more than 100%). Upon completion of the Initial Hedging Period with respect to such Forward, the forward floor price and the forward cap price will be determined by multiplying the weighted average prices at which the Forward Counterparty will have sold the shares of Common Stock during the Initial Hedging Period to establish its hedge position for such Forward by the floor percentage and the cap percentage, respectively. The floor price is intended to mitigate the downside risk of any potential decline in the Reference Price below the floor price during the valuation period, but the cap price would also limit the potential upside benefit to the extent the Reference Price were to exceed the cap price during the valuation period. The Company will determine the scheduled maturity of a Forward at the time we enter into such Forward based, among other factors, upon the market conditions at the time, and the Company currently expects that such scheduled maturity will be approximately six months after completion of the Initial Hedging Period for such Forward.

[Table of Contents](#)

If the Company enters into any Forward with the Forward Counterparty, the Company expects to receive under such Forward, (x) an initial cash payment after completion of the respective Initial Hedging Period for such Forward or shortly thereafter, based on, among other factors, the floor price and prepayment percentage agreed for such Forward, if any and (y) at maturity of such Forward (or a portion thereof), an additional payment, if any, to the extent that the total amount due under such Forward exceeds the initial cash payment. If the number of the shares of Common Stock underlying any Forward is reduced upon completion of the Initial Hedging Period therefor as described above, the Company would not be entitled to receive the full amounts upon prepayment and/or at maturity of such Forward that it may initially anticipate at the time of entry into such Forward.

Through February 20, 2026, the Company was paid \$26.2 million as initial gross cash proceeds for 20.4 million shares of Common Stock sold in at-the-market offerings. Fees paid to sales agents were approximately \$0.5 million.

**Indenture Amendments.** On January 29, 2026, Holdings and Muvico, entered into a letter agreement (the “Letter Agreement”) with certain holders of Muvico’s New 2029 Notes, (such holders, the “New 2029 Noteholders”) pursuant to which Holdings, Muvico, and the 2029 Noteholders agreed to amend the New 2029 Notes Indenture. The amendments (the “Indenture Amendments”) will, among other things, provide the Company with the flexibility to:

- refinance its Credit Agreement and the Odeon Notes issued by Odeon Finco PLC, a wholly-owned direct subsidiary of OCGL and an indirect subsidiary of Holdings, with new debt that may be secured and guaranteed by Holdings, OCGL, and Muvico, and
- incur up to an additional \$50 million of secured debt under the New 2029 Notes Indenture.

Pursuant to the Letter Agreement, the parties agreed to cooperate (including cooperating with the trustee and the notes collateral agent) in good faith to memorialize and effectuate the Indenture Amendments as soon as reasonably practicable, and in any event, no later than February 23, 2026. In consideration for the 2029 Noteholders’ agreement to the Indenture Amendments, the Company will pay the 2029 Noteholders a maximum fee of up to 17,806,866 shares of Common Stock (the “Consent Fee”), subject to a reduction depending on the trading price of the Common Stock for a period following the date of the Letter Agreement.

**Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.**

Not applicable

**Item 9A. Controls and Procedures.**

(a) Evaluation of disclosure controls and procedures.

The Company maintains a set of disclosure controls and procedures designed to ensure that material information required to be disclosed in its filings under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that material information is accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. The Company's Chief Executive Officer and Chief Financial Officer have evaluated these disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K and have determined that such disclosure controls and procedures were effective.

(b) Management's annual report on internal control over financial reporting.

Management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company as defined in Rule 13a-15(f) of the Exchange Act. With management's participation, an evaluation of the effectiveness of internal control over financial reporting was conducted as of December 31, 2025, based on the framework and criteria established in *Internal Control—Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management has concluded that the Company's internal control over financial reporting was effective as of December 31, 2025. The effectiveness of our internal control over financial reporting has been audited by Ernst & Young LLP, an independent registered public accounting firm, as stated in their attestation report in Part II, Item 8 of this Annual Report on Form 10-K.

(c) Changes in internal control over financial reporting.

There were no changes in its internal control over financial reporting as defined in Exchange Act Rule 13a-15(f) during the quarter ended December 31, 2025, that materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

**Item 9B. Other Information.**

**Trading Arrangements**

In the fourth quarter of 2025, no director or officer (as defined in Exchange Act Rule 16a-1(f)) of AMC adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement for the purchase or sale of securities of the Company, within the meaning of Item 408 of Regulation S-K. Additionally, AMC Entertainment Holdings, Inc. did not adopt or terminate any Rule 10b5-1 trading arrangement during the fourth quarter of 2025.

**Compensatory Arrangements of Certain Officers**

In order to recognize the ongoing extraordinary efforts of the Company's management team as the theatrical exhibition industry continues to lag its pre-pandemic performance, encourage continued engagement, and incentivize executives during continued difficult business conditions, on February 19, 2026, the Compensation Committee of the Company's Board of Directors (the "Committee"), in consultation with the Company's independent compensation consultant, approved modification of the performance goals for the fiscal year ended December 31, 2025, applicable to certain Performance Stock Units ("PSUs") granted under the 2013 and 2024 Equity Incentive Plans (collectively, the "EIP") to certain officers, including the named executive officers ("NEOs") and certified achievement measured against such modified performance goals.

As described in the Company's definitive proxy statement on Schedule 14A in connection with its 2025 Annual Meeting of Stockholders, filed on October 24, 2025, each year the Committee approves annual grants under the EIP, a portion of which are designated as PSUs. The PSUs are divided into tranches with each tranche allocated to a fiscal year during the three-year period covered by the grant (each a "Tranche Year"). Each tranche is eligible to vest based upon

[Table of Contents](#)

attainment of certain financial performance goals during its applicable Tranche Year. The performance goals are established at the beginning of the applicable Tranche Year based upon the Company's financial plan, which in turn is highly dependent upon forecasts of overall industry box office. For the 2025 Tranche Year, primarily due to changes to studio movie release schedules and weaker than expected consumer demand for the titles released, which were outside the control of the Company, industry box office was lower than the forecasts upon which the performance goals were predicated. As a result, PSUs allocated to the 2025 Tranche Year with unindexed Adjusted EBITDA performance goals would have vested at 0% and PSUs allocated to the 2025 Tranche Year with unindexed free cash flow performance goals would have vested at 0%. The Committee determined that it was equitable to index the 2025 Tranche Year performance goals to reflect actual industry conditions during the 2025 Tranche Year. After modification of the performance goals as described above, the PSUs allocated to the 2025 tranche year with adjusted EBITDA performance goals will vest at a level of 200% and PSUs allocated to the 2025 tranche year with free cash flow performance goals will vest at a level of 200%. Given the management team's continued focus on maximizing results despite industry factors outside its control, the Committee felt that the modifications were justified and consistent with the goals of the Company's executive compensation programs, namely to attract, retain, motivate and reward talented executives.

The table below reflects the incremental number of shares issuable (prior to tax withholding) to NEOs as a result of the modification of the performance goals:

NEO	Common Stock
Adam Aron	1,377,832
Sean Goodman	369,940
Dan Ellis	174,590
Mark Way	157,136
Carla Chavarria	139,598

As a result of the modification of the performance goals, in the first quarter of 2026 the Company estimates it will issue approximately 2.1 million additional shares of Common Stock net of tax withholding, incur approximately \$4.6 million of incremental stock compensation expense, and make estimated incremental cash payments of approximately \$2.1 million to cover tax withholding.

**Retention Bonuses**

On February 19, 2026, the Compensation Committee of the Company's Board of Directors approved one-time cash bonuses (the "Retention Bonuses") to each of the Company's Executive Vice Presidents in the amounts set forth below:

Officer	Title	Retention Bonus
Sean Goodman	Executive Vice President, International Operations, Chief Financial Officer & Treasurer	\$1,000,000
Dan Ellis	Executive Vice President, Chief Operations, Development & Marketing Officer	\$500,000
Mark Way	Executive Vice President, Europe	\$250,000

The Retention Bonuses are payable in two installments with 25% payable on February 19, 2028, and 75% payable on February 19, 2029, subject to the officer's continued employment on such dates.

**2026 Annual Meeting**

The Company plans to hold its 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting") on September 24, 2026. The time and location of the 2026 Annual Meeting will be specified in the 2026 proxy statement. Because the 2026 Annual Meeting will be more than thirty (30) days prior to the anniversary of the Company's 2025 Annual Meeting of Stockholders, the Company is disclosing a new deadline for submission of stockholder proposals for inclusion in the 2026 proxy statement pursuant to Rule 14a-8 under the Exchange Act. In accordance with Rule 14a-5(f) of the Exchange Act, the Company is hereby informing stockholders that to be considered for inclusion in the 2026 proxy statement, stockholder proposals submitted under Rule 14a-8 of the Exchange Act must be in writing and received

[Table of Contents](#)

by the Corporate Secretary at the Company's principal offices at One AMC Way, 11500 Ash Street, Leawood, Kansas 66211, no later than 5:00 pm Central Time on April 30, 2026, which the Company has determined to be a reasonable time before it expects to begin to print and send its proxy materials. Such proposals must also comply with the remaining requirements of Rule 14a-8. Any proposal submitted after the foregoing deadline will not be considered timely and will be excluded from the 2026 proxy statement.

Additionally, in accordance with the advance notice provisions set forth in the Company's Bylaws, in order for a stockholder proposal submitted outside of Rule 14a-8 or a director nomination submitted by a stockholder to be considered timely, it must be received by the Corporate Secretary not earlier than May 27, 2026, and no later than June 26, 2026. In addition to satisfying the foregoing requirements under the Company's Bylaws, to comply with the universal proxy rules, shareholders who intend to solicit proxies in support of director nominees other than the Company's nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than July 26, 2026.

**Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.**

Not applicable

### **PART III**

#### **Item 10. Directors, Executive Officers and Corporate Governance.**

For information with respect to the executive officers of the Company, see “Information about our Executive Officers” included as a separate item at the end of Part I, Item 1 of this Form 10-K.

All other information called for by this item is hereby incorporated herein by reference to the relevant information under the headings “Proposal 2 - Election of Directors”, “Delinquent Section 16(A) Reports”, and “Corporate Governance” in our definitive proxy statement on Schedule 14A in connection with our 2026 Annual Meeting of Stockholders, to be filed within 120 days after December 31, 2025 (the “Annual Meeting Proxy Statement”).

#### **Item 11. Executive Compensation.**

The information called for by this item is set forth under the headings “Executive Compensation” (excluding the information under the subheading “Pay versus Performance”), “Compensation Committee Report on Executive Compensation”, “Compensation Committee Interlocks and Insider Participation”, “Compensation Policies and Practices as They Relate to Risk Management”, “Director Compensation” and “Compensation Discussion and Analysis” in the Annual Meeting Proxy Statement.

#### **Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.**

The information called for by this item is set forth under the headings “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters” and “Equity Compensation Plan Information” in the Annual Meeting Proxy Statement.

#### **Item 13. Certain Relationships and Related Transactions, and Director Independence.**

The information called for by this item is set forth under the headings “Certain Relationships and Related Transactions” and “Director Independence” in the Annual Meeting Proxy Statement.

#### **Item 14. Principal Accountant Fees and Services.**

The information called for by this item is set forth under the headings “Principal Accountant Fees and Services” and “Audit Committee Pre-Approval Policy” in the Annual Meeting Proxy Statement.

**Part IV**

**Item 15. Exhibits and Financial Statement Schedules.**

(a)(1) The following financial statements are included in Part II, Item 8.

	<b>Page</b>
<a href="#">Reports of Independent Registered Public Accounting Firm (PCAOB ID 42)</a>	71
<a href="#">Consolidated Statements of Operations—Years ended December 31, 2025, December 31, 2024, and December 31, 2023</a>	75
<a href="#">Consolidated Statements of Comprehensive Loss—Years ended December 31, 2025, December 31, 2024, and December 31, 2023</a>	76
<a href="#">Consolidated Balance Sheets—December 31, 2025 and December 31, 2024</a>	77
<a href="#">Consolidated Statements of Cash Flows—Years ended December 31, 2025, December 31, 2024, and December 31, 2023</a>	78
<a href="#">Consolidated Statements of Stockholders' Deficit—Years ended December 31, 2025, December 31, 2024, and December 31, 2023</a>	80
<a href="#">Notes to Consolidated Financial Statements—Years ended December 31, 2025, December 31, 2024, and December 31, 2023</a>	81

(a)(2) Financial Statement Schedules—All schedules have been omitted because the necessary information is included in the Notes to the Consolidated Financial Statements.

(b) Exhibits

The Company has attached or incorporated by reference herein certain exhibits as specified below.

[Table of Contents](#)

<b>Exhibit Number</b>	<b>Description</b>
<a href="#">1.1</a>	<a href="#">Sales and Registration Agreement, dated as of December 6, 2024, by and among AMC Entertainment Holdings, Inc., Goldman Sachs &amp; Co. LLC and Goldman Sachs International (incorporated by reference from Exhibit 1.1 to AMC's Current Report on Form 8-K (File No. 1-33892) filed on December 6, 2024).</a>
<a href="#">1.2</a>	<a href="#">Sales and Registration Agreement, dated as of February 9, 2026, by and among AMC Entertainment Holdings, Inc., Goldman Sachs &amp; Co. LLC and Goldman Sachs International (incorporated by reference from Exhibit 1.1 to AMC's Current Report on Form 8-K (File No. 1-33892) filed on February 9, 2026).</a>
<a href="#">3.1</a>	<a href="#">Fourth Amended and Restated Bylaws of AMC Entertainment Holdings, Inc. effective February 22, 2024 (incorporated by reference from Exhibit 3.2 to the Company's Annual Report Form 10-K (File No. 1-33892) filed on February 28, 2024).</a>
<a href="#">3.2</a>	<a href="#">Fourth Amended and Restated Certificate of Incorporation of AMC Entertainment Holdings, Inc. (incorporated by reference from Exhibit 3.1 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on December 11, 2025).</a>
<a href="#">4.1</a>	<a href="#">Indenture, dated as of June 5, 2015, respecting AMC Entertainment Inc.'s 5.75% Senior Subordinated Notes due 2025, among AMC Entertainment Inc., the Guarantors named therein and U.S. Bank National Association, as trustee (incorporated by reference from Exhibit 4.1 to AMC's Current Report on Form 8-K (File No. 1-8747) filed on June 5, 2015).</a>
<a href="#">4.1(a)</a>	<a href="#">Second Supplemental Indenture, dated as of March 31, 2016, with respect to \$600 million aggregate principal amount of 5.75% Senior Subordinated Notes due 2025, by and between AMC Entertainment Holdings, Inc., AMC Entertainment Inc., the guarantors party thereto and U.S. Bank National Association, as trustee (incorporated by reference from Exhibit 4.1 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on March 31, 2016).</a>
<a href="#">4.1(b)</a>	<a href="#">Fourth Supplemental Indenture respecting AMC Entertainment Holdings, Inc.'s 5.75% Senior Subordinated Notes due 2025, by and among AMC Entertainment Holdings, Inc. and U.S. Bank National Association, as trustee, dated as of July 27, 2020 (incorporated by reference from Exhibit 4.9 to AMC's Current Report on Form 8-K (File No. 1-33892) filed on July 31, 2020).</a>
<a href="#">4.2</a>	<a href="#">Indenture, dated as of November 8, 2016, respecting AMC Entertainment Holdings, Inc.'s 5.875% Senior Subordinated Notes due 2026 and 6.375% Senior Subordinated Notes due 2024, among AMC Entertainment Holdings, Inc., the guarantors named therein and U.S. Bank National Association, as trustee (incorporated by reference from Exhibit 4.1 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on November 8, 2016).</a>
<a href="#">4.2(a)</a>	<a href="#">Second Supplemental Indenture respecting AMC Entertainment Holdings, Inc.'s 5.875% Senior Subordinated Notes due 2026 and 6.375% Senior Subordinated Notes due 2024, by and among AMC Entertainment Holdings, Inc. and U.S. Bank National Association, as trustee, dated as of July 27, 2020 (incorporated by reference from Exhibit 4.11 to AMC's Current Report on Form 8-K (File No. 1-33892) filed on July 31, 2020).</a>
<a href="#">4.3</a>	<a href="#">Indenture, dated as of March 17, 2017, respecting AMC Entertainment Holdings, Inc.'s 6.125% Senior Subordinated Notes due 2027, among AMC Entertainment Holdings, Inc., the guarantors named therein and U.S. Bank National Association, as trustee (incorporated by reference from Exhibit 4.1 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on March 17, 2017).</a>

[Table of Contents](#)

<b>Exhibit Number</b>	<b>Description</b>
<a href="#">4.3(a)</a>	<a href="#">Second Supplemental Indenture respecting AMC Entertainment Holdings, Inc.'s 6.125% Senior Subordinated Notes due 2027, by and among AMC Entertainment Holdings, Inc. and U.S. Bank National Association, as trustee, dated as of July 27, 2020 (incorporated by reference from Exhibit 4.10 to AMC's Current Report on Form 8-K (File No. 1-33892) filed on July 31, 2020).</a>
<a href="#">*4.4</a>	<a href="#">Description of the registrant's securities registered pursuant to Section 12 of the Securities Exchange Act of 1934.</a>
<a href="#">4.5</a>	<a href="#">Indenture respecting AMC Entertainment Holdings, Inc.'s 10%/12% Cash/PIK Toggle Second Lien Subordinated Secured Notes due 2026 by and among AMC Entertainment Holdings, Inc., the guarantors party thereto and GLAS Trust Company LLC, as trustee and collateral agent, dated as of July 31, 2020 (incorporated by reference from Exhibit 4.1 to AMC's Current Report on Form 8-K (File No. 1-33892) filed on July 31, 2020).</a>
<a href="#">4.5(a)</a>	<a href="#">Form of 10%/12% Cash/PIK Toggle Second Lien Subordinated Secured Notes due 2026 (incorporated by reference from Exhibit 4.2 (and is included in Exhibit 4.1) to AMC's Current Report on Form 8-K (File No. 1-33892) filed on July 31, 2020).</a>
<a href="#">4.5(b)</a>	<a href="#">Supplemental Indenture, by and among AMC Entertainment Holdings, Inc., the guarantors party thereto, and GLAS Trust Company LLC, as trustee and as notes collateral agent, dated as of July 22, 2024 (as defined therein) from time to time party thereto, dated as of July 22, 2024 (incorporated by reference from Exhibit 4.8 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on July 22, 2024).</a>
<a href="#">4.6</a>	<a href="#">Indenture, dated as of February 14, 2022, among AMC Entertainment Holdings, Inc., the guarantors therein and U.S. Bank Trust Company, National Association, as trustee and collateral agent, including the form of the 7.500% First Lien Notes due 2029 (incorporated by reference from Exhibit 4.1 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on February 14, 2022).</a>
<a href="#">4.7</a>	<a href="#">Indenture, dated as of October 20, 2022, among Odeon Finco PLC, the guarantors named therein and U.S. Bank Trust Company, National Association, as trustee and security agent (including the form of the 12.75% Senior Secured Note due 2027) (incorporated by reference from Exhibit 4.1 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on October 20, 2022).</a>
<a href="#">4.8</a>	<a href="#">Guarantee Agreement, dated as of October 20, 2022, among AMC Entertainment Holdings, Inc. and U.S. Bank Trust Company, National Association (incorporated by reference from Exhibit 4.2 to AMC's Current Report on Form 8-K (File No. 1-33892) filed on October 20, 2022).</a>
<a href="#">4.9</a>	<a href="#">Credit Agreement, by and among AMC Entertainment Holdings, Inc., as a borrower, Muvico, LLC, as a borrower, the lenders from time to time party thereto and Wilmington Savings Fund Society, FSB, as administrative agent and as collateral agent, dated as of July 22, 2024 (incorporated by reference from Exhibit 4.2 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on July 22, 2024).</a>
<a href="#">4.10</a>	<a href="#">Exchangeable Notes Indenture, by and among Muvico, LLC, the guarantors party thereto, and GLAS Trust Company, LLC, as trustee and as notes collateral agent, dated as of July 22, 2024 (incorporated by reference from Exhibit 4.3 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on July 22, 2024).</a>

[Table of Contents](#)

<b>Exhibit Number</b>	<b>Description</b>
<a href="#">4.11</a>	<a href="#">Form of 6.00%/8.00% Cash/PIK Toggle Senior Secured Exchangeable Note due 2030 (included as Exhibit A to Exhibit 4.4 hereto) (incorporated by reference from Exhibit 4.4 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on July 22, 2024).</a>
<a href="#">4.12</a>	<a href="#">First Lien/Second Lien Intercreditor Agreement, by and among AMC Entertainment Holdings, Inc., Muvico, LLC, the other guarantors from time to time party thereto, the New Term Loan Collateral Agent, the Exchangeable Notes Collateral Agent and each Additional Junior Agent (as defined therein) from time to time party thereto, dated as of July 22, 2024 (incorporated by reference from Exhibit 4.5 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on July 22, 2024).</a>
<a href="#">4.13</a>	<a href="#">Credit Facilities Intercreditor Agreement, by and between the Existing Credit Agreement Collateral Agent and the New Term Loan Collateral Agent, and acknowledged by AMC Entertainment Holdings, Inc. and the guarantors party thereto, dated as of July 22, 2024 (incorporated by reference from Exhibit 4.7 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on July 22, 2024).</a>
<a href="#">4.14</a>	<a href="#">Supplemental Indenture, dated as of July 1, 2025, by and among Muvico, the guarantors party thereto and GLAS Trust Company LLC, as trustee and notes collateral agent (incorporated by reference from Exhibit 4.1 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on July 1, 2025).</a>
<a href="#">4.15</a>	<a href="#">New 2029 Notes Indenture, by and among Muvico, the Company, the other guarantors party thereto and CSC Delaware Trust Company, as trustee and as notes collateral agent, dated as of July 24, 2025 (incorporated by reference from Exhibit 4.1 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on July 25, 2025).</a>
<a href="#">4.15(a)</a>	<a href="#">Letter Agreement, by and among Muvico, the Company and the 2029 Noteholders, dated as of January 29, 2026 (incorporated by reference from Exhibit 10.1 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on January 29, 2026).</a>
<a href="#">4.16</a>	<a href="#">Form of Senior Secured Note due 2029 (included as Exhibit A to Exhibit 4.18 hereto) (incorporated by reference from Exhibit 4.2 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on July 25, 2025).</a>
<a href="#">4.17</a>	<a href="#">New Exchangeable Notes Indenture, by and among Muvico, the Company, the other guarantors party thereto and GLAS Trust Company LLC, as trustee and as notes collateral agent, dated as of July 24, 2025 (incorporated by reference from Exhibit 4.3 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on July 25, 2025).</a>
<a href="#">4.17(a)</a>	<a href="#">Supplemental Indenture, by and among Muvico, the Company, the other guarantors party thereto and GLAS Trust Company LLC, as trustee and collateral agent, dated as of January 12, 2026 (incorporated by reference from Exhibit 4.1 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on January 12, 2026).</a>
<a href="#">4.18</a>	<a href="#">Form of Senior Secured Exchangeable Note due 2030 (included as Exhibit A to Exhibit 4.20 hereto) (incorporated by reference from Exhibit 4.4 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on July 25, 2025).</a>

[Table of Contents](#)

<b>Exhibit Number</b>	<b>Description</b>
<a href="#">4.19</a>	<a href="#">First Amendment to Credit Agreement, by and among AMC, the guarantors party thereto, the lenders party thereto, Credit Agreement Collateral Agent, Centertainment, Muvico and the other Existing Guarantors, dated as of July 24, 2025 (incorporated by reference from Exhibit 4.5 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on July 25, 2025).</a>
<a href="#">4.20</a>	<a href="#">First Lien/Second Lien Centertainment Group Intercreditor Agreement, by and among AMC, Centertainment, Muvico, the other Existing Guarantors, the Credit Agreement Collateral Agent, the Existing Exchangeable Notes Collateral Agent, the New Exchangeable Notes Collateral Agent and the New 2029 Notes Collateral Agent, dated as of July 24, 2025 (incorporated by reference from Exhibit 4.6 to AMC's Current Report on Form 8-K (File No. 1-33892) filed on July 25, 2025).</a>
<a href="#">4.21</a>	<a href="#">Joinder No. 5 to Existing Restricted Group First Lien Intercreditor Agreement, by and among Company, the AMC Group Guarantors, the Credit Agreement Collateral Agent and the other agents party thereto, dated as of July 24, 2025 (incorporated by reference from Exhibit 4.7 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on July 25, 2025).</a>
<a href="#">4.22</a>	<a href="#">First Lien/Intermediate Lien Centertainment Group Intercreditor Agreement, by and among the Company, Centertainment, Muvico and the other Existing Guarantors, the Credit Agreement Collateral Agent, the New Exchangeable Notes Collateral Agent and the New 2029 Notes Collateral Agent, dated as of July 24, 2025 (incorporated by reference from Exhibit 4.8 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on July 25, 2025).</a>
<a href="#">4.23</a>	<a href="#">1.25 Lien/1.5 Lien Centertainment Group Intercreditor Agreement, by and among the Company, Muvico, Centertainment and the other Muvico Group Guarantors, the New Exchangeable Notes Collateral Agent and the New 2029 Notes Collateral Agent, dated as of July 24, 2025 (incorporated by reference from Exhibit 4.9 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on July 25, 2025).</a>
<a href="#">4.24</a>	<a href="#">Existing 7.5% Notes Supplemental Indenture, by and among the Company, the guarantors party thereto and CSC Delaware Trust Company, as trustee and collateral agent, dated as of July 24, 2025 (incorporated by reference from Exhibit 4.10 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on July 25, 2025).</a>
<a href="#">4.25</a>	<a href="#">Supplemental Indenture, by and among Muvico, the Company, the other guarantors party thereto and CSC Delaware Trust Company, as trustee and collateral agent, dated as of February 12, 2026 (incorporated by reference from Exhibit 4.1 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on February 13, 2026).</a>
<a href="#">+10.1</a>	<a href="#">Defined Benefit Retirement Income Plan for Certain Employees of American Multi-Cinema, Inc., as Amended and Restated, effective December 31, 2006, and as Frozen, effective December 31, 2006 (incorporated by reference from Exhibit 10.15(a) to AMC's Annual Report on Form 10-K (File No. 1-8747) filed June 18, 2007).</a>
<a href="#">+10.2</a>	<a href="#">American Multi-Cinema, Inc. Supplemental Executive Retirement Plan, as Amended and Restated, generally effective January 1, 2006, and as Frozen, effective December 31, 2006 (incorporated by reference from Exhibit 10.15(b) to AMC's Annual Report on Form 10-K (File No. 1-8747) filed June 18, 2007).</a>

## Table of Contents

<u>Exhibit Number</u>	<u>Description</u>
<u>+10.3</u>	<u><a href="#">Form of Indemnification Agreement by and between AMC Entertainment Holdings, Inc. and its Directors and Executive Officers (incorporated by reference from Exhibit 10.26 to the Company's Registration Statement on Form S-1 (File No. 333-190904) filed on November 22, 2013, as amended).</a></u>
<u>+10.4</u>	<u><a href="#">Employment Agreement, dated as of December 14, 2015, by and among AMC Entertainment Holdings, Inc. and Adam M. Aron (incorporated by reference from Exhibit 10.1 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on December 15, 2015).</a></u>
<u>+10.5</u>	<u><a href="#">AMC Entertainment Holdings, Inc. 2013 Equity Incentive Plan (incorporated by reference from Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q (File No. 1-33892) filed on November 7, 2014).</a></u>
<u>+10.5(a)</u>	<u><a href="#">AMC Entertainment Holdings, Inc. Clarifying Amendment to 2013 Equity Incentive Plan (incorporated by reference from Exhibit 10.27(a) to the Company's Annual Report on Form 10-K (File No. 1-33892) filed on March 10, 2015).</a></u>
<u>+10.5(b)</u>	<u><a href="#">Second Amendment to AMC Entertainment Holdings, Inc. 2013 Equity Incentive Plan, approved as of July 29, 2020 (incorporated by reference from Exhibit 10.1 to AMC's Current Report on Form 8-K (File No. 1-33892) filed on July 31, 2020).</a></u>
<u>+10.5(c)</u>	<u><a href="#">Third Amendment to the AMC Entertainment Holdings, Inc. 2013 Equity Incentive Plan, approved as of October 30, 2020 (incorporated by reference from Exhibit 10.10 to AMC's Current Report on Form 10-Q (File No. 1-33892) filed on November 4, 2020).</a></u>
<u>+10.5(d)</u>	<u><a href="#">Fourth Amendment to the AMC Entertainment Holdings, Inc. 2013 Equity Incentive Plan, effective as of August 15, 2022 (incorporated by reference from Exhibit 10.1 to AMC's Current Report on Form 8-K (File No. 1-33892) filed on August 4, 2022).</a></u>
<u>+10.5(e)</u>	<u><a href="#">Fifth Amendment to the AMC Entertainment Holdings, Inc. 2013 Equity Incentive Plan, effective as of August 25, 2023 (incorporated by reference from Exhibit 10.2 to AMC's Current Report on Form 10-Q (File No. 1-33892) filed on November 8, 2023).</a></u>
<u>+10.5(f)</u>	<u><a href="#">Form of Stock Award Agreement (incorporated by reference from Exhibit 10.29 to the Company's Registration Statement on Form S-1 (File No. 333-190904) filed on November 27, 2013, as amended).</a></u>
<u>+10.5(g)</u>	<u><a href="#">Form of Director Stock Award Notice and Agreement under the AMC Entertainment Holdings, Inc. 2013 Equity Incentive Plan (incorporated by reference from Exhibit 10.3 to AMC's Quarterly Report on Form 10-Q (File No. 1-33892) filed on June 9, 2020).</a></u>
<u>+10.5(h)</u>	<u><a href="#">Form of Restricted and/or Performance Stock Unit Award Notice and Agreement under the AMC Entertainment Holdings, Inc. 2013 Equity Incentive Plan (incorporated by reference from Exhibit 10.4 to AMC's Quarterly Report on Form 10-Q (File No. 1-33892) filed on June 9, 2020).</a></u>
<u>+10.5(i)</u>	<u><a href="#">Form of First Modification to the AMC Entertainment Holdings, Inc. 2013 Equity Incentive Plan Special Performance Stock Unit Award Notice &amp; Agreement Dated February 26, 2020, First Modification Effective October 30, 2020 (incorporated by reference from Exhibit 10.11 to AMC's Quarterly Report on Form 10-Q (File No. 1-33892) filed on November 4, 2020).</a></u>

[Table of Contents](#)

<b>Exhibit Number</b>	<b>Description</b>
<a href="#">+10.5(j)</a>	<a href="#">2013 Equity Incentive Plan Change in Control Policy (incorporated by reference from Exhibit 10.1 to AMC's Quarterly Report on Form 10-Q (File No. 1-33892) filed on May 5, 2023).</a>
<a href="#">+10.6</a>	<a href="#">Employment Agreement between AMC Entertainment Holdings, Inc. and Sean D. Goodman executed on October 6, 2020 (incorporated by reference from Exhibit 10.9 to AMC's Quarterly Report on Form 10-Q (File No. 1-33892) filed on November 4, 2020).</a>
<a href="#">+10.6(a)</a>	<a href="#">Amendment executed March 19, 2021, to the Employment Agreement between AMC Entertainment Holdings, Inc. and Sean D. Goodman executed on October 6, 2020 (incorporated by reference from Exhibit 10.1 to AMC's Current Report on Form 8-K (File No. 1-33892) filed on March 19, 2021).</a>
<a href="#">*+10.7</a>	<a href="#">AMC Entertainment Holdings, Inc. Annual Incentive Compensation Program Continuing Structure, as amended and restated by the Compensation Committee February 19, 2026.</a>
<a href="#">+10.8</a>	<a href="#">Employment Agreement, dated as of December 20, 2016, by and between Daniel E. Ellis and AMC Entertainment Holdings, Inc. (incorporated by reference from Exhibit 10.1 to AMC's Quarterly Report on Form 10-Q (File No. 1-33892) filed on May 9, 2022).</a>
<a href="#">+10.9</a>	<a href="#">Employment Agreement, dated as of August 11, 2023, by and between Ellen Copaken and AMC Entertainment Holdings, Inc. (incorporated by reference from Exhibit 10.1 to AMC's Quarterly Report on Form 10-Q (File No. 1-33892) filed on November 8, 2023).</a>
<a href="#">+10.10</a>	<a href="#">AMC Entertainment Holdings, Inc. 2024 Equity Incentive Plan (incorporated by reference from Exhibit 10.1 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on June 7, 2024).</a>
<a href="#">10.11</a>	<a href="#">Asset Transfer Agreement, by and among American Multi-Cinema, Inc., Centertainment Development, LLC, and Muvico, LLC, dated as of July 22, 2024 (incorporated by reference from Exhibit 10.1 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on July 22, 2024).</a>
<a href="#">10.12</a>	<a href="#">Management Services Agreement, by and among Muvico, LLC, Centertainment Development, LLC, and American Multi-Cinema, Inc. (together with its applicable affiliates thereto), dated as of July 22, 2024 (incorporated by reference from Exhibit 10.2 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on July 22, 2024).</a>
<a href="#">10.13</a>	<a href="#">Intercompany License Agreement, by and among Muvico, LLC and American Multi-Cinema, Inc. (together with its applicable affiliates thereto), dated as of July 22, 2024 (incorporated by reference from Exhibit 10.3 to the Company's Current Report on Form 8-K (File No. 1-33892) filed on July 22, 2024).</a>
<a href="#">10.14</a>	<a href="#">Master Confirmation, dated as of December 6, 2024, by and between AMC Entertainment Holdings, Inc. and Goldman Sachs International (incorporated by reference from Exhibit 10.1 to AMC's Current Report on Form 8-K (File No. 1-33892) filed on December 6, 2024).</a>
<a href="#">10.15</a>	<a href="#">Master Confirmation, dated as of February 9, 2026, by and between AMC Entertainment Holdings, Inc. and Goldman Sachs International (incorporated by reference from Exhibit 10.1 to AMC's Current Report on Form 8-K (File No. 1-33892) filed on February 9, 2026).</a>

[Table of Contents](#)

<b>Exhibit Number</b>	<b>Description</b>
<a href="#">10.16</a>	<a href="#">AMC Entertainment Holdings, Inc. Non-Employee Director Compensation Program, Amended &amp; Restated, Effective January 1, 2025 (incorporated by reference from Exhibit 10.22 to AMC's Annual Report on Form 10-K (File No. 1-33892) filed on February 25, 2025).</a>
<a href="#">+10.17</a>	<a href="#">Employment Agreement, dated as of November 10, 2017, by and among AMC Entertainment Holdings, Inc. and Carla Chavarria (incorporated by reference from Exhibit 10.1 to AMC's Quarterly Report on Form 10-Q (File No. 1-33892) filed on (May 7, 2025).</a>
<a href="#">10.18</a>	<a href="#">Transaction Support Agreement, dated as of July 1, 2025, by and among AMC, Muvico and the Consenting Secured Parties (incorporated by reference from Exhibit 10.1 to AMC's Current Report on Form 8-K (File No. 1-33892) filed on July 1, 2025).</a>
<a href="#">*+10.19</a>	<a href="#">Employment Agreement, dated as of November 18, 2025, by and among AMC Entertainment Holdings, Inc. and Edwin Gladbach.</a>
<a href="#">*+10.20</a>	<a href="#">Senior Executive Services Agreement, dated as of November 30, 2016, by and among Odeon Cinemas Limited and Mark Way.</a>
<a href="#">*+10.21</a>	<a href="#">Employment Agreement, dated as of September 11, 2020, by and among AMC Entertainment Holdings, Inc. and Nikkole Denson-Randolph.</a>
<a href="#">19</a>	<a href="#">AMC Entertainment Holdings, Inc. Insider Trading Policy, revised as of February 23, 2023 (incorporated by reference to Exhibit 19 to AMC's Annual Report on Form 10-K (File No. 1-33892) filed on February 25, 2025).</a>
<a href="#">*21</a>	<a href="#">Subsidiaries of AMC Entertainment Holdings, Inc.</a>
<a href="#">*23.1</a>	<a href="#">Consent of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm.</a>
<a href="#">*31.1</a>	<a href="#">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Acts of 2002.</a>
<a href="#">*31.2</a>	<a href="#">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Acts of 2002.</a>
<a href="#">*32.1</a>	<a href="#">Section 906 Certifications of Adam M. Aron (Chief Executive Officer) and Sean D. Goodman (Chief Financial Officer) furnished in accordance with Securities Act Release 33-8212.</a>
<a href="#">97.1</a>	<a href="#">AMC Entertainment Holdings, Inc. Executive Compensation Clawback Policy, effective as of October 2, 2023 (incorporated by reference to Exhibit 97.1 to AMC's Annual Report on Form 10-K (File No. 1-33892) filed on February 25, 2025).</a>
<a href="#">**101.INS</a>	Inline XBRL Instance Document
<a href="#">**101.SCH</a>	Inline XBRL Taxonomy Extension Schema Document
<a href="#">**101.CAL</a>	Inline XBRL Taxonomy Extension Calculation Linkbase Document
<a href="#">**101.DEF</a>	Inline XBRL Taxonomy Extension Definition Linkbase Document
<a href="#">**101.LAB</a>	Inline XBRL Taxonomy Extension Label Linkbase Document
<a href="#">**101.PRE</a>	Inline XBRL Taxonomy Extension Presentation Linkbase Document



[Table of Contents](#)

<hr/> Marcus Glover	Director	February 23, 2026
/s/ SONIA JAIN		
<hr/> Sonia Jain	Director	February 23, 2026
/s/ SEAN D. GOODMAN		
<hr/> Sean D. Goodman	Executive Vice President, International Operations Chief Financial Officer and Treasurer (principal financial officer)	February 23, 2026
/s/ CHRIS A. COX		
<hr/> Chris A. Cox	Senior Vice President and Chief Accounting Officer (principal accounting officer)	February 23, 2026

## DESCRIPTION OF CAPITAL STOCK

The following description summarizes important terms of the capital stock of AMC Entertainment Holdings, Inc. (“AMC,” “we,” “us” or “our”). The summary does not purport to be complete and is qualified in its entirety by reference to the Delaware General Corporation Law (“DGCL”), our amended and restated certificate of incorporation (the “certificate of incorporation”) and our amended and restated bylaws (the “bylaws”). Our certificate of incorporation and bylaws have been filed as exhibits to our most recent Annual Report on Form 10-K.

Our authorized capital stock consists of 1,100,000,000 shares of common stock and 50,000,000 shares of preferred stock, par value \$0.01 per share. As of December 31, 2025, our Class A common stock was the only class of stock registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and there were no shares of preferred stock outstanding. Our common stock is listed on the New York Stock Exchange under the symbol “AMC.” The transfer agent and registrar for our common stock is Computershare Trust Company, N.A.

### Voting Rights

Holders of common stock are entitled to one vote per share. Our directors are elected by all of the common stockholders voting together as a single class.

Generally, all matters to be voted on by stockholders must be approved by a majority (or, in the case of election of directors, by a plurality) of our outstanding voting power. Except as otherwise required by the DGCL, our certificate of incorporation or voting rights granted to any subsequently issued preferred stock, the holders of outstanding shares of our common stock and our preferred stock entitled to vote thereon, if any, vote as one class with respect to all matters to be voted on by our stockholders. Under the DGCL, amendments to our certificate of incorporation that would alter or change the powers, preferences or special rights of the common stock so as to affect them adversely also must be approved by a majority of the votes entitled to be cast by the holders of the shares affected by the amendment, voting as a separate class.

### Conversion

The common stock is not convertible into any other shares of our capital stock.

No class of common stock may be subdivided or combined unless the other class of common stock concurrently is subdivided or combined in the same proportion and in the same manner.

### Dividends

Holders of common stock share ratably (based on the number of shares of common stock held) in any dividend declared by our board of directors (the “AMC Board”), subject to any preferential rights of any outstanding preferred stock.

### Other Rights

Upon liquidation, dissolution or winding up, after payment in full of the amounts required to be paid to holders of preferred stock, if any, all holders of common stock, regardless of class, will be entitled to share ratably in any assets available for distribution to holders of shares of common stock. No shares of any class of common stock are subject to redemption or have preemptive rights to purchase additional shares of common stock.

---

**Preferred Stock**

Our certificate of incorporation authorizes the AMC Board to issue from time to time up to an aggregate of 50,000,000 shares of preferred stock in one or more series without further stockholder approval. The AMC Board is authorized, without further stockholder approval, to establish one or more series of preferred stock and to determine, with respect to each such series, the designations, preferences, rights and any qualifications, limitations or restrictions of the shares of each such series thereof, including the dividend rights, dividend rates, conversion rights, voting rights, terms of redemption (including sinking fund provisions), redemption price or prices, liquidation preferences and the number of shares constituting any series or designations of such series. The issuance of our preferred stock could have the effect of decreasing the trading price of our common stock, restricting dividends on our capital stock, diluting the voting power of our common stock, impairing the liquidation rights of our capital stock, or delaying or preventing a change in control of AMC.

**Anti-Takeover Effects of Certain Provisions of Delaware Law, the Certificate of Incorporation and the Bylaws**

Certain provisions of our certificate of incorporation and bylaws may be considered to have an anti-takeover effect and may delay or prevent a tender offer or other corporate transaction that a stockholder might consider to be in its best interest, including those transactions that might result in payment of a premium over the market price for our shares. These provisions are designed to discourage certain types of transactions that may involve an actual or threatened change of control of AMC without prior approval of the AMC Board. These provisions are meant to encourage persons interested in acquiring control of AMC to first consult with the AMC Board to negotiate terms of a potential business combination or offer. For example, the certificate of incorporation and bylaws:

- provide for a classified board of directors, pursuant to which the AMC Board is divided into three classes whose members serve three-year staggered terms;
  - provide that the size of the AMC Board will be set by members of the AMC Board, and any vacancy on the AMC Board, including a vacancy resulting from an enlargement of the AMC Board, may be filled only by vote of a majority of the directors then in office;
  - do not permit stockholders to take action by written consent;
  - provide that, except as otherwise required by law, special meetings of stockholders can only be called by the AMC Board;
  - establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of stockholders, including proposed nominations of candidates for election to the AMC Board;
  - limit consideration by stockholders at annual meetings to only those proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the AMC Board or by a stockholder of record on the record date for the meeting who is entitled to vote at the meeting and who has delivered timely written notice in proper form to our secretary of the stockholder's intention to bring such business before the meeting;
  - authorize the issuance of "blank check" preferred stock that could be issued by the AMC Board to increase the number of outstanding shares or establish a stockholders rights plan making a takeover more difficult and expensive; and
  - do not permit cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates.
-

The certificate of incorporation expressly states that we have elected not to be governed by Section 203 of the DGCL, which prohibits a publicly held Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years after the time the stockholder became an interested stockholder, subject to certain exceptions, including if, prior to such time, the board of such corporation approved the business combination or the transaction which resulted in the stockholder becoming an interested stockholder. “Business combinations” include mergers, asset sales and other transactions resulting in a financial benefit to the “interested stockholder.” Subject to various exceptions, an “interested stockholder” is a person who, together with his or her affiliates and associates, owns, or within three years did own, 15% or more of the corporation’s outstanding voting stock. These restrictions generally prohibit or delay the accomplishment of mergers or other takeover or change-in-control attempts that are not approved by a company’s board. Although we have elected to opt out of the statute’s provisions, we could elect to be subject to Section 203 in the future.

The bylaws state that unless AMC consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of AMC, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of AMC to AMC or AMC’s stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL or the certificate of incorporation or bylaws, or (iv) any action asserting a claim against AMC governed by the internal affairs doctrine; provided, however, that this provision of the bylaws does not apply to any actions arising under the Securities Act of 1933, as amended, or the Exchange Act.

#### **Special Meeting of Stockholders**

Special meetings of our stockholders may be called only by a majority of our directors.

#### **No Actions by Written Consent**

Stockholder action can be taken only at an annual or special meeting of stockholders.

#### **Advance Notice Requirements for Stockholder Proposals and Director Nominations**

The bylaws provide that stockholders seeking to bring business before an annual meeting of stockholders, or to nominate candidates for election as directors at an annual meeting of stockholders, must provide timely notice thereof in writing. To be timely, a stockholder’s notice generally must be delivered to and received at our principal executive offices, not less than 90 days nor more than 120 days prior to the first anniversary of the preceding year’s annual meeting; *provided*, that in the event that the date of such meeting is advanced more than 30 days prior to, or delayed by more than 70 days after, the anniversary of the preceding year’s annual meeting of our stockholders, a stockholder’s notice to be timely must be so delivered not earlier than the close of business on the 120th day prior to such meeting and not later than the close of business on the later of the 90th day prior to such meeting or the 10th day following the day on which public announcement of the date of such meeting is first made. The bylaws also specify certain requirements as to the form and content of a stockholder’s notice. These provisions may preclude stockholders from bringing matters before an annual meeting of stockholders or from making nominations for directors at an annual meeting of stockholders.

#### **Authorized but Unissued Shares**

The authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval. These additional shares may be used for a variety of corporate purposes, including future public offerings to raise additional capital, corporate acquisitions, employee benefit plans and debt for equity exchanges. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult or discourage an attempt to obtain control of AMC by means of a proxy contest, tender offer, merger or otherwise.

---

**Amendments to Certificate of Incorporation or Bylaws**

The certificate of incorporation provides that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend the certificate of incorporation. In addition, under the DGCL, an amendment to the certificate of incorporation that would alter or change the powers, preferences or special rights of the common stock so as to affect them adversely also must be approved by a majority of the votes entitled to be cast by the holders of the shares affected by the amendment, voting as a separate class. Subject to the bylaws, the AMC Board may from time to time make, amend, supplement or repeal the bylaws by vote of a majority of the AMC Board.

**Limitation of Liability and Indemnification of Directors and Officers**

As permitted by the DGCL, we have adopted provisions in the certificate of incorporation that limit or eliminate the personal liability of our directors and officers for monetary damages for a breach of their fiduciary duty of care as a director or officer. The duty of care generally requires that, when acting on behalf of the corporation, directors and officers exercise an informed business judgment based on all material information reasonably available to them. Consequently, a director or officer will not be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director or officer, except for liability for:

- any breach of the person's duty of loyalty to us or our stockholders;
- any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
- any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or
- any transaction from which the person derived an improper personal benefit.

These limitations of liability do not generally affect the availability of equitable remedies such as injunctive relief or rescission.

As permitted by the DGCL, the certificate of incorporation and bylaws provide that:

- we will indemnify our current and former directors and officers and anyone who is or was serving at our request as the director or officer of, or legal representative in, another entity, and may indemnify our current or former employees and other agents, to the fullest extent permitted by the DGCL, subject to limited exceptions; and
- we may purchase and maintain insurance on behalf of our current or former directors, officers, employees or agents against any liability asserted against them and incurred by them in any such capacity, or arising out of their status as such.

We currently maintain liability insurance for our directors and officers.

The certificate of incorporation requires us to advance expenses to our directors and officers in connection with a legal proceeding, subject to receiving an undertaking from such director or officer to repay advanced amounts if it is determined he or she is not entitled to indemnification. The bylaws provide that we may advance expenses to our employees and other agents, upon such terms and conditions, if any, as we deem appropriate.

---

**AMC ENTERTAINMENT HOLDINGS, INC.**  
**ANNUAL INCENTIVE COMPENSATION PROGRAM**  
**CONTINUING STRUCTURE**  
**(As Amended & Restated by the Compensation Committee February 19, 2026)**

AMC Entertainment Holdings, Inc. (along with all of its subsidiaries, the “Corporation”) shall have an Annual Incentive Compensation Program (“AIP”) structured as set forth below. The AIP shall automatically be continued for each of the Corporation’s fiscal years until terminated or revised by the Compensation Committee.

**1. Structure:** Each participant shall have an incentive at target based upon a percentage of his or her base salary (the “Incentive at Target”). The Incentive at Target shall be allocated between (i) a component paid out based upon attainment of the Company Performance Target (defined below) during the applicable fiscal year (the “Company Component”) and (ii) a component paid out based on the participant’s achievement of individual Key Performance Metrics with supervisory discretion during the applicable fiscal year (the “Individual Component”).

**2. Participation:**

**a. Named Executive Officers:** The Corporation’s Named Executive Officers (as determined pursuant to SEC Rules), shall participate in the AIP at the following Incentive at Target levels and allocations:

Position	Target (% of Salary)	Mix Company/Individual
President & CEO	200%	100/0
EVP, International Operations, Chief Financial Officer & Treasurer	100%	100/0
Other Executive Vice Presidents	75%	80/20
All Other Named Executive Officers	65%	80/20

**b. Other Employees:** All other participants along with their Incentive at Target level and allocation shall be determined at the discretion of the CEO in consultation with the SVP & Chief Human Resources Officer.

**3. Payout:** Unless otherwise provided in a written agreement with the employee, an employee must remain employed on the last day of the applicable fiscal year to be eligible for any payout under the AIP and employees hired after the beginning of the applicable fiscal year shall have their payouts prorated. Payments for each fiscal year shall be made to employees during the 2-½ month period immediately following the close of such fiscal year. All payments shall be made in a manner that either complies with or is exempt from the requirements of Section 409A of the Internal Revenue Code and the regulations and guidance issued thereunder and the AIP shall be administered and construed in conformity with such requirements.

**a. Company Component:** The Company Component payout shall be determined based upon the attainment as certified by the Compensation Committee of the Company Performance Target.

**i. Company Performance Target:** The Company Performance Target shall be the Adjusted EBITDA (as defined in the Corporation’s public financial reporting) provided for in the Corporation’s annual financial performance plan for the applicable fiscal year as approved by the Board of Directors (the “Financial Plan”). Supplemental or alternative Company performance metrics may be applied to employees related to specific operational areas or regions under their supervision.

- ii. **Payout Scale:** The Company Component payout shall be on a scale as set forth on Appendix A attached hereto (payout for performance that falls between two stated levels shall be determined by linear interpolation).
  - b. **Individual Component:** The Individual Component payout shall be determined as follows:
    - i. **Named Executive Officers:** The payout shall be determined by the Compensation Committee in consultation with the CEO.
    - ii. **Other Participants:** The payout shall be determined by each participant's supervisor subject to parameters established by the CEO in consultation with the SVP & Chief Human Resources Officer.
-

**PAYOUT SCALE**

<b>% Attained (Actual vs Target)</b>	<b>Payout</b>
80%	50%
81%	54%
82%	58%
83%	62%
84%	66%
85%	70%
86%	74%
87%	78%
88%	82%
89%	86%
90%	90%
91%	91%
92%	92%
93%	93%
94%	94%
95%	95%
96%	96%
97%	97%
98%	98%
99%	99%
100%	100%
101%	105%
102%	110%
103%	115%
104%	120%
105%	125%
106%	130%
107%	135%
108%	140%
109%	145%
110%	150%
111%	155%
112%	160%
113%	165%
114%	170%
115%	175%
116%	180%
117%	185%
118%	190%
119%	195%
120% (or higher)	200%



## EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into this **18th day of November, 2025**, by and between AMC Entertainment Holdings, Inc., a Delaware corporation (the “Company”), and **Edwin “Eddie” Gladbach** (the “Officer”).

### RECITALS

THE PARTIES ENTER THIS AGREEMENT on the basis of the following facts, understandings and intentions:

- A. The Company desires to obtain the services of the Officer on the terms and conditions set forth in this Agreement.
- B. This Agreement shall govern the employment relationship between the Officer and the Company and supersedes and negates all previous agreements with respect to such relationship.
- C. The Officer desires to be employed by the Company on the terms and conditions set forth in this Agreement.

### AGREEMENT

NOW, THEREFORE, in consideration of the above recitals incorporated herein and the mutual covenants and promises contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby expressly acknowledged, the parties agree as follows:

#### 1. Retention and Duties.

- 1.1 **Retention.** The Company does hereby hire, engage and employ the Officer beginning on the date first set forth above (the “Effective Date”), and concluding on the last day of the Period of Employment (as such term is defined in Section 2) on the terms and conditions expressly set forth in this Agreement. The Officer does hereby accept and agree to such hiring, engagement and employment, on the terms and conditions expressly set forth in this Agreement. Officer’s employer of record will be Company’s wholly owned subsidiary, American Multi-Cinema, Inc.
- 1.2 **Duties.** During the Period of Employment, the Officer shall serve the Company as its **Senior Vice President, General Counsel & Secretary** and shall have the powers, authorities, duties and obligations of management usually vested in such position of a company of a similar size and similar nature as the Company, and such other powers, authorities, duties and obligations commensurate with such position as the Company’s Board of Directors (the “Board”) or the Company’s Chief Executive Officer may assign from time to time, all subject to the directives of the Board and the corporate policies of the Company as they are in effect from time to time throughout the Period of Employment (including, without limitation, the Company’s business conduct and ethics policies, as they may change from time to time).
- 1.3 **No Other Employment; Minimum Time Commitment.** During the Period of Employment, the Officer shall (i) devote substantially all of the Officer’s business time, energy and skill to the performance of the Officer’s duties for the Company, (ii) perform such duties in a faithful, effective and efficient manner to the best of the Officer’s abilities,

and (iii) hold no other employment. The Officer's service on the boards of directors (or similar body) of other for-profit business entities is subject to the approval of the Board or the Company's Chief Executive Officer. The Company shall have the right to require the Officer to resign from any board or similar body (including, without limitation, any association, corporate, civic or charitable board or similar body) on which Officer may then serve if the Board or the Company's Chief Executive Officer reasonably determines that the Officer's service on such board or body interferes with the effective discharge of the Officer's duties and responsibilities to the Company or that any business related to such service is then in competition with any business of the Company or any of its Affiliates (as such term is defined in Section 5.5), successors or assigns.

**1.4 No Breach of Contract.** The Officer hereby represents to the Company that: (i) the execution and delivery of this Agreement by the Officer and the Company and the performance by the Officer of the Officer's duties hereunder do not and shall not constitute a breach of, conflict with, or otherwise contravene or cause a default under, the terms of any other agreement or policy to which the Officer is a party or otherwise bound or any judgment, order or decree to which the Officer is subject; (ii) the Officer has no information (including, without limitation, confidential information and trade secrets) relating to any other Person (as such term is defined in Section 5.5) which would prevent, or be violated by, the Officer entering into this Agreement or carrying out their duties hereunder; (iii) the Officer is not bound by any employment, consulting, non-compete, confidentiality, trade secret or similar agreement with any other Person; and (iv) the Officer understands the Company will rely upon the accuracy and truth of the representations and warranties of the Officer set forth herein and the Officer consents to such reliance.

**1.5 Location.** The Officer's principal place of employment shall be in Leawood, Kansas. The Officer agrees that they will be regularly present at that office. The Officer acknowledges that they will be required to travel from time to time in the course of performing their duties for the Company.

**2. Period of Employment.** The "Period of Employment" shall be a period of two (2) years commencing on the Effective Date and ending at the close of business on the second anniversary of the Effective Date (the "Termination Date"); provided, however, that this Agreement shall be automatically renewed, and the Period of Employment shall be automatically extended, for one (1) additional year on the Termination Date and each anniversary of the Termination Date thereafter. The term "Period of Employment" shall include any extension thereof pursuant to the preceding sentence. Notwithstanding the foregoing, the Period of Employment is subject to earlier termination as provided below in this Agreement.

**3. Compensation.**

**3.1 Base Salary.** During the Period of Employment, the Company shall pay the Officer a base salary (the "Base Salary"), which shall be paid in accordance with the Company's regular payroll practices in effect from time to time, but not less frequently than monthly. The Officer's Base Salary shall be at an annualized rate of **four hundred fifty thousand dollars (\$450,000)**. The Board (or a committee thereof) will review the Officer's rate of Base Salary on an annual basis and may, in its sole discretion, increase (but not decrease) the rate then in effect.

**3.2 Incentive Bonus.** The Officer shall be eligible to receive an incentive bonus for each fiscal year of the Company that occurs during the Period of Employment ("Incentive Bonus");

provided, that the Officer must be employed by the Company at the end of the fiscal year in order to be eligible for an Incentive Bonus with respect to that fiscal year. If the Officer is not so employed at such time, the Officer shall not be considered to have “earned” any Incentive Bonus with respect to the fiscal year in question. Any Incentive Bonus shall be paid to the Officer in the immediately following fiscal year at the same time that the Company pays its annual bonuses to officers generally. The Officer’s target Incentive Bonus amount for a particular fiscal year of the Company shall be determined by the Company in its sole discretion, based on performance objectives (which may include corporate, business unit or division, financial, strategic, individual or other objectives) established with respect to that particular fiscal year by Company.

### 3.3 Long Term Incentives.

- (a) The Officer will be considered for long term incentive awards on terms and conditions established by the Board.
- (b) Upon the occurrence of a Change in Control, the vesting of all outstanding long term incentive awards granted the Officer shall be accelerated to occur immediately prior to the occurrence of such Change in Control event. For purposes of accelerated vesting upon a Change in Control, any outstanding awards with performance-based vesting conditions, shall be deemed to have attained the applicable Performance Goals at the higher of (i) actual attainment at the time of the Change in Control event or (ii) 100% of the target.
- (c) For purposes of this Section 3.3, the following definitions shall apply:
  - (i) “*Beneficial Owner*” shall have the meaning ascribed to such term in Rule 13d-3 under the Securities Exchange Act of 1934, as amended.
  - (ii) “*Change in Control*” shall mean the occurrence of one of the following events:
    1. Any Person becomes the Beneficial Owner, directly or indirectly, of more than thirty-five percent (35%) of the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of its directors (the “*Outstanding Company Voting Securities*”) including by way of merger, consolidation or otherwise; *provided, however*, that for purposes of this definition, the following acquisition shall not constitute a Change in Control: any acquisition by the Company or any of its Subsidiaries of Outstanding Company Voting Securities, including any employee benefit plan or related trust sponsored or maintained by the Company or any of its Subsidiaries.
    2. The election or appointment to the Board of the lesser of (i) three directors or (ii) a number of directors equal to or greater than thirty-five (35%) of the Board (based upon then-current Board size) who (x) are not nominees approved by at least a majority of the Board, or (y) are appointed or elected in connection with an actual or threatened election contest or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board.

3. Consummation of a reorganization, merger, or consolidation to which the Company is a party or a sale or other disposition of all or substantially all of the assets of the Company (a "*Business Combination*"), unless, following such Business Combination: (i) any individuals and entities who were the Beneficial Owners of Outstanding Company Voting Securities immediately prior to such Business Combination are the Beneficial Owners, directly or indirectly, of more than fifty percent (50%) of the combined voting power of the outstanding voting securities entitled to vote generally in the election of directors (or election of members of a comparable governing body) of the entity resulting from the Business Combination (the "*Successor Entity*") in substantially the same proportions as their ownership immediately prior to such Business Combination; (ii) no Person (excluding any employee benefit plan or related trust of the Company, such Successor Entity, or any of their Subsidiaries) is the Beneficial Owner, directly or indirectly, of more than thirty-five percent (35%) of the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors (or comparable governing body) of the Successor Entity, except to the extent that such ownership existed prior to the Business Combination; and (iii) at least sixty-five percent (65%) of the members of the board of directors (or comparable governing body) of the Successor Entity were members of the Board of the Company at the time of the execution of the initial agreement or of the action of the Board providing for such Business Combination.
4. Notwithstanding the foregoing, to the extent necessary to comply with Section 409A of the Code with respect to the payment of "nonqualified deferred compensation", "Change of Control" shall be limited to a "change in control event" as defined under Section 409A of the Code.

(iii) "*Person*" shall have the meaning ascribed to such term in Section 3(a)(9) of the Securities Exchange Act of 1934, as amended, and used in Sections 13(d) and 14(d) thereof, including a "group" as defined in Section 13(d) thereof or any other group acting in concert to achieve actions or outcomes that would be covered by the foregoing provisions if undertaken by an individual acting alone.

- 3.4 Clawback** Notwithstanding any other provisions in this Agreement to the contrary, any incentive-based compensation or any other compensation paid to the Officer pursuant to this Agreement or any other agreement or arrangement with the Company which is subject to recovery under any law, government regulation or stock exchange listing requirement, will be subject to such deductions and clawback as may be required to be made pursuant to such law, government regulation or stock exchange listing requirement (or any policy adopted by the Company (whether in existence as of the Effective Date or later adopted) pursuant to any such law, government regulation or stock exchange listing requirement or otherwise).

4. **Benefits.**

4.1 **Retirement, Welfare and Fringe Benefits.** During the Period of Employment, the Officer

shall be entitled to participate in all retirement and welfare benefit plans and programs, and fringe benefit plans and programs, made available by the Company to the Company's executive officers generally, in accordance with the eligibility and participation provisions of such plans and as such plans or programs may be in effect from time to time.

4.2 **Reimbursement of Business Expenses.** The Officer is authorized to incur reasonable expenses in carrying out the Officer's duties for the Company under this Agreement and shall be entitled to reimbursement for all reasonable business expenses that the Officer incurs during the Period of Employment in connection with carrying out the Officer's duties for the Company, subject to the Company's expense reimbursement policies and any pre-approval policies in effect from time to time.

4.3 **Vacation and Other Leave.** During the Period of Employment, the Officer's annual rate of vacation accrual shall conform with Company's vacation policies in effect from time to time. The Officer shall also be entitled to all other holiday and leave pay generally available to other Officers of the Company.

5. **Termination.**

5.1 **Termination by the Company.** The Officer's employment by the Company, and the Period of Employment, may be terminated at any time by the Company: (i) with Cause (as such term is defined in Section 5.5), or (ii) without Cause, or (iii) in the event of the Officer's death, or (iv) in the event that the Board determines in good faith that the Officer has a Disability (as such term is defined in Section 5.5).

5.2 **Termination by the Officer.** The Officer's employment by the Company, and the Period of Employment, may be terminated by the Officer with no less than ninety (90) days' advance written notice to the Company (such notice to be delivered in accordance with Section 16); provided, however, that in the case of a termination with Good Reason, the Officer may provide immediate written notice of termination once the applicable cure period (as contemplated by the definition of Good Reason) has lapsed if the Company has not reasonably cured the circumstances that gave rise to the basis for the termination with Good Reason.

5.3 **Benefits Upon Termination.** If the Officer's employment by the Company is terminated during the Period of Employment for any reason by the Company or by the Officer (in any case, the date that the Officer's employment by the Company terminates is referred to as the "Severance Date"), the Company shall have no further obligation to make or provide to the Officer, and the Officer shall have no further right to receive or obtain from the Company, any payments or benefits except as follows:

(a) The Company shall pay the Officer (or, in the event of Officer's death, the Officer's estate) any Accrued Obligations (as such term is defined in Section 5.5);

(b) If, during the Period of Employment, the Officer's employment with the Company terminates as a result of an Involuntary Termination, the Company shall pay the Officer (in addition to the Accrued Obligations), subject to tax withholding and other authorized deductions, an amount equal to one (1) times the Officer's annualized Base Salary. Such

amount is referred to hereinafter as the “Severance Benefit.” Subject to Section 5.8(a), the Company shall pay the Severance Benefit to the Officer in substantially equal installments in accordance with the Company’s standard payroll practices over a period of twelve (12) consecutive months, with the first installment payable on the last day of the month following the month in which the Officer’s Separation from Service (as such term is defined in Section 5.5) occurs. (For purposes of clarity, each such installment shall equal the applicable fraction of the aggregate Severance Benefit. For example, if such installments were to be made on a monthly basis, each installment would equal 1/12<sup>th</sup> of the Severance Benefit.)

(c) Notwithstanding the foregoing provisions of this Section 5.3, if the Officer breaches their obligations under Section 6 or under any other agreement that imposes restrictions with respect to the Officer’s activities at any time, from and after the date of such breach and not in any way in limitation of any right or remedy otherwise available to the Company, the Officer will no longer be entitled to, and the Company will no longer be obligated to pay, any remaining unpaid portion of the Severance Benefit; provided that, if the Officer provides the release contemplated by Section 5.4, in no event shall the Officer be entitled to a Severance Benefit payment of less than \$5,000, which amount the parties agree is good and adequate consideration, standing alone, for the Officer’s release contemplated by Section 5.4.

(d) The foregoing provisions of this Section 5.3 shall not affect: (i) the Officer’s receipt of any benefits otherwise due terminated employees under group insurance coverage consistent with the terms of an applicable Company welfare benefit plan; (ii) the Officer’s rights to continued health coverage under COBRA; (iii) the Officer’s receipt of benefits otherwise due in accordance with the terms of the Company’s 401(k) plan (if any); or (iv) the Officer’s rights (if any) to stock options or other equity-based awards or incentive previously granted, which shall be governed by the terms of the applicable equity incentive plan and award documents.

#### **5.4 Release; Exclusive Remedy.**

(a) This Section 5.4 shall apply notwithstanding anything else contained in this Agreement. As a condition precedent to payment of the Severance Benefit, the Officer shall, prior to the last day of the month following the month in which Executive’s Separation from Service (as such term is defined in Section 5.5) occurs, provide the Company and its Affiliates with a valid, executed general release agreement in a form acceptable to the Company (which form shall be substantially in the same form as that attached hereto as Exhibit A), and such release agreement shall have not been revoked or remain revocable by the Officer pursuant to any revocation rights afforded by applicable law.

(b) The Officer agrees that the payments and benefits contemplated by Section 5.3 shall constitute the exclusive and sole remedy for any termination of the Officer’s employment and the Officer covenants not to assert or pursue any other remedies, at law or in equity, with respect to any termination of employment. The Officer agrees to resign, on the Severance Date, as an officer and director of the Company and any Affiliate of the Company, and as a fiduciary of any benefit plan of the Company or any Affiliate of the Company, and to promptly execute and provide to the Company any further documentation, as requested by the Company, to confirm such resignation.

**5.5 Certain Defined Terms.**

- (a) As used herein, “Accrued Obligations” means:
- (i) any Base Salary that had accrued but had not been paid on or before the Severance Date;
  - (ii) any Incentive Bonus for a completed fiscal year that has not yet been paid, to the extent the Officer is eligible for any such Incentive Bonus for such fiscal year; and
  - (iii) any reimbursement due to the Officer pursuant to Section 4.2 for expenses reasonably incurred by the Officer on or before the Severance Date and documented and pre-approved, to the extent applicable, in accordance with the Company’s expense reimbursement policies in effect at the applicable time.
- (b) As used herein, “Affiliate” of the Company means a Person that directly or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, the Company. As used in this definition, the term “control,” including the correlative terms “controlling,” “controlled by” and “under common control with,” means the possession, directly or indirectly, of the power to direct or cause the direction of management or policies (whether through ownership of securities or any partnership or other ownership interest, by contract or otherwise) of a Person.
- (c) As used herein, “Cause” shall mean, as reasonably determined by the Board (excluding the Officer, if they are then a member of the Board) or Company’s Chief Executive Officer based on the information then known to it, that one or more of the following has occurred:
- (i) the Officer has committed a felony (under the laws of the United States or any relevant state, or a similar crime or offense under the applicable laws of any relevant foreign jurisdiction);
  - (ii) the Officer has engaged in acts of fraud, dishonesty, gross negligence or other misconduct including abuse of controlled substances, that is injurious to the Company, its Affiliates or any of their customers, clients or employees;
  - (iii) the Officer willfully fails to perform or uphold their duties under this Agreement and/or willfully fails to comply with reasonable directives of the Board or Company’s Chief Executive Officer, in either case, that is not remedied by the Officer within fifteen (15) days after written notice thereof has been delivered to the Officer; or
  - (iv) any breach by the Officer of any provision of Section 6, or any material breach by the Officer of any other contract they are a party to with the Company or any of its Affiliates including the code of ethics or another material written policy.
- (d) As used herein, “Good Reason” shall mean a termination of the Officer’s employment by means of resignation by the Officer after the occurrence (without the Officer’s consent) of any one or more of the following conditions:

- (i) a material diminution in the Officer's rate of Base Salary;
- (ii) a material diminution in the Officer's authority, duties, or responsibilities;
- (iii) a material change in the geographic location of the Officer's principal office with the Company (for this purpose, in no event shall a relocation of such office to a new location that is not more than fifty (50) miles from the current location of the Company's executive offices constitute a "material change"); or
- (iv) a material breach by the Company of this Agreement;

provided, however, that any such condition or conditions, as applicable, shall not constitute grounds for a termination with Good Reason unless (x) the Officer provides written notice to the Company of the condition claimed to constitute grounds for a termination with Good Reason within thirty (30) days after the initial existence of such condition(s) (such notice to be delivered in accordance with Section 16), and (y) the Company fails to remedy such condition(s) within thirty (30) days of receiving such written notice thereof; and (z) the termination of the Officer's employment with the Company shall not constitute a termination with Good Reason unless such termination occurs not more than one hundred and twenty (120) days following the initial existence of the condition claimed to constitute grounds for a termination with Good Reason.

(e) As used herein, "Disability" shall mean a physical or mental impairment which, as reasonably determined by the Board, renders the Officer unable to perform the essential functions of their employment with the Company, even with reasonable accommodation that does not impose an undue hardship on the Company, for more than 90 days in any 180-day period, unless a longer period is required by federal or state law, in which case that longer period would apply.

(f) As used herein, "Involuntary Termination" shall mean (i) a termination of the Officer's employment by the Company without Cause (and other than due to Officer's death or in connection with a good faith determination by the Board that the Officer has a Disability), or (ii) a termination with Good Reason.

(g) As used herein, the term "Person" shall be construed broadly and shall include, without limitation, an individual, a partnership, a limited liability company, a corporation, an association, a joint stock company, a trust, a joint venture, an unincorporated organization and a governmental entity or any department, agency or political subdivision thereof.

(h) As used herein, a "Separation from Service" occurs when the Officer dies, retires, or otherwise has a termination of employment with the Company that constitutes a "separation from service" within the meaning of Treasury Regulation Section 1.409A-1(h)(1), without regard to the optional alternative definitions available thereunder.

**5.6 Notice of Termination.** Any termination of the Officer's employment under this Agreement shall be communicated by written notice of termination from the terminating party to the other party. This notice of termination must be delivered in accordance with Section 16 and must indicate the specific provision(s) of this Agreement relied upon in effecting the termination.

**5.7 Limitation on Benefits.**

(a) To the extent that any payment, benefit or distribution of any type to or for the benefit of the Officer by the Company or any of its Affiliates, whether paid or payable, provided or to be provided, or distributed or distributable pursuant to the terms of this Agreement or otherwise (including, without limitation, any accelerated vesting of stock options or other equity-based awards or incentives) (collectively, the “Total Payments”) would be subject to the excise tax imposed under Section 4999 of the Internal Revenue Code of 1986, as amended (the “Code”), then the Company shall submit for the vote of the stockholders of the Company (the “Stockholders”) the payments to the Officer in a manner that complies with the requirements of Section 280G(b)(5)(B) of the Code and the Treasury Regulations promulgated thereunder. It shall be a prerequisite to the Company’s obligations under this Section 5.7(a) that the Officer shall have executed a valid waiver in a form reasonably satisfactory to the Company and sufficient to enable the Stockholders’ approval to have the effect that no payments to the Officer would be subject to the excise tax under Section 4999 of the Code. If the exemption described in Section 280G(b)(5)(B) of the Code and the Treasury Regulations promulgated thereunder does not apply, then the procedures set forth in Section 5.7(b) and Section 5.7(c) hereof shall apply.

(b) Notwithstanding anything contained in this Agreement to the contrary, to the extent that the Total Payments would be subject to Section 4999 of the Code, then the Total Payments shall be reduced (but not below zero) so that the maximum amount of the Total Payments (after reduction) shall be one dollar (\$1.00) less than the amount which would cause the Total Payments to be subject to the excise tax imposed by Section 4999 of the Code. Unless the Officer shall have given prior written notice to the Company to effectuate a reduction in the Total Payments that complies with the requirements of Section 409A of the Code to avoid the imputation of any tax, penalty or interest thereunder, the Company shall reduce or eliminate the Total Payments by first reducing or eliminating any cash severance benefits (with the payments to be made furthest in the future being reduced first), then by reducing or eliminating any accelerated vesting of stock options or similar awards, then by reducing or eliminating any other remaining Total Payments. The preceding provisions of this Section 5.7(b) shall take precedence over the provisions of any other plan, arrangement or agreement governing the Officer’s rights and entitlements to any benefits or compensation.

(c) Any determination that Total Payments to the Officer must be reduced or eliminated in accordance with Section 5.7(b) and the assumptions to be utilized in arriving at such determination, shall be made by the Board in the exercise of its reasonable, good faith discretion based upon the advice of such professional advisors it may deem appropriate in the circumstances. As a result of the uncertainty in the application of Section 4999 of the Code at the time of the initial determination by the Board hereunder, it is possible that Total Payments to the Officer which will not have been made by the Company should have been made (“Underpayment”). If an Underpayment has occurred, the amount of any such Underpayment shall be promptly paid by the Company to or for the benefit of the Officer. In the event that any Total Payment made to the Officer shall be determined to otherwise result in the imposition of any tax under Section 4999 of the Code, then the Officer shall promptly repay to the Company the amount of any such Underpayment together with interest on such amount (at the same rate as is applied to determine the present value of payments under Section 280G of the Code or any successor thereto), from the date the reimbursable payment was received by the Officer to the date the same is repaid to the Company.

**5.8 Section 409A.**

(a) If the Officer is a “specified employee” within the meaning of Treasury Regulation Section 1.409A-1(i) as of the date of the Officer’s Separation from Service and the Severance Benefit or any other amount payable under this Agreement constitutes deferred compensation within the meaning of Section 409A of the Code, the Officer shall not be entitled to such Severance Benefit or other amount until the earlier of (i) the date which is six (6) months after the Officer’s Separation from Service for any reason other than death, or (ii) the date of the Officer’s death. The provisions of this paragraph shall apply only if, and to the extent, required to avoid the imputation of any tax, penalty or interest pursuant to Section 409A of the Code after taking into account all applicable exemptions available thereunder. Any amounts otherwise payable to the Officer upon or in the six (6) month period following the Officer’s Separation from Service that are not so paid by reason of this Section 5.8(a) shall be paid (without interest) as soon as practicable (and in all events within thirty (30) days) after the date that is six (6) months after the Officer’s Separation from Service (or, if earlier, as soon as practicable, and in all events within thirty (30) days, after the date of the Officer’s death).

(b) It is intended that any amounts payable under this Agreement and the Company’s and the Officer’s exercise of authority or discretion hereunder shall comply with and avoid the imputation of any tax, penalty or interest under Section 409A of the Code. This Agreement shall be construed and interpreted consistent with that intent. Nothing contained herein is intended to provide a guarantee of tax treatment to the Officer. For purposes of Section 409A of the Code, the Officer’s right to receive installment payments pursuant to Section 5.3(b) shall be treated as a right to receive a series of separate and distinct payments.

**6. Protective Covenants.**

**6.1 Confidential Information; Inventions.**

(a) The Officer shall not disclose or use at any time, either during the Period of Employment or thereafter, any confidential information (as defined below) of which the Officer is or becomes aware, whether or not such information is developed by the Officer, except to the extent that such disclosure or use is directly related to and required by the Officer’s performance in good faith of duties for the Company. The Officer will take all appropriate steps to safeguard confidential information in their possession and to protect it against disclosure, misuse, espionage, loss and theft. The Officer shall deliver to the Company at the termination of the Period of Employment, or at any time the Company may request, all memoranda, notes, plans, records, reports, computer tapes and software and other documents and data (and copies thereof) relating to the confidential information or the Work Product (as hereinafter defined) of the business of the Company or any of its Affiliates which the Officer may then possess or have under their control. Notwithstanding the foregoing, the Officer may truthfully respond to a lawful and valid subpoena or other legal process, but shall give the Company the earliest possible notice thereof, shall, as much in advance of the return date as possible, make available to the Company and its counsel the documents and other information sought, and shall assist the Company and such counsel in resisting or otherwise responding to such process.

(b) As used in this Agreement, the term “Confidential Information” means information that is not generally known to the public and that is used, developed or obtained

by the Company or its Affiliates in connection with their respective businesses, including, but not limited to, information, observations and data obtained by the Officer while employed by the Company or any predecessors thereof (including those obtained prior to the Effective Date) concerning (i) the business or affairs of the Company or its Affiliates (or such predecessors), (ii) products or services, (iii) fees, costs, compensation and pricing structures, (iv) designs, (v) analyses, (vi) drawings, photographs and reports, (vii) computer software, including operating systems, applications and program listings, (viii) flow charts, manuals and documentation, (ix) data bases, (x) accounting and business methods, (xi) inventions, devices, new developments, methods and processes, whether patentable or unpatentable and whether or not reduced to practice, (xii) customers and clients and customer or client lists, (xiii) other copyrightable works, (xiv) all production methods, processes, technology and trade secrets, and (xv) all similar and related information in whatever form. Confidential Information will not include any information that has been published (other than a disclosure by the Officer in breach of this Agreement) in a form generally available to the public prior to the date the Officer proposes to disclose or use such information. Confidential Information will not be deemed to have been published merely because individual portions of the information have been separately published, but only if all material features comprising such information have been published in combination.

(c) As used in this Agreement, the term “Work Product” means all inventions, innovations, improvements, technical information, systems, software developments, methods, designs, analyses, drawings, reports, service marks, trademarks, trade names, logos and all similar or related information (whether patentable or unpatentable, copyrightable, registerable as a trademark, reduced to writing, or otherwise) which relates to the Company’s or any of its Affiliates’ actual or anticipated business, research and development or existing or future products or services and which are conceived, developed or made by the Officer (whether or not during usual business hours, whether or not by the use of the facilities of the Company or any of its Affiliates, and whether or not alone or in conjunction with any other person) while employed by the Company (including those conceived, developed or made prior to the Effective Date) together with all patent applications, letters patent, trademark, trade name and service mark applications or registrations, copyrights and reissues thereof that may be granted for or upon any of the foregoing. All Work Product that the Officer may have discovered, invented or originated during Officer’s employment by the Company or any of its Affiliates prior to the Effective Date, that Officer may discover, invent or originate during the Period of Employment or at any time in the period of twelve (12) months after the Severance Date, shall be the exclusive property of the Company and its Affiliates, as applicable, and Officer hereby assigns all of Officer’s right, title and interest in and to such Work Product to the Company or its applicable Affiliate, including all intellectual property rights therein. Officer shall promptly disclose all Work Product to the Company, shall execute at the request of the Company any assignments or other documents the Company may deem necessary to protect or perfect its (or any of its Affiliates’, as applicable) rights therein, and shall assist the Company (or any of its Affiliates, as applicable), at the Company’s expense, in obtaining, defending and enforcing the Company’s (or any of its Affiliates’, as applicable) rights therein. The Officer hereby appoints the Company as their attorney-in-fact to execute on the Officer’s behalf any assignments or other documents deemed necessary by the Company to protect or perfect the Company’s (and any of its Affiliates’, as applicable) rights to any Work Product.

- 6.2 Restriction on Competition.** The Officer agrees that if the Officer were to become employed by, or substantially involved in, the business of a competitor of the Company or any of its Affiliates during the twelve (12) months following the Severance Date, it would be very difficult for the Officer not to rely on or use the Company's and its Affiliates' trade secrets and confidential information. Thus, to avoid the inevitable disclosure of the Company's and its Affiliates' trade secrets and confidential information, and to protect such trade secrets and confidential information and the Company's and its Affiliates' relationships and goodwill with customers, during the Period of Employment and for a period of twelve (12) months after the Severance Date, the Officer will not directly or indirectly through any other Person engage in, enter the employ of, render any services to, have any ownership interest in, nor participate in the financing, operation, management or control of, any Competing Business. For purposes of this Agreement, the phrase "directly or indirectly through any other Person engage in" shall include, without limitation, any direct or indirect ownership or profit participation interest in such enterprise, whether as an owner, stockholder, member, partner, joint venturer or otherwise, and shall include any direct or indirect participation in such enterprise as an employee, consultant, director, officer, licensor of technology or otherwise. For purposes of this Agreement, "Competing Business" means a Person anywhere in the continental United States or elsewhere in the world where the Company or any of its Affiliates engage in business, or reasonably anticipate engaging in business, on the Severance Date (the "Restricted Area") that at any time during the Period of Employment has competed, or at any time during the twelve (12) month period following the Severance Date competes, with the Company or any of its Affiliates in any of its or their businesses, including, without limitation, theatrical exhibition, digital cinema, internet ticketing and virtual box office for theatrical exhibitions, IMAX or other three dimensional screened entertainment, pre-show content, cinema or lobby advertising products, meeting and event services or special in-theater events. Nothing herein shall prohibit the Officer from (i) being a passive owner of not more than 2% of the outstanding stock of any class of a corporation that is publicly traded, so long as the Officer has no active participation in the business of such corporation, (ii) providing services to a Person otherwise engaged in a Competing Business, provided the Officer provides no services to any business operated, managed or controlled by such Person that causes such Person to constitute a Competing Business, or (iii) providing services to a Person the business or businesses of which are unrelated to theatrical exhibition.
- 6.3 Non-Solicitation of Employees and Consultants.** During the Period of Employment and for a period of twelve (12) months after the Severance Date, the Officer will not directly or indirectly through any other Person (i) induce or attempt to induce any employee or independent contractor of the Company or any Affiliate of the Company to leave the employ or service, as applicable, of the Company or such Affiliate, or in any way interfere with the relationship between the Company or any such Affiliate, on the one hand, and any employee or independent contractor thereof, on the other hand, or (ii) hire any person who was an employee of the Company or any Affiliate of the Company until twelve (12) months after such individual's employment relationship with the Company or such Affiliate has been terminated.
- 6.4 Non-Solicitation of Customers.** During the Period of Employment and for a period of twelve (12) months after the Severance Date, the Officer will not directly or indirectly through any other Person influence or attempt to influence customers, vendors, suppliers, licensors, lessors, joint venturers, associates, consultants, agents, or partners of the Company or any Affiliate of the Company to divert their business away from the Company

or such Affiliate, and the Officer will not otherwise interfere with, disrupt or attempt to disrupt the business relationships, contractual or otherwise, between the Company or any Affiliate of the Company, on the one hand, and any of its or their customers, suppliers, vendors, lessors, licensors, joint venturers, associates, officers, employees, consultants, managers, partners, members or investors, on the other hand.

- 6.5 Nondisparagement.** For the Period of Employment and five years thereafter, the Officer and the Company (acting through any of its executive officers or directors), acknowledge and agree that neither party will defame, disparage or publicly criticize, directly or through another Person, the services, business or reputation of the Company or any of its officers, directors, partners, employees, Affiliates or agents, on the one hand, or the Officer, on the other, in either a professional or personal manner.
- 6.6 Understanding of Covenants.** The Officer acknowledges that, in the course of Officer's employment with the Company and/or its Affiliates and their predecessors, Officer has become familiar, or will become familiar, with the Company's and its Affiliates' and their predecessors' trade secrets and with other confidential and proprietary information concerning the Company, its Affiliates and their respective predecessors and that the Officer's services have been and will be of special, unique and extraordinary value to the Company and its Affiliates. The Officer agrees that the foregoing covenants set forth in this Section 6 (together, the "Restrictive Covenants") are reasonable and necessary to protect the Company's and its Affiliates' trade secrets and other confidential and proprietary information, good will, stable workforce, and customer relations.

Without limiting the generality of the Officer's agreement in the preceding paragraph, the Officer (i) represents that they are familiar with and has carefully considered the Restrictive Covenants, (ii) represents that they are fully aware of their obligations hereunder, (iii) agrees to the reasonableness of the length of time, scope and geographic coverage, as applicable, of the Restrictive Covenants, (iv) agrees that the Company and its Affiliates currently conducts business throughout the Restricted Area, and (v) agrees that the Restrictive Covenants will continue in effect for the applicable periods set forth above in this Section 6 regardless of whether the Officer is then entitled to receive severance pay or benefits from the Company. The Officer understands that the Restrictive Covenants may limit their ability to earn a livelihood in a business similar to the business of the Company and any of its Affiliates, but Officer nevertheless believes that they have received and will receive sufficient consideration and other benefits as an employee of the Company and as otherwise provided hereunder or as described in the recitals hereto to clearly justify such restrictions which, in any event (given the Officer's education, skills and ability), the Officer does not believe would prevent them from otherwise earning a living. The Officer agrees that the Restrictive Covenants do not confer a benefit upon the Company disproportionate to the detriment of the Officer.

- 6.7 Enforcement.** The Officer agrees that the Officer's services are unique and that they have access to Confidential Information and Work Product. Accordingly, the Officer agrees that a breach by the Officer of any of the covenants in this Section 6 would cause immediate and irreparable harm to the Company that would be difficult or impossible to measure, and that damages to the Company for any such injury would therefore be an inadequate remedy for any such breach. Therefore, the Officer agrees that in the event of any breach or threatened breach of any provision of this Section 6 or any similar provision, the Company shall be entitled, in addition to and without limitation upon all other remedies the Company may have under this Agreement, at law or otherwise, to obtain specific performance,

injunctive relief and/or other appropriate relief (without posting any bond or deposit) in order to enforce or prevent any violations of the provisions of this Section 6 or any similar provision, as the case may be, and/or require the Officer to account for and pay over to the Company all compensation, profits, moneys, accruals, increments or other benefits derived from or received as a result of any transactions constituting a breach of this Section 6 or any similar provision, as the case may be, if and when final judgment of a court of competent jurisdiction or arbitrator is so entered against the Officer. The Officer further agrees that for the applicable period of time any Restrictive Covenant is in effect following the Severance Date, as determined pursuant to the foregoing provisions of this Section 6, such period of time shall be extended by the same amount of time that Officer is in breach of any Restrictive Covenant. Any action to enforce this Agreement pursuant to this Section 6.7 shall be instituted in the United States Federal Court for the District of Kansas or the courts of the State of Kansas located in Johnson County, Kansas, and each party irrevocably submits to the exclusive jurisdiction of such courts in any such suit, action or proceeding. Service of process, summons, notice or other document by mail to such party's address set forth herein shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or any proceeding in such courts and irrevocably waive and agree not to plead or claim in any such court that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum.

**6.8** The Officer agrees to execute any additional documentation as may reasonably be requested by the Company in furtherance of the enforcement of any Restrictive Covenant.

**7.** **Withholding Taxes.** Notwithstanding anything else herein to the contrary, the Company may withhold (or cause there to be withheld, as the case may be) from any amounts otherwise due or payable under or pursuant to this Agreement such federal, state and local income, employment, or other taxes as may be required to be withheld pursuant to any applicable law or regulation.

**8.** **Successors and Assigns.**

**8.1** This Agreement is personal to the Officer and without the prior written consent of the Company shall not be assignable by the Officer otherwise than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by the Officer's legal representatives.

**8.2** This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns. As used in this Agreement, "Company" shall mean the Company as hereinbefore defined and any assignee or successor to all or substantially all of the Company's assets, as applicable, which assumes this Agreement by operation of law or otherwise.

**9.** **Number and Gender; Examples.** Where the context requires, the singular shall include the plural, the plural shall include the singular, and any gender shall include all other genders. Where specific language is used to clarify by example a general statement contained herein, such specific language shall not be deemed to modify, limit or restrict in any manner the construction of the general statement to which it relates.

**10.** **Section Headings.** The section headings of, and titles of paragraphs and subparagraphs contained in, this Agreement are for the purpose of convenience only, and they neither form a part of this Agreement nor are they to be used in the construction or interpretation thereof.

**11. Governing Law; Arbitration; Waiver of Jury Trial.**

**11.1** THIS AGREEMENT WILL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE, WITHOUT GIVING EFFECT TO ANY CHOICE OF LAW OR CONFLICTING PROVISION OR RULE (WHETHER OF THE STATE OF DELAWARE OR ANY OTHER JURISDICTION) THAT WOULD CAUSE THE LAWS OF ANY JURISDICTION OTHER THAN THE STATE OF DELAWARE TO BE APPLIED. IN FURTHERANCE OF THE FOREGOING, THE INTERNAL LAW OF THE STATE OF DELAWARE WILL CONTROL THE INTERPRETATION AND CONSTRUCTION OF THIS AGREEMENT, EVEN IF UNDER SUCH JURISDICTION'S CHOICE OF LAW OR CONFLICT OF LAW ANALYSIS, THE SUBSTANTIVE LAW OF SOME OTHER JURISDICTION WOULD ORDINARILY APPLY.

**11.2** Except for the limited purpose provided in Section 6.7, any legal dispute related to this Agreement and/or any claim related to this Agreement, or breach thereof, shall, in lieu of being submitted to a court of law, be submitted to arbitration, in accordance with the applicable dispute resolution procedures of the American Arbitration Association. The award of the arbitrator shall be final and binding upon the parties. The parties hereto agree that (i) one arbitrator shall be selected pursuant to the rules and procedures of the American Arbitration Association, (ii) the arbitrator shall have the power to award injunctive relief or to direct specific performance, (iii) each of the parties, unless otherwise required by applicable law, shall bear its own attorneys' fees, costs and expenses and an equal share of the arbitrator's and administrative fees of arbitration and the arbitrator shall award to the prevailing party a sum equal to that party's share of the arbitrator's and administrative fees of arbitration, and (iv) the arbitration shall be conducted in Johnson County, Kansas. Nothing in this Section 11 shall be construed as providing the Officer a cause of action, remedy or procedure that the Officer would not otherwise have under this Agreement or the law.

**11.3** EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT.

**12. Severability.** It is the desire and intent of the parties hereto that the provisions of this Agreement be enforced to the fullest extent permissible under the laws and public policies applied in each jurisdiction in which enforcement is sought. Accordingly, if any particular provision of this Agreement shall be adjudicated by an arbitrator or court of competent jurisdiction to be invalid, prohibited or unenforceable under any present or future law, and if the rights and obligations of any party under this Agreement will not be materially and adversely affected thereby, such provision, as to such jurisdiction, shall be ineffective, without invalidating the remaining provisions of this Agreement or affecting the validity or enforceability of such provision in any other jurisdiction, and to this end the provisions of this Agreement are declared to be severable; furthermore, in lieu of such invalid or unenforceable provision there will be added automatically as a part of this Agreement, a legal, valid and enforceable provision as similar in terms to such invalid or unenforceable provision as may be possible. Notwithstanding the foregoing, if such provision could be more narrowly drawn (as to geographic scope, period of duration or otherwise) so as not to be invalid, prohibited or unenforceable in such jurisdiction, it shall, as to such jurisdiction, be so narrowly drawn, without invalidating the remaining provisions of this Agreement or affecting the validity or enforceability of such provision in any other jurisdiction.

13. **Entire Agreement.** This Agreement embodies the entire agreement of the parties hereto respecting the matters within its scope. This Agreement supersedes all prior and contemporaneous agreements of the parties hereto that directly or indirectly bears upon the subject matter hereof, including, without limitation, any term sheet prepared in connection herewith. Any prior negotiations, correspondence, agreements, proposals or understandings relating to the subject matter hereof shall be deemed to have been merged into this Agreement, and to the extent inconsistent herewith, such negotiations, correspondence, agreements, proposals, or understandings shall be deemed to be of no force or effect. There are no representations, warranties, or agreements, whether express or implied, or oral or written, with respect to the subject matter hereof, except as expressly set forth herein. Notwithstanding the foregoing integration provisions, the Officer acknowledges having received and read the Company's code of ethics and agrees to conduct himself in accordance therewith as in effect from time to time.
14. **Modifications.** This Agreement may not be amended, modified or changed (in whole or in part), except by a formal, definitive written agreement expressly referring to this Agreement, which agreement is executed by both of the parties hereto.
15. **Waiver.** Neither the failure nor any delay on the part of a party to exercise any right, remedy, power or privilege under this Agreement shall operate as a waiver thereof, nor shall any single or partial exercise of any right, remedy, power or privilege preclude any other or further exercise of the same or of any right, remedy, power or privilege, nor shall any waiver of any right, remedy, power or privilege with respect to any occurrence be construed as a waiver of such right, remedy, power or privilege with respect to any other occurrence. No waiver shall be effective unless it is in writing and is signed by the party asserted to have granted such waiver.
16. **Notices.** Any notice provided for in this Agreement must be in writing and must be either personally delivered, transmitted via telecopier, mailed by first class mail (postage prepaid and return receipt requested) or sent by reputable overnight courier service (charges prepaid) to the recipient at the address below indicated or at such other address or to the attention of such other person as the recipient party has specified by prior written notice to the sending party. Notices will be deemed to have been given hereunder and received when delivered personally, when received if transmitted via telecopier, five days after deposit in the U.S. mail and one day after deposit on a weekday with a reputable overnight courier service.

if to the Company:

AMC Entertainment Holdings, Inc.  
11500 Ash Street  
Leawood, KS 66211  
Facsimile: 913-213-2059  
Attn: Chief Executive Officer  
General Counsel

if to the Officer, to the address most recently on file in the payroll records of the Company.

17. **Counterparts.** This Agreement may be executed in any number of counterparts, each of which shall be deemed an original as against any party whose signature appears thereon, and all of which together shall constitute one and the same instrument. This Agreement shall become binding when one or more counterparts hereof, individually or taken together, shall bear the signatures of all of the parties reflected hereon as the signatories. Photographic copies of such signed counterparts may be used in lieu of the originals for any purpose.

18. **Legal Counsel; Mutual Drafting.** Each party recognizes that this is a legally binding contract and acknowledges and agrees that they have had the opportunity to consult with legal counsel of their choice. Each party has cooperated in the drafting, negotiation and preparation of this Agreement. Hence, in any construction to be made of this Agreement, the same shall not be construed against either party on the basis of that party being the drafter of such language. The Officer agrees and acknowledges that Officer has read and understands this Agreement, is entering into it freely and voluntarily, and has been advised to seek counsel prior to entering into this Agreement and has had ample opportunity to do so.

THIS AGREEMENT CONTAINS A BINDING ARBITRATION PROVISION WHICH MAY BE ENFORCED BY THE PARTIES.

*[The remainder of this page has intentionally been left blank.]*

**IN WITNESS WHEREOF**, the Company and the Officer have executed this Agreement as of the day and year first set forth above.

**“COMPANY”**

AMC Entertainment Holdings, Inc.

By: /s/ Carla Chavarria

Carla Chavarria

**“OFFICER”**

By: /s/ Eddie Glabach

Eddie Glabach

---

FORM OF RELEASE<sup>1</sup>

1. Release by Officer \_\_\_\_\_ (the “Officer”), on their own behalf, on behalf of any entities Officer controls and on behalf of Officer’s descendants, dependents, heirs, executors, administrators, assigns and successors, and each of them, hereby acknowledges full and complete satisfaction of and releases and discharges and covenants not to sue AMC ENTERTAINMENT HOLDINGS, INC. , a Delaware corporation (the “Company”), its divisions, subsidiaries, parents, or affiliated corporations, and each of its and their employees, officers and directors, past and present, and each of them, as well as its assignees and successors (individually and collectively, “Company Releasees”), from and with respect to any and all claims, agreements, obligations, demands and causes of action, known or unknown, suspected or unsuspected, arising out of or in any way connected, in whole or in part, with the Officer’s employment, the termination thereof, or any other relationship with or interest in the Company, including without limiting the generality of the foregoing, any claim for severance pay, profit sharing, bonus or similar benefit, pension, retirement, life insurance, health or medical insurance or any other fringe benefit, or disability, or any other claims, agreements, obligations, demands and causes of action, known or unknown, suspected or unsuspected, resulting from or arising out of, in whole or in part, any act or omission by or on the part of Company Releasees committed or omitted prior to the date of this release agreement (this “Agreement”), including, without limiting the generality of the foregoing, any claim under Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act, the Family and Medical Leave Act, or any other federal, state or local law, regulation or ordinance; provided, however, that the foregoing release does not apply to any obligation of the Company to the Officer pursuant to the benefits due to the Officer in connection with the execution and delivery of this Release Agreement pursuant to Officer’s employment agreement with \_\_\_\_\_ dated as of \_\_\_\_\_, 20\_\_ by and between the Company and the Officer. In addition, this release does not cover any claim that cannot be released as a matter of applicable law.

2. Waiver of Civil Code Section 1542. This Agreement is intended to be effective as a general release of and bar to each and every claim, agreement, obligation, demand and cause of action hereinabove specified (collectively, the “Claims”). Accordingly, the Officer hereby expressly waives any rights and benefits conferred by Section 1542 of the California Civil Code as to the Claims. Section 1542 of the California Civil Code provides:

“A GENERAL RELEASE DOES NOT EXTEND TO A CLAIM WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN THEIR FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY THEM MUST HAVE MATERIALLY AFFECTED THEIR SETTLEMENT WITH THE DEBTOR.”

The Officer acknowledges that Officer later may discover claims, demands, causes of action or facts in addition to or different from those which the Officer now knows or believes to exist with respect to the subject matter of this Agreement and which, if known or suspected at the time of executing this Agreement, may have materially affected its terms. Nevertheless, the Officer hereby waives, as to the Claims, any claims, demands, and causes of action that might arise as a result of such different or additional claims, demands, causes of action or facts.

<sup>1</sup> Subject to revision to the extent advisable based on changes in law or legal interpretation.

\_\_\_\_\_



3. ADEA Waiver. The Officer expressly acknowledges and agrees that by entering into this Agreement, Officer is waiving any and all rights or claims that Officer may have arising under the Age Discrimination in Employment Act of 1967, as amended, which have arisen on or before the date of execution of this Agreement. The Officer further expressly acknowledges and agrees that:

- (a) In return for this Agreement, Officer will receive consideration beyond that to which Officer would have been entitled had Officer not entered into this Agreement;
- (b) Officer is hereby advised in writing by this Agreement to consult with an attorney before signing this Agreement;
- (c) Officer was given a copy of this Agreement on [\_\_\_\_, 20\_\_] and informed that they had twenty-one (21) days within which to consider the Agreement; and
- (d) Officer was informed that they have seven (7) days following the date of execution of the Agreement in which to revoke the Agreement.

4. No Transferred Claims. The Officer represents and warrants to the Company that Officer has not heretofore assigned or transferred to any person other than the Company any released matter or any part or portion thereof.<sup>2</sup>

The undersigned has read and understands the consequences of this Agreement and voluntarily signs it. The undersigned declares under penalty of perjury under the laws of the State of [Delaware] that the foregoing is true and correct.

EXECUTED this \_\_\_\_\_ day of \_\_\_\_\_, 20\_\_, at \_\_\_\_\_ County, [State].

“Officer”

~~Name~~ \_\_\_\_\_

Acknowledged and agreed:

AMC ENTERTAINMENT HOLDINGS, INC. on behalf of  
itself and its divisions, subsidiaries, parents, and affiliated  
companies, past and present, and each of them

By:

Name:

Title: \_\_\_\_\_

<sup>2</sup> If requested by the Company, the Officer shall provide a separate release from the Officer’s spouse at the time of execution.

\_\_\_\_\_

\_\_\_\_\_

DATED 30 NOVEMBER 2016

(1) ODEON CINEMAS LIMITED  
(2) MARK WAY

SENIOR EXECUTIVES SERVICE AGREEMENT

---

## CONTENTS

Clause		Page
1	DEFINITIONS	1
2	EMPLOYMENT	4
3	FREEDOM TO TAKE UP THE APPOINTMENT	4
4	TERM OF EMPLOYMENT	4
5	DUTIES OF THE EXECUTIVE	5
6	HOURS OF WORK	7
7	PLACE OF WORK	7
8	SALARY AND BONUS	7
9	EXPENSES	8
10	PENSION AND LIFE ASSURANCE	8
11	PRIVATE MEDICAL EXPENSES INSURANCE SCHEME	9
12	COMPANY CAR ALLOWANCE	9
14	CRITICAL ILLNESS INSURANCE SCHEME	9
16	HOLIDAY	9
17	SICKNESS	10
18	TERMINATION OF EMPLOYMENT	12
19	DISCIPLINARY AND GRIEVANCE PROCEDURES	15
20	DIRECTORSHIPS AND SHAREHOLDINGS	15
21	RECONSTRUCTION	16
22	CONFIDENTIAL INFORMATION	16
23	POST TERMINATION COVENANTS	17
24	INTELLECTUAL PROPERTY	20
25	MISREPRESENTATION	21
26	REFERENCES	21
27	DATA PROTECTION	21
28	THIRD PARTY RIGHTS	22
29	PREVIOUS AGREEMENTS	22
30	NOTICES	22

---

31	LAW AND JURISDICTION	23
32	GENERAL PROVISIONS	23
	SCHEDULE 1 - STATEMENT OF TERMS AND CONDITIONS	25

---

THIS DEED is made on

BETWEEN:-

- (1) **ODEON CINEMAS LIMITED** (Number 01854132) whose registered office is at 54 Whitcomb Street, London WC2H (the "Company"); and
- (2) **MARK WAY** (the "Executive") **THE PARTIES AGREE** as follows:-

1. **DEFINITIONS**

1.1 In this Agreement the following words and expressions shall have the following meanings:-

- "the Act"** means the Employment Rights Act 1996
- "Associated Company"** means a company or undertaking (which is not a Subsidiary or Holding Company of the Company or of a Group Company) of which more than 20 per cent of the Equity Share Capital is for the time being owned by the Company or a Group Company or which for the time being owns more than 20 per cent of the Equity Share Capital of the Company or a Group Company
- "Board"** means the Board of Directors of the Company from time to time, or any duly delegated committee of the Board so appointed from time to time
- "Civil Partner"** means a person who has entered into a civil partnership under the Civil Partnership Act 2004
- "Confidential Information"** means:-
- (a) all information which relates to the business, finances, transactions, affairs, products, services, processes, equipment or activities of the Company and any Group Company which is designated by the Company or any Group Company as confidential; and
  - (b) all information relating to such matters which comes to the knowledge of the Executive in the course of the Employment and which, by reason of its character and/or the manner of its coming to his knowledge, is evidently confidential; and
  - (c) all information which relates to the business, finances, transactions, affairs, products, processes, equipment or activities of actual or potential clients, customers, suppliers or other persons which has been given to the Company or any Group Company in confidence; and
  - (d) shall include without limitation all such information held or contained in any media, including on social media sites, and information as to any of the following subjects: business plans, business methods, corporate plans, management systems,

finances, maturing new business opportunities, research and development projects, concepts, ideas, new products, product formulae, source code, software, software designs, graphic designs, artwork, processes, inventions, discoveries or know-how, sales statistics, sales techniques, marketing surveys and plans, costs, profit or loss, prices and discount structures, the names, addresses and contact details of customers and suppliers or potential customers and suppliers

provided that information shall not be, or shall cease to be Confidential Information if and to the extent that it comes to be in the public domain otherwise than as a result of the unauthorised act or default of the Executive

means the employment of the Executive under this Agreement or, where the context so requires, the duration of the employment of the Executive under this Agreement

**"Employment"**

has the meaning given to it in section 548 of the Companies Act 2006

**"Equity Share Capital"**

means the Financial Conduct Authority

means

- (i) the Company
- (ii) any Holding Company for the time being of the Company
- (iii) any Subsidiary for the time being of the Company or of the Company's Holding Company
- (iv) any Associated Company and
- (v) any other company or body corporate or other form of business entity the name of which is notified in writing to the Executive by the Company as being a member of the Group

**"FCA"**

**"Group"**

means any member of the Group, other than the Company, from time to time

have the meanings given to them respectively in section 1159 of the Companies Act 2006

means patents, rights to inventions, copyright and related rights, trade names and domain names, rights in get-up, rights in goodwill or to sue for passing off, unfair competition rights, rights in designs, rights in computer software, database rights, topography rights, rights in confidential information (including know-how and trade secrets) and any other intellectual property rights, trade marks, service marks, logos, trade dress, trade names, internet domain names, rights in designs, copyright (including rights in computer software) and moral rights, database rights, semiconductor topography rights, utility models, in each case whether registered or unregistered and including all applications for registration (or rights to apply) for, and renewals or extensions of, such rights and all similar or equivalent rights or forms of protection which subsist or will subsist now or in the future in any

**"Group Company"**

**"Holding Company"  
and "Subsidiary"**

**"Intellectual Property  
Rights"**

---

part of the world.

**"Invention"**

means any invention, discovery or improvement including (without limitation) any know how, design, image, process, plan, drawing, formula, computer programme, software (including source code and object code), system or specification which in any way affects or relates to the business of the Company or any Group Company (including without limitation any current, potential or future product, service, process, equipment, system or activity of the Company or any Group Company) whether or not now, or at any future time, capable of being the subject of patent protection (whether in the United Kingdom or in any other territory in the World)

**"Material"**

means any and all written, audio and/or visual work, any know-how, show-how, information, technique, invention, design, drawing, specification, component list, manual, instruction, catalogue, image, photograph, plan, formula, computer program, software or system, record, document, compilation or database which in any way affects or relates to the business of the Company or any Group Company (including without limitation any current, potential or future product, service, process, equipment, system or activity of the Company or any Group Company)

means a person who, whether solely or jointly,

**"Minority Holder"**

holds or is beneficially interested in the shares or securities of any company quoted on any Recognised Investment Exchange provided that such holding or interest does not exceed 3 per cent of any single class of such shares or securities. In calculating whether a person is a Minority Holder there shall be aggregated with any shares or securities held by him or to which he is beneficially entitled any shares or securities of the same class which his spouse or Civil Partner or any dependent child holds or is beneficially entitled to

has the meaning given to it in section 285 of the Financial Services and Markets Act 2000

means any 17 week period during the Employment

means all Salary, compensation, bonus and benefits (in whatever form) that you receive from the Company or any Group Company and shall be taken to include (but is not limited to) any payments that are made in connection with the Employment, the holding of any office and the termination of the Employment and/or any office that you hold in the Company or any Group Company.

**"Recognised Investment Exchange"**

**"Reference Period"**

**"Remuneration"**

**"Salary"** has the meaning given in Clause 8.1 as the same may be amended from time to time

is the state pensionable age determined in

accordance with  
the  
**"State  
Pensionable  
Age"**  
rules in  
paragraph  
1 of  
Schedule  
4 to the  
Pensions  
Act 1995

**"Working Time"** has the  
meaning  
given to it  
in  
Regulation  
2 of the  
Working  
Time  
Regulations  
1998

1.2 The  
headings in  
this  
Agreement  
are for  
convenience  
only and  
shall not  
affect its  
interpretation  
or  
construction.

1.3 A  
reference  
to any  
statutory  
or  
legislative  
provision  
includes  
a  
reference  
to that  
provision  
as  
modified,  
replaced,  
amended  
and/or re-  
enacted  
from time  
to time.

1.4 Any  
reference to the  
Executive shall, if  
appropriate,  
include his  
personal  
representatives.

- 1.5 Words importing one gender include the other gender.
- 1.6 References to a "person" include any individual, firm, company, corporation, body corporate, government, state or agency of state, trust or foundation, or any association, partnership or unincorporated body (whether or not having separate legal personality).
- 1.7 Any reference in this Agreement to a clause or sub-clause is to the relevant clause or sub-clause of this Agreement.
- 1.8 The Schedules to this Agreement form an integral part of this Agreement and any reference to this Agreement includes a reference to such Schedules.
- 1.9 This Agreement includes the written statement of particulars of employment which the Company is required to give the Executive under section 1 of the Act and therefore no separate written statement will be provided. Whilst most of the particulars are set out in the body of the Agreement, additional particulars are set out in Schedule 1.

## **2. EMPLOYMENT**

The Company shall employ the Executive and the Executive agrees to act as Managing Director of Odeon and UCI Cinemas Group Limited, and President - Europe of AMC Entertainment Holdings, Inc. ("**AMCEH**"), or in such capacity of a like status as the Board shall from time to time reasonably require on the terms set out in this Agreement.

## **3. FREEDOM TO TAKE UP THE APPOINTMENT**

- 3.1 The Executive warrants that by virtue of entering into or performing any of his duties under this Agreement or any other agreement made or to be made between the Company or a Group Company and the Executive he will not be in breach of any express or implied terms of any contract or of any other obligation binding to any third party, including any restrictive covenants, and declares that he is not directly or indirectly interested in any capacity in any other business, trade or occupation. The Executive undertakes to indemnify the Company and any Group Company against any costs, claims, liabilities and expenses (including legal expenses on an indemnity basis) arising out of any such breach or alleged breach by him.
- 3.2 The Executive warrants that he is legally entitled to work in the United Kingdom. Should the Company discover that the Executive does not have permission to live and work in the United Kingdom or if any such permission is revoked or if the Executive is unable to present evidence of the right to work in the United Kingdom so that the Company can comply with the prescribed requirements under Section 15 of the Immigration, Asylum and Nationality Act 2006, the Company reserves the right to terminate the Employment immediately without notice or pay in lieu of notice.

## **4. TERM OF EMPLOYMENT**

- 4.1 The Employment shall begin on 30 November 2016 but the Executive's period of continuous employment began on 1 September 2014.
- 4.2 Subject to Clause 18 (Termination of Employment), the Employment shall be subject to termination by either party giving 12 months notice in writing.
- 4.3 Upon the conclusion of 1 calendar year from the date of this Agreement, and at the reasonable discretion of the Board, the Employment shall be subject to termination on the following terms:
- 4.3.1 the Executive giving the Company 6 months prior notice; and
- 4.3.2 the Company giving the Executive 12 months prior notice.

4.4 Any period of notice given shall commence immediately after it is given, irrespective of the time or date in receipt.

4.5 **Garden Leave**

Without prejudice to the provisions of Clauses 18.3 (*Payment in Lieu of Notice*) and 18.1 (*Summary Dismissal*), the Company may, at any time during the Employment, including without limitation for the purpose of investigating any matter relating to the Executive's conduct or performance, require the Executive to cease performing all or any of the Executive's duties for such period or periods as the Company shall in its absolute discretion determine (the "**Garden Leave**"). During any such period of Garden Leave:-

- 4.5.1 the Company shall continue to pay the Salary and shall provide all benefits to which the Executive is entitled under this Agreement;
- 4.5.2 without prejudice to the Company's rights under Clause 5.3 (performance of alternative duties) the Company shall be under no obligation to provide any work for the Executive and shall be entitled to appoint any other person or persons to perform the Executive's duties under this Agreement whether on a temporary or a permanent basis;
- 4.5.3 the Executive shall not, without the prior written permission of the Company enter or attend any Group premises or to contact any employees, officers, customers, clients, agents or suppliers of the Group without its prior consent;
- 4.5.4 the Executive shall, at the request of the Board, immediately deliver to the Company all or any property in his possession or control which belongs to the Company or any Group Company or which relates to the business of the Company or any Group Company, including without limitation, all items mentioned in Clause 18.6.1;
- 4.5.5 the Executive shall keep the Board informed of his whereabouts so that he can be called upon to perform any appropriate duties as required by the Board; and
- 4.5.6 for the avoidance of doubt the Executive shall continue to be bound by all the Executive's obligations under this Agreement insofar as they are compatible with the Executive being on garden leave including, without limit, the Executive's duty of good faith and the Executive's duties under Clause 5.6 (Executive not to be employed in any other business).

5. **DUTIES OF THE EXECUTIVE**

- 5.1 The Executive shall, in his capacity as Managing Director of Odeon and UCI Cinemas Group Limited, be responsible to the Board for the day-to-day management of the Company's affairs.
- 5.2 The Executive accepts that without being entitled to further remuneration:-
  - 5.2.1 the Company may require him to perform duties for any Group Company whether for the whole or part of his Working Time, and whether or not by way of a formal secondment;
  - 5.2.2 the Company may require him to act as an officer of the Company or any Group Company or hold any other appointment or office as nominee or representative of the Company or any Group Company, including as President of AMCEH, provided the Executive consents to such appointment, such consent not to be unreasonably withheld; and
  - 5.2.3 the Company may transfer the Employment to any other Group Company.
- 5.3 The Executive accepts that the Company may at its reasonable discretion require him to perform other duties or tasks not within the scope of his normal duties and the Executive agrees to perform those duties or undertake those tasks as if they were specifically required under this Agreement.

- 5.4 During the Employment the Executive shall at all times:-
- 5.4.1 use his best endeavours to promote the success, interests and reputation of the Group giving at all times the full benefit of his knowledge, experience, expertise and skill;
  - 5.4.2 faithfully and diligently and to the best of his ability exercise such powers and perform such duties in relation to the business of the Group as the Board may from time to time require;
  - 5.4.3 comply with his duties under Part 10 of the Companies Act 2006;
  - 5.4.4 keep the Board promptly and fully informed (in writing if so required by the Board) of his conduct of the business of the Company and any Group Company and provide the Board with all information regarding the affairs of the Company and any Group Company and his conduct in relation thereto as it shall require;
  - 5.4.5 conform to the instructions or directions of the Board and implement and apply the policies of the Company as determined by the Board from time to time;
  - 5.4.6 refrain from making any false or misleading statements about the Company or any Group Company;
  - 5.4.7 refrain from entering into any arrangement on behalf of the Company or any Group Company which is outside its normal course of business or his normal duties or which contains unusual or onerous terms without the approval of the Board.
- 5.5 The Company may, upon notice to terminate Employment being given in accordance with Clause 4 above, appoint any other person or persons to act jointly with the Executive to perform the duties of the Executive under this Agreement.
- 5.6 The Executive shall not during the Employment without the prior written consent of the Board be directly or indirectly employed, engaged, concerned or interested, whether as a director, employee, sub-contractor, partner, consultant, proprietor, agent or otherwise, in any other business, undertaking or occupation or the setting up of any other business, undertaking or occupation, or accept any other engagement or public office but the Executive may nevertheless be or become a Minority Holder provided that the Executive discloses this in writing to the Board.
- 5.7 The Executive shall not during the Employment knowingly or willingly do or cause or permit to be done anything which is calculated or may tend to prejudice or injure the interests of the Company or any Group Company and if during the Employment the Executive shall learn of any act or omission by any other person whether or not employed by the Company or any Group Company which is calculated or may tend to prejudice or injure the interests of the Company or any Group Company he shall promptly report it to the Board giving all necessary particulars, irrespective of whether this may involve some degree of self-incrimination. This shall include without limit any behaviour by any current or former officer or employee of the Company or any Group Company which could reasonably be construed as an attempt to entice the Executive or any other employee of the Company or any Group Company to leave the employment of the Company or any Group Company.
- 5.8 The Executive shall at all times comply with any policies of the Company relating to anti-bribery and corruption, and/or gifts and hospitality and shall not instruct, authorise or condone, expressly or impliedly, any corrupt activity. The Executive shall promptly report any breach or suspected breach of these policies, using the Company's whistleblowing procedures for this purpose. The Executive shall cooperate fully with the Company in its investigation of any suspected bribery or corruption of which he becomes aware and, in accordance with any existing or revised Company policy, he shall take reasonable preventative measures to stop bribery or corruption for which the Company or any Group Company may be liable.
- 5.9 The Executive shall hold any office in the Company and any Group Company subject to the Articles of Association of the relevant Company as amended from time to time. If the provisions of this

Agreement conflict with the Articles of Association of the relevant Company, the Articles of Association will prevail.

## 6. HOURS OF WORK

- 6.1 Subject to the performance of any activities permitted by the Board under Clause 5.6 the Executive shall devote the whole of his working time and attention to the service of the Group except during holidays and any periods of absence due to illness or injury.
- 6.2 The Executive shall be obliged to work such hours as may be necessary for the proper discharge of his duties and shall not be entitled to receive any additional remuneration for work outside normal business hours of the Company.
- 6.3 The Executive acknowledges that the limit in Regulation 4(1) of The Working Time Regulations 1998 shall not apply to him and accordingly agrees that his/her Working Time (including overtime) may exceed an average of 48 hours for each 7 day period in the Reference Period whenever necessary for the proper discharge of his duties or in any event as may be required by the Company. The Executive shall be entitled to withdraw such agreement by giving 3 months prior written notice to the Company.
- 6.4 The Executive agrees that he will comply with all policies or requirements of the Company from time to time in force, in relation to the recording of Working Time.

## 7. PLACE OF WORK

- 7.1 The Executive will work at the principal office of the Company or anywhere else required by the Board for the proper performance of his powers and duties under this Agreement.
- 7.2 For the purpose of performing his duties, the Executive shall undertake such journeys in the United Kingdom and elsewhere as the Board shall require. Travelling and other expenses shall be reimbursed in accordance with Clause 9.

## 8. SALARY AND BONUS

- 8.1 During the Employment the Company shall pay to the Executive a basic salary at the rate of £420,000 per year which shall accrue from day to day and be payable by equal monthly instalments in arrears on or about the last working day of each month (the "**Salary**"). The Salary shall be deemed to include any fees or other remuneration receivable by the Executive as a director of the Company or any Group Company or in respect of any other company or unincorporated body in which he holds office or any other appointment as nominee or representative of the Company or any Group Company.
- 8.2 The Salary shall be reviewed by the Board from time to time and the rate of the Salary may be increased by the Company with effect from that date by such amount, if any, as it shall think fit. For the avoidance of doubt it is agreed that the Executive shall have no contractual right to any increase in the Salary under this Clause 8, and there will be no review of the Salary after notice has been given in accordance with Clause 4.2.
- 8.3 The Company may, in its sole discretion, award to the Executive an annual bonus based on a target of 75% of Salary in respect of each financial year, in accordance with any bonus scheme in force from time to time (the "**Bonus Award**"). Any Bonus Award is subject, amongst other factors, to the achievement of individual and Company performance targets as may be notified to the Executive by the Board each year. Achievement of such targets will be determined by the Board acting in its sole discretion and its decision shall be final and binding.
- 8.4 Notwithstanding the achievement or non-achievement of any of the personal or Company performance targets as set out in Clause 8.3 above, the Board's decision as to the amount of any Bonus Award made, if any in respect of each financial year, is final. In the event that a Bonus Award is made, such a Bonus Award shall be payable as soon as reasonably practicable following the end of the financial year to which the Bonus Award relates (the "**Payment Date**"). The Board reserves the right to amend the terms of any bonus scheme from time to time in its absolute

discretion. The Bonus Award does not form part of the Executive's terms and conditions of employment, and the payment of a Bonus Award in any financial year is not a guarantee or indication that a Bonus Award will be paid in any subsequent financial year.

- 8.5 Without prejudice to the discretionary nature of any Bonus Award, to be eligible for payment of a Bonus Award, at the Payment Date:
- (a) subject to Clause 8.6 below, the Executive must be employed by the Company;
  - (b) the Executive shall not have given notice to terminate the Employment; and
  - (c) the Executive must not be subject to any formal disciplinary or performance management action or under any disciplinary investigation or suspended pursuant to any disciplinary process, although if, after completion of the disciplinary process, investigation or at the end of the suspension, the Company has not imposed a disciplinary sanction on the Executive, the Company will re consider its discretion at such time.
- 8.6 In circumstances where the Company is not entitled to terminate in accordance with Clause 18.1 of this Agreement, the Executive shall be eligible to receive any Bonus Award, such award being prorated to reflect the Termination Date. In accordance with Clause 8.3, such Bonus Award will be made at the discretion of the Company.
- 8.7 For the purposes of sections 13 to 16 of the Act, the Executive hereby consents to the deduction from the Salary and bonus, including any Bonus Award (or from any other sum due from the Company or any Group Company to the Executive which falls within the definition of "Wages" in section 27 of the Act) of any sums owing by the Executive to the Company or to any Group Company at any time and he also agrees to make payment to the Company or any Group Company of any sums owed by him to the Company or any Group Company upon demand by the Company at any time. This Clause is without prejudice to the right of the Company and any Group Company to recover any sums or balance of sums owed by the Executive to the Company or any Group Company by legal proceedings.
- 8.8 If, at any time during the Employment or subsequent to the termination of Employment, the Executive is found to have breached any of the terms of this Agreement or the Executive's duties to the Company during the Employment such that the Company would have been entitled to terminate the Employment without notice or payment in lieu of notice, the Company shall be entitled to recover any payments made under Clauses 8 and/or to cease making further payments under Clause 8 with immediate effect. Any such payments already made shall be recoverable from the Executive as a debt.
- 9. EXPENSES**
- 9.1 The Company shall refund to the Executive all reasonable expenses properly incurred by him in performing his duties under this Agreement, provided that these are incurred in accordance with Company policy from time to time. The Company will require the Executive to produce receipts or other documents as proof that he has incurred any expenses he claims.
- 9.2 If the Company provides the Executive with any credit or charge card the Executive shall use such card solely for those expenses referred to in Clause 9.1 and he shall immediately return any such card to the Company whenever so required by the Board, and in any event in accordance with the provisions of Clause 4.5 (*Garden Leave*), Clause 18.6.1(b) (*termination of employment*) and Clause 19.3 (*suspension from employment*) where applicable.
- 10. PENSION AND LIFE ASSURANCE**
- 10.1 The Company shall pay to the Executive, in lieu of any contribution to the Executive's pension arrangements, an additional gross amount of 20% of the Salary per annum, which shall accrue from day to day and be payable by equal monthly instalments in arrears on or about the last working day of each month. Each payment under this Clause shall be reduced by any amounts

that the Company is required to pay into the Executive's pension arrangements by law from time to time.

- 10.2 The Company shall contribute to the Executive's pension arrangements to the minimum extent required by law from time to time.
- 10.3 The Company maintains a life assurance scheme (the "**Life Assurance Scheme**") and, subject to Clause 10.4 below, the Executive shall be entitled to become and remain throughout the Employment a member of the Life Assurance Scheme which will provide cover of four times the Executive's Salary minus the lower earnings limit for National Insurance purposes, subject to the rules of the Life Assurance Scheme from time to time in force, details of which will be provided to the Executive on request by the Executive Vice President, Global Development, AMC Entertainment Holdings, inc., or his/her designee.
- 10.4 The Company shall be entitled at any time to withdraw or amend any of the rules or benefits of the Life Assurance Scheme and/or to terminate the Executive's participation in the Life Assurance Scheme.

**11. PRIVATE MEDICAL EXPENSES INSURANCE SCHEME**

During the Employment the Executive shall be entitled to participate at the Company's expense for himself, for any spouse or Civil Partner and any dependent children in the Company's private medical expenses insurance scheme (the "**Private Medical Insurance Scheme**") subject always to the rules of the Private Medical Insurance Scheme for the time being in force (details of which are available on request) and to the approval of the relevant insurer.

- 11.2 The Company reserves the right at any time to withdraw or amend any of the rules or benefits of the Private Medical Insurance Scheme (including the level of cover) and/or terminate the Executive's participation in the Private Medical Insurance Scheme and subject to Clause 11.2 any such changes shall take effect as between the Company and the Executive upon the Executive receiving written notice of the same from the Company.
- 11.3 Where the Executive is notified of any change in accordance with Clause 11.2, any entitlement to benefit which has already accrued to him at the time of the change will be dealt with in accordance with the rules of the relevant scheme immediately prior to the change provided that thereafter the Executive's entitlement under the scheme (if any) shall be subject to any changes which have been duly notified to him in accordance with Clause 11.2.
- 11.4 Notwithstanding the generality of Clause 11.2, the Company may withdraw the benefits of and/or terminate the Executive's membership of the Private Medical Insurance Scheme once the Executive has reached the age of 65 or the State Pensionable Age, if higher. Any entitlement to benefit which has already accrued will be dealt with in accordance with the rules of the Private Medical Insurance Scheme for the time being in force.

**12. COMPANY CAR ALLOWANCE**

- 13. Subject to the Executive holding a current full United Kingdom driving licence the Company shall during the Employment provide the Executive a car allowance for use of the Employee's own car of £15,000 a year which shall be payable together with and in the same manner as the salary in accordance with Clause 8. The car allowance shall not be treated as part of the basic salary for any purpose and shall not be pensionable.

**14. CRITICAL ILLNESS INSURANCE SCHEME**

- 15. The Executive shall be entitled to participate in the critical illness insurance scheme operated by the Company from time to time.

**16. HOLIDAY**

- 16.1 In addition to such bank and other public holidays as are observed by the Company, the Executive shall be entitled to the following paid holiday days in each complete holiday year worked:

- (a) 25 days initially;
  - (b) increasing to 26 days after 5 years complete service; and
  - (c) increasing to 27 days after 10 years complete service.
- 16.2 The holiday year runs from 1 January to 31 December and, subject to the provisions of Clause 16.8, holiday entitlement is to be taken at such times and on such notice as is agreed by the Board.
- 16.3 The Executive shall not under any circumstances (including, for the avoidance of doubt, where the Executive is absent on sick leave) be entitled to carry forward any unused part of his contractual holiday entitlement to a subsequent holiday year.
- 16.4 Where the Employment starts or terminates during a holiday year the Executive will be entitled in that year to such proportion of his annual holiday entitlement as equals the proportion of time he is employed under this Agreement in that year, rounded to the nearest day.
- 16.5 The Executive shall not be entitled to payment in lieu of any unused part of his holiday entitlement, except on termination of the Employment in accordance with Clause 16.7.
- 16.6 The Executive shall not accrue any entitlement to holiday in respect of periods of absence due to injury or illness of more than 28 consecutive days absence in any holiday year, save in relation to statutory holiday (if any) to which the Executive is entitled as a matter of law.
- 16.7 On termination of the Employment the Executive shall be entitled to be paid in lieu of any outstanding holiday entitlement for the holiday year in which termination takes place or, as the case may be, shall be obliged to repay to the Company Salary in respect of holiday taken in excess of his entitlement in his final holiday year and the basis for calculation in either case shall be  $\frac{1}{260}$  of the Salary for each day.
- 16.8 No holiday may be taken by the Executive during any notice period without the consent of the Board. The Company may however require the Executive to take all or part of his holiday entitlement on a particular day or days or during any notice period, or any period of Garden Leave.
- 16.9 For the avoidance of doubt:-
- 16.9.1 Regulations 15(1) to 15(4) of the Regulations do not apply to the Employment;
  - 16.9.2 the Executive may take all or part of his holiday entitlement before it has accrued under Regulation 15A of the Regulations provided that the Executive has the Board's permission to do so in accordance with Clause 16.1; and
  - 16.9.3 the Executive may take his statutory holiday entitlement or any part of it during a period of sickness absence at such times and on such notice as is agreed by the Board.
17. **SICKNESS**
- 17.1 If during the Employment the Executive is absent from work due to illness or injury he must notify the Executive Vice President, Global Development, AMC Entertainment Holdings, inc., or his/her designee as soon as possible and, if practicable, on the first working day of incapacity. Subject to Clause 17.10 below, the Executive shall complete any self-certification forms which are required by the Company immediately upon his return to work and, if his incapacity continues for more than 7 consecutive days (whether working days or not) shall produce medical certificates to cover the duration of his absence from work. Provided the Executive complies with these requirements, undergoes any medical examination or tests required by the Company under Clause 17.5, provides any medical evidence required by the Company pursuant to Clause 17.10 and provided the Company is satisfied that the Executive's absence is due to illness or injury, the Executive's absence will be regarded as authorised.

- 17.2 The Executive shall be entitled to receive the Salary due to him under this Agreement during any authorised period or periods of absence due to illness or injury up to a maximum of 26 weeks in aggregate in any 12 month period ("**Contractual Sick Pay**"). Thereafter he will not be entitled to any further payment from the Company or any Group Company (other than by way of any Statutory Sick Pay or paid statutory holiday due to him or any pay due to him pursuant to the terms of Clause 14) nor to the continued provision of his benefits under this Agreement except such benefits as provided for at Clauses 11, 12 and 14 until the resumption of his duties.
- 17.3 Contractual Sick Pay shall be subject to set off by the Company in respect of any statutory sick pay or social security benefits to which the Executive is entitled (whether or not such benefits are actually received).
- 17.4 For statutory sick pay purposes the Executive's qualifying days shall be his/her normal working days.
- 17.5 The Executive may at the Company's expense be required during the course of the Employment to attend a medical practitioner or clinic nominated by the Company for the purpose of a medical examination to help determine his fitness for continued Employment and he shall undergo any tests and examinations reasonably required by the said medical practitioner or clinic and shall authorise disclosure of and co-operate in ensuring the prompt delivery of any resulting report to the Company. Such an examination may include or consist of tests for alcohol or drugs (including "**controlled drugs**" as defined by the Misuse of Drugs Act 1971) where the Company has reason to believe that the use of alcohol or drugs is adversely affecting the Executive's performance at work or is posing a risk to health and safety. Notwithstanding the provisions of the Access to Medical Reports Act 1988 the Executive hereby consents to the Company obtaining any medical report relating to his physical or mental health prepared by a medical practitioner who is or has been responsible for the clinical care of the Executive.
- 17.6 The Executive shall not be entitled to any Contractual Sick Pay in respect of any period of absence during which the Executive is under investigation for misconduct, is subject to ongoing disciplinary proceedings or is subject to ongoing performance management proceedings.
- 17.7 Without prejudice to Clause 5.5 (*power to appoint joint executive*) the Company shall be entitled during any period during which the Executive is absent due to illness or injury to appoint any other person or persons to perform the duties and exercise the powers of the Executive in his place on such terms and conditions as the Company shall see fit.
- 17.8 **Third Party Injury to Executive**
- 17.8.1 If the Executive is absent from work by reason of any illness or injury caused wholly or partly by any act or omission of any third party in relation to which the Executive may be or become entitled to recover damages or compensation, then all net payments made to the Executive under this Clause 17 in respect of the said absence shall be repaid by the Executive if and to the extent that he recovers damages or compensation for loss of earnings from the said third party and/or from the Criminal Injuries Compensation Authority or the Motor Insurers' Bureau or any other similar body (the "**Relevant Bodies**") by action or otherwise.
- 17.8.2 Where the Executive receives any damages or compensation for loss of earnings as referred to in Clause 17.8.1, he shall notify the Company in writing forthwith and shall repay the amount due to the Company under this Clause 17.8.1 within 28 days of receipt of the said damages or compensation.
- 17.8.3 For the avoidance of doubt, where the Executive receives damages or compensation from a third party and/or the Relevant Bodies in the circumstances referred to in Clause 17.8.1, and that compensation includes an unspecified sum for loss of earnings, then the amount owing to the Company under Clause 17.8.1 will be such sum as is reasonable in all the circumstances.
- 17.9 For the avoidance of doubt:-

17.9.1 the term "**illness or injury**" as used in this Clause 17 includes any mental or psychiatric illness and any injury, whether or not this has been sustained in the course of the Executive's duties; and

17.9.2 the provisions of this Clause 17 are subject to the termination provisions set out in Clause 18 and in particular the Company's right in Clause 18.5 to terminate on account of illness or injury.

#### 17.10 **Reclassifying Holiday as Sickness**

If the Executive becomes ill or is injured during a period of statutory holiday and seeks to reclassify all or any part of such holiday as sick leave, the Company reserves the right to require the Executive to provide satisfactory (in the opinion of the Company) medical evidence from a recognised medical practitioner showing that the Executive is unable to work due to illness or injury and such medical evidence should cover the duration of the illness or injury whilst on holiday.

### 18. **TERMINATION OF EMPLOYMENT**

#### 18.1 **Summary Dismissal**

Notwithstanding the provisions of Clauses 4.2 and 4.3 (*notice clause*), 18.3 (*Payment in Lieu of Notice*) and 18.5 (*Termination on Account of Illness or Injury*), the Company may by written notice to the Executive forthwith terminate the Employment (without being under any obligation to pay any further sums to the Executive whether by way of compensation, damages or otherwise in respect of or in lieu of any notice period or unexpired term of this Agreement, and without prejudice to any other rights of the Company) if the Executive:-

18.1.1 fails or neglects efficiently and diligently to carry out his duties to the reasonable satisfaction of the Board;

18.1.2 does not comply with any lawful order or direction given to him by the Board;

18.1.3 is guilty of any material or persistent breach or non-observance of any of the provisions of this Agreement;

18.1.4 in the performance of his duties or otherwise commits;

(a) any act of gross misconduct; or

(b) any act of misconduct having already received a final written warning;

18.1.5 through his acts or omissions (whether at or outside work) adversely prejudices or is likely in the reasonable opinion of the Board to prejudice adversely the interests or reputation of the Group;

18.1.6 resigns as a director of the Company without the written consent of the Board or is disqualified from holding or ceases to hold office as a director of the Company or any Group Company by virtue of any court order, under any provision of general law or under any provision of the Company's Articles of Association as then in force.

18.1.7 is convicted of any criminal offence (excluding an offence under road traffic legislation in the United Kingdom and elsewhere for which a penalty of imprisonment cannot be imposed);

18.1.8 is made the subject of a bankruptcy order or has a receiving order or an administration order made against him or makes any composition or arrangement with his creditors generally or otherwise takes advantage of any statute from time to time in force offering relief for insolvent debtors;

- 18.1.9 becomes addicted to or is habitually under the influence of alcohol or any drug (not being a drug prescribed for the Executive by a medical practitioner for the treatment of a condition other than drug addiction) the possession of which is controlled by law;
- 18.1.10 becomes a patient within the meaning of the Mental Health Act 1983;
- 18.1.11 fails to comply with any obligation set out in Clause 5.8 (*anti-bribery and corruption etc*);
- 18.2 In the event that any part of the share capital of the Company shall be quoted on any Recognised Investment Exchange it shall be a fundamental term of this Agreement that the Executive shall comply at all times with such of the Listing Rules, the Disclosure and Transparency Rules and the Prospectus Rules issued from time to time by the FCA, the AIM Rules for Companies issued from time to time by the London Stock Exchange PLC, the Share Dealing Code, the City Code on Takeovers and Mergers, the Code of Market Conduct and the Price Stabilisation Rules as are applicable to the Company, and it shall be the responsibility of the Executive to make himself aware of the provisions of such rules and codes and the parties agree that (without prejudice to the effect of any other conduct of the Executive) any breach by the Executive of such rules and codes shall be gross misconduct for the purpose of Clause 18.1.4
- 18.3 **Payment in Lieu of Notice**
- 18.3.1 The Company may at any time in its absolute discretion elect to terminate the Employment forthwith and with immediate effect by notifying the Executive in writing:
- (a) that the Employment is being terminated in exercise of the right under this Clause 18.3;
  - (b) the date upon which the employment is so terminated ("the Early Termination Date"); and
  - (c) that the Executive shall be entitled to receive in lieu of the notice period referred to in Clauses 4.2, 4.3 or Clause 18.5 (*Termination on Account of Illness or Injury*) or any part thereof, an amount which shall be an amount equivalent to the Executive's basic Salary (at the rate then payable under this Agreement) for such period or part period and the value of the contractual benefits at Clauses 10.1, 11 and 12, excluding any bonus (the "Notice Payment");
- 18.3.2 In the event that the Company exercises its right under this Clause 18.3 the Company shall make payment of the Notice Payment or the first instalment thereof under Clause 18.3.4 within 28 days of the Early Termination Date.
- 18.3.3 Any Notice Payment paid pursuant to this Clause 16.4 shall be subject to such deductions for tax and national insurance as are required by law and to any other authorised deductions.
- 18.3.4 The Company may, at its discretion and subject to the terms of this Clause 18.3.4, pay the Notice Payment in equal monthly instalments for what would have been the duration or remaining duration of the notice period (the "Instalment Period"), the first instalment being payable within 28 days of the Early Termination Date
- In the event that the Company decides to pay the Notice Payment in instalments the Executive agrees that:
- (a) if the Executive begins alternative employment during the Instalment Period which provides the Executive with any remuneration (to include wages, salary and bonus from any employment, consultancy or other paid work and which shall be referred to for the purposes of this Clause as "**Other Income**") which in any calendar month is greater than the monthly instalment of the Notice Payment, then the Executive will not be entitled to receive any Notice Payment for that month;
  - (b) if the Executive begins alternative employment during the Instalment Period and for any calendar month during that period the Executive's Other Income is less

than the monthly instalment of the Notice Payment, the Executive shall only be entitled to receive the balance of the monthly instalment of the Notice Payment having been reduced by the Executive's Other Income for that month;

- (c) if the Executive does not obtain alternative employment and receives no Other Income, the Notice Payment will continue to be paid in monthly instalments until the expiry of the Instalment Period;
- (d) if the Executive obtains alternative employment, consultancy or other paid work that is to begin during the Instalment Period, the Executive agrees to advise the Company of this fact and of his total Other Income from that employment, consultancy or work immediately;
- (e) the Executive shall be under a continuing duty during the Instalment Period:
  - (i) to use reasonable endeavours to secure other income; and
  - (ii) not to unreasonably refuse any offer of alternative employment or other paid work;
  - (iii) and in the event that the Executive fails to comply with either of these obligations, his entitlement to receive payments under this Clause 18 shall cease.

18.4 If subsequent to the termination of Employment, the Executive is found to have breached any of the terms of this Agreement or the Executive's duties to the Company during the Employment such that the Company would have been entitled to terminate the Employment without notice or payment in lieu of notice, the Company shall be entitled to recover any payments made under Clauses 8 and/or 18.3 and/or to cease making further payments under Clause 18.3 with immediate effect. Any such payments already made shall be recoverable from the Executive as a debt.

#### 18.5 Termination on Account of Illness or Injury

18.5.1 Without prejudice to Clauses 18.1 (*Summary Dismissal*) and 18.3 (*Payment in Lieu of Notice*), but notwithstanding any other provision of this Agreement, if the Executive shall become unable to perform his duties properly by reason of illness or injury for a period or periods aggregating at least 26 weeks in any period of 12 consecutive calendar months (the "**Period or Periods of Incapacity**") then the Company may, by not less than 12 months prior written notice to the Executive, terminate the Employment provided that the Company shall withdraw any such notice if during the currency of the notice the Executive returns to full time duties and provides a medical practitioner's certificate satisfactory to the Board to the effect that he has fully recovered his health and that no recurrence of his illness or injury can reasonably be anticipated.

#### 18.6 Miscellaneous

18.6.1 Upon termination of the Employment for whatever reason the Executive shall forthwith deliver to the Company or its authorised representative such of the following as are in his possession or control:-

- (a) all keys, security and computer passes, plans, statistics, documents, records, papers, magnetic disks, Confidential Information, tapes, or other software storage media including any copies thereof and all matter derived from such sources which is in his possession or under his control which belong to the Group or which relate to the business of the Group including all copies, records and memoranda (whether or not recorded in writing or on computer disk or tape) made by the Executive of any Confidential Information;
- (b) all credit cards and charge cards provided for the Executive's use by the Company; and

(c) all other property of the Group not previously referred to in this Clause.

18.6.2 The Executive will provide a signed statement that he has complied fully with his obligations under this Clause 18.6 together with such reasonable evidence of compliance as the Company may request.

18.7 Upon termination of the Executive's employment howsoever arising the Executive shall have no rights as a result of this Agreement (or any alleged breach of it) to any compensation under or in respect of any share options, bonus or long-term incentive plans in which he may have participated or have received grants or allocations at or before the date the Executive's employment terminates. Any rights which he may have under such schemes shall be exclusively governed by the rules of such schemes.

## **19. DISCIPLINARY AND GRIEVANCE PROCEDURES**

19.1 The Company's normal disciplinary (which cover decisions regarding dismissal) and grievance procedures from time to time apply to the Executive's employment with such modifications as the Company may deem to be necessary to take account of the Executive's seniority. The said disciplinary and grievance procedures shall not have contractual effect and the Company shall not therefore be obliged to follow the procedures or any part thereof in whole or in part at any stage of the Employment.

19.2 If the Executive is dissatisfied with any disciplinary decision taken against him (including a decision to dismiss him) or if the Executive seeks redress for any grievance relating to the Employment he should raise the issue in writing with the Board. Full details of how to go about this and the steps that follow such application are set out in the Company's disciplinary and grievance procedures.

19.3 The Company may suspend the Employee from any or all of his duties during any period in which the Company is investigating any disciplinary or performance matter involving the Employee or while any disciplinary or performance procedure against the Employee is outstanding. During any period of suspension, the provisions of the second sentence of Clause 4.5 shall apply.

## **20. DIRECTORSHIPS AND SHAREHOLDINGS**

20.1 During the Employment the Executive will not do anything which could cause him to be disqualified from continuing to act as a director of the Company or any Group Company.

20.2 The Executive shall not resign his office as a director of the Company or any Group Company without the agreement of the Company.

20.3 The Executive shall, at the written request of the Board:-

20.3.1 immediately resign (without claim for compensation) from all and any directorships and other offices held in the Company and any Group Company and from any other appointments or offices which he holds as nominee or representative of the Company and/or any Group Company; and

20.3.2 transfer without payment as the Company may direct any qualifying shares held by the Executive in accordance with the Articles of Association of the Company and/or any Group Company

and in the event of his failure to do so within 7 days of the said request the Executive hereby irrevocably authorises any director of the Company for the time being in his name and on his behalf to execute any documents or do anything else that is necessary to effect such resignations and/or transfers. For the avoidance of doubt, the Board may make a request in accordance with this Clause at any time, including, but not limited to, in circumstances where the Executive is on garden leave pursuant to Clause 4.5, has been suspended from the Employment pursuant to this Agreement or where the Employment has terminated for any reason.

20.4 If during the Employment the Executive shall cease to be a director of the Company or any Group Company (otherwise than for a reason justifying summary dismissal pursuant to Clause 18.1.6) the

Company may by written notice terminate the Employment or alternatively, at the discretion of the Company, the Employment shall continue as if the Executive had been employed as an Executive Manager and the terms of this Agreement (save those relating to the holding of the office of director) shall continue in full force and effect.

21 **RECONSTRUCTION**

If the Employment of the Executive is terminated by reason of the liquidation, reorganisation, or other reconstruction of the Company or any Group Company or as part of any other rearrangement of the affairs of the Company or any Group Company not involving a liquidation, and the Executive is offered employment by a reconstructed Company or by another Group Company on terms which (considered in their entirety) are no less favourable to any material extent than the terms of this Agreement then, subject to the provisions of the Transfer of Undertakings (Protection of Employment) Regulations 2006, the Executive shall be obliged to accept such offer and shall have no claim against the Company or any reconstructed or Group Company in respect of the termination of the Employment.

22. **CONFIDENTIAL INFORMATION**

22.1 The Executive is aware that in the course of the Employment he will have access to and be entrusted with information in respect of the business and finances of the Company and its dealings, transactions and affairs and likewise in relation to any Group Company all of which information is or may be Confidential Information. Accordingly the Executive gives the undertakings set out in this Clause 22 to the Company for itself and for the benefit of and as trustee for any Group Company.

22.2 The Executive shall not during the Employment or afterwards use, exploit (except for the benefit of the Group) or divulge to any third party by any means any Confidential Information except he shall be permitted to do so:-

22.2.1 when necessary in the proper performance of the duties of the Employment;

22.2.2 with the express written consent of the Board; or

22.2.3 where and to the extent that this is required by law.

22.3 The Executive shall, during the Employment, use his best endeavours to prevent the unauthorised use or disclosure of any Confidential Information whether by any other officer, employee or agent of the Group or otherwise and shall be under an obligation promptly and fully to report to the Board any such unauthorised use or disclosure which comes to his knowledge.

22.4 The Executive shall not, during the Employment or at any time thereafter make, except for the benefit of the Company or any Group Company, any copy, record, or memorandum (whether recorded in writing, on computer disk or tape or otherwise) of any Confidential Information and any such copy record or memorandum made by the Executive during the Employment shall be and remain the property of the Company and accordingly shall be returned by the Executive to the Company at any time during the Employment at the request of the Board and in any event upon the termination of the Employment for whatever reason in accordance with Clause 18.6.1(a).

22.5 The Executive shall not during the Employment either directly or indirectly publish, to the extent that this could be a breach of this wider Clause 22 or be damaging to the reputation or interests of the Company any opinion, fact or material or deliver any lecture or address or participate in the making of any film, radio broadcast or television transmission or communicate with any representative of the media or any third party relating to:-

22.5.1 the business or affairs of the Company or any Group Company or of any of their officers, employees, customers, clients, suppliers, distributors, agents or shareholders; or

22.5.2 the development or exploitation of any Intellectual Property Rights, Inventions or Confidential Information

and for the purposes of this Clause media shall include television (terrestrial, satellite and cable), radio, newspapers and other journalistic publications.

22.6 Nothing in this Clause 22 shall prevent the Executive from disclosing information which he is entitled to disclose under the Public Interest Disclosure Act 1998 provided that the disclosure is made in the appropriate way to an appropriate person having regard to the provisions of the Act and he has first complied with the Company's procedures relating to such disclosures.

22.7 This Clause is without prejudice to the Executive's obligations under Clause 27 (*Data Protection*).

### 23. POST TERMINATION COVENANTS

23.1 For the purposes of this Clause 23 the following words and expressions shall have the following meanings:-

23.1.1	<b>"Business"</b>	the business or businesses of the Company or any other Group Company in or with which the Executive has been involved or concerned at any time during the period of 12 months prior to the Termination Date
23.1.2	<b>"directly or indirectly"</b>	the Executive acting either alone and on his own behalf or jointly with or on behalf of any other person, whether as principal, partner, manager, employee, contractor, director, consultant, investor or otherwise
23.1.3	<b>"Key Personnel"</b>	any person who is at the Termination Date or was at any time during the period of 12 months prior to the Termination Date employed in the Business or in an executive or senior managerial capacity and with whom the Executive has had dealings other than in a de minimis way during the course of the Employment
23.1.4	<b>"Prospective Customer"</b>	any person, firm or company which has been engaged in negotiations, with which the Executive has been personally involved, with the Company or any Group Company with a view to purchasing goods or services from the Company or any Group Company during the period of 6 months prior to the Termination Date
23.1.5	<b>"Relevant Area"</b>	the United Kingdom or any other country
23.1.6	<b>"Relevant Customer"</b>	any person, firm or company which at any time during the 12 months prior to the Termination Date was a customer of the Company or any Group Company, with whom or which the Executive dealt other than in a de minimis way or for whom or which the Executive was responsible in a supervisory or managerial capacity on behalf of the Company or any Group Company at any time during the said period
23.1.7	<b>"Relevant Goods and Services"</b>	any goods and services competitive with those supplied by the Company or any Group Company at any time during the 12 months prior to the Termination Date in the supply of which the Executive was involved or concerned other than in a de minimis way at any time during the said period
23.1.8	<b>"Relevant Period"</b>	for the purposes of Clause 23.2, the period of 6 months from the Termination Date and, for the purposes of Clauses 23.3, 23.4 and 23.5, the period of 12 months from the Termination Date except that any period of

garden leave served by the Executive pursuant to Clause 4.5 in the 12 months prior to the Termination Date shall reduce the Relevant Period accordingly

- 23.1.9       **"Relevant Supplier"** any person, firm or company which at any time during the 12 months prior to the Termination Date was a supplier of any goods or services (other than utilities and goods or services supplied for administrative purposes) to the Company or any Group Company and with whom or which the Executive had personal dealings during the Employment other than in a de minimis way
- 23.1.10       **"Termination Date"** the date on which the Employment shall terminate
- 23.2       Without prejudice to Clause 5.6 (Executive not to be employed in any other business) the Executive shall not without the prior written consent of the Board directly or indirectly at any time within the Relevant Period engage or be materially concerned or materially interested in any business within the Relevant Area which (a) competes or (b) will at any time during the Relevant Period compete with the Business. Nothing in this Clause 23.2 shall prevent the Executive from being or becoming a Minority Holder provided that the Executive discloses this to the Board.
- 23.3       The Executive shall not, other than during the Employment in the ordinary and proper course of his duties and for the benefit of the Company, without the prior written consent of the Board directly or indirectly at any time within the Relevant Period:-
- 23.3.1       solicit the custom of; or
- 23.3.2       facilitate the solicitation of; or
- 23.3.3       deal with
- any Relevant Customer in respect of any Relevant Goods and Services; or
- 23.3.4       solicit the custom of; or
- 23.3.5       facilitate the solicitation of; or
- 23.3.6       deal with
- any Prospective Customer in respect of any Relevant Goods and Services; or
- 23.3.7       interfere; or
- 23.3.8       endeavour to interfere
- with the continuance of supplies to the Company and/or any Group Company (or the terms relating to those supplies) by any Relevant Supplier.
- 23.4       The Executive shall not without the prior written consent of the Board directly or indirectly at any time during the Relevant Period:-
- 23.4.1       entice away from the Company or any Group Company; or
- 23.4.2       endeavour to entice away from the Company or any Group Company
- any Key Personnel.
- 23.5       The Executive shall not without the prior written consent of the Board directly or indirectly at any time during the Relevant Period:-
- 23.5.1       employ or engage; or

23.5.2 endeavour to employ or engage

any Key Personnel.

- 23.6 The Executive acknowledges that because of the nature of his duties and the particular responsibilities arising as a result of such duties he has or will have knowledge of Confidential Information and has/will have developed relationships with and have knowledge of and influence over the Group's customers and staff and is therefore in a position to harm the goodwill and interests of the Company and any Group Companies (the "Interests") if he were to make use of such Confidential Information or knowledge or influence for his own purposes or the purposes of another. Accordingly, having regard to the above and having taken independent legal advice, the Executive acknowledges that the provisions of this Clause are fair, reasonable and necessary to protect the Interests. Whilst the provisions of this Clause 23 have been framed with a view to ensuring that the Interests are adequately protected taking account of the Group's legitimate expectations of the future development of the business, it is acknowledged by the Executive that the business may change over time and as a result it may become necessary to amend the provisions of this Clause 23 in order to ensure that the Interests remain adequately protected. The Executive, therefore, agrees that the Company shall be entitled to amend the provisions of this Clause 23 in accordance with Clause 23.7 below in order to protect the Interests.
- 23.7 In order to amend the provisions of this Clause 23, the Company shall notify the Executive in writing of why it believes it is necessary to amend Clause 23 and the amendments which it proposes. The Executive shall then have a period of 14 calendar days in which to put forward any objections which he might have to the proposed amendments. In the event of the Executive not putting forward any such objections, then this Clause 23 shall take effect with the proposed amendments on the expiry of the 14 day period. In the event of the Executive putting forward any objections, the Company shall endeavour to accommodate them, insofar as they are reasonable and where reasonably possible, given that the Company's overriding objective must be to ensure adequate protection of the Interests, to agree the amendments with the Executive. The Company shall then, having considered the Executive's objections, serve a further written notice on the Executive informing him of the final amendments to this Clause 23 which will thereafter take immediate effect.
- 23.8 The Executive acknowledges that the provisions of this Clause 23 shall constitute severable undertakings given to the Company for itself and for the benefit of and as trustee for each of the other Group Companies and the said undertakings may be enforced by the Company on its own behalf and on behalf of any of the Group Companies.
- 23.9 Each of the obligations in this Clause 23 is an entire separate and independent restriction on the Executive. If any part is found to be invalid or unenforceable the remainder will remain valid and enforceable.
- 23.10 If any of the restrictions or obligations contained in this Clause 23 is held not to be valid on the basis that it exceeds what is reasonable for the protection of the goodwill and interests of the Company or any Group Company but would be valid if part of the wording were deleted then such restrictions or obligations shall apply with such deletions as may be necessary to make it enforceable.
- 23.11 The Executive acknowledges and agrees that he shall be obliged to draw the provisions of this Clause 23 to the attention of any third party who may at any time before or after the termination of the Employment offer to employ or engage the Executive in any capacity and for whom or with whom the Executive intends to work during the Relevant Period.
- 23.12 The Executive shall, at the request and cost of the Company, enter into a direct agreement or undertaking with any Group Company to which the Executive provides services whereby he will accept restrictions corresponding to the restrictions in this Clause (or such of them as may be appropriate in the circumstances) as the Company may require in the circumstances.
- 23.13 The Executive agrees that if the Company transfers all or any part of its business to a third party (the "**Transferee**"), the restrictions contained in this Clause 23 shall, with effect from the date that the Executive becomes an employee of the Transferee, apply to the Executive as if references to

the Company include the Transferee and references to any Group Company include any Group Company of the Transferee.

**24. INTELLECTUAL PROPERTY**

- 24.1 It shall be a duty of the Executive during the Employment to consider and keep under review the ways if any in which the products, services, processes, equipment, systems and activities of the Company and any Group Company might be improved, enhanced and/or developed.
- 24.2 If during the course of his Employment the Executive alone or with others (including without limitation those others who are under his direction) makes, discovers, develops, or directs the discovery of any Invention he shall promptly disclose it to the Board giving full particulars of it including all necessary drawings, know how, models, specifications or other material related to the Invention, and the Executive agrees and acknowledges that:-
- 24.2.1 because of the nature of his duties and the responsibilities arising from them he has a special obligation to further the interests of the Company so that all Inventions made, discovered, developed, or directed by the Executive in the performance of his duties or as a result of any special project for the Company outside the scope of his normal duties and all rights in such Inventions shall belong to the Company; and
- 24.2.2 the provisions of this Clause 24.2.2:-
- (a) shall not entitle the Executive to any compensation beyond the Salary and bonus to which he is entitled under Clause 8 of this Agreement except that nothing in this Agreement excludes or restricts any rights which the Executive may have to claim additional compensation by virtue of section 40 of the Patents Act 1977, in the case of any Invention in relation to which a British patent has been granted, and in relation to which the Company has derived outstanding benefit from such Invention and/or the patent for it; and
- (b) shall not restrict the Executive's rights under sections 39 to 43 of the Patents Act 1977.
- 24.3 The Executive shall promptly disclose to the Board (and hand over on demand) any and all Material written, originated, produced, devised, conceived, created, developed or directed by the Executive during the course of the Employment (whether alone or with others (including without limitation those others who are under his direction) and whether in the performance of his duties or as a result of any special project for the Company outside the scope of his normal duties) and hereby acknowledges that by virtue of the Employment and his position in the Company the Intellectual Property Rights in such Material vest automatically and forthwith in the Company.
- 24.4 The Executive hereby waives all and any moral rights (as defined in Chapter IV of the Copyright Designs and Patents Act 1988).
- 24.5 The Executive shall, at the cost of the Company and on demand, execute all such documents and do all such other acts as the Company shall require to enable the Company or its nominee to obtain the full benefit of any Invention (and all the rights therein) or Intellectual Property Rights in any Material to which the Company is entitled and to secure (in the case of all registered Intellectual Property Rights) such registration or similar protection in any part of the world as the Company may consider appropriate.
- 24.6 The Executive shall, give to the Company, or any successor in title there from, such assistance as the Company may require (in its absolute discretion) in connection with any dispute or threatened dispute directly or indirectly relating to any Invention or Intellectual Property Right in any Material or any associated right or registration or other protection in respect thereof (including but not limited to the execution of documents, the swearing of any declarations or oaths, the providing of information and the participation in any proceedings before any Court or tribunal).

- 24.7 The Executive shall not disclose to any other Person without the consent of the Company being previously obtained (which if given may be subject to conditions) the details of any Invention or Material.
- 24.8 The Executive hereby irrevocably appoints the Company to be his attorney in his name and on his behalf to execute or sign all such documents and to do all such acts as may be necessary or desirable to give effect to this Clause 24.
- 24.9 If the Executive shall during the Employment make or discover any Invention, or write, originate, produce, devise, conceive, create, develop or direct any Material (whether alone or with others (including without limitation those others who are under his direction) and whether in the performance of his duties or as a result of any special project for the Company outside the scope of his normal duties), in which despite the previous provisions of this Clause, any Intellectual Property Rights (including any patents) belong to the Executive and not the Company then the Executive shall if so required by the Board until such rights shall be fully and absolutely vested in the Company shall hold the same as trustee for the Company.
- 24.10 Decisions as to the patenting and exploitation of any Invention shall be at the sole discretion of the Company and the Company shall not be under any obligation to take any step or register any patent or other right in respect of, or to develop or exploit, any Invention or Material discovered, written, originated, produced, devised, conceived, created, developed or directed by the Executive.
- 24.11 Nothing in this Clause shall be taken to limit or derogate from the obligations of the Executive under Clause 22 (confidential information).

## **25. MISREPRESENTATION**

The Executive shall not, after termination of the Employment, wrongfully represent himself as being employed by, or connected with or interested in the Company or any Group Company.

## **26. REFERENCES**

The Company is under no obligation to provide a reference in respect of the Executive either during or after the Employment. However, if it agrees to do so it will use reasonable efforts to ensure that any such reference is accurate. The Company shall not, in the absence of malice, be liable to the Executive for any error in or omission from any such reference.

## **27. DATA PROTECTION**

- 27.1 The Executive shall at all times during the Employment act in accordance with the Data Protection Act 1998 (the "**1998 Act**") and shall comply with any policy introduced by the Company from time to time to comply with the 1998 Act. Breach of this undertaking will constitute a serious disciplinary offence.
- 27.2 The Executive agrees to provide the Company in its capacity as Data Controller with all Personal Data relating to him which is necessary or reasonably required for the proper performance of this Agreement, the administration of the employment relationship (both during and after the Employment) or the conduct of the Company's business or where such provision is required by law (the "**Authorised Purposes**").
- 27.3 The Executive explicitly consents to the Company or any Group Company processing his Personal Data, including his Sensitive Personal Data, where this is necessary or reasonably required to achieve one or more of the Authorised Purposes (including without limitation any self-certification forms or medical certificates supplied to the Company to explain the Executive's absence by reason of illness or injury, any records of sickness absence, any medical reports or health assessments, any details of his trade union membership and any information relating to any criminal convictions or any criminal charges secured or brought against him).
- 27.4 The Executive acknowledges that the Company may, from time to time collect or disclose his Personal Data (including his Sensitive Personal Data) from and to third parties (including without limitation the Executive's referees, any management consultants or computer maintenance

companies engaged by the Company, the Company's professional advisers, other Group Companies and any potential purchasers of the business). The Executive consents to such collection and disclosure even where this involves the transfer of such data outside the European Economic Area where this is necessary or reasonably required to achieve one or more of the Authorised Purposes or is in the interests of the Company and/or its shareholders.

27.5 The Company agrees to process any Personal Data made available to it by the Executive in accordance with the provisions of the 1998 Act.

27.6 In this Clause "**Data Controller**" "**Personal Data**" "**processing**" and "**Sensitive Personal Data**" shall have the meaning set out in sections 1 and 2 of the 1998 Act.

## **28. THIRD PARTY RIGHTS**

28.1 The Company and the Executive agree that no term of this Agreement (including the terms of any documents incorporated either expressly or by implication into this Agreement) shall be enforceable by a Third Party in his own right by virtue of section 1(1) of the Contracts (Rights of Third Parties) Act 1999 and for the avoidance of doubt this Agreement may be rescinded or varied in whole or in part by agreement between the Company and the Executive without the consent of any such Third Party.

28.2 For the purposes of this Clause a "**Third Party**" means any person who is not named as a party to this Agreement.

## **29. PREVIOUS AGREEMENTS**

29.1 This Agreement including any documents incorporated into this Agreement constitutes the entire understanding between the parties with respect to its subject matter and supersedes all previous agreements and undertakings (if any) relating to the employment of the Executive by the Company or any Group Company.

29.2 The Executive acknowledges that he has not been induced to enter into this Agreement by any representation, warranty or undertaking not expressly incorporated into it. The Executive agrees and acknowledges that his only rights and remedies in relation to any representation, warranty or undertaking made or given in connection with this Agreement (unless such representation, warranty or undertaking was made fraudulently) will be for breach of the terms of this Agreement, to the exclusion of all other rights and remedies (including those in tort or arising under statute).

## **30. NOTICES**

30.1 Other than dealings in the normal course of business, any notice, request, demand or other communication (collectively Notices) to be given under this Agreement will be deemed to be duly given by either party if:

30.1.1 sent by first class post addressed to the other party at (in the case of a Notice to the Company) its registered office for the time being or (in the case of a Notice to the Executive) the Executive's last known address; or

30.1.2 given personally to (in the case of a Notice to the Company) the Chief Executive of the Company or (in the case of a notice to the Executive) the notice is left at the Executive's last known address or given to the Executive; or

30.1.3 sent by electronic mail to the company email address of the Chief Executive in the case of the Company and the Executive's email address as notified in writing to the Chief Executive from time to time.

30.2 Any such Notice will be deemed to have been given:

30.2.1 if sent by first class post, 48 hours (or, if sent to or from a place outside the United Kingdom, seven days) after the time of posting and, in proving service, it will be sufficient

to prove that the envelope containing such Notice was properly addressed, stamped and put in the post;

30.2.2 if given personally to another director or Chief Executive at the time it is so given;

30.2.3 if left at the Executive's address or given personally, at the time the notice is left or given to the Executive; or

30.2.4 if sent by email, 24 hours after sending.

31 **LAW AND JURISDICTION**

31.1 This Agreement is governed by and shall be construed in accordance with English law.

31.2 The parties submit to the exclusive jurisdiction of the English courts with regard to any dispute or claim arising under this Agreement except to the extent that it is provided elsewhere in this Agreement that such dispute or claim should be resolved by any person acting as an expert.

32. **GENERAL PROVISIONS**

32.1 Any amendment to this Agreement (other than an amendment to Clause 23 which must be made in accordance with Clause 23.7) must be recorded in writing and signed by the parties to be effective.

32.2 The complete or partial invalidity or unenforceability of any provision of this Agreement for any purpose shall in no way affect:-

32.2.1 the validity or enforceability of such provision for any other purpose;

32.2.2 the remainder of such provisions; or

32.2.3 the remaining provisions of this Agreement.

32.3 No waiver by the Company other than one made in writing by resolution of the Board of any breach by the Executive of any provision of this Agreement and no failure, delay or forbearance by the Company in exercising any of its rights shall be taken to be a waiver of such breach or right or shall prevent the Company from later taking any action or making any claim in respect of such breach or right.

32.4 This Agreement may be executed in counterparts which together shall constitute one Agreement. Either party may enter into this Agreement by executing a counterpart and this Agreement shall not take effect until it has been executed by both parties. Delivery of an executed counterpart of a signature page by facsimile shall take effect as delivery of an executed counterpart of this Agreement provided that the relevant party shall give the other the original counterpart (including such signature page) as soon as reasonably practicable thereafter.

**EXECUTED AS A DEED** by the parties on the date which first appears in this Deed.

**SIGNED** as a Deed )  
(but not delivered until dated) by  
**MARK WAY**  
in the presence of:-

Signature of witness:

Name of witness:

Address:

Occupation:

**EXECUTED** as a Deed (but not delivered  
until dated) by **ODEON CINEMAS LIMITED**  
acting by two Directors or a Director  
and the Secretary:-

)  
)  
)  
)  
)

Director

e-Director/Secretary

**SCHEDULE 1**

**STATEMENT OF TERMS AND CONDITIONS**

**(Clause 5.1)**

The following information is given to supplement the information given in the body of the Agreement and to comply with the requirements of section 1 of the Employment Rights Act 1996:-

33. There are no collective agreements which directly affect the terms and conditions of the Employment.
34. The Executive is not required to work outside the UK for a period in excess of one month and accordingly there are no particulars in this regard relevant to the Employment.



**EMPLOYMENT AGREEMENT**

THIS EMPLOYMENT AGREEMENT (this "Agreement") is made and entered into this **11th day of September, 2020**, by and between AMC Entertainment Holdings, Inc., a Delaware corporation (the "Company"), and **Nicole Denson-Randolph** (the "Officer").

**RECITALS**

THE PARTIES ENTER THIS AGREEMENT on the basis of the following facts, understandings and intentions:

- A. The Company desires to obtain the services of the Officer on the terms and conditions set forth in this Agreement.
- B. This Agreement shall govern the employment relationship between the Officer and the Company and supersedes and negates all previous agreements with respect to such relationship.
- C. The Officer desires to be employed by the Company on the terms and conditions set forth in this Agreement.

**AGREEMENT**

NOW, THEREFORE, in consideration of the above recitals incorporated herein and the mutual covenants and promises contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby expressly acknowledged, the parties agree as follows:

**1. Retention and Duties.**

- 1.1 Retention.** The Company does hereby hire, engage and employ the Officer beginning on the date first set forth above (the "Effective Date"), and concluding on the last day of the Period of Employment (as such term is defined in Section 2) on the terms and conditions expressly set forth in this Agreement. The Officer does hereby accept and agree to such hiring, engagement and employment, on the terms and conditions expressly set forth in this Agreement. Officer's employer of record will be Company's wholly owned subsidiary, American Multi-Cinema, Inc.
- 1.2 Duties.** During the Period of Employment, the Officer shall serve the Company as its **Senior Vice President, Content Strategy & Inclusive Programming** and shall have the powers, authorities, duties and obligations of management usually vested in such position of a company of a similar size and similar nature as the Company, and such other powers, authorities, duties and obligations commensurate with such position as the Company's Board of Directors (the "Board") or the Company's Chief Executive Officer may assign from time to time, all subject to the directives of the Board and the corporate policies of the Company as they are in effect from time to time throughout the Period of Employment (including, without limitation, the Company's business conduct and ethics policies, as they may change from time to time).
- 1.3 No Other Employment; Minimum Time Commitment.** During the Period of Employment, the Officer shall (i) devote substantially all of the Officer's business time, energy and skill to the performance of the Officer's duties for the Company, (ii) perform such duties in a faithful, effective and efficient manner to the best of her abilities,

and (iii) hold no other employment. The Officer's service on the boards of directors (or similar body) of other for-profit business entities is subject to the approval of the Board or the Company's Chief Executive Officer. The Company shall have the right to require the Officer to resign from any board or similar body (including, without limitation, any association, corporate, civic or charitable board or similar body) on which Officer may then serve if the Board or the Company's Chief Executive Officer reasonably determines that the Officer's service on such board or body interferes with the effective discharge of the Officer's duties and responsibilities to the Company or that any business related to such service is then in competition with any business of the Company or any of its Affiliates (as such term is defined in Section 5.5), successors or assigns.

**1.4 No Breach of Contract.** The Officer hereby represents to the Company that: (i) the execution and delivery of this Agreement by the Officer and the Company and the performance by the Officer of the Officer's duties hereunder do not and shall not constitute a breach of, conflict with, or otherwise contravene or cause a default under, the terms of any other agreement or policy to which the Officer is a party or otherwise bound or any judgment, order or decree to which the Officer is subject; (ii) the Officer has no information (including, without limitation, confidential information and trade secrets) relating to any other Person (as such term is defined in Section 5.5) which would prevent, or be violated by, the Officer entering into this Agreement or carrying out their duties hereunder; (iii) the Officer is not bound by any employment, consulting, non-compete, confidentiality, trade secret or similar agreement with any other Person; and (iv) the Officer understands the Company will rely upon the accuracy and truth of the representations and warranties of the Officer set forth herein and the Officer consents to such reliance.

**1.5 Location.** The Officer's principal place of employment shall be in the metropolitan Los Angeles, California. The Officer agrees that she will be regularly present at that office. The Officer acknowledges that she will be required to travel from time to time in the course of performing her duties for the Company including periodically to Leawood, Kansas and Beijing, China.

**2. Period of Employment.** The "Period of Employment" shall be a period of two (2) years commencing on the Effective Date and ending at the close of business on the second anniversary of the Effective Date (the "Termination Date"); provided, however, that this Agreement shall be automatically renewed, and the Period of Employment shall be automatically extended, for one (1) additional year on the Termination Date and each anniversary of the Termination Date thereafter. The term "Period of Employment" shall include any extension thereof pursuant to the preceding sentence. Notwithstanding the foregoing, the Period of Employment is subject to earlier termination as provided below in this Agreement.

**3. Compensation.**

**3.1 Base Salary.** During the Period of Employment, the Company shall pay the Officer a base salary (the "Base Salary"), which shall be paid in accordance with the Company's regular payroll practices in effect from time to time, but not less frequently than monthly. The Officer's Base Salary shall be at an annualized rate of **two hundred eighty thousand dollars (\$280,000)**. Officer will also receive a market allowance at an annualized rate of **seventeen thousand dollars (\$17,000)** ("Market Allowance"). The Board (or a committee thereof) will review the Officer's rate of Base Salary on an annual basis and may, in its sole discretion, increase (but not decrease) the rate then in effect.

3.2 **Incentive Bonus.** The Officer shall be eligible to receive an incentive bonus for each fiscal year of the Company that occurs during the Period of Employment (“Incentive Bonus”); provided, that the Officer must be employed by the Company at the end of the fiscal year in order to be eligible for an Incentive Bonus with respect to that fiscal year. If the Officer is not so employed at such time, she shall not be considered to have “earned” any Incentive Bonus with respect to the fiscal year in question. Any Incentive Bonus shall be paid to the Officer in the immediately following fiscal year at the same time that the Company pays its annual bonuses to officers generally. The Officer’s target Incentive Bonus amount for a particular fiscal year of the Company shall be determined by the Company in its sole discretion, based on performance objectives (which may include corporate, business unit or division, financial, strategic, individual or other objectives) established with respect to that particular fiscal year by Company.

3.3 **Long Term Incentives.** The Officer will be considered for long term incentive awards on terms and conditions established by the Board.

3.4 **Clawback.** Notwithstanding any other provisions in this Agreement to the contrary, any incentive-based compensation or any other compensation paid to the Officer pursuant to this Agreement or any other agreement or arrangement with the Company which is subject to recovery under any law, government regulation or stock exchange listing requirement, will be subject to such deductions and clawback as may be required to be made pursuant to such law, government regulation or stock exchange listing requirement (or any policy adopted by the Company (whether in existence as of the Effective Date or later adopted) pursuant to any such law, government regulation or stock exchange listing requirement or otherwise).

#### 4. **Benefits.**

4.1 **Retirement, Welfare and Fringe Benefits.** During the Period of Employment, the Officer shall be entitled to participate in all retirement and welfare benefit plans and programs, and fringe benefit plans and programs, made available by the Company to the Company’s executive officers generally, in accordance with the eligibility and participation provisions of such plans and as such plans or programs may be in effect from time to time.

4.2 **Reimbursement of Business Expenses.** The Officer is authorized to incur reasonable expenses in carrying out the Officer’s duties for the Company under this Agreement and shall be entitled to reimbursement for all reasonable business expenses that the Officer incurs during the Period of Employment in connection with carrying out the Officer’s duties for the Company, subject to the Company’s expense reimbursement policies and any pre-approval policies in effect from time to time.

4.3 **Vacation and Other Leave.** During the Period of Employment, the Officer’s annual rate of vacation accrual shall conform with Company’s vacation policies in effect from time to time. The Officer shall also be entitled to all other holiday and leave pay generally available to other Officers of the Company.

#### 5. **Termination.**

5.1 **Termination by the Company.** The Officer’s employment by the Company, and the Period of Employment, may be terminated at any time by the Company: (i) with Cause (as such term is defined in [Section 5.5](#)), or (ii) without Cause, or (iii) in the event of the

Officer's death, or (iv) in the event that the Board determines in good faith that the Officer has a Disability (as such term is defined in Section 5.5).

**5.2 Termination by the Officer.** The Officer's employment by the Company, and the Period of Employment, may be terminated by the Officer with no less than ninety (90) days' advance written notice to the Company (such notice to be delivered in accordance with Section 16); provided, however, that in the case of a termination with Good Reason, the Officer may provide immediate written notice of termination once the applicable cure period (as contemplated by the definition of Good Reason) has lapsed if the Company has not reasonably cured the circumstances that gave rise to the basis for the termination with Good Reason.

**5.3 Benefits Upon Termination.** If the Officer's employment by the Company is terminated during the Period of Employment for any reason by the Company or by the Officer (in any case, the date that the Officer's employment by the Company terminates is referred to as the "Severance Date"), the Company shall have no further obligation to make or provide to the Officer, and the Officer shall have no further right to receive or obtain from the Company, any payments or benefits except as follows:

(a) The Company shall pay the Officer (or, in the event of her death, the Officer's estate) any Accrued Obligations (as such term is defined in Section 5.5);

(b) If, during the Period of Employment, the Officer's employment with the Company terminates as a result of an Involuntary Termination, the Company shall pay the Officer (in addition to the Accrued Obligations), subject to tax withholding and other authorized deductions, an amount equal to one (1) times her annualized Base Salary plus Market Allowance. Such amount is referred to hereinafter as the "Severance Benefit." Subject to Section 5.8(a), the Company shall pay the Severance Benefit to the Officer in substantially equal installments in accordance with the Company's standard payroll practices over a period of twelve (12) consecutive months, with the first installment payable on the last day of the month following the month in which the Officer's Separation from Service (as such term is defined in Section 5.5) occurs. (For purposes of clarity, each such installment shall equal the applicable fraction of the aggregate Severance Benefit. For example, if such installments were to be made on a monthly basis, each installment would equal 1/12<sup>th</sup> of the Severance Benefit.) For the avoidance of doubt, the Severance Benefit is not subject to a duty to mitigate or an offset based on compensation earned after such Involuntary Termination.

(c) Notwithstanding the foregoing provisions of this Section 5.3, if the Officer breaches her obligations under Section 6 or under any other agreement that imposes restrictions with respect to the Officer's activities at any time, from and after the date of such breach and not in any way in limitation of any right or remedy otherwise available to the Company, the Officer will no longer be entitled to, and the Company will no longer be obligated to pay, any remaining unpaid portion of the Severance Benefit; provided that, if the Officer provides the release contemplated by Section 5.4, in no event shall the Officer be entitled to a Severance Benefit payment of less than \$5,000, which amount the parties agree is good and adequate consideration, standing alone, for the Officer's release contemplated by Section 5.4.

(d) The foregoing provisions of this Section 5.3 shall not affect: (i) the Officer's receipt of any benefits otherwise due terminated employees under group insurance

coverage consistent with the terms of an applicable Company welfare benefit plan; (ii) the Officer's rights to continued health coverage under COBRA; (iii) the Officer's receipt of benefits otherwise due in accordance with the terms of the Company's 401(k) plan (if any); or (iv) the Officer's rights (if any) to stock options or other equity-based awards or incentive previously granted, which shall be governed by the terms of the applicable equity incentive plan and award documents.

#### **5.4 Release; Exclusive Remedy.**

(a) This Section 5.4 shall apply notwithstanding anything else contained in this Agreement. As a condition precedent to payment of the Severance Benefit, the Officer shall, prior to the last day of the month following the month in which Executive's Separation from Service (as such term is defined in Section 5.5) occurs, provide the Company and its Affiliates with a valid, executed general release agreement in a form acceptable to the Company (which form shall be substantially in the same form as that attached hereto as Exhibit A), and such release agreement shall have not been revoked or remain revocable by the Officer pursuant to any revocation rights afforded by applicable law.

(b) The Officer agrees that the payments and benefits contemplated by Section 5.3 shall constitute the exclusive and sole remedy for any termination of her employment and the Officer covenants not to assert or pursue any other remedies, at law or in equity, with respect to any termination of employment. The Officer agrees to resign, on the Severance Date, as an officer and director of the Company and any Affiliate of the Company, and as a fiduciary of any benefit plan of the Company or any Affiliate of the Company, and to promptly execute and provide to the Company any further documentation, as requested by the Company, to confirm such resignation.

#### **5.5 Certain Defined Terms.**

(a) As used herein, "Accrued Obligations" means:

- (i) any Base Salary that had accrued but had not been paid on or before the Severance Date;
- (ii) any Incentive Bonus for a completed fiscal year that has not yet been paid, to the extent the Officer is eligible for any such Incentive Bonus for such fiscal year; and
- (iii) any reimbursement due to the Officer pursuant to Section 4.2 for expenses reasonably incurred by the Officer on or before the Severance Date and documented and pre-approved, to the extent applicable, in accordance with the Company's expense reimbursement policies in effect at the applicable time.

(b) As used herein, "Affiliate" of the Company means a Person that directly or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, the Company. As used in this definition, the term "control," including the correlative terms "controlling," "controlled by" and "under common control with," means the possession, directly or indirectly, of the power to direct or cause the direction of management or policies (whether through ownership of securities or any partnership or other ownership interest, by contract or otherwise) of a Person. The term

“Affiliate” shall not include any entity that would not otherwise be an Affiliate of the Company but for the controlling ownership interest of Dalian Wanda Group Co., Ltd. or its successors or related investment funds.

(c) As used herein, “Cause” shall mean, as reasonably determined by the Board (excluding the Officer, if she is then a member of the Board) or Company’s Chief Executive Officer based on the information then known to it, that one or more of the following has occurred:

- (i) the Officer has committed a felony (under the laws of the United States or any relevant state, or a similar crime or offense under the applicable laws of any relevant foreign jurisdiction);
- (ii) the Officer has engaged in acts of fraud, dishonesty, gross negligence or other misconduct including abuse of controlled substances, that is injurious to the Company, its Affiliates or any of their customers, clients or employees;
- (iii) the Officer willfully fails to perform or uphold her duties under this Agreement and/or willfully fails to comply with reasonable directives of the Board or Company’s Chief Executive Officer, in either case, that is not remedied by the Officer within fifteen (15) days after written notice thereof has been delivered to the Officer; or
- (iv) any breach by the Officer of any provision of Section 6, or any material breach by the Officer of any other contract she is a party to with the Company or any of its Affiliates including the code of ethics or another material written policy.

(d) As used herein, “Good Reason” shall mean a termination of the Officer’s employment by means of resignation by the Officer after the occurrence (without the Officer’s consent) of any one or more of the following conditions:

- (i) a material diminution in the Officer’s rate of Base Salary;
- (ii) a material diminution in the Officer’s authority, duties, or responsibilities;
- (iii) a material change in the geographic location of the Officer’s principal office with the Company (for this purpose, in no event shall a relocation of such office to a new location that is not more than fifty (50) miles from the current location of the Company’s executive offices constitute a “material change”); or
- (iv) a material breach by the Company of this Agreement;

provided, however, that any such condition or conditions, as applicable, shall not constitute grounds for a termination with Good Reason unless (x) the Officer provides written notice to the Company of the condition claimed to constitute grounds for a termination with Good Reason within thirty (30) days after the initial existence of such condition(s) (such notice to be delivered in accordance with Section 16), and (y) the Company fails to remedy such condition(s) within thirty (30) days of receiving such written notice thereof; and (z) the termination of the Officer’s employment with the Company shall not constitute a termination with Good Reason unless such termination occurs not more than one hundred

and twenty (120) days following the initial existence of the condition claimed to constitute grounds for a termination with Good Reason.

(e) As used herein, “Disability” shall mean a physical or mental impairment which, as reasonably determined by the Board, renders the Officer unable to perform the essential functions of their employment with the Company, even with reasonable accommodation that does not impose an undue hardship on the Company, for more than 90 days in any 180-day period, unless a longer period is required by federal or state law, in which case that longer period would apply.

(f) As used herein, “Involuntary Termination” shall mean (i) a termination of the Officer’s employment by the Company without Cause (and other than due to Officer’s death or in connection with a good faith determination by the Board that the Officer has a Disability), or (ii) a termination with Good Reason.

(g) As used herein, the term “Person” shall be construed broadly and shall include, without limitation, an individual, a partnership, a limited liability company, a corporation, an association, a joint stock company, a trust, a joint venture, an unincorporated organization and a governmental entity or any department, agency or political subdivision thereof.

(h) As used herein, a “Separation from Service” occurs when the Officer dies, retires, or otherwise has a termination of employment with the Company that constitutes a “separation from service” within the meaning of Treasury Regulation Section 1.409A-1(h)(1), without regard to the optional alternative definitions available thereunder.

**5.6 Notice of Termination.** Any termination of the Officer’s employment under this Agreement shall be communicated by written notice of termination from the terminating party to the other party. This notice of termination must be delivered in accordance with Section 16 and must indicate the specific provision(s) of this Agreement relied upon in effecting the termination.

**5.7 Limitation on Benefits.**

(a) To the extent that any payment, benefit or distribution of any type to or for the benefit of the Officer by the Company or any of its Affiliates, whether paid or payable, provided or to be provided, or distributed or distributable pursuant to the terms of this Agreement or otherwise (including, without limitation, any accelerated vesting of stock options or other equity-based awards or incentives) (collectively, the “Total Payments”) would be subject to the excise tax imposed under Section 4999 of the Internal Revenue Code of 1986, as amended (the “Code”), then the Company shall submit for the vote of the stockholders of the Company (the “Stockholders”) the payments to the Officer in a manner that complies with the requirements of Section 280G(b)(5)(B) of the Code and the Treasury Regulations promulgated thereunder. It shall be a prerequisite to the Company’s obligations under this Section 5.7(a) that the Officer shall have executed a valid waiver in a form reasonably satisfactory to the Company and sufficient to enable the Stockholders’ approval to have the effect that no payments to the Officer would be subject to the excise tax under Section 4999 of the Code. If the exemption described in Section 280G(b)(5)(B) of the Code and the Treasury Regulations promulgated thereunder does not apply, then the procedures set forth in Section 5.7(b) and Section 5.7(c) hereof shall apply.

(b) Notwithstanding anything contained in this Agreement to the contrary, to the extent that the Total Payments would be subject to Section 4999 of the Code, then the Total Payments shall be reduced (but not below zero) so that the maximum amount of the Total Payments (after reduction) shall be one dollar (\$1.00) less than the amount which would cause the Total Payments to be subject to the excise tax imposed by Section 4999 of the Code. Unless the Officer shall have given prior written notice to the Company to effectuate a reduction in the Total Payments that complies with the requirements of Section 409A of the Code to avoid the imputation of any tax, penalty or interest thereunder, the Company shall reduce or eliminate the Total Payments by first reducing or eliminating any cash severance benefits (with the payments to be made furthest in the future being reduced first), then by reducing or eliminating any accelerated vesting of stock options or similar awards, then by reducing or eliminating any other remaining Total Payments. The preceding provisions of this Section 5.7(b) shall take precedence over the provisions of any other plan, arrangement or agreement governing the Officer's rights and entitlements to any benefits or compensation.

(c) Any determination that Total Payments to the Officer must be reduced or eliminated in accordance with Section 5.7(b) and the assumptions to be utilized in arriving at such determination, shall be made by the Board in the exercise of its reasonable, good faith discretion based upon the advice of such professional advisors it may deem appropriate in the circumstances. As a result of the uncertainty in the application of Section 4999 of the Code at the time of the initial determination by the Board hereunder, it is possible that Total Payments to the Officer which will not have been made by the Company should have been made ("Underpayment"). If an Underpayment has occurred, the amount of any such Underpayment shall be promptly paid by the Company to or for the benefit of the Officer. In the event that any Total Payment made to the Officer shall be determined to otherwise result in the imposition of any tax under Section 4999 of the Code, then the Officer shall promptly repay to the Company the amount of any such Underpayment together with interest on such amount (at the same rate as is applied to determine the present value of payments under Section 280G of the Code or any successor thereto), from the date the reimbursable payment was received by the Officer to the date the same is repaid to the Company.

#### **5.8 Section 409A.**

(a) If the Officer is a "specified employee" within the meaning of Treasury Regulation Section 1.409A-1(i) as of the date of the Officer's Separation from Service and the Severance Benefit or any other amount payable under this Agreement constitutes deferred compensation within the meaning of Section 409A of the Code, the Officer shall not be entitled to such Severance Benefit or other amount until the earlier of (i) the date which is six (6) months after her Separation from Service for any reason other than death, or (ii) the date of the Officer's death. The provisions of this paragraph shall apply only if, and to the extent, required to avoid the imputation of any tax, penalty or interest pursuant to Section 409A of the Code after taking into account all applicable exemptions available thereunder. Any amounts otherwise payable to the Officer upon or in the six (6) month period following the Officer's Separation from Service that are not so paid by reason of this Section 5.8(a) shall be paid (without interest) as soon as practicable (and in all events within thirty (30) days) after the date that is six (6) months after the Officer's Separation from Service (or, if earlier, as soon as practicable, and in all events within thirty (30) days, after the date of the Officer's death).

(b) It is intended that any amounts payable under this Agreement and the Company's and the Officer's exercise of authority or discretion hereunder shall comply with and avoid the imputation of any tax, penalty or interest under Section 409A of the Code. This Agreement shall be construed and interpreted consistent with that intent. Nothing contained herein is intended to provide a guarantee of tax treatment to the Officer. For purposes of Section 409A of the Code, the Officer's right to receive installment payments pursuant to Section 5.3(b) shall be treated as a right to receive a series of separate and distinct payments.

**6. Protective Covenants.**

**6.1 Confidential Information; Inventions.**

(a) The Officer shall not disclose or use at any time, either during the Period of Employment or thereafter, any confidential information (as defined below) of which the Officer is or becomes aware, whether or not such information is developed by her, except to the extent that such disclosure or use is directly related to and required by the Officer's performance in good faith of duties for the Company. The Officer will take all appropriate steps to safeguard confidential information in her possession and to protect it against disclosure, misuse, espionage, loss and theft. The Officer shall deliver to the Company at the termination of the Period of Employment, or at any time the Company may request, all memoranda, notes, plans, records, reports, computer tapes and software and other documents and data (and copies thereof) relating to the confidential information or the Work Product (as hereinafter defined) of the business of the Company or any of its Affiliates which the Officer may then possess or have under her control. Notwithstanding the foregoing, the Officer may truthfully respond to a lawful and valid subpoena or other legal process, but shall give the Company the earliest possible notice thereof, shall, as much in advance of the return date as possible, make available to the Company and its counsel the documents and other information sought, and shall assist the Company and such counsel in resisting or otherwise responding to such process.

(b) As used in this Agreement, the term "Confidential Information" means information that is not generally known to the public and that is used, developed or obtained by the Company or its Affiliates in connection with their respective businesses, including, but not limited to, information, observations and data obtained by the Officer while employed by the Company or any predecessors thereof (including those obtained prior to the Effective Date) concerning (i) the business or affairs of the Company or its Affiliates (or such predecessors), (ii) products or services, (iii) fees, costs, compensation and pricing structures, (iv) designs, (v) analyses, (vi) drawings, photographs and reports, (vii) computer software, including operating systems, applications and program listings, (viii) flow charts, manuals and documentation, (ix) data bases, (x) accounting and business methods, (xi) inventions, devices, new developments, methods and processes, whether patentable or unpatentable and whether or not reduced to practice, (xii) customers and clients and customer or client lists, (xiii) other copyrightable works, (xiv) all production methods, processes, technology and trade secrets, and (xv) all similar and related information in whatever form. Confidential Information will not include any information that has been published (other than a disclosure by the Officer in breach of this Agreement) in a form generally available to the public prior to the date the Officer proposes to disclose or use such information. Confidential Information will not be deemed to have been published merely because individual portions of the information have been separately published, but

only if all material features comprising such information have been published in combination.

(c) As used in this Agreement, the term “Work Product” means all inventions, innovations, improvements, technical information, systems, software developments, methods, designs, analyses, drawings, reports, service marks, trademarks, trade names, logos and all similar or related information (whether patentable or unpatentable, copyrightable, registerable as a trademark, reduced to writing, or otherwise) which relates to the Company’s or any of its Affiliates’ actual or anticipated business, research and development or existing or future products or services and which are conceived, developed or made by the Officer (whether or not during usual business hours, whether or not by the use of the facilities of the Company or any of its Affiliates, and whether or not alone or in conjunction with any other person) while employed by the Company (including those conceived, developed or made prior to the Effective Date) together with all patent applications, letters patent, trademark, trade name and service mark applications or registrations, copyrights and reissues thereof that may be granted for or upon any of the foregoing. All Work Product that the Officer may have discovered, invented or originated during her employment by the Company or any of its Affiliates prior to the Effective Date, that she may discover, invent or originate during the Period of Employment or at any time in the period of twelve (12) months after the Severance Date, shall be the exclusive property of the Company and its Affiliates, as applicable, and Officer hereby assigns all of Officer’s right, title and interest in and to such Work Product to the Company or its applicable Affiliate, including all intellectual property rights therein. Officer shall promptly disclose all Work Product to the Company, shall execute at the request of the Company any assignments or other documents the Company may deem necessary to protect or perfect its (or any of its Affiliates’, as applicable) rights therein, and shall assist the Company (or any of its Affiliates, as applicable), at the Company’s expense, in obtaining, defending and enforcing the Company’s (or any of its Affiliates’, as applicable) rights therein. The Officer hereby appoints the Company as her attorney-in-fact to execute on her behalf any assignments or other documents deemed necessary by the Company to protect or perfect the Company’s (and any of its Affiliates’, as applicable) rights to any Work Product.

**6.2 Intentionally Omitted.**

**6.3 Non-Solicitation of Employees and Consultants.** During the Period of Employment and for a period of twelve (12) months after the Severance Date, the Officer will not directly or indirectly through any other Person (i) induce or attempt to induce any employee or independent contractor of the Company or any Affiliate of the Company to leave the employ or service, as applicable, of the Company or such Affiliate, or in any way interfere with the relationship between the Company or any such Affiliate, on the one hand, and any employee or independent contractor thereof, on the other hand, or (ii) hire any person who was an employee of the Company or any Affiliate of the Company until twelve (12) months after such individual’s employment relationship with the Company or such Affiliate has been terminated.

**6.4 Non-Solicitation of Customers.** During the Period of Employment and for a period of twelve (12) months after the Severance Date, the Officer will not directly or indirectly through any other Person influence or attempt to influence customers, vendors, suppliers, licensors, lessors, joint venturers, associates, consultants, agents, or partners of the Company or any Affiliate of the Company to divert their business away from the Company or such Affiliate, and the Officer will not otherwise interfere with, disrupt or attempt to

disrupt the business relationships, contractual or otherwise, between the Company or any Affiliate of the Company, on the one hand, and any of its or their customers, suppliers, vendors, lessors, licensors, joint venturers, associates, officers, employees, consultants, managers, partners, members or investors, on the other hand.

**6.5 Nondisparagement.** For the Period of Employment and five years thereafter, the Officer and the Company (acting through any of its executive officers or directors), acknowledge and agree that neither party will defame, disparage or publicly criticize, directly or through another Person, the services, business or reputation of the Company or any of its officers, directors, partners, employees, Affiliates or agents, on the one hand, or the Officer, on the other, in either a professional or personal manner.

**6.6 Understanding of Covenants.** The Officer acknowledges that, in the course of her employment with the Company and/or its Affiliates and their predecessors, she has become familiar, or will become familiar, with the Company's and its Affiliates' and their predecessors' trade secrets and with other confidential and proprietary information concerning the Company, its Affiliates and their respective predecessors and that her services have been and will be of special, unique and extraordinary value to the Company and its Affiliates. The Officer agrees that the foregoing covenants set forth in this Section 6 (together, the "Restrictive Covenants") are reasonable and necessary to protect the Company's and its Affiliates' trade secrets and other confidential and proprietary information, good will, stable workforce, and customer relations.

Without limiting the generality of the Officer's agreement in the preceding paragraph, the Officer (i) represents that she is familiar with and has carefully considered the Restrictive Covenants, (ii) represents that she is fully aware of her obligations hereunder, (iii) agrees to the reasonableness of the length of time, scope and geographic coverage, as applicable, of the Restrictive Covenants, (iv) agrees that the Company and its Affiliates currently conducts business throughout the Restricted Area, and (v) agrees that the Restrictive Covenants will continue in effect for the applicable periods set forth above in this Section 6 regardless of whether the Officer is then entitled to receive severance pay or benefits from the Company. The Officer understands that the Restrictive Covenants may limit her ability to earn a livelihood in a business similar to the business of the Company and any of its Affiliates, but she nevertheless believes that she has received and will receive sufficient consideration and other benefits as an employee of the Company and as otherwise provided hereunder or as described in the recitals hereto to clearly justify such restrictions which, in any event (given her education, skills and ability), the Officer does not believe would prevent her from otherwise earning a living. The Officer agrees that the Restrictive Covenants do not confer a benefit upon the Company disproportionate to the detriment of the Officer.

**6.7 Enforcement.** The Officer agrees that the Officer's services are unique and that she has access to Confidential Information and Work Product. Accordingly, the Officer agrees that a breach by the Officer of any of the covenants in this Section 6 would cause immediate and irreparable harm to the Company that would be difficult or impossible to measure, and that damages to the Company for any such injury would therefore be an inadequate remedy for any such breach. Therefore, the Officer agrees that in the event of any breach or threatened breach of any provision of this Section 6 or any similar provision, the Company shall be entitled, in addition to and without limitation upon all other remedies the Company may have under this Agreement, at law or otherwise, to obtain specific performance, injunctive relief and/or other appropriate relief (without posting any bond or deposit) in

order to enforce or prevent any violations of the provisions of this Section 6 or any similar provision, as the case may be, and/or require the Officer to account for and pay over to the Company all compensation, profits, moneys, accruals, increments or other benefits derived from or received as a result of any transactions constituting a breach of this Section 6 or any similar provision, as the case may be, if and when final judgment of a court of competent jurisdiction or arbitrator is so entered against the Officer. The Officer further agrees that for the applicable period of time any Restrictive Covenant is in effect following the Severance Date, as determined pursuant to the foregoing provisions of this Section 6, such period of time shall be extended by the same amount of time that Officer is in breach of any Restrictive Covenant. Any action to enforce this Agreement pursuant to this Section 6.7 shall be instituted in the United States Federal Court for the District of Kansas or the courts of the State of Kansas located in Johnson County, Kansas, and each party irrevocably submits to the exclusive jurisdiction of such courts in any such suit, action or proceeding. Service of process, summons, notice or other document by mail to such party's address set forth herein shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or any proceeding in such courts and irrevocably waive and agree not to plead or claim in any such court that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum.

**6.8** The Officer agrees to execute any additional documentation as may reasonably be requested by the Company in furtherance of the enforcement of any Restrictive Covenant.

7. **Withholding Taxes.** Notwithstanding anything else herein to the contrary, the Company may withhold (or cause there to be withheld, as the case may be) from any amounts otherwise due or payable under or pursuant to this Agreement such federal, state and local income, employment, or other taxes as may be required to be withheld pursuant to any applicable law or regulation.

8. **Successors and Assigns.**

**8.1** This Agreement is personal to the Officer and without the prior written consent of the Company shall not be assignable by the Officer otherwise than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by the Officer's legal representatives.

**8.2** This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns. As used in this Agreement, "Company" shall mean the Company as hereinbefore defined and any assignee or successor to all or substantially all of the Company's assets, as applicable, which assumes this Agreement by operation of law or otherwise.

9. **Number and Gender; Examples.** Where the context requires, the singular shall include the plural, the plural shall include the singular, and any gender shall include all other genders. Where specific language is used to clarify by example a general statement contained herein, such specific language shall not be deemed to modify, limit or restrict in any manner the construction of the general statement to which it relates.

10. **Section Headings.** The section headings of, and titles of paragraphs and subparagraphs contained in, this Agreement are for the purpose of convenience only, and they neither form a part of this Agreement nor are they to be used in the construction or interpretation thereof.

**11. Governing Law; Arbitration; Waiver of Jury Trial.**

**11.1** THIS AGREEMENT WILL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE, WITHOUT GIVING EFFECT TO ANY CHOICE OF LAW OR CONFLICTING PROVISION OR RULE (WHETHER OF THE STATE OF DELAWARE OR ANY OTHER JURISDICTION) THAT WOULD CAUSE THE LAWS OF ANY JURISDICTION OTHER THAN THE STATE OF DELAWARE TO BE APPLIED. IN FURTHERANCE OF THE FOREGOING, THE INTERNAL LAW OF THE STATE OF DELAWARE WILL CONTROL THE INTERPRETATION AND CONSTRUCTION OF THIS AGREEMENT, EVEN IF UNDER SUCH JURISDICTION'S CHOICE OF LAW OR CONFLICT OF LAW ANALYSIS, THE SUBSTANTIVE LAW OF SOME OTHER JURISDICTION WOULD ORDINARILY APPLY.

**11.2** Except for the limited purpose provided in Section 6.7, any legal dispute related to this Agreement and/or any claim related to this Agreement, or breach thereof, shall, in lieu of being submitted to a court of law, be submitted to arbitration, in accordance with the applicable dispute resolution procedures of the American Arbitration Association. The award of the arbitrator shall be final and binding upon the parties. The parties hereto agree that (i) one arbitrator shall be selected pursuant to the rules and procedures of the American Arbitration Association, (ii) the arbitrator shall have the power to award injunctive relief or to direct specific performance, (iii) each of the parties, unless otherwise required by applicable law, shall bear its own attorneys' fees, costs and expenses and an equal share of the arbitrator's and administrative fees of arbitration and the arbitrator shall award to the prevailing party a sum equal to that party's share of the arbitrator's and administrative fees of arbitration, and (iv) the arbitration shall be conducted in Johnson County, Kansas. Nothing in this Section 11 shall be construed as providing the Officer a cause of action, remedy or procedure that the Officer would not otherwise have under this Agreement or the law.

**11.3** EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT.

**12. Severability.** It is the desire and intent of the parties hereto that the provisions of this Agreement be enforced to the fullest extent permissible under the laws and public policies applied in each jurisdiction in which enforcement is sought. Accordingly, if any particular provision of this Agreement shall be adjudicated by an arbitrator or court of competent jurisdiction to be invalid, prohibited or unenforceable under any present or future law, and if the rights and obligations of any party under this Agreement will not be materially and adversely affected thereby, such provision, as to such jurisdiction, shall be ineffective, without invalidating the remaining provisions of this Agreement or affecting the validity or enforceability of such provision in any other jurisdiction, and to this end the provisions of this Agreement are declared to be severable; furthermore, in lieu of such invalid or unenforceable provision there will be added automatically as a part of this Agreement, a legal, valid and enforceable provision as similar in terms to such invalid or unenforceable provision as may be possible. Notwithstanding the foregoing, if such provision could be more narrowly drawn (as to geographic scope, period of duration or otherwise) so as not to be invalid, prohibited or unenforceable in such jurisdiction, it shall, as to such jurisdiction, be so narrowly drawn, without invalidating the remaining provisions of this Agreement or affecting the validity or enforceability of such provision in any other jurisdiction.

13. **Entire Agreement.** This Agreement embodies the entire agreement of the parties hereto respecting the matters within its scope. This Agreement supersedes all prior and contemporaneous agreements of the parties hereto that directly or indirectly bears upon the subject matter hereof, including, without limitation, any term sheet prepared in connection herewith. Any prior negotiations, correspondence, agreements, proposals or understandings relating to the subject matter hereof shall be deemed to have been merged into this Agreement, and to the extent inconsistent herewith, such negotiations, correspondence, agreements, proposals, or understandings shall be deemed to be of no force or effect. There are no representations, warranties, or agreements, whether express or implied, or oral or written, with respect to the subject matter hereof, except as expressly set forth herein. Notwithstanding the foregoing integration provisions, the Officer acknowledges having received and read the Company's code of ethics and agrees to conduct herself in accordance therewith as in effect from time to time.
14. **Modifications.** This Agreement may not be amended, modified or changed (in whole or in part), except by a formal, definitive written agreement expressly referring to this Agreement, which agreement is executed by both of the parties hereto.
15. **Waiver.** Neither the failure nor any delay on the part of a party to exercise any right, remedy, power or privilege under this Agreement shall operate as a waiver thereof, nor shall any single or partial exercise of any right, remedy, power or privilege preclude any other or further exercise of the same or of any right, remedy, power or privilege, nor shall any waiver of any right, remedy, power or privilege with respect to any occurrence be construed as a waiver of such right, remedy, power or privilege with respect to any other occurrence. No waiver shall be effective unless it is in writing and is signed by the party asserted to have granted such waiver.
16. **Notices.** Any notice provided for in this Agreement must be in writing and must be either personally delivered, transmitted via telecopier, mailed by first class mail (postage prepaid and return receipt requested) or sent by reputable overnight courier service (charges prepaid) to the recipient at the address below indicated or at such other address or to the attention of such other person as the recipient party has specified by prior written notice to the sending party. Notices will be deemed to have been given hereunder and received when delivered personally, when received if transmitted via telecopier, five days after deposit in the U.S. mail and one day after deposit on a weekday with a reputable overnight courier service.

if to the Company:

AMC Entertainment Holdings, Inc.  
11500 Ash Street  
Leawood, KS 66211  
Facsimile: 913-213-2059  
Attn: Chief Executive Officer  
General Counsel

if to the Officer, to the address most recently on file in the payroll records of the Company.

17. **Counterparts.** This Agreement may be executed in any number of counterparts, each of which shall be deemed an original as against any party whose signature appears thereon, and all of which together shall constitute one and the same instrument. This Agreement shall become binding when one or more counterparts hereof, individually or taken together, shall bear the signatures of all of the parties reflected hereon as the signatories. Photographic copies of such signed counterparts may be used in lieu of the originals for any purpose.

18. **Legal Counsel; Mutual Drafting.** Each party recognizes that this is a legally binding contract and acknowledges and agrees that they have had the opportunity to consult with legal counsel of their choice. Each party has cooperated in the drafting, negotiation and preparation of this Agreement. Hence, in any construction to be made of this Agreement, the same shall not be construed against either party on the basis of that party being the drafter of such language. The Officer agrees and acknowledges that Officer has read and understands this Agreement, is entering into it freely and voluntarily, and has been advised to seek counsel prior to entering into this Agreement and has had ample opportunity to do so.

THIS AGREEMENT CONTAINS A BINDING ARBITRATION PROVISION WHICH MAY BE ENFORCED BY THE PARTIES.

*[The remainder of this page has intentionally been left blank.]*

**IN WITNESS WHEREOF**, the Company and the Officer have executed this Agreement as of the day and year first set forth above.

**“COMPANY”**

AMC Entertainment Holdings, Inc.

By: /s/ Carla Chavarria

Carla Chavarria

**“OFFICER”**

By: /s/ Nicole Denson-Randolph

Nicole Denson-Randolph

---

**FORM OF RELEASE<sup>1</sup>**

1. Release by Officer \_\_\_\_\_ (the “Officer”), on their own behalf, on behalf of any entities Officer controls and on behalf of Officer’s descendants, dependents, heirs, executors, administrators, assigns and successors, and each of them, hereby acknowledges full and complete satisfaction of and releases and discharges and covenants not to sue AMC ENTERTAINMENT HOLDINGS, INC. , a Delaware corporation (the “Company”), its divisions, subsidiaries, parents, or affiliated corporations, and each of its and their employees, officers and directors, past and present, and each of them, as well as its assignees and successors (individually and collectively, “Company Releasees”), from and with respect to any and all claims, agreements, obligations, demands and causes of action, known or unknown, suspected or unsuspected, arising out of or in any way connected, in whole or in part, with the Officer’s employment, the termination thereof, or any other relationship with or interest in the Company, including without limiting the generality of the foregoing, any claim for severance pay, profit sharing, bonus or similar benefit, pension, retirement, life insurance, health or medical insurance or any other fringe benefit, or disability, or any other claims, agreements, obligations, demands and causes of action, known or unknown, suspected or unsuspected, resulting from or arising out of, in whole or in part, any act or omission by or on the part of Company Releasees committed or omitted prior to the date of this release agreement (this “Agreement”), including, without limiting the generality of the foregoing, any claim under Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act, the Family and Medical Leave Act, or any other federal, state or local law, regulation or ordinance; provided, however, that the foregoing release does not apply to any obligation of the Company to the Officer pursuant to the benefits due to the Officer in connection with the execution and delivery of this Release Agreement pursuant to Officer’s employment agreement with \_\_\_\_\_ dated as of \_\_\_\_\_, 20\_\_ by and between the Company and the Officer. In addition, this release does not cover any claim that cannot be released as a matter of applicable law.

2. Waiver of Civil Code Section 1542. This Agreement is intended to be effective as a general release of and bar to each and every claim, agreement, obligation, demand and cause of action hereinabove specified (collectively, the “Claims”). Accordingly, the Officer hereby expressly waives any rights and benefits conferred by Section 1542 of the California Civil Code as to the Claims. Section 1542 of the California Civil Code provides:

“A GENERAL RELEASE DOES NOT EXTEND TO A CLAIM WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.”

The Officer acknowledges that Officer later may discover claims, demands, causes of action or facts in addition to or different from those which the Officer now knows or believes to exist with respect to the subject matter of this Agreement and which, if known or suspected at the time of executing this Agreement, may have materially affected its terms. Nevertheless, the Officer hereby waives, as to the Claims, any claims, demands, and causes of action that might arise as a result of such different or additional claims, demands, causes of action or facts.

<sup>1</sup> Subject to revision to the extent advisable based on changes in law or legal interpretation.

\_\_\_\_\_

\_\_\_\_\_

3. ADEA Waiver. The Officer expressly acknowledges and agrees that by entering into this Agreement, Officer is waiving any and all rights or claims that Officer may have arising under the Age Discrimination in Employment Act of 1967, as amended, which have arisen on or before the date of execution of this Agreement. The Officer further expressly acknowledges and agrees that:

- (a) In return for this Agreement, Officer he/she will receive consideration beyond that to which Officer would have been entitled had Officer not entered into this Agreement;
- (b) He/She is hereby advised in writing by this Agreement to consult with an attorney before signing this Agreement;
- (c) He/She was given a copy of this Agreement on [\_\_\_\_, 20\_\_] and informed that they had twenty-one (21) days within which to consider the Agreement; and
- (d) He/She was informed that they have seven (7) days following the date of execution of the Agreement in which to revoke the Agreement.

4. No Transferred Claims. The Officer represents and warrants to the Company that Officer has not heretofore assigned or transferred to any person other than the Company any released matter or any part or portion thereof.<sup>2</sup>

The undersigned has read and understands the consequences of this Agreement and voluntarily signs it. The undersigned declares under penalty of perjury under the laws of the State of [Delaware] that the foregoing is true and correct.

EXECUTED this \_\_\_\_\_ day of \_\_\_\_\_, 20\_\_, at \_\_\_\_\_ County, [State].

“Officer”

~~Name~~ \_\_\_\_\_

Acknowledged and agreed:

AMC ENTERTAINMENT HOLDINGS, INC. on behalf of  
itself and its divisions, subsidiaries, parents, and affiliated  
companies, past and present, and each of them

By:

Name:  
Title:

\_\_\_\_\_

<sup>2</sup> If requested by the Company, the Officer shall provide a separate release from the Officer's spouse at the time of execution.

\_\_\_\_\_

\_\_\_\_\_

## AMC ENTERTAINMENT HOLDINGS, INC. AND SUBSIDIARIES (AND JURISDICTION OF ORGANIZATION)

AC JV, LLC (Delaware) (32%)	Delaware
AMC Card Processing Services, Inc.	Arizona
AMC Concessionaire Services of Florida, LLC	Florida
AMC ITD, LLC	Kansas
AMC License Services, LLC	Kansas
AMC of Maryland, LLC	Maryland
AMC of Maryland II, LLC	Maryland
AMC Theatres of UK Limited	England
American Multi-Cinema, Inc.	Missouri
Centertainment Development, LLC	Delaware
Muvico, LLC	Texas
Diginext, LLC (50%)	Delaware
Digital Cinema Distribution Coalition, LLC (Delaware) (14.67%)	Delaware
Digital Cinema Implementation Partners, LLC (Delaware) (29%)	Delaware
Midlands Water Association (NFP)	Illinois
Shawnee Theatres LLC	Delaware
Sundance Cinemas, LLC	Delaware
SVHoldco LLC (18.3%)	Delaware
ABC Cinemas Ltd	England
Bookit Ltd	England
Cinema International Corporation Lda	Portugal
Cinesa – Compania de Inciativas y Espectaculos SA	Spain
Digital Cinema Media Ltd (50%)	England
Odeon and UCI Cinemas Holdings Limited	England
Odeon Cinemas (RL) Ltd	England
Odeon Cinemas Group Limited (fka AMC (UK) Acquisition Limited)	England
Odeon Cinemas Holdings Ltd	England
Odeon Cinemas Ltd	England
UCI Holdings Ireland Limited	Ireland
UCI Italia SPA	Italy
UCI Recupero e Sviluppo SpA	Italy
Digital Cinema Advertising S.r.l. (50%)	Italy
United Cinemas International (Ireland) Ltd	Ireland
United Cinemas International (UK) Ltd	England
United Cinemas International Acquisitions Ltd	England
United Cinemas International Kinoplex GmbH	Germany
United Cinemas International Multiplex BV	Netherlands
United Cinemas International Multiplex GmbH	Germany
NCG Holding AB	Sweden
Astoria Cinemas Grand AB (50%)	Sweden
Bergen Internasjonale Filmfestival AS (49%)	Norway
Bergen Kino AS (49%)	Norway

---

Bio Rex Cinemas Oy (50%)	Finland
Capa Kinoreklame AS (64.45%)	Norway
Ejendomsselskabet Kattjebjerg A/S (50%)	Denmark
Empire Bio A/S (17.75%)	Denmark
Finnkino Oy	Finland
Handelsbolaget Svenska Bio Lidingö (50%)	Sweden
Västerås Biografer, Aktiebolaget Svensk Filmindustri & Co (50%)	Sweden
Kinovsjon Norge AS (28.91%)	Norway
Location Norway AS (24.5%)	Norway
Naestved Bio A/S (50%)	Denmark
Odeon Kino AS (fka: SF Kino SA)	Norway
Odeon Kino Stavanger/ Sandnes AS (49%)	Norway
SBM Holding A/S (50%)	Denmark
Filmstaden AB (fka: SF Bio AB)	Sweden
Sydna Fastighetsforvaltning AB (50%)	Sweden
Winberg Kino AB (50%)	Sweden
Popcorn Companiget AS (24.50%)	Norway
Filmweb AS (4.70%)	Norway
AMC EMEA Holdings LLC	Delaware
AMC UK Holding Limited	England
Odeon Finco PLC	England

---

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the following Registration Statements:

- (1) Registration Statement (Form S-8 No. 333-192912)
- (2) Registration Statement (Form S-8 No. 333-248231)
- (3) Registration Statement (Form S-8 No. 333-276076)
- (4) Registration Statement (Form S-8 No. 333-280063)
- (5) Registration Statement (Form S-3ASR No. 333-293291)

of our reports dated February 23, 2026, with respect to the consolidated financial statements of AMC Entertainment Holdings, Inc., and the effectiveness of internal control over financial reporting of AMC Entertainment Holdings, Inc., included in this Annual Report (Form 10-K) of AMC Entertainment Holdings, Inc. for the year ended December 31, 2025.

/s/ Ernst & Young LLP

Kansas City, Missouri  
February 23, 2026

---

## CERTIFICATIONS

I, Adam M. Aron, certify that:

1. I have reviewed this annual report on Form 10-K of AMC Entertainment Holdings, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 23, 2026

/s/ ADAM M. ARON

Adam M. Aron

*Chairman of the Board, Chief Executive Officer and President*

---

## CERTIFICATIONS

I, Sean D. Goodman, certify that:

1. I have reviewed this annual report on Form 10-K of AMC Entertainment Holdings, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 23, 2026

/s/ SEAN D. GOODMAN

---

Sean D. Goodman  
*Executive Vice President, International Operations, Chief Financial  
Officer and Treasurer*

---

**CERTIFICATION OF PERIODIC REPORT**

The undersigned Chairman of the Board, Chief Executive Officer and President and Executive Vice President, International Operations, Chief Financial Officer and Treasurer of AMC Entertainment Holdings, Inc. (the "Company"), each hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

- (1) the Annual Report on Form 10-K of the Company for the year ended December 31, 2025 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
- (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated February 23, 2026

/s/ ADAM M. ARON

Adam M. Aron

*Chairman of the Board, Chief Executive Officer and President*

/s/ SEAN D. GOODMAN

Sean D. Goodman

*Executive Vice President, International Operations, Chief Financial Officer and Treasurer*

---